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1. Introduction
Functional mitral regurgitation is a disease condition in which the mitral valve becomes insufficient as a consequence of left ventricular wall motion abnormalities. 
As such, it is also referred to as secondary mitral regurgitation (MR). A thorough appre-
ciation of mitral valve opening and closing, and of the forces involved in this process, is 
necessary to understand the mechanism of functional mitral regurgitation, which in 
turn has implications for the (surgical) treatment of this condition. 
The counterpart of functional MR is organic MR. The latter condition involves a 
 structural, anatomical disease of the mitral valve or the subvalvular apparatus. 
In    functional MR, the valve is structurally normal—at least macroscopically—apart 
from a  variable degree of annular dilatation, while the left ventricle (LV) is diseased.
Depending on its cause, functional MR can be classified as ischaemic MR or as MR in 
non-ischaemic cardiomyopathy (also called idiopathic cardiomyopathy). There is a prepon-
derance of data available on the subject of ischaemic MR compared to functional MR in 
non-ischaemic disease, and there are several reasons for this discrepancy. First, ischaemic 
mitral regurgitation has been recognised as a distinct pathological condition since the 
early sixties of the twentieth century. Second, ischaemic cardiomyopathy has a much 
higher incidence in industrialised countries. Third, serious attempts to surgically address 
functional MR in idiopathic cardiomyopathy only started in the nineties of the last 
 century, while ischaemic MR has been the subject of surgical interest for a much longer 
time—although treatment results were disappointing until the concept of restrictive 
mitral annuloplasty emerged. And finally, much knowledge has been obtained from 
animal studies, in which an ischaemic MR model is relatively easy to establish compared 
to an idiopathic cardiomyopathy model.
Regardless of aetiology, functional mitral regurgitation carries a poor prognosis. 
Ischaemic MR is often accompanied by heart failure, which is the most important 
 determinant of mortality following myocardial infarction. In non-ischaemic cardiomyo-
pathy the onset of MR heralds functional decline and, again, death. In both settings, 
functional MR of any degree is an independent risk factor for mortality. This is easily 
explained by the vicious cycle that ensues with MR and subsequent remodelling of the 
left ventricle (Figure 1). As such optimal treatment is warranted and, as will become clear 
from this thesis, a multi-modality approach towards both the mitral valve and the left 
ventricle combining optimal pharmacological management and interventional 
 techniques with modern surgical therapies is necessary.
There are similarities between ischaemic and non-ischaemic functional MR, but there 
are also distinct differences. In this introduction and throughout this thesis we will dis-
cuss the disease entities together when possible, but separately  when necessary. 
An  important distinction in the development of MR between ischaemic and non -
ischaemic MR needs to be pointed out here. In non-ischaemic MR the mitral 
 insufficiency  develops rather late in the natural history when considerable remodelling 
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of the left ventricle has taken place. Low ejection fraction (EF) and the clinical 
 syndrome of heart failure therefore always accompany it. Ischaemic MR can develop in 
the same way when diffuse ischaemia leads to LV remodelling and thus ischaemic 
cardio myopathy. However, more frequently MR results from a local LV wall motion 
abnormality,  following a myocardial infarction or local ischaemia. In this situation the 
left ventricle (and EF) can be relatively preserved and the syndrome of heart failure may 
not yet have become manifest (Figure 2).
LV Remodelling LV Volume Overload
Mitral Regurgitaon
↑ Wall stress
↓ Myocardial perfusion
Localized infarcon
Generalized ischaemia
Figure 1. Schematic 
 representation of the 
vicious cycle involved 
in  ischaemic mitral 
regurgitation. A simi-
lar process occurs in 
non-ischaemic dilated 
cardiomyopathy. 
LV, left ventricular.
Ejecon fracon (%)
10 20 30 40 50 
    Ischaemic mitral regurgitaon
  Non-ischaemic mitral 
regurgitaon
HEART
FAILURE
Figure 2. Differences 
in the range of left 
ventricular ejection 
fraction and the pres-
ence of heart failure 
symptoms between 
ischaemic and non -
ischaemic mitral 
regurgitation.
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Defining Ischaemic Mitral Regurgitation
Ischaemic mitral regurgitation encompasses two distinct disease conditions. First, there 
is acute ischaemic MR, typically caused by a rupture of (a head of ) a papillary muscle. 
This is a dramatic condition leading to massive mitral regurgitation with acute pulmo-
nary oedema often necessitating urgent surgery. Echocardiographically this type of 
ischaemic MR is easily recognised by leaflet prolapse and a flail segment that protrudes 
through the valvular orifice into the left atrium in systole. On rare occasions, acute 
ischaemic MR does not involve papillary muscle rupture but only systolic leaflet 
 restriction; two cases are described in chapter 5 of this thesis.
Ischaemic MR typically presents as chronic ischaemic MR, which is always a functional 
disease. It is very important to use a proper definition of chronic ischaemic MR in order 
to differentiate between true chronic ischaemic MR and patients who have (organic) 
MR and incidental coronary artery disease. The latter patient category has a much better 
prognosis. Basically a definition should appreciate the fact that the mitral insufficiency 
is  caused by coronary artery disease (CAD). This means that a patient should have 
 coronary artery disease that has led to LV wall motion abnormalities (due to ischaemia, 
infarction, or both) that induce mitral insufficiency. In addition, the mitral valve should 
be free from organic disease. As such, a definition of chronic ischaemic mitral regurgita-
tion would be “insufficiency of an anatomically normal mitral valve in a setting of wall 
motion abnormalities of the left ventricle that are caused by the sequelae of coronary artery 
disease”.
2. Historical Notes on Functional Mitral Regurgitation
Ischaemic Mitral Regurgitation
In 1963 Burch and colleagues suggested that the sequelae of ischaemia could cause mitral 
regurgitation as a functional phenomenon - rather than only following papillary muscle 
rupture caused by myocardial infarction –in a report on two patients.1 They related the 
occurrence of a new systolic murmur, appearing shortly after myocardial infarction, to a 
“syndrome of papillary muscle dysfunction”, and hypothesised that “failure of the 
infarcted papillary muscle to contract during systole results in mitral regurgitation”. 
Their theory was that the absence of shortening of the papillary muscle during systole 
would create a situation in which the portion of the mitral valve leaflet supported by 
that papillary muscle is not held down and therefore will bulge into the left atrium 
(actually prolapsing) following the phase of isometric LV contraction. Interestingly, in 
the same paper they also propose a model suggesting that patients with an LV aneurysm 
might have outward bulging of the LV wall supporting the papillary muscle during iso-
metric contraction, pulling a portion of the mitral valve down into the left ventricle. 
This is actually similar to what we nowadays call systolic restriction following the 
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functional classification of Carpentier. The proposed pathophysiologic mechanisms 
were further developed into a model presented in more detailed fashion in 1968.2
It should be noted that imaging of mitral regurgitation at that time was mainly 
restricted to LV angiography. The fact that prolapse can be demonstrated by ventriculo-
graphy, whereas restriction cannot, explains why the occurrence of MR in the presence 
of prolapse following myocardial infarction was believed to prove the existence of the 
papillary muscle dysfunction syndrome. Although experimental studies in dogs showed 
already in 1971 that damage to the papillary muscle alone does not lead to MR, while 
MR does occur when this injury also involves the adjacent LV wall,3 papillary muscle 
dysfunction as such was considered a major determinant in the development of 
 ischaemic MR.
An important contribution in this field is the paper by Godley and associates in 1981.4 
In this study “cross-sectional echocardiography” is used to examine three patient groups: 
those with evidence of transmural infarction (clinical symptoms and ECG abnormali-
ties) and evidence of clinical papillary muscle dysfunction (typical murmur related to 
the occurrence of the infarction); those with evidence of infarction without papillary 
muscle dysfunction; and a group of healthy subjects. In this study, it was found that in 
91% of infarct patients with MR incomplete leaflet closure occurred. Morphologically it 
was observed that “one or both leaflets were effectively arrested within the cavity of the 
left ventricle during ventricular systole”, a nice description of systolic restrictive motion. 
Interestingly, the anterior leaflet was always involved in this process, while the posterior 
leaflet was involved in only 12% of cases. Patients with such incomplete leaflet closure 
demonstrated dyskinetic wall motion in the region immediately surrounding one of the 
papillary muscles in 96% of cases. In 16 of 23 patients (70%) the posteromedial papillary 
muscle was primarily affected. In the second patient group (infarction without clinical 
signs of papillary muscle dysfunction), incomplete closure with dyskinesia was observed 
in 3 of 40 patients, who were classified as having “clinically silent MR”—perhaps this 
concerned patients with ischaemic MR that manifests during exercise only. Five patients 
in this group showed hypokinesia involving a papillary muscle area, with normal leaflet 
closure. The authors underline that the assumption that prolapse plays a role in the 
pathophysiology of ischaemic MR is probably false and that their simultaneous occur-
rence is simply explained by the fact that prolapse is often present in patients with MR, 
but that it cannot be related to an ischaemic cause when critically examined.
Further insights, which will be discussed in this chapter, have gradually replaced the 
concept of papillary muscle dysfunction. We now realize that all components of the 
mitral valve complex may play a role in functional MR—regardless of aetiology—which 
has implications for the therapeutic approach.
Mitral Regurgitation in Non-ischaemic Dilated Cardiomyopathy
Historically, the presence of functional MR in non-ischaemic cardiomyopathy has been 
less clearly recognized as a distinct disease condition. Cardiomyopathies have been 
General Introduction 15
studied since the sixties of the twentieth century, and were defined as “disorders of 
 cardiac muscle for which known secondary causes (…) are not responsible”,5 or as 
“a  disorder that directly affects one or both cardiac ventricles in a diffuse or multilocal 
fashion, and that produces heart failure at least in some patients”.6 Goodwin and Oakley 
introduced the distinction between congestive (later also called dilated) cardiomyopathy 
and hypertrophic (also called restrictive) cardiomyopathy, the first being characterized 
by depressed systolic ventricular function and increased LV end-diastolic volume.7 
Initially, a left ventricle damaged by multiple sustained myocardial infarctions was not 
recognized as cardiomyopathy, but nowadays the term “ischaemic cardiomyopathy” has 
gained widespread use.
Non-ischaemic cardiomyopathy is still often referred to as idiopathic cardiomyopathy. 
Currently, the disease is regarded as having a multifactorial aetiology in which genetic 
factors sometimes play a role. Several environmental factors that contribute to the 
 development of idiopathic cardiomyopathy have been identified, e.g. alcohol abuse, 
infectious diseases (mostly viral) and chemotherapy; the condition is also observed in 
the postpartum period.
Historically, outcome has been reported as poor, with 5-year survival ranging from 25 to 
40%.6 This high mortality rate was attributed to a high incidence of thrombo-embolism 
(routine warfarin use was only recommended starting in the early eighties) and ventricu-
lar arrhythmias secondary to interstitial fibrosis. The outcome of surgery in patients 
with non-ischaemic cardiomyopathy will be discussed in more detail in paragraph 8 of 
this chapter.
The presence of MR in idiopathic cardiomyopathy was quantified in a series of 36 patients 
who underwent cardiac catheterization.5 MR was measurable in 23 patients (64%), and 
exceeded 0.70 l/min/m2 in 16 patients (for an average patient with a heart rate of 70 beats 
per minute, this equals a regurgitant volume of approximately 20 mL per beat). It was 
observed that patients with MR had a significantly higher end-diastolic volume, which 
led the authors to relate the occurrence of MR to annulus dilatation. However, the 
 overlapping range in end-diastolic volumes in patients with and without MR made the 
authors conclude that other factors were also involved, in particular “an altered position 
of the papillary muscles and their axes of tension”, as suggested by Perloff.8 Three-year 
survival in this series was as low as 33%.
Treatment of MR in this subset of patients was regarded inappropriate until quite 
recently. In their 1982 review article on cardiomyopathies, Johnson and Palacios state: 
“Severe mitral regurgitation, present in a small number of patients with idiopathic con-
gestive cardiomyopathy, may tempt the physician to advise replacement of the mitral 
valve. We believe that this temptation should be resisted: the perioperative mortality is 
high in patients whose LV ejection fraction is as low as it is in idiopathic  cardiomyopathy, 
and long-term survival is probably unimproved by operation”.6
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Introduction of Undersized or Restrictive Mitral Annuloplasty as a Surgical 
Treatment for Functional Mitral Regurgitation
For a very long time, the only type of surgery considered possible in patients with 
 functional MR and cardiomyopathy was cardiac transplantation, the results of which 
were improving in the 1980’s. The poor reputation of mitral valve surgery in end-stage 
cardiomyopathy of any cause was due to the poor outcome that was found in surgical 
series of mitral valve replacement in patients with systolic heart failure. At that time a 
major concern was that by abolishing MR the poorly functioning left ventricle would 
lose its low-impedance left atrial “pop-off” and would deteriorate further. The case series 
 presented in 1994 by Bach and Bolling from the University of Michigan and published 
in 1995 represented a major breakthrough by demonstrating that mitral valve repair 
using an annuloplasty ring was feasible with low mortality and fairly good early 
 outcome.9,10 The original paper by Bach includes 9 patients (mean age 64 years) operated 
between June 1993 and February 1994 who had end-stage heart failure (NYHA class III 
or IV) despite optimal medical therapy, severe MR, dilated cardiomyopathy (5 patients 
with a non-ischaemic aetiology), and a low ejection fraction: mean, 15%; range, 10-25%.9 
The mean duration of symptoms was 5.4 years, ranging from 1 to 16 years. Most patients 
are described as having been stable for a long time but finally deteriorating with recur-
rent episodes of heart failure. Patients underwent mitral valve annuloplasty with a 
 flexible Duran ring, without further details regarding ring size. There were no hospital 
deaths. After a mean follow-up of 17 weeks, all patients showed clinical improvement. 
There was 1 late death (following cholecystectomy). Echocardiography (mean follow-up 
16 weeks) showed mild MR in 38% of patients and no MR in the remainder of patients. 
Mean transmitral gradient was low (3 mmHg), and there was significant reduction in LV 
volumes with increased stroke volume and EF. A subsequent report by Bolling on 
16 patients is quite similar, mentions the use of a Duran or Physio ring and reports an 
actuarial 1-year survival of 75%.10 Bolling refers to a Japanese case report published in 
1992 as the first presentation of mitral valve reconstruction in the setting of (ischaemic) 
cardiomyopathy.11 It is interesting to read the discussion following the presentation of 
Bolling’s paper at the meeting of the Western Thoracic Surgical Association. Bolling 
mentions that he undersizes the trigone-to-trigone distance “perhaps by one size” and 
reports a mean ring size of 29.
The next paper published by the Michigan group in 1998 reported on 48 patients, with 
one perioperative death and 1-year and 2-year survival of 82% and 72%, respectively.12 In 
the discussion of this manuscript, Bolling states that he changed his strategy from 
undersizing by one ring size to using the “smallest ring possible”.
These publications introduced the concept of undersized or restrictive mitral annuloplasty, 
which is the cornerstone of the surgical treatment of functional MR, and as such also 
the basis of the studies presented in this thesis.
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3. Normal Mitral Valve Function and Pathophysiologic Changes 
in Functional Mitral Regurgitation
The mitral valve (valvula mitralis or valvula bicuspidalis) is a complex anatomical 
 structure that involves the mitral annulus (annulus fibrosis mitralis), the two mitral valve 
leaflets (cuspides valvae mitralis), the chordae tendineae, the papillary muscles (musculi 
 papillares) and the remainder of the left ventricle (ventriculus sinister). The mitral valve 
opens (i.e., the leaflets protrude into the left ventricle) when the pressure in the left 
atrium exceeds the pressure inside the left ventricle. Closing of the mitral valve starts just 
before the left ventricle contracts. All components of mitral valve function—both 
 anatomical and mechanical—will be discussed in more detail below.
The Balance of Forces
Opening and closing of the mitral valve are dynamic processes. Since regurgitation 
occurs during the closing phase (systole) it is important to have an understanding of the 
process of mitral leaflet closure. Mitral leaflet closure starts when the mitral orifice area 
decreases at end-diastole and early systole, initiated by anterior movement of the aortic 
root (pre-systolic outward bulging of the sinuses) that causes dorsiflexion of the fibrous 
anterior annulus; by sphincter-like contraction of the atrial fibres encircling the 
 posterior annulus; and by contraction of the LV base.13,14 The decrease of mitral orifice 
area brings both leaflets together and thus constitutes the first phase of coaptation. 
Further closure is enforced by the LV pressure generated—the closing force—which is 
counteracted by the tethering forces exerted by the (contracting) papillary muscles and 
chords. In functional MR, the tethering forces are stronger and retain the leaflets in the 
left ventricular cavity. When LV remodelling sets in, tethering increases and mitral 
 leaflet  closure becomes more dependent on closing forces, which are likely to diminish 
further during the continuing remodelling process (Figure 3). An understanding of 
these  balancing forces is important to appreciate the spectrum of ischaemic MR. It can 
explain how MR severity can increase even in the absence of ischaemia (by taking into 
account the increased tethering imparted by geometrical changes), and how exercise 
induced changes can both increase the severity of MR (due to changes in loading 
 conditions) but also reduce MR (due to recruitment of contractile reserve). Similarly it 
can explain how patients with severe exercise intolerance may only show mild MR on 
 resting echocardiography.
It has been recognised that increased tethering forces (resulting from LV geometrical 
changes) are more important in causing functional MR than reduced closing forces. 
Experimental designs have shown that outward displacement of the papillary muscles 
with maintained LV pressures leads to MR, while pharmacologically reducing LV 
 contraction to an ejection fraction below 20% without concomitant dilatation (using 
external restraint) does not produce MR.15 Similar observations have been made in a 
clinical setting, where it was found that functional MR was principally related to 
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increased tenting, which in itself was related to displacement of the papillary muscles.16 
These studies suggest that local LV remodelling—at least in ischaemic MR—plays a 
more important role than global LV remodelling, and they can also explain why the 
degree of MR varies widely in patients with similar degrees of LV systolic dysfunction.
It is also important to realise that tethering is not always directly proportional to the 
degree of LV dilatation. Experimental studies in sheep by Gorman et al have demon-
strated that infarctions in the posterior region lead to less global remodelling but to 
significantly more functional MR than do infarctions created in the anteroseptal region, 
which induce more remodelling.17 This is consistent with the clinical finding that 
patients with an inferior infarction in general have more MR, more tethering and more 
displacement of the posterior papillary muscle compared to those with an anterior 
infarction, despite the fact that patients with an anterior infarction have more extensive 
global LV remodelling, as manifested by higher LV volumes and lower EF.18
Although they are not the most important factor, closing forces do contribute to the 
severity of functional MR. Compared to organic MR, functional MR was found to 
exhibit typical dynamic changes during systole. Effective regurgitant orifice area changes 
in a biphasic pattern, showing peaks in early and late systole and a drop in midsystole, 
when closing forces are at their peak.19 Hung and co-workers showed that these changes 
are related to temporal alterations in transmitral pressure rather than to anatomical 
changes at the annular level.20 This fact is actually the rationale behind the effect of 
 cardiac resynchronization therapy on functional MR, as will be discussed later.21
The Mitral Leaflets
The changes occurring in mitral valve leaflets in pathologic conditions have been studied 
in vivo by Chaput et al with 3D echocardiography, comparing patients with dilated 
cardiomyopathy (ischaemic and idiopathic) to normal subjects, distinguishing between 
patients with no or mild MR and those with moderate or severe MR.22 They found that 
annular area increased in patients with functional MR—by 21% in patients without 
 significant MR and by 29% in patients with significant MR. Total leaflet area also 
Figure 3. Left: balance of 
forces acting on mitral 
leaflets in systole. LA indi-
cates left atrium; AO, 
aorta. Right: effect of 
 papillary muscle displace-
ment, as in inferobasal 
myocardial infarction; 
Used with permission 
from Liel-Cohen et al.
Copyright 2000, American 
Heart Association, Inc.
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increased—by 35% on average; 39% in case of non-significant MR and 22% in case of 
significant MR. Leaflet closure area (defined as the part of the leaflet that separates the 
atrium and the ventricle, so the part not involved in coaptation) was increased in all 
patients with LV dysfunction, indicating leaflet tethering. This increase was more 
 pronounced in patients who had significant functional MR. Interestingly, the 
 leaflet-to-annular-area ratio was similar in all groups—approximately 2—suggesting 
leaflet adaptation in concordance with annular dilatation. However, leaflet-to-closure-
area ratio was significantly reduced in patients with MR compared to those without 
(1.29 versus 1.78), but not in patients with LV dilatation without MR (1.81). This  suggests 
that patients who do not develop significant MR in a setting of LV dilatation have 
 adequate leaflet adaptation to chronic tethering compared to those who develop MR. 
Adaptation of the leaflets to an increase in annular dimensions was also shown in the 
necropsy studies by Hueb et al for both ischaemic and non-ischaemic 
cardiomyopathy.23
Studies on mitral leaflets obtained from heart transplant recipients with dilated cardio-
myopathy and functional MR (both ischaemic and idiopathic aetiology) demonstrated 
significant alterations in the mitral leaflet extracellular matrix compared to autopsy 
 control specimens.24 Functional MR leaflets showed higher DNA content (increased 
cellularity) and higher collagen and glycosaminoglycan content in their extracellular 
matrix, which was balanced by a reduced amount of water. No significant differences 
were observed comparing idiopathic versus ischaemic aetiology. Proposed mechanisms 
for these changes are leaflet distortion (leading to elongation and changes in stress 
 distribution), and changes in valve loading conditions. In an experimental setup, the 
same group demonstrated collagen and elastic fibre remodelling in the anterior leaflets 
of sheep several weeks after the induction of MR by punching a hole in the posterior 
mitral leaflet.25 The question remains whether these observed changes should be 
 interpreted as adaptational or pathological.
In a sheep model where tethering of the mitral leaflets was induced without creating 
MR, Dal-Bianco et al demonstrated increased mitral leaflet area and matrix thickness 
after 2 months, accompanied by cellular changes that suggest reactivation of embryonic 
valve development pathways.26 This suggests active adaptation of the mitral leaflet when 
exposed to tethering.
Functionally, Tibayan and colleagues demonstrated an increased radius of curvature in 
both mitral leaflets in an ovine chronic ischaemic MR model.27 This increases leaflet 
stress, which might play a role in leaflet adaptation on a (sub)cellular level.
The Mitral Annulus
The normal mitral annulus has a non-planar shape, which is often referred to as a saddle 
shape. There are two higher points—the “riding horns”—situated anteriorly and 
 posteriorly, and two lower points, situated at the commissures. The supposed rationale 
for this shape is that the annulus should be able to compensate for the fact that the 
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leaflet length along its attachment remains constant, while the circumference of the 
annulus decreases during systolic contraction of the LV base. Furthermore, the saddle 
shape would be better able to withstand the leaflet stress exerted by LV pressures.28
The first quantitative analysis of mitral annular changes in a normally functioning mitral 
valve in humans was presented by Ormiston et al in 1981, using echocardiography in 
11  healthy subjects.29 They measured a normal maximum mitral annular area in late 
diastole of 3.8±0.7 cm2/m2 (indexed to body surface area). The maximum area reduction 
throughout the cardiac cycle was 26%, while maximum circumference reduction 
was 13%.
In functional MR, the mitral annulus dilates, flattens (i.e., loses its saddle shape) and 
shows a lack of systolic area reduction with annular motion becoming restricted.14,30,31 
However, the extent to which these changes contribute to functional MR remains 
unclear. Several studies have demonstrated that annulus dilatation by itself does not lead 
to significant MR. It has been demonstrated in vivo that there is an approximate two-
fold surplus of mitral valve tissue to cover the annular cross-sectional area. In a 
 comparison between patients with lone atrial fibrillation and patients with dilated 
 cardiomyopathy, a comparable degree of annular dilatation only led to MR in case of LV 
dilatation, suggesting that annular dilatation alone is not sufficient to cause MR.32
In chronic ischaemic animal models, the annulus was found to increase both in the 
septal-to-lateral dimension and in the commissure-to-commissure dimension. However, 
only septal-to-lateral annular dilatation was associated with the development of 
 ischaemic MR.33,34 In a chronic sheep model, septal-to-lateral cinching (reduction by 
15-20% compared to the baseline diameter before induction of ischaemia) was able to 
abolish ischaemic MR.35
Necropsy studies by Hueb et al showed that—contrary to what was previously believed— 
the changes in annular dimensions in both ischaemic and idiopathic cardiomyopathy 
do not only involve the muscular part of the annulus but also the fibrous part (including 
the intercommissural part where the anterior leaflet is inserted) to a similar extent.23 
They also observed that the degree of LV dilatation was not related to the degree of 
annular dilatation. In vivo, the pathological increase in annular area (of approximately 
60% in diastole) and perimeter (of approximately 24%) was confirmed with 3D trans-
thoracic echocardiography (TTE) comparing 7 patients with ischaemic MR to 5 healthy 
volunteers, together with the finding of restricted annular motion.30 Similar  observations 
were made by Watanabe et al.36 Dilatation in the fibrous part of the annulus that was 
comparable to dilatation in the muscular part (roughly by 20%) was found in a chronic 
ischaemic sheep model.37
The Papillary Muscles and Chordae Tendineae
In the normally functioning heart, the papillary muscles can be regarded as shock 
absorbers: the distance between the papillary muscle tips and the mitral annulus remains 
stable throughout the cardiac cycle, while considerable dynamic changes occur in the 
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distance between the apex and the mitral annulus.38 The chordae are divided into 
 primary chordae (also called marginal chordae) that insert into the free edge of the 
 leaflet, secondary chordae (also called strut or intermediate chordae) that have their 
insertion at the leaflet body, and tertiary chordae (also called basal chordae) that attach 
to the base of the posterior leaflet or to the annulus. During the cardiac cycle, the 
 secondary chordae remain taut, whereas the primary chordae are slack during diastole 
and become taut during systole to prevent leaflet prolapse.
As already mentioned, the concept of “papillary muscle dysfunction” has been only very 
gradually abandoned despite the fact that it was shown that papillary muscle  dysfunction 
by itself does not produce functional MR, both in experimental studies3 as well as by the 
first echocardiographic clinical examinations in humans described by Godley and 
associates.4
In an elegant acute model in sheep, the specific contribution of the papillary muscles in 
ischaemic MR was studied by Messas et al by first inducing ischaemia in the inferobasal 
region (circumflex artery territory) while selectively maintaining perfusion of the 
 papillary muscle.39 It was observed that MR developed in parallel with increased leaflet 
 tethering. When ischaemia was also induced in the papillary muscle, MR stroke volume 
decreased and mitral regurgitant orifice area also decreased—despite a lower LV driving 
force due to a larger ischaemic territory. Reduced papillary muscle contraction 
 (demonstrated by strain rate measurements) was shown to decrease tethering in this 
experiment. In a clinical setting, a similar—paradoxical—attenuation of ischaemic MR 
by reduced contractility of the papillary muscles was assessed with strain rate imaging by 
Uemura et al.40
The role of the papillary muscles in functional MR has received renewed interest with 
the advent of resynchronisation therapy. Papillary muscle dyssynchrony may contribute 
to development or worsening of functional MR. Patients with dilated cardiomyopathy 
and prolonged QRS (>130 ms) show significant MR twice as often as patients with 
normal QRS duration.41 This may be explained by geometrical changes induced by the 
dyssynchrony itself, as well as by delayed LV pressure generation (dP/dt).
Messas and co-workers examined the effects of limited cutting of secondary chords 
(which they refer to as basal chords in his manuscript) of the anterior mitral leaflet in an 
acute ischaemic MR model in sheep.42 This approach reduced leaflet tethering and 
 actually reduced MR, without causing prolapse. In a chronic ovine model, the same 
group demonstrated reduction of MR severity three months after cutting secondary 
chords from either the anterior leaflet or from both leaflets.43 EF remained stable, 
 however at the expense of increased LV volumes (30% end-diastolic and 25% end -systolic 
volume increase). Interestingly, the research group from Stanford demonstrated that 
cutting second order chordae in an acute model could not prevent ischaemic MR.44 This 
group also demonstrated a decline in LV function following second-order chordal 
 cutting using load-independent LV function parameters (pressure-volume loops).45
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The Left Ventricle
Left ventricular changes associated with functional MR include functional changes (wall 
motion abnormalities and reduced contractility), dimensional changes (LV dilatation 
with volume increase) and geometrical changes (globally manifested by increased 
 sphericity and locally by papillary muscle displacement).
LV dilatation alone is not sufficient to cause functional MR. Increased sphericity has 
been related to MR through secondary posterolateral displacement of the papillary 
 muscles.46,47 An experimental study by Kono et al in an acute canine infarction model 
using injection of microspheres into the circumflex artery showed how dyskinesia of the 
ventricular wall overlying the papillary muscle induced geometric LV changes that led 
to what we now call systolic restriction of the mitral leaflet, producing mitral regurgita-
tion.48 These effects were all completely reversible after 3 weeks. The same group 
 examined a chronic heart failure model in dogs by alternately injecting microspheres 
into the left anterior descending and into the circumflex artery.46 After 3 months 
 functional MR developed, preceded by increased sphericity of the left ventricle. 
Interestingly, all other expected changes (annular dilatation, LV dilatation and LV wall 
motion abnormalities) occurred later in time, suggesting that the primary cause of 
 functional MR in chronic cardiomyopathy is a change in the shape of the left ventricle. 
Clinical studies however demonstrated that increased sphericity, LV volume and LV 
function by  themselves have no independent relationship with the development of 
 functional MR.16 Instead, mitral valve geometrical changes (tenting) were independent 
predictors of MR severity. Tenting was determined by local LV alterations, in particular 
papillary muscle displacement. The pivotal role of LV geometric changes, specifically 
the outward  movement of the papillary muscles leading to increased tethering, was also 
nicely demonstrated in both acute and chronic ischaemic models by Otsuji et al.49 
In  summary, outward displacement of one or both papillary muscles has a direct 
 influence on mitral valve morphology and mechanics by increasing tenting; this can 
occur in—but is not limited to—a setting of global LV remodelling with increased 
sphericity.
The influence of an undersized mitral annuloplasty ring on LV geometry was studied in 
an acute ischaemic MR model in sheep, where a Paneth-like suture was used to mimic 
the effect of an undersized ring.50 In this study, the suture slightly reduced LV sphericity, 
but more importantly decreased end-systolic LV anterior and posterior radii of  curvature, 
which are a marker LV wall stress—an important stimulating factor in the process of LV 
remodelling. These changes were observed at the base of the heart, at the  equatorial level 
and even in the apical regions. It is interesting to consider that a reduction in LV wall 
curvature will reduce stress even in the presence of unchanged LV volume, so also in 
situations of persistent LV dilatation.
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4. Mitral Regurgitation and the Left Ventricle
In functional mitral regurgitation, the left ventricle sustains two different injuries: that 
from the initial disease leading to cardiomyopathy and that from the effects of MR—
which is essentially volume overload. It is not easy to distinguish the effects of both 
 injuries, if at all possible, but in this way it is easy to understand that functional MR will 
have a more profound effect on cardiac function (and therewith on clinical status and 
outcome) than organic MR of the same severity. This can also explain why in functional 
MR lower indices of regurgitant orifice area and regurgitant volume are classified as 
“severe” MR compared to organic MR, as will be discussed in paragraph 5. Both the 
 primary injury (ischaemia/infarction in ischaemic cardiomyopathy and a variety of 
 possible causes in non-ischaemic cardiomyopathy) and the volume overload caused by 
MR, lead to similar changes in global LV size, mass, shape and function, that are collec-
tively referred to as “remodelling”. The concept of remodelling is not easy to capture 
clinically. We can assess LV geometry and function and as such have surrogate measures 
for remodelling, but the true changes occurring at a (sub)cellular level are much less 
 visible, and probably some have not been unravelled yet.51,52 As long as we keep that in 
mind our research efforts in this field can be put in the right perspective.
Basically the changes that occur in the remodelling process are adaptational at first and 
aim to compensate for the loss of pump function of the heart resulting from the injury. 
Over time, these changes become pathological because of their deleterious effects. 
The heart will try to maintain stroke volume by increasing its cavity size, i.e., LV dilata-
tion, which is at the expense of ejection fraction. This causes a right shift of the pressure 
-volume curve with increased end-diastolic volume and end-diastolic pressure. This 
leads to increased LV wall stress, which can initially be compensated for by secondary 
hypertrophy (which in volume overload situations is proportional to dilatation, so the 
ratio of LV mass to end-diastolic volume remains unchanged). However, the extent of 
 compensatory hypertrophy is limited, and further dilatation will lead to increased wall 
stress as described by the LaPlace law, which states that wall stress is the product of 
transmural pressure and radius, divided by wall thickness. These changes increase oxygen 
demand—which obviously is additionally limited in patients with coronary artery 
 disease. Ultimately, myocyte length increases and myofibril content decreases which 
further leads to contractile dysfunction. In this way a vicious cycle ensues, and dilatation 
begets dilatation. A detailed description of the changes that occur on a cellular or sub-
cellular level is beyond the scope of this thesis.
An interesting experimental study to distinguish the effects of MR and infarction on LV 
remodelling was described by Beeri et al.53 In an ovine model an anteroapical infarction 
was created known to lead to ischaemic remodelling. Some sheep also received a left-
sided ventricle-to-atrium shunt to mimic moderate MR (comparable to 30% regurgitant 
fraction). Animals in the latter group demonstrated a much larger LV volume increase 
and a more pronounced decline of LV contractility demonstrated by pressure volume 
loop analysis. In the non-infarcted myocardial tissues, sheep with experimental MR 
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initially showed similar expression of hypertrophy-activating and antiapoptotic proteins, 
which however decreased after 3 months to below baseline levels. In contrast, sheep 
without a shunt showed ongoing and progressive expression of these proteins. This 
 suggests that MR results in transformation to a so-called failure phenotype which was 
associated with progressive remodelling.
A simple mathematical example can demonstrate how a given degree of functional MR 
influences haemodynamics. Suppose an EF of 50% and a regurgitant volume of 40 mL. 
A resting cardiac index of 2 L/min/m2 for an average man is equivalent to a cardiac 
output of 4 L/min. At a heart rate of 70 beats per minute, this translates into a forward 
stroke volume of 57 mL. With a regurgitant volume of 40 mL, this adds up to a total 
stroke volume of approximately 100 mL. This means that the end-diastolic volume has 
to be 200 mL to achieve an EF of 50%. This is about twice the normal size, and without 
MR the end-diastolic volume would be 114 mL. For reference, normal indexed values for 
LV end-diastolic volume are 35–75 mL/m2, and for end-systolic volume 12-30 mL/m2, so 
as an easy reference one could take 55 mL/m2 for end-diastolic volume and 25 mL/m2 for 
end-systolic volume. Non-indexed values are slightly higher for male subjects  (67-155 mL) 
than for female subjects (56–104 mL). For LV end-diastolic diameter indexed to body 
surface area, the normal range is 22–31 mm/m2. Non-indexed values range from 42 to 
59 mm for men and from 39 to 53 mm for women.54 This example also  demonstrates 
how EF is only a surrogate marker for LV contractility; it is highly load dependent and 
can remain more or less normal in MR while LV contractility decreases due to the low 
LV impedance in systole created by the mitral insufficiency. It has been demonstrated 
that end-systolic volume is the most reliable non-invasive marker for LV contractility 
since it is not dependent of preload and varies directly and linearly with afterload.55 
The term reverse remodelling is applied to a dilated left ventricle that apparently is no 
longer in the vicious cycle of progressive dilatation, but on a course back towards a 
normal shape and volume. As with remodelling, also in reverse remodelling we can 
usually only assess rather global parameters of this process, where we would rather be 
informed on the pathophysiologic mechanisms occurring on a cellular or molecular 
level. Evidence for such a mechanism is hard to provide since it requires serial biopsies 
from cardiac tissue. In a randomized trial in patients with idiopathic cardiomyopathy, 
patients who received beta blockers after six months showed favourable changes in the 
expression of genes (at the RNA level) encoding sarcoplasmatic reticulum calcium 
ATPase and both α and β myosin heavy chain compared to patients on placebo.56 This 
molecular remodelling indicates reversal of induction of features of the “foetal gene 
programme”, which is regarded as the molecular signature of LV remodelling. The 
changes were accompanied by improvement in EF. Also in patients who had received 
unloading therapy through an LV assist device, normalization of sarcoplasmatic 
 reticulum calcium ATPase in the LV myocardium was observed, as well as beneficial 
changes in LV myocyte diameter.57
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There are no standard definitions on what to consider proof of reverse remodelling.58 
Most studies use cut-off value of 10 or 15% reduction in LV diameters or volumes. 
Reverse remodelling is a theme that is addressed in almost all chapters of this thesis.
5. Incidence, Prevalence and Clinical Outcomes of Functional 
Mitral Regurgitation
Several studies have provided data on incidence and prevalence of functional MR. 
An overview is presented in Table 1 (p. 76). Most studies focus on ischaemic MR, some 
have included both ischaemic and non-ischaemic aetiologies. What can be  concluded is 
that ischaemic MR is a common phenomenon. However, exact data on the occurrence 
of ischaemic MR are hard to give, since there are many differences between the studies 
that report on this subject. These differences relate to the interval between the ischaemic 
event and the occurrence of MR (ranging from several hours to months after the 
 infarction); the technique with which MR was diagnosed (angiography versus 
 echocardiography) and quantified (semiquantitative versus quantitative assessment); 
the  severity of MR; and the characteristics of the study population (observational 
cohorts, patients included in clinical trials, etc). These aspects are discussed in a review 
by Bursi et al.59
Regarding the presence of functional MR in non-ischaemic cardiomyopathy, available 
studies more or less have the same shortcomings as those mentioned for ischaemic MR. 
In addition, many studies have included both ischaemic and non-ischaemic patients, 
and data are presented without stratification. The prevalence of dilated cardiomyopathy 
was estimated as 1:2,500 in the American Heart Association position paper on this 
 subject, and the disease was identified as the third most common cause of heart failure 
and the most frequent cause of cardiac transplantation.60 The European position paper 
states that the prevalence of dilated cardiomyopathy is unknown.61
LV Angiography Based Studies
A commonly cited study regarding the occurrence of ischaemic MR is that of Lamas et 
al, which is a post-hoc analysis of the SAVE (Survival and Ventricular Enlargement) 
trial.62 The SAVE trial was a double-blind placebo-controlled randomized multicentre 
trial that demonstrated improvement in survival and clinical outcome in acute 
 myocardial infarction (MI) survivors with LV dysfunction (EF <40%) following 
 treatment with captopril. Patients with manifest ischaemia underwent catheterization 
before randomization, and their data are used in this manuscript. Using ventriculo-
graphy, ischaemic MR was demonstrated in 19.4% of patients up to 16 days after MI; 
in most cases severity was grade 1+ (14.6%) or grade 2+ (4.5%). Clinically, only 9% of 
patients with MR had an audible murmur. Compared to patients without MR, those 
presenting with MR had more extensive CAD, higher LV volumes with more 
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hypokinesia, as well as more spherical ventricles. In this study a two-fold increase in 
 cardiovascular mortality is observed in the presence of ischaemic MR (29% versus 12% at 
a median follow-up of 3.5 years).
A prospective data analysis from Duke University collecting angiographic data from 
cathlab patients admitted for heart failure with LVEF <40% (n=2,057) revealed the 
 presence of MR of any grade in 56% of patients, with 70% having mild MR and 30% 
having moderate or severe MR.63 These were not only ischaemic patients, 40% of 
patients had no CAD. At a median follow-up of 3.5 years, in both ischaemic and non -
ischaemic patients MR of any grade was an independent risk factor for death (RR 1.23), 
and there was a graded relationship between MR severity and risk of death (3-year 
 mortality for no MR 28%, for mild MR 38% and for moderate or severe MR 49%).
Echocardiography Based Studies
The relationship between functional MR and dilated cardiomyopathy was already 
 established in 1991 by Blondheim et al.64 They studied 91 patients with dilated 
cardiomyo pathy—EF <40% and LV end-diastolic diameter >60 mm—with TTE. 
In this group—62% of patients had an ischaemic aetiology—MR was detected in 57% of 
patients. Patients with MR more often had heart failure and, more importantly, MR of 
any severity was found to be the single predictor for mortality. At 32 months, survival in 
the MR group was 22%, while it was 60% in patients without MR (P<0.005).
Manuscripts in which echocardiography is used to detect MR tend to show a higher 
frequency of post-infarction MR. While the SAVE trial only studied patients who had 
an index infarction 16 days or less before examination, Grigioni and associates examined 
patients with an MI older than 16 days which they qualified as chronic ischaemic MR.65 
This was done between 1990 and 1997 and included 194 patients with ischaemic MR 
who were matched for age, sex and LVEF with 109 post-infarction patients without MR. 
Patients with MR had more heart failure symptoms, more atrial fibrillation and more 
enlargement of the left atrium and ventricle. MR was assessed quantitatively,  determining 
regurgitant volume (RVol) and effective regurgitant orifice (ERO). Ischaemic MR was 
found to be an independent risk factor for death (RR 1.88), irrespective of EF (all-cause 
mortality at 5 years without MR 39% and with MR 62% (P<0.001); cardiac  mortality 
30% and 50%, respectively (P<0.001)). This study also was the first to show that the 
degree of MR was directly associated with mortality. ERO proved to be the most 
 powerful predictor, with ERO ≥20 mm2 showing a relative risk of 2.23. Based on this 
study, ERO ≥20 mm2 is now by many considered severe in functional MR patients—
compared to a cut-off value of 40 mm2 in patients with organic MR. A possible 
 explanation why ERO is a stronger predictor than RVol may be that a large ERO can 
lead to large regurgitant kinetic energy (large RVol), but may also translate into  potential 
energy (low RVol but high left atrial pressure and V wave).
Koelling et al in 2002 reported on a retrospective database evaluation of echocardio-
graphic examinations performed as routine clinical care in Michigan.66 Patients with 
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EF ≤35% were included (n=1,436). Aetiologies were ischaemic in 59% and non-ischaemic 
in 41%. Moderate MR (assessed semiquantitatively) was present in 30% of patients, 
severe MR in 19%. For tricuspid regurgitation (TR), these percentages were 23% and 
12%, respectively. With a mean follow-up of 1 year, both MR and TR proved to be 
 independent risk factors for death (RR for MR 1.84, for TR 1.55). This relationship was 
graded—the more MR or TR, the higher the risk of death. Three-year mortality  (without 
distinguishing between aetiology) was 42% for no or mild MR, 50% for  moderate MR 
and 65% for severe MR. Interestingly, the presence of severe TR showed a high  correlation 
with the presence of severe MR.
A retrospective study by Robbins et al, using TTE in patients with heart failure  (aetiology 
not specified) showed a high incidence of MR.67 In hospitalised patients, 74% showed 
moderate or severe MR compared to 45% of outpatients. Robbins also showed a survival 
difference at 4 years for patients with no or mild MR compared to those with moderate 
of severe MR (81% vs. 61%, P=0.0015). Age, tricuspid regurgitation and EF were predic-
tors for mortality in a multivariate model, while MR was not.
Patel and co-workers retrospectively studied 558 patients with advanced heart failure 
(NYHA class III or IV, EF <35%) in a tertiary referral centre (Mayo Clinic) between 1996 
and 2001.68 Aetiology was ischaemic in 71% of patients, the remainder had idiopathic 
cardiomyopathy. In this selected group of patients, MR severity was moderate or more 
(“haemodynamically significant”) in 39% of patients. NYHA class correlated with MR 
severity. There was also a correlation between MR severity and the presence of at least 
moderate TR (present in 25% of patients with at least moderate MR). Mortality in 
patients with haemodynamically significant MR was higher than in those without, but 
MR was not an independent risk factor for death. Aetiology proved to be an  independent 
risk factor, with a higher mortality in ischaemic patients. Survival rates for ischaemic 
MR were 70% at 1 year, 51% at 2 years, 40% at 3 years and 25% at 5 years; for non-
ischaemic patients these percentages were 87%, 79%, 70% and 54%, respectively. TR was 
also an independent predictor for death.
Bursi et al conducted a population-based study (Olmsted County) in 773 patients over 
10 years.69 Patients with a myocardial infarction were studied by TTE within 30 days 
following MI (mean 3.0 days). Mitral regurgitation was present in 50% of cases, being 
mild in 38% and moderate or severe in 12%. Interestingly, there was no association 
between the development of MR and the location or size of the infarction (based on CK 
levels and presence of Q-waves). This study confirmed that a murmur is frequently 
absent in ischaemic MR. Patients with MR had lower EF, higher LV volumes, higher 
wall motion scores and higher RV systolic pressures. This population-based study 
showed in patients with moderate or severe MR after 3.5 years a more than threefold risk 
for heart failure and a relative risk of 1.55 for death. Survival at 5 years was 72% without 
MR, 62% with mild MR and 40% with moderate or severe MR (P<0.001).
A prospective study by Aronson et al evaluated 1,190 patients with MI without previous 
heart failure between 2001 and 2005.70 On semiquantitative echocardiographic 
 evaluation (at a median of 2 days after infarction), 40% was found to have mild MR and 
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6% had moderate or severe MR. At a median follow-up of 24 months, 11.5% of patients 
had been readmitted for heart failure (2% following a new infarction). There was a 
graded relationship between MR severity and the risk of heart failure, with even patients 
with mild MR showing a threefold increased risk. Similarly, there was a relationship 
with death which was also present in patients with “preserved” LVEF (≥45%).
Agricola et al presented a prospective evaluation between 2002 and 2007 of 404 patients 
with LV systolic dysfunction (echocardiographic EF <50%) and at least mild functional 
MR (graded quantitatively) with a follow-up of 3.3 years.71 Ischaemic aetiology was 
 present in 77% of patients. Many patients used beta-blockers, ACE-inhibitors, 
 aldosterone antagonists or a combination of any. In the ischaemic group, 60% of patients 
were revascularised during follow-up. Agricola found that moderate to severe functional 
MR at rest is an independent predictor of cardiac mortality (not all-cause mortality) and 
heart failure—next to age, NYHA class, renal insufficiency and atrial fibrillation. Overall 
survival at 4 years was 66% for mild MR, 50% for moderate MR and 49% for severe MR; 
for freedom from cardiac mortality these percentages are 94%, 57% and 55%, respectively. 
Interestingly, there was a high percentage (45%) of non-cardiac deaths in this group, and 
a low incidence of sudden cardiac death.
More recently, Rossi and colleagues retrospectively studied 1,256 patients with chronic 
heart failure of both ischaemic and non-ischaemic aetiologies.72 All patients had a 
 quantitative assessment of functional MR, which was found to be mild to moderate in 
49% of patients and severe in 24%. There was a strong relationship between MR severity 
and survival and admission for heart failure. This was independent of clinical and 
 functional (EF) parameters. In general, survival at 5 years was 30% for patients with 
severe functional MR, regardless of aetiology.
Summary
Based on these studies, the occurrence of post-MI mitral regurgitation of any severity is 
frequent and its incidence should roughly be estimated between 20 and 40%. Clinically, 
these patients are older and more often females, and they show more signs of LV 
 remodelling compared to patients without MR. There is no relationship between infarct 
size and the occurrence of MR. Several studies indicate a higher prevalence of ischaemic 
MR following an infarction in the inferior or posterior region, but this is not a 
 consistent finding. Ischaemic MR has a negative effect on prognosis, which is already 
present in patients with mild MR. This excess mortality is graded, i.e., related to the 
severity of MR and independent of LVEF. Finally, ischaemic MR is often clinically silent 
with absence of systolic murmur and has a characteristic dynamic phenomenon. 
Exercise testing is sometimes necessary to assess the true character of an apparently 
 innocent mild ischaemic MR.
With regard to functional MR in non-ischaemic patients, its presence is also frequent. 
Mortality is high and related to the severity of MR, although evidence regarding its 
importance as an independent risk factor is ambiguous. There is an important 
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relationship with tricuspid regurgitation, which may reflect the fact that in  non-ischaemic 
cardiomyopathy both ventricles can be injured. Several studies indicate that prognosis 
in idiopathic cardiomyopathy is somewhat better than in ischaemic cardiomyopathy.
6. Assessment of Functional Mitral Regurgitation
Since functional MR is a dynamic disease condition, its presence and extent can only be 
well appreciated using functional examinations, such as echocardiography or magnetic 
resonance imaging (MRI). On imaging, the previously described tethering forces are 
translated into a restricted leaflet motion in systole. The typical dysfunction of the 
 leaflets was originally described by Carpentier in his classification of mitral valve 
 disease73 as type IIIb, restricted leaflet closing or systolic restriction. Tethering in 
 functional MR  frequently leads to the typical echocardiographic image in which the 
mitral leaflets are concave towards the left atrium as opposed to their normal convex 
appearance, the so-called seagull sign.74 This is caused by excessive tethering of the 
 secondary chords. Jet direction in functional MR depends on the relative degree of 
 tethering of both leaflets. When mainly the posterior leaflet is restricted, jet direction is 
oriented towards the posterior aspect of the left atrial wall; this phenomenon is 
 sometimes called a “pseudo prolapse” of the anterior mitral leaflet—a term we think 
should be avoided because it might be misleading. When restriction is symmetrical, the 
 regurgitant jet has a central orientation.
The dynamic nature of functional MR has important diagnostic and therapeutic 
 implications. While structured intraoperative surgical evaluation of the mitral valve—
on an arrested heart—is the cornerstone of mitral valve surgery in organic disease, this 
assessment has no additional value in functional MR since, again, the valve is  structurally 
normal. At most, the surgeon will see the relative displacement of the papillary muscles 
and will appreciate the globally enlarged left ventricle, with sometimes a localized trans-
mural infarction. Therefore, the diagnosis of functional MR has to be established prior 
to surgery by looking at restrictive leaflet motion, LV geometric changes and LV wall 
motion abnormalities, although assessment of MR severity may produce additional 
problems, as will be discussed later.
Echocardiographic Assessment of MR Severity
Echocardiography is currently the recommended imaging technique to assess valve 
 dysfunction, as endorsed by the current guidelines on the management of valvular heart 
disease.75,76 It is also the most appropriate technique to examine patients with functional 
MR. Apart from assessing the severity of MR and its mechanism, echocardiography is 
also used to establish LV and left atrial function and dimensions, assess function of the 
other valves and estimate pulmonary artery pressure. Currently, a so-called integrative 
approach is advised, which takes into account several parameters of MR severity and 
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morphology, and checks their outcomes against the expected consequences for LV 
 function and pulmonary pressure. Thus, MR severity should not be determined based 
on a single parameter. New developments (stress testing, strain rate imaging) have 
 provided new possibilities to obtain a more comprehensive view of the implications of 
the valvular problem for the patient, and can be used to tailor treatment.
Assessment of the severity of MR has implications for patient prognosis—as discussed 
earlier—and for treatment. Colour Doppler techniques are the most commonly used to 
assess valve regurgitation, both with regard to severity as to spatial orientation of jet 
direction. Several instrument settings can influence its results, however. Historically, 
MR severity assessment has been performed semi-quantitatively using colour flow 
 mapping of the regurgitant jet area in relation to left atrial size. This is a relatively easy 
 technique with a limited accuracy, since several technical and physiological factors 
 influence results; for instance, a lower driving pressure will make a jet relatively smaller. 
The vena contracta is defined as the narrowest portion of a jet, just at or beyond the 
regurgitant orifice. It has laminar flow with high velocity, making it less sensitive to 
technical factors involved. The cross-sectional area of the vena contracta indicates the 
effective regurgitant orifice area (EROA or ERO), which is the narrowest area of actual 
flow. Size of the vena contracta is independent of flow rate and driving pressure for a 
fixed orifice. This means that it can change when the regurgitant orifice is dynamic, as is 
the case in functional MR. The proximal isovelocity surface area (PISA), or flow  convergence 
technique is based on hydrodynamic principles. When fluid (in this case blood) 
approaches a regurgitant orifice, its velocity increases to form concentric shells of 
increasing velocity and decreasing surface area that are roughly hemispheric. After the 
appropriate aliasing velocity (Va) has been set, flow rate (Q) through the regurgitant 
orifice is calculated as the product of hemisphere surface area and aliasing velocity:
Q = 2πr2 * Va.
The maximal ERO can then be derived assuming that the maximal PISA radius occurs 
at the time of peak regurgitant flow and peak regurgitant velocity:
ERO = (2πr2 * Va)/Vpkreg,
where Vpkreg is the peak velocity of the regurgitant jet measured by continuous wave 
Doppler. The regurgitant volume (RVol) can be estimated as the product of ERO and 
the velocity time integral (VTI) of the regurgitant jet:
RVol = ERO * VTI.
The ERO derived by the PISA method is the maximal ERO and therefore might be 
slightly larger than ERO derived by other measures.
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Other quantitative flow techniques are pulsed wave Doppler measurements. 
A    combination of pulsed wave Doppler flow velocities with 2D measurements can 
 provide flow rates and stroke volumes. Stroke volume (SV) at the annulus can be 
 calculated by  multiplying cross sectional area (CSA) of the annulus and the velocity 
time integral of flow at the annulus. Assumption of a circular annulus is accepted and 
has provided accurate results:
SV = CSA * VTI = πr2 * VTI = 1/4 πd2 * VTI (d is the diameter of the annulus).
From this, ERO can be calculated by dividing regurgitant volume by VTI of the 
 regurgitant jet velocity:
ERO = RVol / VTIregjet.
The cut-off values for the assessment of MR severity using these methods are presented 
in both guidelines, and are based on the recommendations by Zoghbi.77 It should be 
noted that these values are valid for organic MR. Data from the Mayo Clinic based on 
patient outcome suggest that in functional MR, lower thresholds should be used for the 
diagnosis of severe MR: 20 mm2 for ERO and 30 mL for regurgitant volume.65 
For organic MR these values are 40 mm2 and 60 mL, respectively. These adapted criteria 
for functional MR are mentioned in the European guidelines, although without further 
recommendation, but not in the American guidelines. While in their previous 2007 
guidelines the ESC still made a distinction between “ischaemic MR” and “functional 
MR”, the newest 2012 ESC guidelines have combined these paragraphs into “secondary 
MR”. As stated, in this thesis the term functional MR is used for both aetiologies. The 
ESC further states that echocardiographic evaluation is similar in functional MR and in 
ischaemic MR, though colour flow mapping of the regurgitant jet overestimates the 
severity of MR in these aetiologies.
New developments in this area include real-time 3D echocardiography (RT3DE). In a 
head-to-head comparison in 64 patients with functional MR, RT3DE proved to be 
better able to quantify ERO and RVol than 2D TTE, compared to the gold standard of 
3D velocity encoded MRI.78 It was shown that 2D echocardiography underestimates the 
severity of functional MR.
Specific Considerations for the Assessment of Functional MR in the 
Perioperative Setting
The dynamic nature of functional MR also plays a role in the preoperative and intra-
operative setting. Bach et al demonstrated significant differences in MR severity when 
patients were studied with TEE preoperatively under conscious sedation and intraopera-
tively under general anaesthesia.79 In 21 patients with myxomatous disease (“flail”), MR 
severity assessed by regurgitant jet area and vena contracta remained the same under 
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anaesthesia, whereas in 19 patients with functional MR (12 ischaemic), jet area decreased 
by 43% and vena contracta width by 28%. These changes were not explained by 
 variations in heart rate or blood pressure, but Bach suggests that the drop in systemic 
vascular resistance under general anaesthesia may cause a decrease in MR severity in 
functional MR. Similar results were described by Grewal et al, who showed a decrease of 
at least 1  grade in functional MR severity in 62% of patients,80 and by Aklog and 
co-workers, who showed downgraded severity in 90% of patients with moderate 
 ischaemic MR.81 Therefore, severity assessment in functional MR should be performed 
prior to  anaesthesia, and the surgical strategy should be determined at that time.
For the surgeon it is also important to consider the influence of heart failure therapy and 
inotropic support on MR severity. Rosario et al demonstrated how vasodilator and 
 diuretic treatment resulted in reduction of the severity of functional MR.82 Therapy led 
to decreased MR by reduction in ERO without reduction in the transmitral gradient 
(the difference between systolic blood pressure and mean pulmonary capillary wedge 
 pressure). He related this decrease to changes in LV dimensions and annular distension. 
Inotropes can decrease LV volumes and potentially increase LV pressure and lower left 
atrial pressure and thus raise transmitral pressure, again resulting in decreased MR 
severity.20
The reduction of MR severity during general anaesthesia has led to intraoperative 
 simulation of more physiological hemodynamic conditions in patients with ischaemic 
MR and mild to moderate MR, or MR that is intermittent, to create a situation in 
which the true severity of MR can be assessed. These so-called loading tests were 
 introduced by Dion and colleagues.83 They include a preload test and, if necessary, an 
afterload test. The preload test is used to increase the pulmonary capillary wedge  pressure 
by 10-15 mmHg by rapid filling through the aortic cannula. An increase of MR severity 
is considered a positive test and justifies mitral valve repair. A negative test is followed 
by an afterload test, using a 5 mg IV bolus of phenylephrine (an alpha-agonist that raises 
systemic vascular resistance without inotropic effects) to increase afterload. If MR 
 severity does not increase, mitral valve repair is not performed. In the series presented 
by Dion, 58% of patients with intermittent or grade 2+ ischaemic MR showed a signifi-
cant increase in MR severity following a loading test. Variations of loading tests have 
been described by others.84-86
Geometry of the Mitral Valve Apparatus in Functional MR
With more advanced echocardiographic imaging, more detailed aspects of mitral valve 
leaflet geometry and the subvalvular apparatus have been described. They can be used in 
clinical decision making and provide some indication about the feasibility and success of 
repair, as will be discussed later. Since these different parameters are used throughout 
this thesis, their definitions are provided here (see also Figure 4). Usually, they are 
assessed by TTE in the parasternal long-axis view or apical 2– or 4–chamber views, or in 
an appropriate view on transoesophageal echocardiography (TEE) at the A2-P2 level in 
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mid-systole, the central point of coaptation. For a more detailed description of these 
parameters and their assessment, the reader is referred to the original 
publications.18,32,36,87-89
•	 Coaptation length: the length of leaflet apposition;
•	 Coaptation depth (coaptation distance, tenting height, tenting length): the shortest 
 distance between the point of coaptation on the atrial side and the annular plane;
•	 Tenting area: the area enclosed by the mitral leaflets and the annular plane;
•	 Tenting volume: similar to tenting area, but in a 3D setting;
•	 Leaflet-tethering length: distance between the papillary muscle tip and the  contralateral 
anterior mitral annulus (for both papillary muscles);
•	 Posterior mitral leaflet angle: angle between the annular plane and the posterior 
 leaflet, an indicator for posterior leaflet tethering;
•	 Basal anterior mitral leaflet angle: angle between the annular plane and the basal 
portion of the anterior leaflet, a basic indicator for anterior leaflet tethering;
•	 Distal anterior mitral leaflet angle: angle between the annular plane and the anterior 
leaflet tip distance (distance between the median part of the mitral annulus and the 
coaptation point). When additional restriction of the anterior leaflet results in a 
concave leaflet on echocardiography, determining the distal anterior leaflet angle 
may more accurately reflect the degree of anterior leaflet tethering.
Posterior leaet length
Anterior leaet tip distance
Coaptation distanceBending distance
Posterior mitral leaet angle
Distal mitral anterior leaet angle
Basal mitral anterior leaet angle
Anterior leaet bending 
distance
Figure 4.
Echocardiographic image 
of the mitral valve in 
apical 4-chamber view 
in mid-systole, indicating 
several commonly used 
parameters of mitral leaf-
let geometry.
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Echocardiographic differences between ischaemic MR and functional MR in non-
ischaemic cardiomyopathy were suggested by Kwan and co-workers.90 They describe a 
symmetrical regurgitation pattern in non-ischaemic patients, while in post-MI patients 
regurgitation often showed two separate jets, with symmetrical tethering on the medial 
side of the mitral valve and only posterior leaflet tethering on the lateral side. However, 
in the ischaemic group the authors only included patients with “unilateral papillary 
muscle displacement”, as opposed to bilateral displacement in the idiopathic group. 
The groups showed statistically significant differences in all LV dimensional parameters, 
as well as in EF. In our opinion, rather than representing a true difference in MR pattern 
caused by the underlying disease, these findings reflect differences in disease stage.
Exercise Testing in the Diagnosis of Functional MR
The role of echocardiographic exercise testing has been extensively evaluated by the 
group from Liège. The feasibility of this method in heart failure was described by 
Lebrun et al.91 In this study, the flow convergence (PISA) technique appeared feasible in 
most patients, and appears the most reproducible and practical method. Although tech-
nically more demanding, the Doppler technique can also be applied. The vena contracta 
method can only be reliably used in patients with large increases in functional MR 
severity during exercise; jet area assessment is unreliable and should not be used. 
Observed changes in pulmonary artery pressure during exercise correlated well with 
increase in regurgitant volume. In another study, exercise induced ERO changes in 
 ischaemic MR could be related to local LV remodelling rather than global LV remodel-
ling, more specifically to papillary muscle displacement, tethering and increased 
 coaptation height.92 In patients with an inferior infarction, reduction in ERO was seen 
following improvement in wall motion.
A study by Lancellotti and co-workers in 89 patients with LV dysfunction (EF <45%) 
and mild ischaemic MR at rest showed that exercise echocardiography could identify 
patients with a higher risk of cardiac death.93 Mortality at 19 months follow-up was 
higher in patients with a resting ERO >20 mm2, but also in patients with an ERO that 
increased during exercise by 13 mm2 or more (value determined using receiver operating 
characteristic analysis). No mortality occurred in patients with decreasing MR severity 
during exercise. This important study underlines the fact that ischaemic MR is a 
dynamic phenomenon, that even mild MR may be detrimental and that in patients 
with mild ischaemic MR additional examinations should be performed to unmask a 
potentially lethal dynamic MR. These results could not be confirmed by others, 
however.94
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The Value of Cardiac Magnetic Resonance Imaging in Functional MR
Cardiac MRI is increasingly used in the evaluation of patients with ischaemic 
 cardiomyopathy. MRI has the advantage of high spatial resolution and it can combine 
in a single examination functional and geometrical assessment of the left ventricle, 
which guides decision-making. Relative disadvantages are its limited availability and the 
fact that patients with pacemakers or defibrillator/resynchronization therapy devices 
(which constitute a large proportion of the heart failure population) cannot be  examined. 
MRI is currently considered the reference standard for the assessment of ventricular 
volume and function and for the visualisation of scar.95
Specific use of cardiac MRI in patients with ischaemic cardiomyopathy is found in the 
assessment of contractile reserve in ischaemia. Late gadolinium enhancement can 
 visualize irreversible myocardial damage (scar, fibrosis) with a very high spatial  resolution. 
Scar transmurality can predict the likelihood of functional recovery following 
 revascularization, which is high in the absence of scar (78%) and low if scar is more than 
75% transmural (2%).96 In the intermediate zone predictive value is limited, with a 
 likeli hood of recovery of approximately 40%. In such patients additional low-dose 
dobutamine stress is advised which can be performed during the same examination— 
42% of segments with an intermediate scar show contractile reserve during stimulation.97 
Predicting functional recovery after revascularization is important because of its 
 influence on global improvement of LV function, which is related to increased  survival.98 
Some studies have examined the effects of localized scar or dysfunction in the area of the 
posterior papillary muscle in ischaemic MR. Flynn et al showed how minimal scarring 
already produces wall motion abnormalities, but that the overall scar burden correlates 
poorly with the severity of wall motion abnormalities.99 Severity of scarring in the 
 posterior papillary muscle region correlated with recurrent MR 6 months after  restrictive 
annuloplasty, although observations were made in patients with mostly flexible annulo-
plasty rings. Takeda et al demonstrated in a small study how the extent of local (basal) 
fibrosis predicted less improvement of EF and restrictive diastolic filling following 
restrictive mitral annuloplasty.100 There are no studies that specifically look at the effect 
of revascularization alone in the setting of ischaemic MR in relation to regional wall 
motion abnormalities. 
The use of MRI in functional MR in non-ischaemic cardiomyopathy is less well defined. 
Because of the excellent results in volume assessment, which is much less observer 
dependent than in echocardiography, MRI can be used as a perfect follow-up tool to 
observe volumetric and geometric changes in non-ischaemic cardiomyopathy, bearing 
in mind the restrictions that follow from the fact that many patients will have device 
implantations during the course of their disease. In this thesis, MRI is used as such in 
patients with early stages of heart failure in chapter 6.
MRI has also proven its value in the assessment of (mitral) valve regurgitation, using 3D 
velocity encoded techniques.101 An additional advantage is that MRI can reliably  measure 
regurgitant flow and as such can also provide a true estimate of ejection  fraction, since 
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it can discriminate between true forward flow through the aortic valve and regurgitant 
flow through the mitral valve. Finally, MRI has demonstrated its usefulness in guiding 
cardiac resynchronization therapy. In a comparison with tissue Doppler imaging, MRI 
was found to have the same accuracy in establishing LV dyssynchrony and LV filling 
pressures.102
7. Results of Surgery for Ischaemic Mitral Regurgitation
The optimal treatment for ischaemic MR is a subject of ongoing debate in the surgical 
and cardiology communities. Published reports convey ambiguous messages and are 
essentially difficult to compare because of different patient populations, different 
 definitions of ischaemic MR, different surgical techniques and different follow-up. This 
 controversy is reflected in the guidelines as well. For ischaemic MR, all recommenda-
tions have a ‘C’ level of evidence in the European guidelines since there are no 
 randomized trials.76 The strongest recommendation (class I) concerns patients with 
severe MR and EF >30%, scheduled for CABG, in whom mitral valve surgery is 
 indicated. In patients with moderate MR, scheduled for CABG, surgery should be 
 considered (class IIA recommendation). This is also advised for symptomatic patients 
with severe MR, EF <30%, an option for revascularization and evidence of viability. 
Patients with severe MR, EF >30%, who remain symptomatic despite optimal medical 
management—including CRT—and who have low comorbidity and no indication for 
revascularization have a class IIb recommendation, i.e., surgery may be considered.
The American guidelines state that the indication for mitral valve surgery in CABG 
patients with mild to moderate MR is still unclear, but that there are data to indicate 
benefit from mitral valve repair in such patients.75 They also mention that CABG alone 
is usually insufficient and leaves many patients with significant residual MR; such 
patients “would benefit from concomitant mitral valve repair at the time of the CABG”. 
It is also stated that mitral annuloplasty alone with a downsized annuloplasty ring is 
often effective at relieving MR. 
Since the underlying cause of ischaemic MR is coronary artery disease, there has been 
much debate as to the question whether CABG alone would be sufficient to treat 
 ischaemic mitral insufficiency, especially in patients with less than severe MR. 
The    rationale behind this approach is to improve wall motion abnormalities and 
 consequently reduce papillary muscle displacement and tethering. Leaving the mitral 
valve untouched would also avoid exposing the patient to the increased perioperative 
morbidity and mortality risk associated with a valvular procedure. In addition, 
 proponents of revascularization alone claim that mitral valve surgery does not influence 
long-term outcome and survival. Another point of discussion is what to do with the 
mitral valve once the decision to address the valve has been made. Replacement or repair, 
and in case of repair, what annuloplasty technique should be chosen to prevent 
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recurrent MR as much as possible? There is a substantial amount of literature on this 
subject, which will be discussed in this paragraph.
Results of Revascularization Only
Duarte et al reported on late results of 58 patients who had moderate (grade 3+) MR of 
different aetiologies and CAD.103 In this group, at least 26% of patients did not have true 
ischaemic MR and procedures also included reoperations and aneurysmectomies. 
All patients underwent CABG between 1977 and 1983 (hospital mortality 3.4%) and had 
a mean EF of 53%. Follow-up was 10.3 years, and 5- and 10-year survival were 81% and 
52%. Predictors of late mortality were age, presence of advanced heart failure and 
 elevated pulmonary capillary wedge pressure. Although often cited in the literature as 
such, this patient population cannot be considered representative of true ischaemic MR 
based on the mixed aetiology of mitral insufficiency and the high ejection fraction.
In Table 2 (p. 78) , studies reporting on the outcomes of revascularization only in chronic 
 ischaemic MR are summarised.
In a retrospective study Aklog et al evaluated 269 patients with an indication for CABG 
and moderate (grade 3+) ischaemic MR between 1992 and 1999.81 One hundred thirty -
six patients underwent CABG only (3.2 distal anastomoses on average). The decision 
not to operate on the mitral valve was at the discretion of the surgeon. NYHA class was 
III or IV in 63% of patients, mean EF was 38%. In 38 patients who underwent an intra-
operative TEE before surgery, downgrading of MR severity was seen in 90% of patients. 
Postoperative mortality was 2.9%. On postoperative TTE 6 weeks after surgery,  available 
in 68 patients, there was a significant reduction in mean MR severity (from 3.0 to 2.3), 
but more interestingly only 8% of patients had trace or less MR, 40% had at least 
 moderate MR and 52% of patients was left with mild MR. This study indicates that 
revascularization alone in patients with moderate ischaemic MR does not reliably reduce 
MR severity.
A study from the Cleveland Clinic focused on patients who underwent a percutaneous 
coronary intervention (PCI) between 1994 and 1997 not in the setting of acute  myocardial 
infarction.104 The researchers examined survival in relation to severity of MR, and found 
that in patients with moderate or severe MR (1.3% of the total study population)  survival 
was significantly lower, especially when LVEF was below 40%. Three-year  survival in 
this latter patient group was 47% for patients with moderate-to-severe MR, compared 
to 76% for patients without MR. Of interest, in the moderate-to-severe MR group, 51% 
of the patients had previously undergone CABG.
The title of the paper presented by Tolis and co-workers in 2002 suggests that 
 revascularization alone suffices in patients with advanced ischaemic cardiomyopathy 
and mild-to-moderate MR.105 A closer look at their data questions the robustness of this 
conclusion. The group did a retrospective study on patients with ischaemic cardiomyo-
pathy (EF <30%) and ischaemic MR who underwent CABG between 1986 and 1996. 
From these 183 patients, data on MR severity by TTE were available in 75 patients (41%). 
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There was no MR in 26 patients, trace MR (1+) in 18 (37%), mild MR (2+) in 26 (53%) 
and moderate MR (3+) in 5 (10%). The 49 patients with any degree of MR were studied 
after CABG (mean number of distal anastomoses 2.8, range 1-5; hospital mortality 2%), 
with regard to survival (at 64 months), NYHA status (at 37 months), EF by MUGA 
scan (at 28 months), and MR severity by TTE (at 14 months). Mean NYHA class (data 
available in 26/49 patients) improved from 3.3 to 1.8. EF improved significantly from 
22 to 32%, to a similar extent as patients without MR. Mean MR grade dropped from 
1.7 to 0.5. For the 5 patients with moderate MR, postoperative MR severity was mild in 1, 
trace in 2 and none in 2 patients. No data are provided for the patients with mild MR 
preoperatively. Survival in the MR group at 1, 3 and 5 years was 88%, 65% and 50%; for 
patients with trace MR, survival percentages were 73%, 50% and 40%, for patients with 
mild MR they were 91%, 78% and 57%. While survival data are similar between the 
different strata of MR severity, and mean MR severity for the whole group dropped, 
it would have been interesting had the authors provided the specific MR outcomes per 
patient category. More importantly, patients with trace MR who would probably not be 
treated with mitral valve surgery in any centre constituted 37% of the study population, 
and for patients with mild MR (53%) surgeons involved in ischaemic MR surgery would 
at least do some provocation tests to evaluate the response of the MR to different  loading 
conditions. So, the studied population does not qualify to represent “mild-to-moderate” 
ischaemic MR patients, and the conclusions therefore cannot be extrapolated to that 
patient group.
A study from Duke university analyzed 2,757 patients with ischaemic MR ≥ grade 2+ on 
ventriculography and compared survival in different groups: medically treated (1,305), 
PCI (537), CABG (687) or CABG + mitral valve surgery (228) between 1986 and 2001.106 
Median follow-up was 3.2 years. PCI and surgery were associated with a better survival 
compared to medical therapy, with a risk reduction of 31% and 42%, respectively. 
 Five-year survival in the medical group was 41%, and in the PCI/surgery group 64 to 
69%. There was no additional survival benefit from mitral valve surgery, although at 
baseline the mitral valve surgery group had more moderate or severe MR patients than 
the CABG only group (81% versus 24%), and also more patients with heart failure in 
NYHA class III or IV (39% versus 16%).
Mallidi also did a retrospective analysis of patients who underwent isolated CABG 
between 1994 and 2002 with mild or moderate MR on ventriculography.107 These 
163 patients (2.5% of the total isolated CABG population) were matched 1:2 to patients 
who underwent CABG only but did not have MR. Baseline differences for the MR 
group were older age, more female patients, lower EF, higher NYHA class and more 
often three vessel disease. After 3.4 years of follow-up, it was found that overall survival 
did not differ between the groups (81-85% at 6 years). Event-free survival was signifi-
cantly lower in the MR group (37% versus 65% at 6 years), with curves starting to 
diverge after 3 to 4 years. Most events were hospitalisations for congestive heart failure. 
Of patients who had echocardiographic follow-up (30%) at 16 months, 31% showed 
progression to moderate or severe MR; of these latter patients, 47% was hospitalised for 
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heart failure which might introduce selection bias and thus affect the interpretation of 
echocardiographic outcomes in this series.
A study from the Cleveland Clinic retrospectively examined 467 patients with moderate 
(defined as grade 2+) ischaemic MR who underwent isolated CABG between 1980 and 
2000.108 They were propensity matched with CABG patients without MR. Hospital 
mortality in the IMR group was 3.3% while it was absent in the no-IMR group. Mean 
follow up was 3.6 years. A postoperative TTE was made in 156 patients (33%), at the 
discretion of the cardiologist, at a median postoperative interval of 2 months. MR proved 
to be dynamic until 6 weeks after surgery, and then stabilised. The percentage of patients 
without MR or MR grade 1+ decreased during these 6 weeks from 73% to 40%, while 
the percentage of patients with grade 2+ or more increased from 27% to 60%; within 
this group, 22% of patients had grade 3+ or 4+ MR after 6 weeks. Interestingly, in this 
study the presence of postoperative MR could not be related to the degree of LV 
 dysfunction or CAD. Long-term survival was different between groups, percentages for 
IMR and no-IMR patients at 6 months, 1 year and 5 years were 91% versus 99%, 89% 
versus 98%, and 73% versus 85%, although the study was not designed to compare long-
term mortality differences. An important limitation of this study is the non-systematic 
echocardiographic follow-up, which might introduce selection bias.
In another retrospective study 251 patients were examined with moderate (grade 3+) 
ischaemic MR, some treated with CABG only (n=219) and some with an additional 
annuloplasty (n=32; 13%).109 The decision to perform mitral valve surgery was at the 
discretion of the surgeon, often when downgrading on intraoperative TEE was observed, 
and in general rings were not undersized. Operative mortality was 5.2%, with a trend 
towards higher mortality in the annuloplasty group (4% versus 13%, P=0.06). Follow-up 
TTE was performed on clinical indication. With a median follow-up of 4.3 years, 
 estimated survival at 1, 5 and 10 years was 84%, 68% and 37%; this survival was similar 
when comparing CABG only and CABG plus annuloplasty groups. In the CABG only 
group, 48% of the patients showed at least moderate MR on TTE, although there was 
also a substantial amount of persistent MR in the annuloplasty group (mean MR grade 
1.6 on intraoperative TEE).
Grossi et al presented a retrospective analysis of all patients who underwent isolated 
CABG between 1996 and 2004 and had less than moderate ischaemic MR on intra-
operative TEE.110 Of these 2,242 patients, 38% had no MR, 51% had mild MR and 12% 
had moderate MR. Overall hospital mortality was 1.9%. Five-year survival was 86% in 
no-MR patients, 84% in mild-MR patients and 70% for patients with moderate MR. 
No follow-up echocardiographic data are provided. By multivariate analysis, both mild 
MR and moderate MR were found to be independently associated with mortality.
The group of Calafiore presented their data on cardiomyopathy patients (EF <30%) with 
moderate (defined as grade 2+) ischaemic MR in 2006.111 Ischaemic cardiomyopathy was 
detected in 239 patients who underwent isolated CABG between 1988 and 2002 (3.9% 
of the total CABG population). Patients with moderate (grade 2+) MR were selected 
(n=70) and propensity matched with ischaemic cardiomyopathy patients with no or 
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mild MR to overcome differences in LV volumes. The only baseline difference apart 
from MR severity between these groups was higher NYHA class in the moderate MR 
group. Mean EF was 27%, mean LV end-diastolic volume was 118 mL. Complete 
 revascularization was achieved in all patients (2.6 distal anastomoses). Thirty-day 
 mortality in the no-or-mild MR group was 4.3% compared to 8.6% in the moderate MR 
group (no difference). At 8 years, survival was lower in the moderate MR group (73% 
versus 47%; P=0.019). Moderate MR was found to be an independent risk factor for 
mortality and for worse functional outcome (NYHA class). A TTE was performed after 
a mean of 5 years in 88% of survivors; this showed in the no-or-mild MR group evidence 
of LV reverse remodelling (decrease of LV volumes and increase of EF) and stable MR 
severity (mean grade 0.7), whereas in the moderate MR group LV volumes and EF 
remained stable and MR had increased from 2.0 to 2.7. Mean NYHA class had  worsened 
in the moderate MR group after CABG only.
The same group reviewed the results of patients with EF >30%.112 They found that mild 
or moderate ischaemic MR was an independent risk factor for worse outcome (cardiac 
death or cardiac events) in patients undergoing first isolated CABG with an EF between 
31% and 40%, but not in patients with higher EF.
Penicka and colleagues examined predictors of improvement of MR severity in patients 
with moderate ischaemic MR (vena contracta between 0.3 and 0.7 mm, and jet area to 
left atrial area ratio between 20 and 40%) who underwent CABG only in 2002 
and 2003.113 The authors identified 135 patients with EF ≤45% who underwent TTE 
follow-up 12 months after surgery. Patients were examined preoperatively with tissue 
Doppler echocardiography to assess dyssynchrony between the papillary muscles, and 
single-photon emission computed tomography (SPECT) to assess viability using a 
16 segment model; nonviability was assumed in the presence of concordant reduction of 
perfusion and metabolism. With CABG, 83% of patients received complete revasculari-
zation (no data provided on the number of grafts and on the distribution between the 
patient categories). Early mortality was 4.4%. TTE at 12 months distinguished patients 
with “improved” MR severity (reduced to no or mild MR; n=57, 47%) and “worsened” 
MR severity (stable moderate or increased to severe MR; n=64, 53%. In the “worsened” 
MR group 30 patients were left with moderate MR while 34 showed progression). 
Postoperative analysis of baseline data revealed that patients with reduced MR severity 
had more viable myocardial segments (6.4 vs. 3.8) and less dyssynchrony between the 
papillary muscles (44 ms vs. 156 ms). Aspects of LV and mitral valve geometry were 
 similar preoperatively. At follow-up, reverse remodelling and improvement in mitral 
valve geometry had occurred in the improved MR severity group, whereas it was absent 
in the worsened group. Predictors of worsening MR severity at 12 months were 
 preoperative presence of dyssynchrony >60 ms (positive predictive value 89%, negative 
 predictive value 85%), and presence of less than 5 dysfunctional viable segments. At a 
median follow-up of 2.7 years, late mortality and readmission for heart failure were 
significantly higher in the group that had no reduction of MR severity. This study 
 provides some preoperative parameters that for a part of the patient population seem to 
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predict regression of moderate MR by CABG alone. There are some interesting points 
to make regarding this study. The authors do not mention whether LV aneurysms were 
present in this series, which is not unlikely when less than 5 segments are viable. 
Furthermore, the group showing the highest predictability of MR decrease (present in 
97% of patients) was the group without dyssynchrony and with sufficient viability; these 
patients represent 34% of the study population. The group with worst probability of 
improvement (82% stable or increased MR severity) represented 42%, while the 
 “intermediate” group (66% stable or worsening) represented 21%. This means that in 63% 
of patients, despite more or less sophisticated predictors, the final result at 12 months is 
still rather unpredictable with 76% of patients showing no improvement.
A retrospective study by Fattouch et al evaluated 180 patients with CAD and moderate 
ischaemic MR (defined as ERO 10-19 mm2 at rest) who underwent isolated CABG 
between 2003 and 2008, and were matched 1:2 with 360 patients without MR who also 
underwent CABG.114 Mean EF was 43%, one-third of patients had an EF of 40% or less. 
Hospital mortality was similar (2%). Survival in the MR group at 5 years, regardless of 
EF, was significantly lower (91% versus 74%), as was freedom from cardiac death and 
from cardiac related events; the presence of ischaemic MR was an independent risk 
factor for long-term mortality. TTE follow-up was performed after a mean interval of 
30 months, and showed a significant decrease in LV diameters in patients without MR, 
but an increase in patients with residual MR, irrespective of baseline EF. In 130 survivors 
who had moderate MR preoperatively, MR had decreased to mild in 30%, remained 
stable in 35% and had increased to severe in 35%. The patients with mild and moderate 
residual MR underwent exercise echocardiography: 43% of patients with mild MR 
showed an increase to moderate MR (29%) or severe MR (14%). In patients with 
 moderate MR, 76% had an increase to severe MR, often with development of cardiac 
symptoms.
Recently, Kang et al presented the outcome of a registry study performed between 1996 
and 2008 including 185 patients with significant ischaemic MR (ERO ≥20 mm2) who 
underwent either PCI or surgical revascularization at the discretion of the treating phy-
sician.115 In the surgical group, mitral valve surgery with a complete undersized rigid or 
semirigid ring could be added to the revascularization as decided by the surgeon. 
Revascularization was only performed in patients with symptoms and signs of  myocardial 
ischaemia or viability. The PCI group consisted of 66 patients and the surgery group 
included 119 patients. Primary endpoint was a composite of in-hospital death, cardiac 
death or hospitalisation for heart failure; secondary endpoint was death from any cause. 
There were some baseline differences: the surgery group had a higher NYHA class (2.6 
vs. 2.3), lower EF (35% vs. 40%), higher ERO (29 mm2 vs. 26 mm2), higher end-systolic 
volume index (58 mL/m2 vs. 50 mL/m2) and more often three-vessel disease (88% 
vs.  44%). Hospital mortality was similar (1.7% for surgery vs. 3% for PCI). Median 
follow -up was similar (4.5 years), as was actuarial survival at 5 and 7 years (for surgery 
74% and 60%, for PCI 66% and 55%). Event-free survival was significantly better in the 
surgery group at 5 and 7 years (surgery 75% and 58%, PCI 55% and 50%); results were 
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independent of MR severity. PCI was independently associated with the occurrence of 
cardiac events. Routine clinical follow-up and TTE were performed after 6 months 
in  98% of survivors. The surgery group had more functional improvement, better 
improvement of MR—defined as reduction to ERO <20 mm2—which occurred in 54% 
of PCI patients and 79% of surgery patients) and more improvement of EF.
In the surgery group, 51 patients underwent CABG only and 68 had additional  restrictive 
mitral annuloplasty; baseline variables were similar in both groups. The mitral valve 
surgery group had significantly higher event-free survival and better improvement of 
MR (in 95% of patients versus 57% at 6 months), while EF increase was similar. Late 
TTE (after more than 4 years median) showed recurrent MR in 2 CABG patients and 
in 1 mitral valve surgery patient; there was a significant increase in LV end-diastolic 
volume in the CABG group from 6 months to late follow-up (from 133 mL to 145 mL). 
The authors used propensity scoring to find 45 matched pairs with similar baseline 
 characteristics. For these matched pairs, surgery also showed a lower cardiac event risk 
and higher event-free survival.
Although these studies differ in many aspects, it can be stated that ischaemic MR in 
patients undergoing revascularization only has a negative influence on survival and 
functional outcome when compared to results from patients with isolated revasculariza-
tion for CAD. The effect is graded and can be already observed when only mild MR is 
present. Furthermore, ischaemic MR treated by revascularization only does not improve 
in two-thirds of patients and leads to ongoing LV remodelling. There are as yet no 
 predictors that reliably identify patients who will improve with revascularization only. 
And finally, several studies demonstrate how residual mild MR at rest after revasculari-
zation may increase during exercise.
Results of Mitral Valve Repair with Revascularization
The literature overview presented in Table 3 (p. 82) reflects and explains the  continuing 
 controversy regarding the true benefit of mitral valve repair in addition to coronary 
revascularization in ischaemic MR. In general, these studies are also difficult to compare 
because of different baseline characteristics. More importantly, the technique of mitral 
valve repair differs, especially with respect to the annuloplasty device used. Other 
important  differences relate to the grafting strategy—completeness of  revascularization 
and the use of arterial conduits—and to the completeness and time interval of echo-
cardiographic follow-up.
 
A paper from Cleveland by McGee et al is very often quoted, especially in relationship 
to recurrent MR after mitral valve repair.116 In this manuscript, 585 patients with mitral 
valve repair for at least moderate (grade 2+) ischaemic MR between 1985 and 2002 were 
studied. CABG was performed in 95% of patients. No further data regarding grafting 
strategy are provided (while not using an ITA graft was found to be a risk factor for early 
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return of MR in this study). Mitral annuloplasty was performed with a Carpentier 
Edwards Classic ring in 21% of patients, a Cosgrove-Edwards annuloplasty system 
(incomplete flexible band) in 68% and bovine pericardium (Peri-Guard) in 11%. 
The Classic ring was more often used in the early era, and downsizing was not performed 
(median ring size 30). Since 1997 the Cosgrove band was mainly used with a median 
size 28. Median follow-up was 2.3 years. Hospital mortality was 6% and 1- and 5-year 
survival were 82% and 60%. Survival was not related to annuloplasty type. TTE was 
available in 75% of patients. Median follow-up time was just 8 days, 75% of echocardio-
grams were made within 2 months after surgery and only 17% were made after one year. 
At 6 months, 28% of patients had grade 3+ or 4+ MR; in the pericardium group this 
was 66%, while for the Classic and Cosgrove groups it was 25%. Eleven patients under-
went reoperation (mitral valve replacement), leading to a five-year freedom from 
 reoperation of 97%. The main limitations of this study are obviously its non-uniform 
mitral valve repair techniques and the very limited echocardiographic follow-up. 
Only one-fifth of patients received a complete nonflexible ring which was mainly used 
in the early era (before 1997) and a structured approach to downsizing was not adopted. 
There are no echocardiography data presented concerning the immediate intraoperative 
results, making a distinction between residual MR and recurrent MR impossible, and 
mean echocardiographic follow-up is limited to 8 days only, while diagrams representing 
the temporal pattern of MR recurrence extend to 5 years. This article is often quoted to 
demonstrate that mitral valve repair does not reliably abolish ischaemic or functional 
MR, but the high recurrence grade after 6 months in our opinion should not be related 
to progression of the underlying disease per se, but to an inappropriate surgical approach 
at the initial operation.
A study from Hamburg focuses on chronic ischaemic MR of at least grade 3+ in patients 
with EF ≤45%.117 Thirty-eight patients (mean age 71 years) underwent CABG (2.3 distal 
anastomoses) and undersized mitral annuloplasty between 2001 and 2004. Downsizing 
was performed in a “dynamic” fashion, depending on EF; for EF <20%, the authors 
used a ring that was 4 ring sizes smaller, for EF 20-30% 3 sizes and for EF >30% 2 sizes. 
A flexible Duran ring (size 25 or 27) was used in 8 patients between 2001 and 2002, and 
a Physio ring (size 24-30) in 30 patients between 2003 and 2004. Repair was considered 
successful when MR was ≤1, coaptation length was ≥5 mm and mitral valve area >2 cm2. 
Early mortality was 2.6% and patients were re-examined after 3 and 13 months. One-year 
survival was 85%, and 93% of patients were in NYHA class I or II. Mean MR grade was 
similar after 3 and 13 months (0.6), 84% of patients had no or mild MR and 
17%  grade  2+  MR. LV diameters and volumes decreased significantly compared to 
 baseline and remained stable at 13 months (no additional reduction observed between 
3 and 13 months). Left atrial size also decreased, while EF increased. Baseline  end-diastolic 
diameter was 60 mm (57 mm at 13 months) and volume was 188 mL (171 mL at 13 months).
A study from Duke University presented in 2005 by Glower reports on 553 patients who 
underwent mitral valve repair between 1993 and 2002.118 In this group, 141 patients 
underwent CABG with mitral repair which consisted of complete rigid rings in 95% of 
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patients. Downsizing was performed by at least one ring size—later during the study 
period it was always two sizes), resulting in a median ring size of 26. Revascularization 
of all vessels ≥1.5 mm with at least 50% stenosis was performed. Comparison of baseline 
parameters showed that patients with ischaemic MR were older, had more  comorbidities, 
higher NYHA class and lower EF (40% vs. 50%) than patients with organic disease. 
The  group also included more reoperations. Thirty-day mortality was higher for 
 ischaemic MR (4.3% vs. 1.3%), as was total operative mortality (6.4% vs. 1.3%). Locally 
available late TTE follow-up (“late” is not defined in the manuscript) was present for 
58% of patents with ischaemic MR (with a median follow-up of 1.4 years) and for 60% 
of patients with organic disease (1.8 years follow-up). Recurrence rates for moderate or 
severe MR were similar: 11% for ischaemic MR (15/141 patients) and 8% for organic MR 
(30/394). However, these percentages are derived by having all patients in the  denominator 
which includes patients who died early and patients with a very limited echocardio-
graphic follow-up, and as such should be interpreted with caution. Nevertheless, it is 
interesting to note that the recurrence rates were similar for both aetiologies, as were the 
rates for reoperation (2.1% vs. 3.0%). Actuarial 5-year survival was lower for ischaemic 
patients: 56% vs. 84% (P<0.001); however, when adjusted for all preoperative variables 
that were different, survival was similar between both groups, suggesting that the 
 different outcomes were explained by the preoperative condition of ischaemic MR 
patients.
Another paper from the Cleveland Clinic presents a retrospective analysis of patients 
with severe (defined as grade 3+ or 4+) ischaemic MR who underwent CABG alone 
(n=100) or CABG with mitral annuloplasty (n=290) between 1991 and 2003.119 
Postoperative TTE was available in 63% of patients (n=247, with 518 assessments of MR 
severity). Median TTE follow-up time was 5.3 months in the CABG only group and 
1.1 months in the combined surgery group. Reasons not to perform mitral valve surgery 
was intraoperative downgrading of MR severity (58% of patients), MR not considered 
clinically significant by the surgeon (11%), MR that improved after CABG (8%), 
 hemodynamic instability (5%), or for undocumented reasons (18%). Propensity scoring 
was used to identify 54 matched pairs, in which only bypass time and myocardial 
 ischaemia times were different between both groups. For revascularization the left 
 internal mammary artery was used in 60% of patients. Mitral annuloplasty size was 
chosen “smaller than the anterior leaflet surface area” and as such considered to be 
undersized. No details on ring sizes are provided. A flexible (Cosgrove) partial band was 
used in 71%, a complete rigid ring (Classic) in 22% and pericardium in 7% of patients. 
Hospital mortality was 7.4% for CABG only and 3.7% for combined surgery (P=0.7). 
Median follow-up was 5 years for the CABG group and 4 years for the combined group. 
Survival was similar for both groups; for the matched cohort, survival at 1, 5 and 10 years 
was 88%, 75% and 47% after CABG only and 92%, 75% and 39% for CABG with mitral 
annuloplasty (P=0.6). Complete absence of postoperative MR dropped in the CABG 
only group from 51% to 8% (without specified data) “within the first few weeks of 
 surgery”. In the mitral annuloplasty group this percentage dropped from 86% 
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 immediately postoperatively to 43% after 6 months. The percentage of patients with 
grade 3+ or 4+ MR (who were grouped in this study because of the low incidence) in the 
mitral valve surgery group increased from 1% to 9%. The difference between the groups 
is more striking when looking at the original graphs: it can be seen that in the CABG 
only group, after 1 week 35% of patients and after 7 weeks 45% of patients have grade 
3+/4+ residual MR (at rest). Thereafter, the percentage remains stable while there is a 
steady increase in the mitral annuloplasty group. In this non-randomized study, no 
survival benefit from adding a mitral annuloplasty to CABG in patients with grade 
3+/4+ ischaemic MR could be demonstrated at 10 years. Symptoms improved both after 
CABG only and following CABG with mitral surgery. There are several remarks to be 
made about this study. Patients were attributed to a group based on treatment provided. 
As such, an unknown percentage of patients will have been scheduled for CABG alone 
but intraoperatively this plan may have been changed by the surgeon for good reasons, 
for instance when MR severity remained significant after CABG. It is also unknown 
how many patients were operated on in an emergency setting in both groups. In the 
CABG group, 28% of patients were in NYHA class IV preoperatively compared to 15% 
in the mitral valve surgery group; patients with acute ischaemia are different from those 
with true chronic ischaemic MR. The early mortality in the CABG only group is 
 strikingly high and twice that of the combined surgery group which had longer  ischaemic 
times. The majority of echocardiographic examinations were clinically driven and cover 
only 65% of patients with again short median follow-up. No data are provided about the 
distribution of echocardiographies across both groups. Furthermore, as in earlier 
Cleveland papers, only 22% of patients received a complete rigid ring and no data about 
the exact downsizing strategy is provided.
Gelsomino et al presented several follow-up studies on combined CABG and undersized 
mitral annuloplasty in chronic ischaemic MR. A manuscript published in 2007 focuses 
on echocardiographic outcomes at 5 years.120 Patients with mild-to-severe ischaemic MR 
underwent CABG and undersized mitral annuloplasty (by 2 ring sizes) between 2001 
and 2007, and were prospectively followed for a median time of 33 months. There were 
251 patients with a mean age of 68 years and mean NYHA class 3.2. Revascularization 
was 100% complete, defined as per territory, but the number of distal anastomoses was 
2.2 per patient (including 1.1 arterial grafts). A Classic ring was used in 53% of patients, 
a Physio ring in 47%. Mean ring size was 27.4, 41% of patients had size 26 or less and 
45% had size 28. A successful repair was defined as residual MR ≤ grade 1+, coaptation 
length of 5 mm or more and a systolic mitral valve area >2 cm2. Excluded from follow-up 
were 3 patients who underwent mitral valve replacement at the initial procedure because 
of unsatisfactory result of repair, and 11 patients (4.4%) with MR ≥ grade 2+ at discharge. 
Early mortality was 0.8%, 5-year survival was 83%; 220 survivors were analysed. 
TTE   follow-up was complete at 1 year for 85% of patients, at 3 years for 55% and at 
5 years for 28%. Quantitative techniques were used to assess MR severity. For the whole 
group, mean MR severity was stable at 1 year (0.3), but increased at 3- and 5-year 
 follow-up to 1.2 and 2.1, respectively. After 5 years, TTE in 61 patients showed grade 2+ 
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recurrent MR in 28%, grade 3+ in 31% and grade 4+ in 13% of patients. Seventeen patients 
underwent reoperation, corresponding to a 78% freedom from  reoperation at 5 years. 
LV  diameters decreased and remained stable at long-term  follow-up. However, 
LV  volumes and sphericity index dropped initially, but increased again at 3 and 5 years. 
Preoperative predictors for recurrent MR with their cut-off values in this cohort were 
systolic sphericity index (≥0.7), myocardial performance index (≥0.9), end-systolic 
volume (≥145 mL) and wall motion score index (≥1.5).
In another manuscript Gelsomino focused on LV reverse remodelling, defined as more 
than 15%  reduction of indexed LV end-systolic volume at late follow-up (median, 
35 months).121 The study comprised 204 patients, excluding 12 patients with residual MR 
at discharge, amongst others. Eighty-four patients (41%) were responders and 120 were 
not. Non-responders showed comparable changes in LV volume, i.e., an initial decrease 
of end-systolic volume at discharge and at 6 months and an increase at late follow-up. 
Non-responders showed an increase in LV end-systolic volume in 10% of patients, stable 
volume in 13%, decrease less than 10% in 69%, and decrease between 10 and 14% in 8%. 
At late follow-up, responders were in a lower NYHA class and showed lower mortality 
(incorrectly stated in the manuscript); survival at 5 years for the whole group was 85%; 
for responders 89% and for non-responders 79%. At early follow-up, recurrent MR 
grade 2+ or more was present in 2% of responders and 44% of non-responders. While 
MR remained stable at late follow-up in the group with responders, it increased further 
in non-responders (67%), with 17% of patients having grade 3+ or 4+ MR. Preoperative 
clinical data were similar for responders and non-responders. Of interest is the median 
number of distal anastomoses, which is 2 for both groups, however with an interquartile 
range of 1–3 in responders versus 1–2 in non-responders; this might indicate less  extensive 
revascularization in non-responders, or less extensive revascularization options in that 
group. There was no effect of ring size or type on reverse remodelling. There were several 
preoperative differences in echocardiographic parameters: concerning the mitral valve, 
non-responders showed higher tenting area, greater coaptation height and lower 
 coaptation length, and jet direction was more often anteriorly directed or central; 
regarding the left ventricle, there was more global LV remodelling, greater sphericity, 
more displacement of the papillary muscles and higher wall motion score index of the 
segments overlying the anterior papillary muscle compared to the posterior papillary 
muscle, which in contrast showed higher scores in the responder group. Of special 
 interest is the fact that in non-responders leaflet coaptation length was always <5 mm on 
any follow-up examination, while 5 mm was the minimum length necessary to accept 
the result of repair during the initial surgery.
The Mayo Clinic reported their results in 179 patients with ischaemic MR and heart 
failure.122 Patients with EF ≤35% and treatment for heart failure with mostly severe MR 
were operated between 1978 and 2002. Mean age was 69 years, median EF was 30%. 
Repair was performed in 70% of patients and consisted of an annuloplasty device only 
(downsized flexible posterior band without further details on sizing) in 46% of patients, 
posterior leaflet resection with band in 14% and repair without band in 9%. The era 
General Introduction 47
during which surgery was performed was recognized as an important factor in this study. 
The earliest era saw the most patients with a mitral valve replacement. Perioperative and 
late mortality were also higher for patients who were operated earlier. Perioperative 
mortality for the whole group was 9.5%. With a median follow-up of 2.6 years, actuarial 
survival at 1, 3 and 5 years was 84%, 71% and 51%, respectively. Risk factors for late 
 mortality were preoperative renal dysfunction and concomitant tricuspid valve surgery 
(performed in 7% of patients); there was no difference between mitral valve repair and 
replacement. With TTE follow-up in 109 patients—no data on the time interval 
 provided—freedom from moderate or severe MR at 1, 2 and 3 years was 86%, 77% 
and  63%. Five percent of patients underwent reoperation of the mitral valve. Mean 
NYHA class (from 3.0 to 2.0) and EF (from 28% to 32%) improved during follow-up; 
the increase in EF was significantly higher in repair patients than in patients who 
 underwent replacement.
Results from Washington University were reported by Crabtree in 2008.123 
He   documented the results of 257 patients with ischaemic MR who underwent CABG 
with mitral annuloplasty (56% with a complete ring, 44% with a band) between 1996 
and 2005. MR was grade 3+ or 4+ in 98% of patients. Mean ring size was 27 with smaller 
rings being used in more recent years. Operative mortality was 10%, with previous 
CABG being a risk factor for death.  At a mean follow-up of 3.2 years, actuarial survival 
at 3 and 5 years was 68% and 52%, respectively. Follow-up TTE was available in 57% of 
patients with a mean interval of 20 months. On latest TTE, 28% of patients showed MR 
grade 3+ or 4+; MR recurrence was not related to annuloplasty type or size. Observed 
mortality in patients with MR recurrence was higher compared to patients without 
significant recurrence. No data were provided on EF or LV geometry.
Onorati et al reported on CABG and restrictive mitral annuloplasty in 64 patients in 
NYHA class III or IV with chronic ischaemic MR ≥ grade 3+ between 2004 and 2007.124 
Mean number of distal anastomoses was 2.3, downsizing was done by 2 ring sizes. 
In  case of symmetrical annulus dilatation a Physio ring was used, while in patients with 
restrictive leaflet motion a McCarthy-Adams disease specific ring was applied. Mean 
ring size was 25.8 (median size, 26; range, 24–30). Mean transmitral gradient was 
4.6 mmHg and mitral valve area was 2.8 cm2. Tricuspid annuloplasty was performed in 
25% of patients. Hospital mortality was 6.2%, 2-year actuarial survival was 97%, with 
72% freedom from heart failure. TTE was performed at discharge, 6 months follow-up 
and late follow-up (mean 22 months). MR ≥ grade 2+ was present in 27% of patients at 
2 years, providing an actuarial freedom of 58%. There was no relationship between MR 
recurrence and ring type or size. Patients with recurrent MR more often experienced 
heart failure and hospitalisations. In these patients, reverse LV remodelling did not 
occur as opposed to patients without recurrent MR. At discharge patients with late MR 
recurrence showed reduced coaptation height, but to a lesser extent than patients who 
did not develop MR (7 mm vs. 4 mm); coaptation height increased again during 
 follow-up together with a decrease in transmitral gradient. There were no differences in 
preoperative variables between patients who developed recurrent MR and those who 
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did not. Patients with a preoperative LV end-diastolic diameter >70 mm had low 
 freedom from heart failure (21%) and also more often developed recurrent MR. 
In another report from Duke University, results are presented from 222 patients who 
underwent CABG and undersized mitral annuloplasty between 1999 and 2006.125 
Preoperative EF was 30%, LV end-diastolic and end-systolic dimension were 54 mm and 
43 mm. Mean number of distal anastomoses was 2.8 and nonflexible complete rings 
(mean size 24.8) were used almost exclusively. Perioperative mortality was 6.3%. With a 
mean follow-up time of 2.2 years, actuarial survival at 1 and 5 years was 72% and 55%, 
respectively. Echocardiographic follow-up was available in 68% of patients, with a 
median follow-up time of 10.6 months. This showed severe recurrent MR in 1.3% of 
patients and moderate MR in 9.4%, mainly related to progressive posterior leaflet teth-
ering. Significant decreases in LV diameters were observed (end-diastolic from 55 to 
51 mm, end-systolic from 43 to 42 mm). Mean transmitral gradients were measured in 
123 patients, and were ≥5 mmHg in 54% and ≥8 mmHg in 13% of patients. There was no 
relationship between gradients and study endpoints (all-cause mortality and a  composite 
of death or rehospitalisation for heart failure). Although no specification of downsizing 
policy was provided, the small mean ring size indicates adequate undersizing. A  limitation 
of this study is the fact that echocardiographic follow-up for one-third of patients is 
missing.
Results from a single-centre randomized trial in patients with moderate (grade 2+) 
chronic ischaemic MR were presented by Fattouch et al.126 Forty-eight patients 
 underwent CABG with restrictive mitral annuloplasty (Physio ring, size based on TEE 
measurement of anterior leaflet height at the A2 level, and then downsizing by 8 to 
10 mm) and 52 underwent CABG only between 2003 and 2007. Mean number of distal 
anastomoses was 2.9, and 97% of patients received a left internal mammary artery graft. 
Successful mitral repair was defined as residual MR trivial or less and coaptation length 
≥8 mm. Early mortality was similar—1.8% for CABG only and 4% for mitral annulo-
plasty; P=0.12. Mean follow-up was 32 months. Survival at 1, 3 and 5 years for the CABG 
only group was 98%, 93% and 89 %, and for the mitral annuloplasty group it was 96%, 
96% and 94%. The mitral surgery group showed better clinical improvement (by NYHA 
class). Patients who underwent mitral repair did not show recurrent MR more than 
trivial. In the CABG group, at discharge MR was mild in 24.5% and moderate in 
75.5% of patients; at late follow-up 25% had moderate MR and 35% had moderate-to- 
severe MR, which means that 40% of patients showed reduction of MR severity at rest. 
In the mitral surgery group, there was LV reverse remodelling (decrease of LV end -
diastolic diameter from 59 to 52 mm and end-systolic from 45 to 37 mm), reduction of 
left atrial size (from 39 to 36 mm), improvement of EF (from 42% to 48%) and lower 
pulmonary artery pressures (from 40 to 26 mmHg) at 2.5 years, while such changes did 
not occur in the CABG only group. Exercise testing in all patients with mitral annulo-
plasty did not show increase in MR. In the CABG only group, 40% of patients with 
mild MR showed worsening to moderate MR while 75% of patients with moderate MR 
at rest showed increased MR severity accompanied by dyspnoea. In conclusion, adding 
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restrictive mitral annuloplasty to CABG resulted in more extensive clinical improve-
ment, reduction of MR severity and LV reverse remodelling compared to CABG only in 
a randomized trial. Furthermore, a substantial increase in MR severity was observed 
with exercise in the CABG only group. At 2.5 years follow-up, no survival benefit was 
demonstrated for mitral annuloplasty in moderate ischaemic MR patients, which is not 
surprising taking into account the short follow-up period and relatively small groups; 
it should also be noted that survival was not a study endpoint.
Pocar et al presented data on 57 patients with grade 2+ or 3+ ischaemic MR who 
 underwent CABG (2.5 distal anastomoses on average) and mitral annuloplasty between 
2000 and 2007.127 Patients with severe MR were not included, and patients with MR 
grade 2+ at discharge were excluded. In general downsizing was applied by two ring sizes, 
using a complete rigid (Classic) ring in 18%, a complete flexible (St Jude Tailor) ring in 
41% and a posterior pericardial band in 40% of patients. As such, mean ring size was 26.8. 
Early mortality was 5.3%. Early improvement in LV dimensions and MR severity were 
observed, but no improvement in EF. Mean follow-up was 43 months, actuarial survival 
at 1, 3, 5 and 7 years was 89%, 87%, 66% and 51%. On multivariate analysis, only wall 
motion score index was found to predict early and late mortality as well as the 
 development of heart failure and recurrent MR grade 2+. Recurrent MR grade 2+ or 3+ 
was observed in 37% and 10% of patients, respectively. A more rigid ring resulted in 
earlier LV reverse remodelling, defined as 20% decrease of indexed LV end-systolic 
volume compared to baseline.
Results from a multicenter randomized trial were presented by Grossi and co-workers.128 
The RESTOR-MV (Randomized Evaluation of a Surgical Treatment for Off-pump 
Repair of the Mitral Valve) trial compared the results of CABG versus external reshaping 
in patients with ischaemic MR. Further details of this study are discussed in paragraph 11. 
In the control arm of this trial, a stratum of 75 patients underwent CABG and  “reduction 
annuloplasty” in 21 centres. The study entry criteria favoured exclusion of high-risk 
patients in order to evaluate differences in mid-term survival. Patients were included 
with severe (or moderate symptomatic) ischaemic MR, with EF ≥25% and LV end -
diastolic diameter ≤70 mm. The cohort in this paper had a mean age of 66 years, 
EF of 38%, mean MR grade of 2.9 and no patients were in NYHA class IV. Revascularization 
was performed with 2.8 distal anastomoses on average. A variety of annuloplasty devices 
were used with a mean size of 27 (range 24-30); 21% of devices were non-rigid. Hospital 
mortality was 4.1%. Sixteen percent of patients had moderate or worse recurrent MR at 
2 years follow-up. Mean MR severity decreased to 0.52 and 0.35 at 1 and 2 years  follow-up, 
respectively. EF increased to 47%, and NYHA class improved significantly. Ring type 
and size had no influence on outcome. The authors claim that “mandating annuloplasty 
device and sizing was beyond the scope of the trial”.
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Studies Comparing Mitral Valve Repair and Mitral Valve Replacement
Comparing the results of mitral valve replacement versus repair is difficult because of 
obvious differences in patient characteristics and because techniques for repair and 
replacement vary throughout the literature.
Gillinov et al reported on a retrospective analysis of all patients with isolated CABG and 
a mitral valve procedure for at least grade 2+ ischaemic MR between 1985 and 1997.129 
In 482 patients, 85 (18%) had mitral valve replacement and 397 underwent repair. CABG 
was performed in 95% of patients; 97% in the repair group and 88% in the replacement 
group. The use of an internal mammary artery was more prevalent in the repair group 
than in the replacement group: 47% vs. 20%. Tricuspid valve surgery was performed in 
4% of patients. The authors defined three mechanisms for ischaemic MR: ruptured 
 papillary muscle (9%), infarcted papillary muscle without rupture (24%) and  “functional 
MR” (67%). Mean follow-up was 3.3 years. There were important differences between 
the groups, with repairs performed more often in a nonemergency setting, in isolated 
functional MR, in patients with lower NYHA class and less severe MR. To account for 
these differences, patients were attributed to 5 quintiles that had similar baseline charac-
teristics based on propensity matching. The three highest quintiles however contained 
only 4 patients with a replacement. Overall operative mortality was 13%, survival at 
1 and 5 years was 77% and 55%. The main conclusion of this study is that repair confers 
survival benefit to most patients with ischaemic MR. This is explained by the fact that 
replacement has uniformly poor results in all patient categories, while repair has a 
 “modulated” effect across the quintiles. The beneficial effect of mitral valve repair is 
 mitigated in the most severely ill patients; when the internal mammary artery is not 
used; when there is a complex mitral regurgitation jet; and when bovine pericardium is 
used as an annuloplasty device. The durability of mitral repair was only examined by 
reoperation rate in this study and not based on echocardiography. In addition, no data 
are provided with regard to chordal sparing techniques in the replacement group, which 
influence late outcome. In addition, the time frame during which surgery was  performed 
should also be taken into consideration: most operations were performed before the 
introduction of undersized annuloplasty by Bolling.
In the same journal edition a study from Grossi et al was published that examined the 
outcome of severe ischaemic MR patients operated between 1976 and 1996.130 Of these 
223 patients, 152 underwent repair (77% with a complete ring and 23% with a suture 
annuloplasty) and 71 had a replacement, most often with preservation of the posterior 
leaflet. Repairs were almost not performed before 1988. Mean age in this group was 
68 years, 86% of patients underwent concomitant CABG. Baseline differences included 
a higher percentage of patients in NYHA class IV and more heart failure in the 
 replacement group. Median follow-up was 15 months (mean, 31 months). The authors 
state that the baseline differences between the groups were so large that they could not 
balance them with propensity matching. Other sophisticated statistical techniques were 
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used to conclude that the results “suggest evidence of improved immediate outcomes 
among patients selected for mitral valve reconstruction”. The one-year survival  following 
repair performed after 1987 was 78%. It is also stated that the type of surgery has little 
effect on prognosis following adjustment for NYHA status and presence of angina at the 
time of surgery. However, after exclusion of these confounding variables, results were 
better in the repair group.
The value of these two papers is nicely evaluated in an editorial comment by Miller.131
Calafiore et al presented results in 49 patients with functional MR and end-stage 
 cardiomyopathy with ischaemic (37 patients) and non-ischaemic aetiology (12 patients).132 
This retrospective study covered the 1990-2000 era. Patients included had LV end -
diastolic volume ≥110 mL/m2, EF ≤35% and functional MR. All patients were in NYHA 
class III or IV, with a mean EF of 27%. Calafiore propagates to intervene on the mitral 
valve also with grade 2+ regurgitation (9 patients in this study) because of its deleterious 
effects in dilated ventricles. In this series 20 replacements were performed (mainly in the 
early era; with growing experience, replacement was performed when the mitral valve 
coaptation depth was 11 mm or more) and 29 repairs, using glutaraldehyde treated 
 autologous pericardium from trigone to trigone (compatible with a ring size 26), or a 
De Vega like suture in the same area tied down over a size 26 sizer. CABG was  performed 
in 33 patients (2.2 mean distal anastomoses). Operative mortality was 4.1% and long-
term survival for the whole group was 90%, 87%, 78% and 73% at 1, 3, 5 and 10 years, 
respectively. At 5 years, similar survival was observed in the ischaemic and non -ischaemic 
groups. There was a trend towards better survival in the repair group. In all but 2 patients 
undergoing repair, residual MR was present, occurring within 6 months in general and 
stabilising thereafter. Although Calafiore describes that there was no recurrent dilatation 
of the annulus, the repair technique could be criticised because theoretically it does not 
provide sufficient and durable reduction of the anteroposterior annular diameter. 
Another important consideration regarding this study is the divergence of mean 
 follow-up times: 15 months in the repair group and 41 months in the replacement group. 
In this paper Calafiore advises to replace the valve when coaptation depth is >10 mm, 
indicating too severe tethering. In a more recent review of 147 patients with ischaemic 
MR by the same author, only 7% of patients had such a coaptation depth and thus 
required mitral valve replacement according to this criterion.133
In 2004 Calafiore and co-workers presented results from ischaemic MR patients only.134 
Amongst 102 patients operated between 1988 and 2002, 82 patients underwent repair 
and 20 underwent replacement of the mitral valve (using a coaptation depth of 11 mm 
or more as a cut-off point). Grade 2+ MR was considered an indication for surgery when 
end-diastolic volume was >110 mL/m2, or EF was 35% or less. Repair was performed 
with a suture annuloplasty (18%), autologous pericardium (76%) or a posterior ring 
(6%). Thirty-day mortality was 4%. Five-year survival for the whole group was 74%, for 
the repair group it was 77%, for the replacement group 66% (not significant). Most 
patients died of cardiac causes (23/26). Postoperative echocardiographic data at a mean 
follow-up time of 2 years are presented for 46 patients; in the repair group (n=40) MR 
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was absent or mild in 50% of patients and moderate in 48%. LV dimensions, stroke 
volume and EF did not change over time. For the whole group, NYHA status improved, 
also for patients with moderate MR at follow-up.
The Mayo Clinic presented their experience in mitral valve procedures with CABG for 
chronic ischaemic MR in 2011.135 They retrospectively reviewed 387 patients (mean age 
70 years, 67% male) with EF ≤45% (mean 34%) who underwent surgery between 1993 
and 2007. There were 302 (78%) repairs and 85 replacements. In the repair group, ring 
or band size ≤28 was used in 42% of patients. In-hospital mortality was 5%. Mean 
 follow-up was 4.2 years. Actuarial survival at 1, 5 and 10 years was 84%, 55% and 25%, 
respectively. The risk factors for death in the early phase (first year after surgery) were 
patient factors (higher age, lower EF) and technical aspects (previous CABG, emergency 
or urgent surgery); for the late phase, they were age, diabetes and renal insufficiency. 
Propensity matching identified 76 pairs, and it was found that there was no survival 
difference between repair and replacement.
This overview of the literature reflects and explains the continuing controversy regarding 
the true benefit of mitral valve repair in addition to coronary revascularization in 
 ischaemic MR. This is mainly caused by the non-uniformity of surgical techniques. 
However, if we consider studies that present a structured approach to repair, in terms of 
annuloplasty ring type, extent of downsizing and intraoperative assessment of  parameters 
indicating successful repair, it is safe to say that the application of complete  nonflexible 
rings that are downsized by 2 ring sizes with adequate leaflet coaptation length on TEE 
results in consistent and durable reduction of MR severity and LV reverse remodelling 
in a majority of patients. Nevertheless, at long-term follow-up approximately 15% of 
patients have recurrent MR ≥ grade 2+, and preoperative identification of such patients 
would be mandatory to provide the optimal surgical solution to all patients. Due to the 
absence of randomized trials and relatively short follow-up, a survival benefit resulting 
from additional mitral valve repair has not been demonstrated. Improvement in 
 functional status is a consistent finding, however. There is sufficient evidence that CABG 
alone does not reliably improve MR severity in patients with moderate MR, and in 
patients with mild MR—especially in those with symptoms of heart failure and impaired 
LV function—additional examinations should assess how MR changes during exercise 
or during intraoperative loading. 
Our experience in patients with ischaemic MR combining complete revascularization 
and restrictive mitral annuloplasty using a semi-rigid complete ring (Physio) that is 
downsized by two ring sizes and aiming at an intraoperative coaptation length of 8 mm 
or more after surgery is presented in chapters 2, 3 and 4.
8. Results of Surgery for MR in Non-ischaemic Cardiomyopathy
In ischaemic MR the “ventricular component” can be addressed through coronary 
 revascularization, but in non-ischaemic dilating cardiomyopathy there are no 
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straightforward surgical alternatives other than cardiac transplantation or implantation 
of an LV assist device, which both fall beyond the scope of this thesis. The discussion of 
the literature will thus focus on results of mitral valve surgery and external cardiac 
restraint. A summary of these papers is provided in Table 4 (p. 89).
A paper from the Michigan group is often cited to demonstrate that mitral valve annulo-
plasty does not influence patient outcome in terms of mortality.136 The paper requires 
careful reading to appreciate its value. The study is a retrospective analysis of all patients 
who underwent TTE at the Michigan echo laboratory between 1995 and 2002 and were 
diagnosed with an EF <30% and at least moderate to severe MR (supposedly functional 
in origin, although not stated). The medical records of these 682 patients were all 
reviewed by two cardiologists who determined whether patients were candidates for 
mitral valve surgery using several exclusion criteria (i.e., cancer, severe COPD, inotrope 
dependency, peripheral vascular disease, etc.). As such, three patient groups were defined: 
those who were not candidates for surgery (n=263, 39%), those who were candidates but 
did not undergo surgery (n=293, 43%) and those who were candidates and underwent 
mitral valve surgery (n=126, 18% of total and 30% of candidates). The primary endpoint 
was a combination of death, LV assist device implantation or cardiac transplantation 
from an urgent waiting list (UNOS status 1). For patients who did not undergo surgery, 
event-free survival was determined from the moment of index TTE until the event or 
date of last follow-up. For surgical patients, the time from TTE to surgery was  attributed 
to the non-surgical group; from the date of surgery, survival time was attributed to the 
surgery group.
Thirty-day mortality in the surgical group was 4.8%. During follow-up, in the 
 no-candidates group 67% of patients died, compared to 38% in the  candidate/ no-surgery 
group and 48% in the surgery group (non-significant difference). The combined end-
point was reached by 41% of patients in the no-surgery group and by 49% in the surgery 
group (no significant difference). Mitral valve surgery in this study was not a predictor 
for survival. Risk factors that increased the risk of reaching the combined endpoint were, 
amongst others, coronary artery disease and cancer, while risk reduction was related to 
the use of beta-blockers and ACE inhibitors. Since coronary artery disease was 
 significantly more present in the mitral valve surgery group (71% versus 51% in the 
no-surgery group), an additional analysis was performed on patients without CAD 
(defined as any stenosis ≥70%, prior infarction or prior revascularization). This analysis 
included 276 patients (40% of the initial population), of whom 96 were no surgical 
candidates, 143 were candidates but did not undergo mitral surgery and 37 underwent 
surgery (29% of all mitral valve surgery patients). Again, mitral valve surgery was not a 
predictor for the prevention of adverse outcome.
There are some important limitations in this study. First, there are important baseline 
differences; the factors that favour the no-surgery patients were lower age (61 vs. 66 years; 
and although in this study age was not a risk factor for adverse outcome, it is in almost 
all other studies on heart failure); the fact that patients were followed for a longer time 
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prior to the index echocardiogram (13 months vs. 7 months); lower CAD prevalence 
(51% vs. 71%; CAD was an independent risk factor for reaching the  combined endpoint 
in this study, and the subgroup analysis for non-CAD patients had small patient 
 numbers); more often ICD therapy (30% vs. 18%), and more spironolactone use (28% 
vs.  15%). There were also factors that might negatively influence outcome in the 
 no-surgery group: a higher heart rate (85 versus 80 per minute); higher LV end-systolic 
diameter (57 versus 54 mm); and lower EF (19% versus 23%). Another factor that must 
be taken into account in this particular study is the effect of lead time bias: the time 
from TTE to surgery is attributed to the no-surgery group, whereas the survival curve 
for the surgery group start with 4.8% operative mortality. Mitral valve surgery for this 
particular pathology was just being developed during the study period, which implies 
that learning curve and limited experience play a role. In fact, with growing experience 
the surgeons in Michigan started to downsize more, and until the year 2000 only  flexible 
rings were used.137 The effect of patient opinion regarding the decision to perform 
 surgery or not is also not taken into consideration. More importantly, there is no 
 information regarding clinical status (not even preoperatively), and there is 
no   echocardiographic follow-up to correlate possible residual MR and LV reverse 
 remodelling to outcome. These observations must be taken into consideration when 
interpreting these data.
The earliest results from the Michigan group regarding restrictive mitral annuloplasty in 
mainly non-ischaemic cardiomyopathy are discussed in detail in paragraph 2. In 1998 
they reported on 48 patients, with one perioperative death and 1-year and 2-year survival 
of 82% and 72%, respectively.12 LV end-diastolic volume decreased from 281 to 206 mL, 
while EF improved from 17% to 26%, with a rise in cardiac output from 3.3 to 5.2 l/min. 
Regurgitant fraction decreased from 68% to 15%. Peak oxygen uptake during exercise 
improved from 14.5 to 18.6 mL/kg/min after a mean follow-up of 22 months. In the 
discussion of this manuscript, Bolling mentions that he changed his strategy from 
undersizing by one ring size to using the smallest ring possible, without providing exact 
numerical data. The latest report from this group appeared in 2004, when over 
200 patients had been operated with a 30-day mortality below 4%.138 Actuarial survival 
at 1, 2 and 5 years was 82%, 71% and 52%, respectively.
The Leipzig group presented their experience with restrictive mitral annuloplasty in a 
group of mainly non-ischaemic dilated cardiomyopathy patients in 2003.139 Patients 
were operated between 1996 and 2002 with undersized complete rigid mitral  annuloplasty 
rings (median ring size 28). Most patients had a non-ischaemic aetiology (53 patients, 
versus 13 ischaemic). Mean EF was 23% and LV end-diastolic diameter was 69 mm. 
Thirty-day mortality was 6.1%. Mean follow-up was 28 months. There were 16 late 
deaths (13 cardiac), 3 patients underwent redo surgery for recurrent MR and 7 patients 
underwent cardiac transplantation. Actuarial 1- and 5-year survival were 86% and 66%; 
when heart transplantation is included as an event, event-free survival is 86% and 46% 
at 1 and 5 years. NYHA improved in survivors. EF improved significantly from 25% to 
34%, while end-diastolic diameter showed an early reduction from 69 to 65 mm, and 
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then remained stable at 67 mm (P=0.093). Mean MR grade was 0.7 at early follow-up 
and 1.0 after 28 months. Age and ischaemic aetiology were predictors for mortality, 
although the survival curves strongly suggest that this is mainly related to early mortality. 
One of the interesting points in this study is the relatively high mean end-diastolic LV 
diameter, which might explain the high number of patients who ultimately needed car-
diac transplantation.
Horii et al studied an exclusively non-ischaemic population (n=55) operated between 
1996 and 2002.140 This group included very ill patients, 19 were inotrope dependent and 
9 underwent emergency surgery. In 37 patients (67%) a restrictive annuloplasty (1 or 
2 sizes downsizing) with a complete ring was performed whereas in 18 patients the mitral 
valve was replaced, mainly in the earlier era. Tricuspid valve surgery was performed in 
69% of patients. Hospital mortality was 15% (8 patients); in the elective group it was 4% 
(n=2) versus 67% in the emergency surgery group (n=6). Mean follow-up was 29 months. 
For elective patients, 1-, 3- and 5-year survival is 73%, 58% and 52%, respectively. Because 
of the wide range in ventricular sizes (indexed end-systolic volume between 70 and 
270 mL/m2) the authors decided to stratify the elective patients into a “small LV” group 
(n=21) and a “large LV” group (n=25), using the mean indexed end-systolic volume 
(150 mL/m2) as a discriminator. The small LV group had more favourable baseline echo-
cardiographic parameters: mean end-diastolic diameter 67 mm vs. 75 mm, mean EF 25% 
vs. 22%, and indexed LV end-diastolic and end-systolic volumes of 153 vs. 233 mL/m2 
and 114 vs. 183 mL/m2, respectively. There were no differences in LV end-diastolic 
 pressure or pulmonary artery pressure. Early mortality in both groups was similar (one 
patient in each group). During follow-up, 5 patients in the small LV group and 
10 patients in the large LV group died; in the latter group, congestive heart failure was 
the cause of death in 6 patients. Actuarial survival at 1 year and 3 years was 84% vs. 60% 
and 67% vs. 42%, respectively (P=0.03). The small LV group showed improvement in 
NYHA class whereas the large LV group did not. After 3 years, reverse LV remodelling 
was observed in the small LV group: end-diastolic diameter dropped from 66 to 61 mm, 
end-systolic volume index decreased from 114 to 92 mL/m2 and EF increased from 25% 
to 34%. Favourable changes did not occur in the large LV group. Horii concludes that 
mitral valve surgery alone might not be sufficient in patients with severely dilated 
cardiomyopathy.
Much information regarding the effect of undersized mitral annuloplasty in non -
ischaemic cardiomyopathy has been obtained from the Acorn Clinical Trial.141 In brief, 
this study examined the effect of external cardiac restraint applied by a cardiac support 
device (CSD), specifically the CorCap device, on the course of heart failure in dilated 
cardiomyopathy. The concept of the CSD is described in more detail in paragraph 11. 
This prospective multi-centre randomized trial was performed in the United States and 
Canada and involved 300 patients with NYHA class III or IV heart failure and non -
ischaemic dilated cardiomyopathy, with EF ≤35%, LV end-diastolic diameter ≥60 mm 
and a 6-minute walking distance <450 m. Depending on the need for mitral valve 
 surgery, patients entered either the mitral valve surgery stratum (n=193) or the no mitral 
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valve surgery stratum (n=107). The primary objective of this trial was to see whether the 
CSD would add incremental value to mitral valve surgery in terms of clinical and echo-
cardiographic improvement. The mitral valve surgery stratum thus provides interesting 
data regarding the effects of undersized mitral annuloplasty with or without the CSD. 
It should be noted that in the mitral surgery stratum, also patients with NYHA class II 
heart failure and EF up to 45% could be enrolled. The stratum included 91 “treatment” 
patients (mitral valve surgery + CSD) and 102 “control” patients (mitral surgery only).142 
Mean age was 54 years, 54% were female patients, 72% were in NYHA class III and 5% in 
class IV. Six percent of patients had an ischaemic aetiology. Baseline LV end-diastolic 
diameter was 70 mm, end-diastolic volume was 270 mL and EF was 24%. MR grading 
was 2+ in 23%, 3+ in 26% and 4+ in 33%; MR was absent in 7% and grade 1+ in 11% (core 
laboratory readings). The mitral valve was replaced in 16% of patients, the remainder 
received an annuloplasty ring (65% complete rings); ring size was 26 or smaller in 59% 
of patients. Thirty-day mortality was 1.6%, actuarial survival was 87% and 85% at 1 and 
2 years, respectively. For the whole group, significant symptomatic and functional 
improvement was observed (by NYHA class, but also through MLHF and SF-36 heart 
failure questionnaires and by 6-minute walking test). Mean MR severity decreased from 
2.7 to 0.6, which was maintained until 18 months follow-up. Significant decreases of LV 
end-diastolic and end-systolic volumes at all follow-up times were observed and EF had 
significantly increased after 18 and 24 months. LV mass also decreased and the ventricle 
became less spherical.
The CSD in the mitral valve surgery stratum did not lead to improved survival. A trend 
towards less major cardiac procedures in the CSD group was observed (including heart 
transplants, LVAD implantation, biventricular pacing, repeat mitral surgery, tricuspid 
valve surgery or CABG). The CorCap led to a significantly greater decrease in LV end -
diastolic volume (an additional 16 mL on average) and end-systolic volume (by 15 mL). 
The ventricles became less spherical in the CSD group, while MR end EF changes were 
similar in both groups. Residual MR after 6 months in the CSD group was absent in 
60% of patients, grade 1+ in 28% and 2+ in 3%; for the mitral valve surgery only group, 
these percentages were 62%, 16% and 15% (no significant difference). Clinical improve-
ment on MLHF and SF-36 questionnaires was significantly better in the CSD group.
Several conclusions can be drawn from this paper. The low perioperative mortality 
achieved in 30 different centres demonstrates the current safety of mitral valve surgery 
in heart failure patients. There is a low recurrence of significant MR at 18 months 
 follow-up, with LV reverse remodelling achieved with mitral valve surgery alone 
although this was even more pronounced when the CSD was added. The CorCap did 
not confer survival benefit, which however might not be expected at this short  follow-up 
time. Several specific aspects should be taken into consideration when comparing results 
of this study to other heart failure studies. Patients were on optimal medical therapy 
(97% on ACE-inhibitors and 80% on beta-blockers) which is the cornerstone of heart 
failure treatment. The patients in this study are relatively young and almost one-fourth 
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of the patients were in NYHA class II. Mean MR severity is also not very high, but the 
degree of LV dilatation is impressive on the other hand.
Results of these patients at 5 years follow-up were reported in 2011.143 In this paper, 
it appears that the aetiology in the non-ischaemic cardiomyopathy group was idiopathic 
in 61% and valvular in 17%. Five-year total mortality was 30%, with an annual mortality 
rate of 6%. Survival at 5 years was 70%. The effects of mitral valve annuloplasty with 
regard to volume reduction and improvement in EF and sphericity were unchanged at 
5 years, as well as the additive effect of the CSD on these parameters. End-diastolic 
volume had decreased by 75 mL on average, or 28% of the baseline volume. Significant 
recurrent MR grade 3+ or 4+ was present in 19 patients, and 5 patients underwent repeat 
mitral surgery; the cumulative event rate for this combined endpoint was 19%. Also at 
5 years, addition of a CSD did not influence survival or freedom from recurrent MR. 
It  is also important to notice that there were 23 cardiac transplants and 11 LV assist 
device implantations in this study group.
9. Choosing the Annuloplasty Ring in Functional Mitral Regurgitation
The available studies that focus on functional MR show that there are different views on 
ring choice: complete or incomplete, flexible or nonflexible, saddle shaped or flat, and 
several so-called disease specific rings have been introduced for functional MR. Several 
considerations regarding ring choice are discussed in this paragraph based on the 
 available literature.
Rationale for Undersizing
In his initial publications, which are also discussed in paragraph 2, Bolling mentions the 
use of an undersized ring for the first time in 1995, without technical details.10 His idea 
then was to stabilize the mitral annulus to establish a more favourable LV geometry. 
In his later work, he mentions the concept of “acute remodelling of the base of the heart” 
to re-establish an “ellipsoid shape to the base of the heart”.12
The concept of additional reduction of the septal-lateral dimension of the mitral  annulus 
was studied in a chronic ischaemic ovine model by Tibayan et al.35 In this study, a 2-0 
Prolene suture was anchored to the midseptal annulus and exteriorized through the 
lateral annulus with an adjustable tourniquet. One week later a lateral infarction was 
created, and another 7 weeks later the annular suture was tightened by 8-12 mm. This 
reduced the septal-lateral dimension to below baseline levels (15-20% decrease compared 
to baseline level and 25-30% compared to the dimension resulting after infarction). 
In this study, commissure-to-commissure dimension remained the same, but MR was 
abolished. Interestingly, the septal-lateral reduction reduced the mitral annulus area 
compared to the post-infarction state, but the area was similar to baseline values. In this 
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model (where no ring was used), cinching did not reduce normal mitral annular motion, 
nor did it affect leaflet geometry. 
Theoretical Considerations on Choosing an Annuloplasty Ring
Carpentier introduced the concept of the remodelling annuloplasty ring in mitral valve 
repair, which proved to be a major factor in improving the success rate and long term 
durability of mitral reconstructive surgery.144 The idea behind the rigid Classic ring was 
to remodel the annulus, decrease tension on suture lines, increase leaflet coaptation and 
prevent recurrent annular dilatation. Duran introduced a flexible ring in order to 
achieve less interference with physiologic motion of the annulus.145 In 1995 Carpentier 
introduced the Physio ring, which after some time was referred to as a semirigid ring.146 
This ring still had the normal 3:4 ratio in systole between the anteroposterior 
 (septal-to-lateral) and transverse (commissure-to-commissure) diameters, but featured 
differential flexibility in the commissural and posterior region, which means that in the 
longitudinal direction the material is not deformable (to prevent plication or a 
 pursestring effect) while it is flexible in the transverse axis. Compared with the Classic 
ring, the anteroposterior diameter is also slightly increased. In addition, the anterior 
part of the ring is “saddle-shaped” to a very limited extent to better accommodate the 
bulging of the aortic root. The general idea of this “selective rigidity and selective 
 flexibility” is to further reduce suture stress.
One study showed improved LV systolic function parameters by pressure-volume loop 
analysis comparing flexible rings to rigid rings, but at longer follow-up (>1 year) these 
difference had disappeared.147 Okada et al showed that patients with a flexible ring had 
better LV fractional shortening and lower transmitral peak velocities during exercise 
echocardiography 6 months after implantation.148 In addition, mitral annular dynamics, 
in particular mitral area change, were sustained in patients with a flexible ring compared 
to those with a rigid ring; however, patients with a flexible ring were studied 6 months 
after surgery compared to 30 months in the rigid group. In an experimental study, 
 fixation of the posterior leaflet following ring implantation was similar for flexible and 
rigid rings.33 As such, theoretical advantages of the flexible ring over rigid or semirigid 
rings have not been proven clinically; the current notion is that after implantation and 
neo-endothelialization of the ring the benefits of flexibility are greatly diminished as the 
ring becomes more rigid.
Another annular remodelling device is the incomplete flexible band designed by 
Cosgrove et al.149 The Cosgrove-Edwards annuloplasty system was introduced to 
 maintain annular motion because of its flexible properties while only providing  posterior 
annulus plication. The rationale for the latter approach was Carpentier’s observation 
that the intertrigonal distance does not dilate. However, as discussed in the paragraph 
on pathophysiologic changes in functional MR, the anterior part of the annulus shows 
similar dilatation as the posterior part according to several studies.
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Based on these theoretical considerations, combined with observational and  experimental 
data, the use of an incomplete ring in functional MR seems inappropriate, since it will 
not reduce the anterior annular dimension and, more importantly, it will not  sufficiently 
reduce septal-to-lateral dimension, which is the most important factor on an annular 
level that contributes to MR. The latter consideration also supports the use of a  complete 
nonflexible ring rather than a complete flexible ring, especially when we consider that 
we have to undersize. Since flexible rings have a variable septal-to-lateral dimension 
throughout the cardiac cycle, at least during the first months after implantation, their 
ability to abolish MR completely in functional MR may be insufficient. In addition, 
undersizing by 2 ring sizes will put considerable tension on the annular sutures which 
might be better compensated for by a (semi)rigid ring. Finally, a non flexible ring might 
be better able to achieve the reduction in circumferential radii of curvature of the left 
ventricle (remodelling of the LV base) and therewith reduce wall stress, as described in 
an acute ischaemic MR model.50
Saddle shaped annuloplasty rings that resemble more the physiologic situation in vivo 
were proven to change the flattened annulus in chronic MR patients toward a more 
saddle-shaped annulus while still reducing all mitral annular dimension.150 The Physio 
ring that was used in the same study for comparison made the annulus even more flat. 
For both rings similar percentage reductions were observed in septal-to-lateral 
 dimensions, although no data regarding ring size are provided. However looking at the 
data it seems that the Physio ring provided more reduction of the anterior annular 
length. The rationale behind saddle shaped rings—reduction of leaflet stress to possibly 
provide a more durable repair—still has to be proven. Theoretically, these rings could be 
used in functional MR, although exact data regarding the dimensions of these rings, 
especially with regard to the ratio of the commissure-to-commissure and the 
 septal-to-lateral dimension, and how these ratios vary per ring size, should be taken into 
consideration. Another issue that has not been addressed is the fact that flattening of the 
annulus in functional MR theoretically helps to retain coaptation, since the A2 and P2 
regions are brought down towards the subvalvular apparatus. Restoration of the original 
saddle shape could thus have counteractive effects in this specific population.
The Michigan group reviewed their experience in functional MR with regard to the use 
of flexible and non-flexible rings.137 From the year 2000 onwards they changed their 
policy to using only nonflexible rings. There was a significant difference in the number 
of reoperations for recurrent MR: 16/170 in the flexible group versus 3/119 in the non-
flexible group (P=0.012). Cases of recurrence were always the result of ongoing 
 remodelling and not of dehiscence or technical failure. Although several remarks can be 
made with regard to the study outline—the confounding effect of the different eras in 
which both rings were used; the fact that reoperation was not examined as a time-related 
event; and the fact that reoperation is a surrogate endpoint for repair failure—the 
 findings suggest that flexible rings might not be the best option for this pathology.
Silberman et al examined outcome of patients with ischaemic MR who underwent 
CABG and mitral valve repair and compared flexible (Duran) versus “rigid” (Physio) 
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rings.151 Also in this study, patients operated earlier (between 1996 and 2004) received a 
flexible ring while in later years ring choice was at the surgeon’s discretion, which implies 
that results should be interpreted with caution. Flexible rings were used in 117 patients, 
semirigid rings in 52. Follow-up time in the flexible group was longer (median 60 versus 
15 months). There was a significant difference in mean ring size (flexible 25.7, nonflexible 
26.1), however flexible Duran rings are only available in odd sizes and semirigid Physio 
rings only in even sizes. Early mortality was similar (9%), actuarial survival in the  flexible 
group at 1, 3 and 5 years was 85%, 79% and 75%, while there was no late mortality in the 
semirigid group. Age and ring type were independent risk factors for mortality. 
LV dimension reduction was similar, while there was a higher percentage of moderate or 
more recurrent MR in the flexible group (34% versus 15% (P=0.03). Exact follow-up 
intervals were not provided and MR was not treated as a time-related event, although 
the authors state that most recurrences occurred within 6 to 12 months after implanta-
tion). Predictors of late MR recurrence were preoperative end-systolic LV diameter and 
ring type. Again, the absence of randomization and the different eras in which the rings 
were used limit the strength of this study.
In 2007, Chang et al published the results of a randomized study comparing rigid 
(Classic) rings to flexible (Duran) rings in patients with MR of any aetiology.152 There 
were no differences in clinical outcome or with regard to LV function at a follow-up of 
4 years. Recurrence of MR ≥ grade 3 occurred in 8/187 patients (4.3%) with a Classic ring 
and in 15/170 patients (8.8%) with a Duran ring; this difference was not statistically 
significant (P=0.172). Reoperations for recurrent MR were performed in 4 patients with 
a Duran ring and in 1 patient with a Classic ring. Freedom from reoperation was 
 significantly lower in patients with functional MR (77% at 7 years, compared to 98% in 
 degenerative and 93% in rheumatic disease). The small numbers do not allow a 
 comparison between the different ring types within specific pathology subgroups.
Disease Specific Rings
An undersized annuloplasty ring effectively reduces mitral septal-to-lateral dimension, 
but also decreases valve orifice area. The fear of creating a relative mitral stenosis with 
the typically used small ring sizes 24 and 26 prompted the introduction of so-called 
 disease-specific annuloplasty rings. They are designed to provide further reduction in 
septal-to-lateral dimension while maintaining or even increasing the commissure -to-
commissure dimension, providing a relatively larger orifice area. Evaluating and 
 comparing these rings is highly complex, and actually makes a proper ring choice even 
harder for the surgeon. A paper by Bothe et al provides measured dimensions of four 
 disease-specific rings and compares them to those of the Physio ring.153 Disease-specific 
rings provide a varying amount of additional septal-to-lateral dimension reduction 
 compared to the Physio ring of the same size (10 to 25%), but when compared to a 
Physio ring that is two sizes smaller—so truly undersized—the septal-to-lateral 
 dimension is actually larger in three out of four rings. Preferably, the effects of these 
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devices on mitral valve and LV geometry should be tested ex-vivo, for instance in a finite 
element model.154
The single intermediate term clinical follow-up study in the English literature performed 
with a disease-specific ring (GeoForm) does not reveal better freedom from recurrent 
MR or more extensive LV remodelling after almost 2 years, but does also not show 
 significant mitral stenosis on exercise.155 In our opinion, disease specific rings introduce 
more ambiguity into the discussion on downsizing while their potential benefit is still 
unproven. A ring that was specifically designed to treat ischaemic MR has additional 
reduction of the anteroposterior dimension at the A3-P3 level. This suggests that in all 
ischaemic MR cases such a configuration would be the case, which is not true. Patients 
with that specific condition can be identified by echocardiography, but this requires 
additional skills and experience. Inadvertent use of these rings can lead to residual MR.
10. Recurrence of Mitral Regurgitation after Mitral Annuloplasty
Recurrence of mitral regurgitation following mitral annuloplasty negatively influences 
the results of surgery. Since functional MR is more than a valvular problem, MR 
 recurrence is also related to the course of the underlying disease which makes it different 
from recurrence in organic pathologies. In the previous paragraphs a wide range of MR 
recurrence rates were presented in different studies for which several reasons can be 
given. When interpreting these studies, a distinction should be made between residual 
MR and true recurrent MR. The first phenomenon is the result of an inappropriate 
application of a surgical technique, while the latter might be the consequence of disease 
progression but may also result from inappropriate surgical repair. Again, we insist on a 
proper downsizing strategy with adequate ring choice and obtaining a supra-physiologic 
minimum coaptation length at the end of surgery.
Hung et al tested the hypothesis that recurrent MR following annuloplasty is related to 
continued LV remodelling.156 They examined 30 consecutive patients who underwent 
CABG and mitral annuloplasty for moderate to severe ischaemic MR between 1996 and 
1998 in two institutions. Mean EF was 43%, end-systolic volume was 151 mL. Patients 
received a variety of rings (53% semirigid and 47% flexible) and mean ring size was 
 relatively large (mean, 30, range, 24 to 36 mm). Intraoperatively, mean MR grade 
decreased to mild after surgery (no further specification given). Early (4 months) and 
late (4 years) echocardiographic follow-up was performed. Early results showed that 
70% of patients had mild MR and 30% severe MR; at late follow-up, results were reversed 
with 72% of patients having moderate to severe recurrent MR. These changes paralleled 
changes in LV volumes, without change in EF; so initially there was a reduction in LV 
volume followed by an increase at late follow-up. A similar pattern for LV sphericity was 
observed. Linear regression analysis identified end-systolic LV sphericity index at late 
follow-up as a predictor for recurrent MR. However, one could argue that the two are 
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observed together, which does not necessarily imply a causal relationship. Furthermore, 
as the authors state themselves, markedly undersized rings were not inserted. The authors 
also argue that undersizing can potentially shift the posterior annulus farther anteriorly 
and increase its displacement relative to the papillary muscles, which may exacerbate 
tethering.
This latter concept was further explored by Japanese colleagues in 2005.157 They  examined 
the amount of tethering of both leaflets before and after surgery in 31 patients with 
annuloplasty and CABG for ischaemic MR and in 20 normal control subjects. There 
were 12 patients with a semirigid ring and 19 with a flexible—often incomplete—ring. 
The surgical group also included 11 patients with LV restoration surgery, which makes 
the study population highly diverse. Postoperative echocardiographic evaluation was 
performed between 2 weeks and 2 months after surgery. Six patients had significant 
“persistent” MR, defined as vena contracta width ≥3 mm. In these patients, LV volumes 
and EF did not improve, whereas they did in 25 patients without MR. Assessment of 
mitral valve geometry showed that the preoperative tethering degree was similar for 
both leaflets. In patients with persistent MR, tethering was still present, but much more 
extensive for the posterior leaflet compared with patients without MR. Posterior leaflet 
angle was 57° preoperatively, 83° postoperatively in patients without MR, 111° in patients 
with MR and 30° in normal controls. Coaptation length (indexed to body surface area) 
was 2.0 mm/m2 preoperatively, 1.9 in patients with postoperative MR, 4.5 in patients 
without MR and 5.2 in normal controls. The authors also found that reduction in 
end-systolic volume was strongly correlated with decreased leaflet tethering.
The same researchers examined a comparable group of 30 patients with late follow-up 
echocardiographic examinations, performed between 10 and 45 months  postoperatively.158 
Nine patients had significant MR on late echocardiography (2 already during early 
follow-up). Essentially, similar observations were made: late recurrent MR was seen 
together with augmented posterior leaflet tethering which was not yet present at early 
follow-up. In patients with MR, end-systolic volume dropped at early follow-up, but 
increased again at late follow-up. Again it should be appreciated that these phenomena 
are observed simultaneously while a causal relationship thus cannot be assessed. It is also 
important to realize that in this study at early follow-up no distinction could be made 
between patients who would later develop MR and those who would not.
The results from the Cleveland Clinic have already been discussed in paragraph 6.116,119 
As mentioned, these results are often cited when it comes to recurrence of MR following 
mitral valve annuloplasty in ischaemic MR. Again, we would like to emphasize that 80% 
of patients in their series had an incomplete annuloplasty (20% with pericardium), and 
that echo follow-up was performed at a median of only 8 days. The fact that at 6 months 
follow-up even with a complete semirigid ring 25% of patients had grade 3 or 4 recurrent 
MR in our opinion does not suggest disease progression with ongoing LV remodelling 
but rather an imperfect surgical strategy. This is reflected in the median ring size used—
size 30—and there seems to be no consistent strategy with respect to the desired final 
intraoperative result in terms of residual MR and minimum coaptation length.
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The Cleveland Clinic presented data on 365 patients who underwent annuloplasty for 
ischaemic MR between 1990 and 2002 and had a complete preoperative TEE study.159 
Ninety-four percent of patients had an incomplete ring. Patients who developed MR 
grade 2+ or more were classified as failures. Mean follow-up time was 269 days. 
Preoperative parameters studied as potential predictors for MR recurrence were 
LV   volumes, jet direction, MR severity, mitral annular diameter and tethering area and 
height. Failures were observed in 19% of patients; these patients had higher LV volumes, 
more severe MR, a larger mitral annulus and more tethering. Regression analysis 
 identified three independent predictors of recurrent MR, with cut-off values provided 
by ROC analysis: mitral annulus diameter in 4-chamber view ≥37 mm, tethering area 
≥1.6 cm2, and MR severity >3.5+. Simultaneous presence of all three parameters had a 
positive predictive value of 55%, which is actually quite low. It is also unclear how to 
identify grade 3.5+ MR in an individual patient.
More recently this group focused on late MR recurrence, defined as MR ≥ grade 2+ 
developing at least 6 months after surgery.160 An analysis of 106 ischaemic MR patients 
learned that 33% of patients had such MR recurrence at a mean follow-up of 45 months. 
Compared to patients without recurrence, these patients had lower rates of stable or 
increased EF (40% vs. 67%), lower rates of stable or decreased LV end-systolic diameter 
(17% vs. 59%) and higher LV sphericity index, all indicating ongoing LV remodelling. 
Again, no temporal relationship between the occurrence of these phenomena is  provided. 
The subgroup of patients with successful repairs but without EF improvement was 
found to have decreased LV end-systolic diameters. 
A study by De Bonis et al reviewed 79 patients who underwent restrictive mitral 
 annuloplasty with a complete ring (Classic or Seguin) and, in case of coaptation height 
≥10 mm, an additional edge-to-edge technique.161 Patients had end-stage cardio myopathy 
(51 ischaemic, 28 idiopathic) with EF ≤35% and grade 3+ or 4+ MR, were operated 
between 1998 and 2005 and had less then grade 1+ residual MR at discharge, with a 
follow-up of at least 6 months. Baseline EF was 28%, indexed end-diastolic volume 
113 mL/m2 and indexed end-systolic volume 81 mL/m2. LV reverse remodelling 
(15% decrease of indexed end-systolic volume) was present in 52% of patients early after 
surgery, and over time LV volumes further decreased. The remainder of patients showed 
no volume changes at early follow-up, and throughout follow-up end-diastolic volume 
remained stable whereas end-systolic volume gradually increased to values higher than 
preoperatively. In the group without reverse remodelling sphericity index and  coaptation 
depth showed an initial decrease, but they gradually increased at longer follow-up. 
MR at late follow-up in this group was 2+ in 42% of patients and 3+ in 19%. In the 
reverse remodelling group 10% of patients had grade 2+ MR. In this study, LV geometry 
changes precede recurrence of MR: in the absence of recurrent MR, the ventricle starts 
to dilate again after which MR recurrence is observed. In multivariable regression 
 analysis, only shorter duration of heart failure symptoms was a predictor for reverse 
remodelling. There was a trend towards more reverse remodelling when the edge-to-
edge technique (used only in patients with more severe tethering) was also applied. 
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Baseline LV volumes and diameters did not predict reverse remodelling. In the reverse 
remodelling group, clinical outcome was significantly better (in terms of NYHA class 
and cardiac events).
An analysis of early residual significant MR (defined as vena contract width >3 mm) 
following restrictive annuloplasty and CABG was presented by Magne et al.87 This group 
studied 51 patients with ischaemic MR by early postoperative TTE after 5 days; 22% of 
patients had significant MR (MR-group), 20% had MR with vena contracta ≤3 mm, 
and in 58% MR was not detectable; these latter 78% compose the no-MR group. There 
were no preoperative clinical differences between both groups, but the MR patients had 
higher preoperative LV end-diastolic diameter (63 vs. 58 mm) and volume (180 vs. 
168 mL), higher coaptation distance (12 vs. 8 mm), tenting area (2.7 vs. 1.7 cm2), anterior 
leaflet angle (45° vs. 32°) and posterior leaflet angle (53° vs. 46°). Statistical  analysis 
revealed that preoperative posterior leaflet angle ≥45° was the best predictor for persistent 
MR, followed by tenting area ≥2.5 cm2 and coaptation distance ≥1 cm. LV diameters 
were less accurate. Importantly, 3-year cardiac event-free survival was  significantly 
reduced in the MR group (26% vs. 75%).
The same group also specifically analyzed late MR recurrence in similar patients (n=26) 
with early (after 6 days) and late (after 1.5 years) echocardiographic follow-up.162 
This time, they more specifically looked at anterior leaflet configuration by examining 
the degree of bending at the insertion of the second order chords. Overall, 62% of 
patients showed no significant MR recurrence (defined as vena contracta width >3 mm). 
These patients also showed reverse remodelling and improved EF without significant 
change in sphericity index. Among the 10 patients with recurrent MR, 5 showed 
 continuing LV remodelling with concomitant changes in coaptation depth, tenting area 
and leaflet angles. The remaining 5 patients did not show continuing reverse  remodelling; 
however, in this group further anterior leaflet tethering at the bending point was 
observed while other leaflet angles and tethering area had remained unchanged. 
The authors suggest that this might be explained by local adverse remodelling at the 
vicinity of the papillary muscles, or that it may be caused by localized fibrosis and 
 stiffening of the LV wall. Their retrospective analysis did not permit to investigate these 
hypotheses by, for instance, strain rate analysis.
Analysis of mitral valve geometry in the mitral valve stratum of the Acorn trial was 
 presented by Lee et al.88 All patients with restrictive annuloplasty and at least 6 months 
echocardiographic follow-up were selected. At 6 months, 25 patients (21% of total) had 
MR ≥ grade 2+. These patients were compared to 79 patients without significant MR. 
Sixty-one percent of patients had a CorCap implanted. There were no differences in 
clinical parameters between both groups. Echocardiographically, baseline indexed 
end-diastolic and end-systolic volumes were higher for patients who developed MR 
(349 vs. 242 mL/m2, and 271 vs. 176 mL/m2). Detailed preoperative analysis of mitral 
valve geometry revealed that distal and basal anterior leaflet angle, coaptation depth and 
tenting area were also significantly more increased in the MR group. Postoperatively, 
posterior leaflet angle increased to a similar extent in both groups. Anterior leaflet angles 
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were significantly reduced in the no-MR group, while they were unchanged in the MR 
group. Coaptation depth and tenting area decreased in both groups, but to a larger 
extent in the no-MR group. The only significant preoperative predictors for MR 
 recurrence were distal anterior leaflet angle and LV end-diastolic volume. The cut-off 
value for the distal anterior leaflet angle was 25°. Based on their analysis, the authors 
identify three anterior leaflet tethering patterns: one in which both anterior leaflet angles 
are narrow (<25°), characterized by a minimal anterior leaflet bend; one with a prominent 
anterior leaflet bend caused by a wide basal angle (>25°) but narrow distal angle; and one 
where both angles are wide (>25°), leading to a milder bend. Prevalence of these three 
types were 21%, 55% and 24%, respectively, and they led to recurrent MR ≥ grade 2+ in 
0%, 5% and 88% of patients, respectively. The authors suggest that, since annuloplasty 
did not affect anterior leaflet tethering, postoperative tethering can largely be predicted 
from preoperative values. The CorCap did not influence the results with regard to MR 
in this study.
Onorati et al also examined baseline clinical data, LV geometry and mitral valve 
 coaptation depth with regard to late MR recurrence at 18 months follow-up in patients 
with ischaemic MR following CABG and restrictive annuloplasty.163 The researchers 
found recurrent MR ≥ grade 2+ in 26% of 78 hospital survivors. These patients had 
worse  survival, more congestive heart failure and less functional improvement compared 
to patients without MR. In addition, there was no evidence of LV reverse remodelling 
and no improvement of EF. Coaptation depth showed an initial decrease, but later 
increased. Patients without MR did show reverse remodelling with improved EF, stable 
decreased coaptation depth and reduction of tricuspid insufficiency grade and  pulmonary 
artery pressure. Three independent predictors for recurrent MR identified were 
 combined anterior and posterior infarction, preoperative LV end-diastolic diameter 
≥70 mm and coaptation height >5 mm at discharge.
Gelsomino et al also studied patients with late MR recurrence, defined as MR ≥ grade 
2+ at intermediate (median 6 months) and late (median 33 months) follow-up in patients 
with no or trivial MR at discharge.121 In 230 patients, 22% had late recurrent MR. It was 
found that patients with recurrent MR had greater local LV remodelling of the 
LV    segments underlying the anterior papillary muscle, greater displacement of the 
 anterior papillary muscles and wider papillary muscle separation. Interestingly, these 
differences did not reflect different infarction patterns. In addition, leaflet tethering was 
more symmetrical in recurrent MR, with more pronounced anterior leaflet tethering 
and a smaller anterior leaflet bending angle compared to the more asymmetrical 
 tethering in patients without MR. The latter group had more often a posteriorly directed 
regurgitation jet. When recurrent MR developed, tethering pattern was different than 
preoperatively, as it became progressively more asymmetrical. Independent predictors 
for failure were anterior leaflet angle ≥39.5°, an anterior to posterior tethering angle ratio 
≥0.76, an anterior leaflet excursion angle <35° and coaptation depth ≥11 mm. Interestingly, 
postoperative coaptation length in patients without MR was higher (8.4 vs. 5.1 mm at 
discharge) and always ≥8 mm. The importance of anterior mitral leaflet angle in 
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predicting recurrent MR ≥2+, absence of LV reverse remodelling and absence of 
 normalization of sphericity indexed was reconfirmed in a larger multi-centre study by 
the same author.164
As these studies show, MR recurrence usually occurs in the presence of continuing LV 
remodelling, but may also occur when this is absent. Late MR recurrence also seems to 
be related to the degree of preoperative tethering (and thus remodelling), but it is not 
easy to capture the extent of preoperative mitral leaflet tethering in a set of echocardio-
graphic parameters. Our studies on MR recurrence are presented in chapters 4, 7 and 8 
of this thesis.
11. Alternative and Adjunct Therapies for Functional Mitral 
Regurgitation
Several alternative or adjunctive therapies have been described for functional MR. These 
can address the mitral valve itself, or act on the left ventricle.
Surgical Techniques Addressing the Mitral Valve Leaflets
Valvular adjunctive procedures address loss of coaptation due to excessive tethering. 
In 2007, Borger et al presented preliminary clinical results of cutting secondary chords 
as an adjunctive procedure to reduce tethering in 43 patients with ischaemic MR,165 
 following experimental work by Messas et al 42 and several case reports. He severed all 
secondary chords (to both leaflets and the corresponding commissure) that arose from 
the papillary muscle or muscles affected by infarcted myocardium, followed by insertion 
of a moderately undersized flexible incomplete band. In-hospital mortality was 9% and 
2-year survival was 79%. MR recurrence ≥ grade 2+ was 15% at 2 years. The relative 
increase of EF was 10±28% (crude data not provided). Theoretically, this approach may 
further compromise the already diminished LV function because it disrupts the 
 continuity between the mitral valve and the left ventricle. No long-term follow-up 
 studies have been published, and we feel that this technique may only be used, if at all, 
as a  bailout procedure in cases where valve replacement should be avoided at all cost.
The edge-to-edge technique, also referred to as the Alfieri stitch, has been applied in 
functional MR, but only as adjunct to an undersized annuloplasty ring.161,166 The Milano 
group has a structured echo-guided approach to functional MR: in patients with 
 coaptation depth ≥1 cm the edge-to-edge technique is added to restrictive annuloplasty. 
The suture is placed depending on the origin of the regurgitant jet, either centrally or 
posteromedially. In their latest report, the technique was used in 49% of 79 patients, and 
the technique showed a trend towards more reverse remodelling than annuloplasty 
alone.
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Another valvular approach is posterior leaflet augmentation. The largest clinical series 
was presented by De Varennes et al, following case reports from Sweden and Spain. In 
his series, 44 ischaemic MR patients underwent partial posterior leaflet augmentation 
using bovine pericardium followed by insertion of true-sized annuloplasty rings.167 
Baseline EF was 33%, LV end-diastolic diameter was 57 mm and end-systolic diameter 
was 44 mm. After detachment of the posterior leaflet at its base starting at the middle of 
the P2 segment up to the posterior commissure, an oblong patch of bovine pericardium 
(1 cm in height and 3.5 to 4.5 cm wide) was inserted, followed by ring annuloplasty. 
Median ring size was 28. In-hospital mortality was 11%, late mortality after 38 months of 
follow-up was an additional 16%. Clinical improvement was good. Echocardiography at 
one year showed moderate MR in 3/32 patients (9.4%). LV diameters and EF showed 
stable values after three years. The fact that reverse remodelling was not observed may be 
related to the revascularization approach that resulted in 1.6 anastomoses per patient, 
and to the use of non-undersized rings. Apart from that, freedom from significant MR is 
high, and this approach might also be used as an adjunct to restrictive annuloplasty in 
cases of severe tethering, especially when a small posterior leaflet is present, although 
this might be technically challenging.
A single report on anterior leaflet extension was published earlier.168 Twenty-five patients 
underwent such therapy with a flexible annuloplasty ring and CABG. Early mortality 
was 12%. Echocardiographic follow-up is very limited.
Surgical Techniques Addressing the Subvalvular Apparatus
Several techniques applied from inside the ventricle have been described to address 
 tethering by direct action on papillary muscle displacement. Hvass and Joudinaud 
reported on the use of the papillary muscle sling technique combined with mitral annu-
loplasty and CABG in 37 ischaemic MR patients.169 Patients had MR 2+ to 4+, EF 
between 15 and 45% (mean 30%) and LV end-diastolic and end-systolic dimensions of 70 
and 55 mm, respectively. The papillary sling technique involved positioning of a 4 mm 
polytetrafluoroethylene (PTFE) tube through the left atrium around the base of both 
papillary muscles which is then progressively tightened to form a ring approximating 
the papillary muscles until they are in close contact, and then secured with strong 
sutures. Once tightened, there is no residual gap between the papillary muscles. Mitral 
annuloplasty was performed using moderately undersized or normally sized rings (mean 
size, 30 mm), mostly Physio rings. CABG was performed with a mean of 2 distal anasto-
moses per patient. Early mortality was 5.4%. Results after 4.5 years are impressive with 
low mortality (80% survival), low MR recurrence (2 patients) and significant LV reverse 
remodelling at 1-year follow-up: end-diastolic diameter changing from 70 to 50 mm, 
and EF from 29% to 45%. Coaptation height was reported to decrease from 14 mm to 
4 mm, and the distance between the papillary muscles from 3.6 to 0.8 mm (follow-up 
interval not provided). Theoretically, this approach addresses the ventricular problem by 
influencing subvalvular anatomy, but also by direct volume reduction of the left 
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 ventricle, which makes it an interesting approach for ischaemic MR patients with 
advanced LV dilatation. Unfortunately, no data on coaptation length are provided, and 
echocardiographic follow-up is limited to one year. A similar approach was also 
described in patients with LV aneurysmectomy by colleagues from Tehran with the 
addition of a circumferential pericardial strip around the mitral annulus.170 Patients 
showed less recurrent MR and more reduction of leaflet tethering, more improvement 
of EF and decrease of sphericity index compared to patients without a sling. Other 
 techniques for papillary muscle relocation or approximation have been described 
 without intermediate-term outcomes.171-173
Langer and co-workers introduced the RING + STRING technique, which adds 
 repositioning of the posterior papillary muscle using a 3-0 PTFE suture that is 
 exteriorized through the aortomitral continuity and then tied in the loaded beating 
heart under echocardiographic guidance, “achieving the most physiological shape of the 
anterior mitral leaflet along its entire body and locating the coaptation point as close to 
the annular plane as possible”.174 This suture is applied through the aortic valve after the 
ring (a partial flexible ring with 1 to 2 sizes downsizing, range, 27 to 32) has been inserted. 
The group studied 30 ischaemic MR patients with extensive tethering (coaptation height 
≥10 mm) using this technique, and compared results to a historical group of 30 patients 
with similar pathology who only received an annuloplasty ring. In the 
RING + STRING group, coaptation height decreased from 14 to 6 mm, and tenting 
area from 3.0 to 1.0 cm2. At 2 years, freedom from recurrent MR ≥ grade 2+ was 94% in 
the RING + STRING group (one patient underwent reoperation for leaflet prolapse), 
compared to 71% in the ring only group (P=0.01); in the latter group, recurrence was 
already present in 2/6 patients after 2 to 4 weeks. LV reverse remodelling (end-diastolic 
dimension from 62 to 55 mm and end-systolic dimension from 49 to 43 mm) was 
observed following papillary muscle repositioning but not in the ring only group. This is 
also an interesting technique, although its reproducibility should be demonstrated by 
results from other centers.
Surgical Ventricular Techniques: External Ventricular Restraint or Reshaping
In paragraph 7, details on the combined effect of mitral valve surgery and the CorCap 
cardiac support device (CSD) with regard to clinical improvement and reduction of MR 
severity and LV reverse remodelling have been described. The CorCap CSD is a fabric 
mesh implantable device that is surgically positioned around the heart to provide 
 circumferential diastolic support. The device passively reduces LV wall stress, and thus 
counteracts the deleterious changes that occur during the remodelling process. 
The  device comes in various sizes and proper sizing is done based on intraoperative 
measurement of the circumference of the base of the heart and the distance from base to 
apex. When used in combination with mitral valve surgery, the CSD is attached onto 
the dorsal base of the heart and, after mitral surgery has been performed, it is fit into its 
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final size on the beating heart based upon intraoperative measurement of LV dimensions 
prior to opening the pericardium.
After a median follow-up of 4.3 years, the CSD showed a significantly greater decrease 
in LV end-diastolic volume compared to controls, which became apparent early (after 
3 months) and was maintained throughout follow-up;175 the additional volume decrease 
was 19 mL. Volume reduction was observed both in the mitral valve surgery stratum and 
in patients without mitral valve surgery; in the latter cohort, which lacked the effect of 
MR reduction, the decrease was more pronounced, as expected (average difference 
25 mL vs. 16 mL). End-systolic volume also decreased by 14 mL in the mitral valve  surgery 
stratum and by 22 mL in the other cohort. EF was almost unchanged and not different 
between subgroups. Sphericity index improved, but addition of the CSD only led to a 
significant difference in the mitral valve surgery group. Results after 5 years of follow-up 
for the mitral valve surgery stratum show that the 3-year results remained stable—a total 
mean end-diastolic volume reduction of 75 mL (28% reduction from baseline) with a 
similar difference of 17 mL in favour of the CSD group.143 A comparable effect was 
demonstrated on end-systolic volume, which decreased by 55 mL. Implantation of the 
CorCap device has not led to adverse events, more specifically diastolic dysfunction was 
not observed. The device is contra-indicated when patent bypass grafts are present; its 
use in patients with previous CABG is therefore not possible. In primary ischaemic 
cardiomyopathy, CABG can be combined with CSD implantation, but the grafts should 
have their course outside the mesh.
Another externally applied technique that addresses LV shape is the Coapsys device that 
was studied in the previously mentioned RESTOR-MV trial. The Coapsys device 
reshapes the ventricle and reduces wall stress by compressing the mitral annulus and 
subvalvular apparatus. The device consists of two epicardial pads connected by a flexible 
transventricular chord. Intraoperatively, the device is sized by shortening the chord with 
echocardiographic assessment of MR reduction. This multicentre randomized trial 
involved patients with ischaemic MR and EF ≥25%. Patients were assigned to CABG 
alone (n=16) or CABG + mitral valve surgery (n=149), and then randomized to 
 “treatment” (CABG + Coapsys in both strata) or “control” (CABG only and CABG + 
mitral valve repair). As stated previously, the technique of mitral valve repair was not 
standardized in this trial. The study was prematurely terminated when the sponsor failed 
to secure ongoing funding, after randomization of 165 patients. Median follow-up upon 
presentation of results was 27 months.176 Two-year survival rate for the treatment group 
was significantly higher (87% vs. 77%). The survival curves show that initial mortality 
was higher in the control group after which the curves show a parallel course, although 
perioperative mortality data is not provided in the manuscript. In the mitral valve 
 surgery stratum, MR reduction was significantly greater in the control group (CABG + 
mitral valve surgery) at 1 and 2 years (mean MR grade at 2 years 0.4 vs. 1.2). Functional 
improvement was similar. LV end-diastolic dimension provided for the as-treated  analysis 
only shows significantly more reduction in the Coapsys group compared to CABG + 
mitral repair (from 60 to 54 mm, and from 59 to 56 mm, respectively). The Coapsys 
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device has the advantage of off-pump application and acute LV shape alteration and size 
reduction, although no data on LV geometry are provided. At this moment the manu-
facturer of the Coapsys device (Myocor) has closed; the rights and intellectual property 
for this device have been obtained by Edwards LifeSciences, and the device is now not 
on the market.
Surgical Ventricular Techniques: Surgical Ventricular Reconstruction
In patients who are evaluated for functional MR and appear to have a large akinetic or 
dyskinetic anterior wall, a surgical ventricular reconstruction should be considered as it 
will promote reverse remodeling. Treating the MR alone will usually not help these 
patients because of the extent of remodelling. In this thesis, patients with a left 
 ventricular aneurysm are not included since they represent a group of patients with 
 different pathology. Although MR is usually functional in these patients as well, 
 restoration of LV  shape directly affects papillary muscle displacement, which has an 
unpredictable effect on MR severity. Our strategy in this patient category has been 
described elsewhere.177 Basically, we recommend to perform restrictive mitral annulo-
plasty in patients with MR ≥ grade 2+, which may also appear after having performed 
the surgical LV reconstruction.
For idiopathic cardiomyopathy, the groups from Tokyo and Kagawa, based on the fact 
that outcome after restrictive mitral annuloplasty was worse in patients with extremely 
enlarged left ventricles, introduced the septal anterior ventricular exclusion procedure 
(SAVE) as an adjunct to restrictive mitral annuloplasty.178 This procedure is applied in 
patients with LV end-diastolic dimension >75 mm and akinesia of the septum in whom 
lateral wall function is still relatively good assessed by echocardiography, MRI and an 
intraoperative volume reduction test (to asses regional improvement of contractility on 
TEE following decompression on cardiopulmonary bypass). Briefly, the septum is 
excluded by inserting a large oval patch parallel to the septum from base to apex. The 
initial report on 36 patients shows a hospital mortality of 14% (7% in elective patients, 
60% after emergency surgery), improvement of EF (from 21% to 28%), reduction of 
end-diastolic diameter (82 to 70 mm) and reduction of volume indexes. Three-year 
 survival rate was 61%. The technique has also been used in patients with end-stage 
ischaemic cardiomyopathy.179 With pressure-volume loop analysis, it has been demon-
strated that surgical ventricular reconstruction leads to sustained improvement in 
LV systolic function, reduced dyssynchrony and decreased wall stress, at the expense of 
some diastolic dysfunction; judging from clinical improvement the benefits outweigh 
the impairment of diastolic function.180
The Tricuspid Valve
Tricuspid regurgitation (TR) without severe annular dilatation has been neglected 
during cardiac surgery for left-sided lesions for a long time, since it was thought that 
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successful correction of the left-sided lesion would decrease pulmonary artery pressure 
and subsequently abolish TR. Recent studies that mainly included patients with 
 operated degenerative mitral valve disease have shown that TR may develop very late 
after left-sided surgery, that it is independent of the results of left-sided surgery, and that 
reoperation for isolated TR carries a high perioperative mortality. 
The extent of TR in functional mitral valve disease has not been well established. 
Matsunaga and Duran reviewed 70 patients who underwent CABG and mitral annulo-
plasty with a flexible (Duran) ring without significant residual MR directly after surgery 
and with sufficient TTE follow-up.181 They found that significant TR (defined 
as ≥ grade 3+ assessed by jet-area/right atrial area ratio) was present before surgery in 
30% of patients, and not corrected in 57%. After a mean follow-up of 27 months, 31% of 
patients had significant recurrent MR, and 49% had significant TR. There was no 
 relationship between the development of MR and TR. The only difference between 
patients with and without TR preoperatively was a higher tricuspid annulus/body 
 surface area ratio in the TR group (22 vs. 20 mm/m2). The ratio increased further during 
follow-up, as did the right ventricular sphericity index in patients with TR; values 
remained stable in patients without TR. 
De Bonis et al examined the fate of TR in the Milano cohort of patients with dilated 
cardiomyopathy (ischaemic and non-ischaemic) who underwent restrictive mitral 
annulo plasty with or without CABG, and tricuspid valve surgery when TR was ≥ grade 
3+.182 In 91 patients, 12 (14%) had preoperative TR ≥ grade 3+ and underwent a De Vega 
(n=7) or ring annuloplasty. After a mean follow-up of 1.8 years, 12% of patients had 
TR ≥ grade 3+ (1 failed repair). Patients without tricuspid surgery had worsening TR by 
at least 2 grades in 18% of cases. At 3.5 years, actuarial freedom from TR ≥ grade 3+ was 
78%; freedom from a combination of TR ≥ grade 3+ or increase by at least 2 grades or 
more was 61%. This was predicted by the degree of TR at discharge and degree of right 
ventricular dysfunction. It was not related to recurrent MR, but there was a relationship 
with the presence of pulmonary hypertension and with the absence of LV reverse 
 remodelling; in patients without reverse remodelling, significant TR occurred in 24% of 
patients while it occurred in a single patient (2%) with reverse remodelling.
In chapter 9 of this thesis our approach to functional tricuspid regurgitation is 
presented.
Cardiac Resynchronization Therapy
Beneficial effects of cardiac resynchronization therapy (CRT) in moderate to severe 
heart failure patients with intraventricular conduction delay have been demonstrated 
with regard to improvements in functional class, exercise capacity and quality of life.183 
Other trials have demonstrated a 36% mortality reduction by CRT alone in patients 
with class III and IV heart failure and ventricular dyssynchrony.184 It is assumed that 
these changes are related to LV functional improvement and decreased severity of MR.
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The relationship between intraventricular conduction delay and severity of functional 
MR has been described by Erlebacher and Barbarash.41 Severity is strongly associated 
with prolongation of QRS in general (≥130 ms), and with LBBB and right ventricular 
pacing in particular.
The immediate effects of CRT on functional MR in patients with heart failure with 
LBBB were examined by Breithardt et al.21 The hypothesis for acute reduction of MR 
severity is that recoordination of LV contraction by CRT increases the maximum rate of 
LV systolic pressure rise—the “closing force”—which then acutely increases transmitral 
pressure (the pressure difference between the left ventricle and the left atrium) and 
 consequently decreases ERO. In this study, an acute reduction in MR severity by 
 approximately 40% was observed in 23 of 24 patients (ERO decreased from 25 to 13 mm2 
and RVol from 32 to 19 mL/beat), which was paralleled by an increase in the rate of 
systolic LV pressure rise and transmitral pressure gradient. End-systolic volume decreased 
significantly (from 208 to 198 mL) and EF increased from 21% to 26%. More detailed 
studies by Kanzaki et al confirmed these results and revealed that MR occurred later in 
systole and had shorter duration (41% time decrease) during CRT.185 Using activation 
strain mapping, this group demonstrated that the interpapillary muscle activation time 
delay was the principal factor in determining MR severity in patients with heart failure 
and LBBB. Lancellotti et al demonstrated that exercise-induced increase in functional 
MR severity was mitigated by CRT; during exercise with CRT on, MR was related to 
mitral valve deformation (tenting), while it was related to inadequate increase in mitral 
closing force when CRT was off.186
Apart from these acute effects, CRT has long-term effects on LV reverse remodelling 
which translate into MR reduction as well, as was observed in several randomized 
trials.187,188 After 3 months, LV volumes had decreased by 10% compared to baseline, and 
by 19% after 29 months. It is important to realize that still 30% of patients are non -
responders. Ypenburg and colleagues nicely showed that MR reduction can occur 
immediately in patients with LV dyssynchrony involving the posterior papillary muscle 
area, while in patients without such particular dyssynchrony MR reduction occurs 
 secondary to LV reverse remodelling.189 It also appears that patients with non-ischaemic 
cardiomyopathy show more LV reverse remodelling than ischaemic patients.190 
In   clinical practice, CRT in heart failure patients is often combined with implantable 
 cardiac defibrillation (ICD) to reduce mortality related to cardiac arrhythmias.191 
Guideline indications overlap to a large extent.
CRT-ICD therapy has become an important therapeutic alternative or adjunct therapy 
in the treatment of heart failure patients with functional MR, and its role in our pro-
gramme is discussed in chapter 7 of this thesis.
Other Therapies
The role of optimal pharmacological therapy in functional improvement and mortality 
reduction in heart failure is beyond the scope of this thesis. However, it should be 
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 evident that pharmacological therapy has brought major advances in the treatment of 
heart failure patients and as such is the cornerstone of medical therapy, also after surgery 
has been performed.
Since many patients with heart failure and dilated cardiomyopathy die from ventricular 
arrhythmias, intraoperative therapies directed at the substrate for these abnormalities 
could improve late outcome. At this moment, our knowledge in this field is limited, 
especially for patients with idiopathic cardiomyopathy.
Surgical alternatives for heart failure other than those mentioned above include cardiac 
transplantation and implantation of ventricular assist devices. Transplantation is now a 
reasonably safe procedure with predictable long-term outcome. Shortage of donor 
organs has always limited the use of this technique and it is not expected that this will 
change in the future. A more promising evolution is seen in assist devices. Newer 
 generations show much lower thrombo-embolic complication rates and even lower 
infection rates. Experience with these devices as so-called “destination therapy” is 
increasing at high rate and shows promising results. A combination of assist device ther-
apy to unload the ventricle while other therapies aiming to regenerate the damaged 
myocytes (e.g., stem cell therapy, gene therapy) might be the solution of the future for 
patients who do not benefit from what we now address as “conventional heart failure 
surgery”.
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Outline of this Thesis
This thesis is the result of several studies on the clinical and echocardiographic outcomes 
of the treatment of functional mitral regurgitation. While the focus of this thesis is on 
the surgical approach to the functionally insufficient mitral valve, it will become clear 
that treatment of the patient with heart failure resulting from functional mitral 
 regurgitation is a joint effort between the cardiologist and the cardiothoracic surgeon, 
combined in the heart failure team.
Studies on ischaemic MR are presented in chapters 2 through 5. In chapter 2, the 2-year 
clinical and echocardiographic outcome of restrictive mitral annuloplasty and coronary 
revascularization is presented with special attention to LV reverse remodelling. 
In    chapter  3 the analysis of preoperative predictors for LV reverse remodelling is 
 presented, while in chapter 4 the focus lies on the long-term outcome of the structured 
approach to patients with functional ischaemic MR. In chapter 5 two rare cases of acute 
ischaemic MR without papillary muscle rupture, treated with restrictive mitral annulo-
plasty, are presented.
Heart failure related to non-ischaemic functional MR is the subject of the next two 
chapters. In chapter 6, magnetic resonance imaging is used as an imaging modality to 
assess LV reverse remodelling in patients with mild heart failure. Chapter 7 discusses our 
team’s individualised approach to patients with non-ischaemic cardiomyopathy.
Chapter 8 focuses on the topic of MR recurrence following treatment of functional MR. 
In chapter 9, results of treatment of functional tricuspid regurgitation are presented. The 
final chapter presents an overview and critical appraisal of latest developments in the 
treatment of patients with functional ischaemic MR and poor LV function.
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List of Abbreviations
CABG  Coronary artery bypass grafting 
CAD  Coronary artery disease 
CSD  Cardiac support device 
EF  Ejection fraction 
ERO  Effective regurgitant orifice area 
LV  Left ventricle / left ventricular
MI  Myocardial infarction
MR  Mitral regurgitation
MRI  Magnetic resonance imaging
NYHA  New York Heart Association
PCI  Percutaneous coronary intervention 
RR  Relative risk 
RVol  Regurgitant volume 
TEE  Transesophageal echocardiography
TR  Tricuspid regurgitation 
TTE  Transthoracic echocardiography
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TABLE 1
Overview of studies reporting on the presence and severity of functional mitral regurgitation in ischaemic and non-ischaemic aetiologies
Author, year 
of publication 
(study interval)
Number of 
patients
Aetiology EF (%) Assesment 
technique
MR presence 
and severity
Survival with 
MR present
Heart 
failure
Remarks
Lamas 199762 
(1987-1990)
727 ischaemic 32±7 angiography 19.4% overall; 
MR 1+ 75%, 
MR 2+ 23%
71% at 3.5 years survivors ≤ 16 
days following 
MI, EF ≤ 40%
Trichon 200363 
(1986-2000)
2,057 60% ischaemic 25 angiography 56% overall; 
MR 2+ 70%, 
MR 3+/4+ 30%
heart failure 
 patients, 
EF <40%
Blondheim 199164 
(1986-1988)
91 62% ischaemic 19±7 semiquantitative 
 echocardiography
57%  overall; 
mild 57%, 
 moderate 33%, 
 severe 9%
22% at 2.7 years 62% during 
follow-up
patients with 
dilated cardio-
myopathy, 
EF <40% and 
LVEDD >60 mm
Grigioni 200165 
(1990-1997)
303 
(194 with MR)
ischaemic  33±14 quantitative 
 echocardiography
38% at 5 years patients with 
MI > 16 days
Koelling 200266 
(1986-1990)
1,436 59% ischaemic 20±5 semiquantitative 
 echocardiography
moderate 30%, 
severe 19%
at 3 years: 
mild MR 57%, 
 moderate 50%, 
severe 35%
patients with 
EF ≤35%
Robbins 200367 
(1998)
221 
(111 inpatient)
not specified 28±8 semiquantitative 
 echocardiography
59% moderate or 
 severe; 
inpatient 74%, 
 outpatient 45%
61% at 5 years heart failure 
 patients, 
EF <40%
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Patel 200468 
(1996-2001)
558 71% ischaemic 21±7 quantitative 
 echocardiography
moderate 22%, 
 moderate or severe 
17%
at 3 years: 
 ischaemic 40%, 
non-ischaemic 
70% 
heart failure 
 patients, 
EF <35%
Bursi 200569 
(1988-1998)
773 ischaemic 45 semiquantitative 
echocardiography
mild 38%, 
moderate or severe 
12%
at 5 years:  
mild MR 62%, 
moderate or 
severe MR 40%, 
no MR 72% 
RR for heart 
failure with 
moderate 
or severe 
MR 3.44
population 
based cohort 
study (Olmsted 
County) follow-
ing myocardial 
infarction
Aronson 200670 
(2001-2005)
1,190 ischaemic 43 semiquantitative 
echocardiography
mild 40%, 
moderate or severe 
6%
at 3.3 years: 
mild MR 85%, 
moderate or 
 severe MR 67% 
graded 
 relationship 
with heart 
failure
patients 
with acute 
MI  without 
previous heart 
failure
Agricola 200971 
(2002-2007)
404 77% ischaemic 34±11 quantitative 
 echocardiography
only patients with 
MR selected: 
41% mild, 
59% moderate or 
severe
at 4 years: 
mild MR 64%, 
moderate MR 50%, 
severe MR 49%
graded 
 relationship 
with heart 
failure
prospective; 
patients 
with at least 
mild MR and 
EF <50%
Rossi 201172 1,256 both  aetiologies 
included, 
distribution not 
provided
32±8 quantitative 
 echocardiography
mild to moderate 
MR 49%, 
severe MR 24%
at 5 years: 
for  ischaemic 
mild to moderate 
MR: 60%, severe 
MR 23%; 
for non-ischaemic 
mild to moderate 
MR 50%, severe 
MR 27% at 4 years
chronic heart 
failure patients 
in 4 centres
EF, ejection fraction; MI, myocardial infarction; MR, mitral regurgitation; RR, relative risk
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TABLE 2
Overview of studies examining the effects of revascularization only on ischaemic MR
Author, year of 
publication 
(study interval)
Number of 
patients
Population characteristics Early 
 mortality
MR during follow-up Survival 
(by  preoperative MR 
grade if available)
Remarks
Aklog 200181 
(1992-1999)
136 CABG indication,MR grade 3+. 
Mean EF 38%. 
CABG only performed 
(at surgeon’s discretion) 
2.9% At 6 weeks: 
8% trace MR, 
52% mild MR, 
40% moderate/severe 
MR
Study shows that 
after CABG alone 92% 
of  patients have at least 
grade 2+ MR, and 40% 
show no improvement at 
all. Retrospective
Ellis 2002104 
(1994-1997)
4,221 total; 
53 with MR 3-4+
PCI patients 
(any indication except 
acute MI)
At 3 years for EF ≤40%: 
no MR 76%, moderate/
severe MR 47%
Study shows the adverse 
effect of MR on survival 
following PCI. No FU 
data on MR provided. 
Retrospective
Tolis 2002105 
(1986-1996)
75 pts with TEE, 
49 with MR 
(37% trace, 
53% mild)
Ischaemic cardiomyopathy, 
EF ≤ 30%, isolated CABG and 
MR 1+ to 3+. 
Mean EF 22% 
2.0% At 14 months: mean 
MR grade decreased 
from 1.7 to 0.5
With MR present: 
65% at 3 years, 
50% at 5 years
Limitations: low mean 
MR grade preoperatively; 
limited data provided. 
Retrospective
Trichon 2003106 
(1986-2001)
2,757 total; 
1,385  medical 
treatment, 
537 PCI, 
687 CABG, 
228 CABG + 
mitral valve 
surgery. Strategy 
determined by 
physician
Ischaemic MR > grade 2+ At 5 years: 
medical treatment 41%, 
PCI 64%, surgery 69%
Median follow-up 3.2 
years. No additional sur-
vival benefit from mitral 
valve surgery compared 
to CABG only (although 
higher NYHA class and 
higher MR grade in MV 
surgery stratum, so 
groups not comparable)
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Mallidi 2004107 
(1994-2002)
489 total; 
163 patients with 
mild to moderate 
MR, matched 1:2 
to 326 patients 
without MR 
Isolated CABG patients 
(n=6,443), MR severity 
based on preoperative 
LV  angiography
MR 3.5%, 
no MR 2.8% 
(P=0.86)
FU TTE available 
for 30% of patients 
in MR group at 16 
months: 31% showed 
 progression to 
 moderate or severe MR
At 6 years similar 
 survival (81% with MR, 
85% without MR)
Matched cohort. 
Mean FU 3.4 years. 
 Lower event-free survival 
in MR group at 6 years  
(37% vs. 65%), 
mainly CHF events
Lam 2005108 
(1980-2000)
467 Isolated CABG patients with 
grade 2+ ischaemic MR. 
 Propensity matched to 
CABG patients without 
MR for  survival analysis 
(210 matched pairs)
MR 3.3%, 
no MR 0 
(P=0.01)
FU TTE available 
for 33% of patients 
(at  discretion) at 
2 months median FU 
time. 
MR 0/1+ 40%, 
MR 2+ 38%, 
MR 3/4+ 22%
At 5 years: 
no MR 85%, MR 73% 
(P=0.003)
Mean FU 3.6 years. 
Moderate ischaemic MR 
was a risk factor for early 
mortality after CABG. 
Moderate ischaemic 
MR does not reliably 
resolve after CABG only 
and leads to reduced 
survival. Limitation: 
non -systematic and short 
echocardiographic FU
Wong 2005109 
(1991-2001)
251 total; 
219 CABG, 
32 CABG + MV 
 annuloplasty 
 (variety of rings) 
Patients with grade 3+ 
 ischaemic MR. Surgical 
 strategy at surgeon’s 
 discretion. 
Mean EF 39-42%
5.2% – 
CABG only 
4.1%, MV 
surgery 13%; 
P=0.06
Postoperative echo in 
109 patients. 
In CABG only group, 
48% showed MR 3+ 
or greater. Mean MR 
CABG only 2.6 vs. 2.0 in 
CABG + MV surgery
At 1, 5 and 10 years: 
84%, 68% and 37%; 
similar for CABG only 
compared to CABG + MV 
annuloplasty
Median FU 4.3 years. 
MV surgery not 
 standardized 
 (intraoperatively mean 
residual MR grade 1.6). 
Limited echocardio-
graphic FU
Grossi 2006110 
(1996-2004)
2,242 total; 
38% no MR, 
51% mild MR, 
12% moderate MR
CABG patients with less than 
severe MR on intraoperative 
TEE
1.9% At 5 years: 
no MR 86%, 
mild MR 84%, 
moderate MR 70% 
(P<0.001)
No data on postoperative 
MR severity. 
Mild and moderate MR 
were independently 
 associated with late 
mortality
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TABLE 2 (continued)
Author, year of 
publication 
(study interval)
Number of 
patients
Population characteristics Early 
 mortality
MR during follow-up Survival 
(by  preoperative MR 
grade if available)
Remarks
Di Mauro 2006111 
(1988-2002)
140 propensity 
matched patients; 
70 with grade 
2+ MR, 
70 with MR 0/1+
Isolated CABG patients with 
ischaemic cardiomyopathy 
(EF <30%) and grade 2+ MR 
or less. 
Mean EF 27%, EDV 118 mL
Total 6.4%; 
MR 0/1+ 
4.3%, 
MR 2+ 8.6% 
(NS)
At 5 years (TTE in 88% 
of patients): MR 0/1+ 
showed stable results 
(mean MR grade 0.7), 
MR2+ increased 
(mean MR grade from 
2.0 to 2.7)
At 8 years: 
MR 0/1+ 73%, 
MR 2+ 47% 
(P=0.029)
MR grade 2+ was an 
independent risk factor 
for late mortality. 
MR grade 2+ patients 
showed NYHA increase, 
stable LV diameters and 
volumes and increased 
MR. In MR 0/1+ patients, 
NYHA and MR were 
stable and LV reverse 
remodelling occurred
Calafiore 2008112 
(1994-2002)
4,226 total; 
no MR 2,805; 
MR 1+ 1,421; 
MR 2+ 167
Isolated CABG patients 
with EF >30% and 
ischaemic MR ≤ grade 2+
Total 2.2% Median FU 8.5 years. 
Presence of MR 
 independent risk factor 
for cardiac mortality  (not 
all-cause mortality) in 
patients with EF between 
31 and 40%, but not in 
patients with EF >40%
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Fattouch 2010114 
(2003-2008)
640 total; 
180 patients with 
moderate MR 
matched 1:2 to 
patients without 
MR
Isolated CABG patients with 
moderate MR (ERO 10-19 
mm2) or without MR
Total 1.9%; 
MR 2.2%, 
no MR 1.6% 
(P=0.42)
At 2.5 years: patients 
with moderate MR 
showed decrease 
(to mild MR) in 30% 
of cases, stable MR in 
35% and increase (to 
severe MR) in 35%. 
Exercise TTE in patients 
with mild MR showed 
increase of MR severity 
in 43%, and in patients 
with moderate MR in 
76% of cases
At 5 years: 
no MR 91%, 
moderate MR 74% 
(P<0.001)
Mean FU 2.5 years. MR is 
significant risk factor for 
mortality in patients with 
EF <40%. 
Ischaemic MR led to 
LV remodelling in all 
patients. 
No reliable reduction of 
MR severity with CABG 
alone. 
Often increase of MR 
severity with exercise
Kang 2011115 
(1996-2008)
185 total; 66 PCI, 
119 surgery 
(51 CABG, 
68 CABG with MV 
annuloplasty)
Patients with ischaemic MR, 
ERO ≥20 mm2, treated with 
PCI or surgery at discretion 
of physician. All patients had 
evidence of viability
Surgery 1.7%, 
PCI 3% 
(P=0.62)
At 6 months TTE in 
98% of survivors: 
 improvement of MR 
after PCI in 54% and 
after surgery in 79% of 
patients 
(P=0.001)
At 7 years: 
surgery 60%, 
PCI 55% (P=0.21). 
Event-free survival after 
surgery 58%, 
after PCI 50% 
(P=0.034). 
Registry study. 
Median FU 4.4 years. 
In surgery group better 
functional improvement 
(by NYHA class) and 
better EF improvement. 
Comparing CABG only 
to CABG + MV surgery, 
the latter had higher 
event-free survival, more 
improvement of MR 
(95% vs. 57%) and lasting 
reduction of LV volumes
CABG, coronary artery bypass grafting; CHF, congestive heart failure; EF, ejection fraction; ERO, effective regurgitant orifice area; FU, follow-up; 
LV, left ventricle/ventricular; MI, myocardial infarction; MR, mitral regurgitation; MV, mitral valve; NS, not significant; NYHA: New York Heart Association; 
PCI, percutaneous coronary intervention; RR, relative risk; TEE, transoesophageal echocardiogram; TTE: transthoracic echocardiogram
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TABLE 3
Overview of studies combining revascularization with mitral valve repair in ischaemic mitral regurgitation
Author, year of 
publication 
(study interval) 
Number of 
patients and 
characteristics
Techniques Early 
mortality
MR during 
follow-up
Actuarial survival 
and reoperations
Remarks
Bax, 2004 
Chapter 1
51 patients, 
MR grade 3-4+, 
mean EF 31%, 
LVEDD 64 mm
CABG with 3.3 grafts. 
Complete semirigid rings, 
downsizing by 2 ring sizes 
(mean size 28)
5.6% Complete echo FU. 
At 1.5 years 
mean MR grade 0.8; 
MR grade 2+ in 2%, 
MR 1+ in 22%
At 2 years: 84%. 
Reoperation rate 2.1%.
Significant functional 
 improvement (NYHA from 
3.4 to 1.3). Mean LVEDD 
from 64 to 58 mm and LVESD 
from 51 to 43 mm. 
LVRR (10% reduction LVEDD) 
in 58% of patients. Stringent 
MV repair protocol and FU
Mc Gee Jr, 2004116 
(1985-2002)
585 patients, MR 2-4+ No CABG data. 
MV annuloplasty: 
21% rigid ring (no down-
sizing), 
68% incomplete flexible 
band, 
11% bovine pericardium. 
6.3% In 75% of patients. 
Median FU 8 days. 
75% of echocardio-
grams made within 
2 months, 17% after 
1 year. 
At 6 months: MR 
3-4+ in 28% 
At 1 year: 82%, 
at 5 years 60%. 
Freedom from 
 reoperation 
at 5 years 97%
Median FU 2.3 years. 
Use of pericardium risk 
factor for recurrent MR. 
Limitations: non-uniform 
MV repair; no intraoperative 
echocardiography; very 
 limited echocardiographic 
FU; no details on bypass 
grafts
Glower, 2005118 
(1993-2002)
141 patients, 
moderate/severe MR, 
mean EF 40%.
MV annuloplasty: 
complete (semi-)rigid ring. 
Undersizing by 1 ring size. 
Median size 26
6.4% Mean FU 1.4 years, 
in 58% of patients. 
Recurrence rate 
moderate or severe 
MR 11%
At 5 years: 56%. 
Reoperation rate 2.1%
Study compares results to 
patients with non -functional 
MR; lower survival for 
ischaemic MR is explained 
by differences in preopera-
tive risk factors and not by 
ischaemic MR per se
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Braun, 2005 
(2000-2004) 
Chapter 2
87 patients, 
MR grade 3-4+, 
mean EF 32%, 
LVEDD 64 mm 
CABG with 3.3 grafts. 
Complete semirigid rings, 
downsizing by 2 ring sizes 
(mean size 26). 
Intraoperative goal of 8 mm 
coaptation length
8.0% Complete echo FU. 
At 1.5 years mean 
MR grade 0.6; 
MR grade 2+ in 8%, 
MR 1+ in 44%
At 2 years: 86%. 
Reoperation rate 2.5%.
Study identifies preoperative 
LVEDD ≤65 mm as predictor 
for LVRR. 
LVRR (10% reduction of 
LVEDD) in 61% of patients. 
Mean LVEDD decreased from 
64 to 58 mm and LVESD from 
52 to 44 mm. 
Significant functional 
 improvement (NYHA from 
3.0 to 1.3). 
Stringent MV repair protocol 
and FU
Geidel 2005117 
(2001-2004)
38 patients, 
MR grade 3-4+, 
EF ≤45% (mean 31%), 
mean LVEDD 60 mm
CABG with 2.3 grafts. 
Complete flexible (n=8) or 
semirigid rings. 
Dynamic downsizing by 2 to 
4 ring sizes. 
Intraoperative goal of 
≥5 mm coaptation length
2.6% Complete FU. 
Mean 13 months; 
17% MR grade 2+, 
31% grade 1+
At 1 year: 85%. 
No reoperations
Significant functional 
improvement. 
Mean LVEDD decreased from 
60 to 57 mm and LVESD from 
47 to 42 mm. 
LVRR (10% reduction) for 
LVEDD in 38% of patients and 
for LVEDV in 48%. 
Stringent MV repair protocol 
and FU
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TABLE 3 (continued)
Author, year of 
publication 
(study interval) 
Number of 
patients and 
characteristics
Techniques Early 
mortality
MR during 
follow-up
Actuarial survival 
and reoperations
Remarks
Mihaljevic, 2007119 
(1991-2003)
390 patients, 
MR grade 3-4+, 
EF <45%. 
100 patients CABG 
only, 
290 patients CABG + 
MV annuloplasty (at 
surgeon’s discretion). 
By propensity match-
ing 54 pairs
CABG without mammary 
artery in 40% of cases. 
MV annuloplasty: 
22% rigid ring, 
71% incomplete flexible 
band, 
7% bovine pericardium. 
Unclear downsizing
CABG only 
7.4%, 
CABG + MV 
surgery 3.7% 
(P=0.7)
Median TTE FU CABG 
only 5.5 months, 
CABG + MV surgery 
1.1 month. 
Postoperative MR 
grade 3/4+ after 7 
weeks in CABG only 
in 45% of patients, 
in CABG + MV sur-
gery 5%. 
After 7.4 years: 45% 
vs. 20% (estimate)
Similar survival for 
matched pairs and 
total cohort. 
For matched pairs at 
5 years: CABG only 
75%, CABG + MV 
surgery 75%. 
At 10 years: 47% and 
39%, respectively 
(P=0.6)
Median FU 5 years for CABG, 
4 years for CABG + MV 
surgery. 
Similar functional improve-
ment in both groups, no 
survival difference. 
High percentage of MR 
recurrence after CABG only. 
Limitations: non-uniform 
MV repair; no intraoperative 
echocardiography; low use 
of mammary artery grafts; 
 limited echocardiographic 
FU. 
Selection bias in treatment 
groups likely. Exact data 
on MR recurrence not 
 presented in a clear way
Gelsomino 2007120 
(2001-2007)
220 patients with 
mild to severe isch-
aemic MR. 
Patients with MV 
replacement (n=3) 
and residual MR 
≥ grade 2+ (n=11) 
were excluded and 
only survivors were 
 studied (from the 
original 251 patients)
CABG with 2.2 grafts 
 (complete as defined per 
territory). 
Complete (semi-)rigid rings 
with downsizing by 2 ring 
sizes; mean ring size 27. 
Intraoperative goal of 
≥5 mm coaptation length
0.8% Prospective TTE FU; 
after 1 year 85% 
of patients, after 3 
years 55%, after 5 
years 28%. 
Mean MR grade at 
1 year 0.3, at 3 years 
1.2, at 5 years 2.1. 
After 5 years, grade 
3-4+ in 44% of 
patients. LV volumes 
decreased at 1 year, 
but re-increased 
beyond that point
At 5 years: 83%. 
Freedom from 
 reoperation at 5 years 
78%
Median FU 2.8 years. 
Selected patients. High 
MR recurrence; predictors 
were sphericity index, 
 myocardial performance 
index, LV end-systolic volume 
(≥145 ml) and wall motion 
score index (≥1.5)
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Gelsomino, 2008121 
(2001-2006)
204 patients with 
mild to severe 
 ischaemic MR. 
Patients with MV 
replacement (n=4) 
and residual MR 
≥ grade 2+ (n=12) 
 excluded, as well as 
early deaths (n=4)
Same as in 2007 study. 
Median ring size 28.
Prospective TTE 
FU: early, mid-
term (median 6 
months) and late 
(median 2.9 years). 
Depending on late 
echocardiogram, 
41% of  patients 
were classified as 
responders (≥15% 
 reduction of indexed 
LV end-systolic 
volume). Recurrent 
MR ≥ grade 2+ in 
2% of responders 
and in 44% of non -
responders
At 5 years: 83% for 
whole population, 
89% for responders 
and 79% for non -
responders (P=0.036)
Median FU 2.9 years. 
Selected patients. 
Non-responders had 
more tethering and more 
LV remodelling signs on 
 preoperative echo. During 
FU, they also had an MV 
coaptation length <5 mm
Ngaage, 2008122 
(1978-2002)
179 patients with 
mostly severe MR 
and EF ≤35%
30% MV replacement, 
70% repair (60% downsized 
flexible incomplete band, 
9% repair without annu-
loplasty) 
9.5% TTE in 109 patients 
(no data on time 
interval provided): 
freedom from 
 moderate or severe 
MR at 3 years 63%
At 3 years: 71%, 
at 5 years: 51% . 
Reoperation rate 5%
Median FU 2.6 years. 
Heterogeneous approach to 
mitral valve, also affected by 
time era. No differences in 
survival between MV repair 
or replacement, but repair 
patients had significantly 
 better improvement of EF
Crabtree, 2008123 
(1996-2005)
257 patients; MR 
grade 3-4+, mean EF 
35%
CABG + MV annuloplasty 
with complete ring (56%) 
or band (44%); mean ring 
size 27
10.1% TTE in 57% of 
patients with mean 
interval of 1.7 years. 
Recurrent MR grade 
3-4+ in 28% of 
patients
At 3 years 68%, at 5 
years 52%
Mean FU 3.2 years. Observed 
mortality higher in patients 
with recurrent MR. 
Limitations: no data on 
grafting strategy provided; 
no data on LV geometry 
provided; limited echocar-
diographic FU
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TABLE 3 (continued)
Author, year of 
publication 
(study interval) 
Number of 
patients and 
characteristics
Techniques Early 
mortality
MR during 
follow-up
Actuarial survival 
and reoperations
Remarks
Braun, 2008 
(2000-2004) 
Chapter 3
100 patients, 
MR grade 3-4+, 
mean EF 27%, 
mean LVEDD 61 mm
CABG with 3.3 grafts. 
Complete semirigid rings, 
downsizing by 2 ring 
sizes (median size 26). 
Intraoperative goal of 8 mm 
coaptation length
8% Complete TTE FU, 
mean 3.8 years. 
MR ≥ grade 2+ in 
16% of patients 
(1 patient grade 3+, 
others grade 2+). 
In patients with 
preoperative LVEDD 
>65 mm, only 25% 
of survivors show 
LVRR (defined as 10% 
decrease of LVEDD)
At 3 years: 80%, 
at 5 years: 71% for 
the whole population. 
When stratified by 
LVEDD ≤65 mm, 
at 3 years: 87%, 
at 5 years: 80%, 
and for LVEDD >65 mm 
at 3 years: 61%, 
at 5 years: 49% 
(P=0.002)
Mean FU 4.3 years. 
Cut-off value of preoperative 
LVEDD 65 mm identified as 
independent predictor of 
mortality, and as a predictor 
for long-term LVRR 
Onorati, 2009124 
(2004-2007)
64 patients, 
NYHA III/IV, 
MR ≥ grade 3+
CABG with 2.3 grafts. 
Complete semi-rigid rings 
(including disease specific 
rings), downsizing by 2 ring 
sizes; median ring size 26 
6.2% At discharge, 
6 months, and late 
FU (mean 1.8 years). 
At 2 years MR ≥ 
grade 2+ in 27% of 
patients
At 2 years: 97% Mean FU 1.8 years. 
More CHF episodes in 
patients with MR recurrence. 
Patients with preoperative 
LVEDD >70 mm have more 
heart failure and more often 
developed recurrent MR
Williams, 2009125 
(1999-2006)
222 patients, 
MR severity not 
provided. 
Median EF 30%, 
mean LVEDD 54 mm, 
LVESD 43 mm
CABG with 2.8 grafts. 
Almost exclusively 
 complete nonflexible rings 
(mean ring size 24.8)
6.3% TTE FU available 
for 68% of patients, 
median 10.6 months. 
Severe recurrent MR 
in 1.3% of patients, 
moderate MR in 
9.4%
At 2 years: 72%, 
at 5 years: 55%
Median FU 2.2 years.
Limitations: no details on 
ring sizing provided (small 
mean size suggests adequate 
downsizing); 
limited echocardiographic 
FU. 
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Fattouch, 2009126 
(2003-2007)
100 patients with MR 
grade 2+, randomized 
to CABG only (n=52) 
or CABG + MV repair 
(n=48). 
Mean EF 43%, 
mean LVEDD 58 mm, 
LVESD 44 mm
CABG with 2.9 grafts, 
98% left ITA use. 
Complete semirigid rings, 
downsizing 8-10 mm based 
on echocardiographic 
anterior mitral leaflet 
length; no data on ring size. 
Intraoperative goal of 8 mm 
coaptation length
2.9% for 
whole group; 
CABG only 
1.8%,CABG + 
MV surgery 
4% (P=0.12)
Complete TTE FU. 
Mean FU 2.7 years. 
In CABG + MV 
surgery group only 
trivial MR (mean 
grade 0.08); 
in CABG only group, 
40% improved, 
25% had  moderate 
MR and 35% 
 moderate to severe 
MR
At 3 years 
CABG only: 93%, 
CABG + MV surgery: 
96%. 
At 5 years 
CABG only: 89%, 
CABG + MV surgery: 
94% (p=NS)
Single centre randomized 
trial. Mean FU 2.7 years. 
Better clinical improvement 
in CABG + MV surgery group 
(by NYHA class). 
Significant regression of LV 
dimensions and PA pressures 
in CABG + MV surgery group 
and improvement of EF, 
all of which were absent in 
CABG only group. 
CABG only group showed 
substantial increase in MR 
severity on exercise echo-
cardiography. No  survival 
difference (with short FU)
Pocar, 2010127 
(2000-2007)
57 patients, 
MR grade 2-3+
CABG with 2.5 grafts, 
ITA use in all patients. 
MV annuloplasty with 
downsizing by 2 ring 
sizes; complete rigid ring 
in 18%, complete flexible 
ring in 41%, and posterior 
 pericardial band calibrated 
on sizer in 40%; 
mean ring size 26.8
5.3% Recurrent MR 
grade 2+ in 37% of 
patients, 
grade 3+ in 10%
At 3 years: 87%, 
at 5 years: 66%
Mean FU 3.6 years. 
Limitations: non-structured 
approach to annuloplasty 
type; mean ring size hard to 
interpret
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TABLE 3 (continued)
Author, year of 
publication 
(study interval) 
Number of 
patients and 
characteristics
Techniques Early 
mortality
MR during 
follow-up
Actuarial survival 
and reoperations
Remarks
Grossi, 2011128 
(2003-2008)
73 patients with 
severe or moderate 
symptomatic MR, 
EF ≥ 25%, 
LVEDD <70 mm. 
Control arm of 
 multicenter random-
ized controlled trial 
(RESTOR-MV). 
Mean MR grade 2.54. 
Mean EF 38%
CABG with 2.8 grafts. 
Variety of MV annuloplasty 
devices, 21% non-rigid, 
mean size 27
4.1% At 2 years, moderate 
or worse  recurrent 
MR in 16% of pa-
tients. 
Mean MR grade at 1 
and 2 years 0.52 and 
0.35, respectively. 
EF increased from 38 
to 47% at 2 years
Crude mortality 24.7% 
at 2 years, no actuarial 
data provided
Control arm of randomized 
controlled trial.  Mean FU 
2.1 years. 
Significant improvement of 
NYHA functional class. 
Limitations: several annu-
loplasty devices used.
CABG, coronary artery bypass grafting; CHF, congestive heart failure; EF, ejection fraction; FU, follow-up; ITA, internal thoracic artery; 
LV, left ventricle/ventricular; LVEDD, left ventricular end-diastolic diameter; LVESD, left ventricular end-systolic diameter; 
LVRR, left ventricular reverse remodelling; MR, mitral regurgitation; MV, mitral valve; NS, not significant; NYHA, New York Heart Association; 
PCI, percutaneous coronary intervention; TTE, transthoracic echocardiogram
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TABLE 4
Overview of studies on mitral valve repair in non-ischaemic functional mitral regurgitation
Author, year of 
publication 
(study interval) 
Number of 
patients and 
characteristics
Techniques Early 
 mortality
MR during 
 follow-up
Actuarial survival 
and reoperations
Remarks
Bolling, 199812 
(1993-1997)
48 patients, 
24 non-ischaemic, 
24 ischaemic without 
ongoing ischaemia. 
Mean NYHA 3.9. 
Mean EF 16%
Undersized flexible ring 2.1% Decreased LVEDV 
from 281 to 206 mL. 
Increased EF 
from 17 to 26%
At 1 year: 82%, 
at 2 years: 72%.. 
One patient 
 underwent HTX
Mean FU 1.8 years. 
Functional improvement: 
NYHA from 3.9 to 1.8. 
Limitations: no exact data 
on ring size; no data on 
 postoperative MR
Gummert, 2003139 
(1996-2002)
66 patients, 
53 non-ischaemic, 
13 ischaemic. 
Mean EF 25%, 
LVEDD 69 mm
Complete downsized  
semirigid ring 
(mean size 28)
6.1% Postoperative mean 
MR grade 0.7 
at early FU and 
1.0 at late FU. 
Stable LVEDD 
(67 mm, P=0.093), 
increased EF from 25 
to 34% (P=0.028) 
At 1 year: 86%, 
at 5 years: 66%. 
Seven patients under-
went HTX, 
3 underwent reopera-
tion for recurrent MR 
Mean FU 2.3 years. 
Significant functional 
 improvement 
Romano, 2004138 
(1994-2003)
200 patients, 
mean EF 16%
Undersized flexible 
annuloplasty ring
5% At 1 year: 82%, 
at 3 years: 71%, 
at 5 years: 52% 
Mean FU 4.1 years. 
 Limitations: very limited data 
provided: no data on 
ring size, no echocardio-
graphic data (MR, LVRR)
Chapter 1
90
TABLE 4 (continued)
Author, year of 
publication 
(study interval) 
Number of 
patients and 
characteristics
Techniques Early 
mortality
MR during 
follow-up
Actuarial survival 
and reoperations
Remarks
Horii, 2006140 
(1998-2005)
55 patients, 
9 underwent 
 emergency surgery. 
Mean EF 25%, 
LVEDD 71 mm, 
 indexed LVEDV 
194 mL/m2, indexed 
LVESV 148 mL/m2 
MV repair in 67% of 
 patients: complete down-
sized (1-2 sizes) semirigid 
ring; mean size 26. 
Remainder had MV replace-
ment
15% for total 
population; 
4.3% for 
non-emergent 
cases
Elective patients 
divided into “small” 
(n=21) and “large” 
(n=25) groups based 
on preoperative 
mean indexed LVESV 
(150 mL/m2)
For elective patients, 
at 1 year: 73%, 
at 3 years: 58%, 
at 5 years: 52%. 
For “small LV” group: 
84%, 67% and 67%, 
respectively; for “large 
LV” group: at 1 year 
60%, at 3 years 42% 
(P=0.03)
Mean FU 2.4 years. 
In “small LV” group signifi-
cant functional improvement 
and reduction of LVEDD 
(66 to 61 mm) and indexed 
LVESV from 25 to 34 mL/m2. 
Significant increase in EF (25 
to 34%). No beneficial effects 
in the “large LV” group
Acker, 2006142 193 patients, 
mean EF 24%, 
mean LVEDD 70 mm, 
mean LVESV 270 mL. 
Part of the Acorn 
multicenter random-
ized controlled trial; 
102 patients MV 
surgery only, 
91 patients MV 
 surgery + CSD. 
6% ischaemic 
 aetiology
16% MV replacement, 
remainder MV annulo-
plasty: 65% complete rings, 
median ring size 26
1.6% Between 6 and 18 
months >80% of 
patients MR 0/1+. 
Whole group: 
significant and 
progressive decrease 
of LV volumes, and 
increase of EF. Mean 
MR grade reduced at 
1.5 years (from 2.7 
to 0.6). MR 2+ in MV 
surgery only in 15% 
of patients, with CSD 
in 3% (p=NS)
At 1 year: 87%, 
at 2 years: 85%
Very low mortality. Patients 
have highly dilated LV, but 
relatively low MR  severity. 
Patients with EF up to 
45% included. Significant 
functional improvement 
(by NYHA class but also on 
questionnaires and 6-minute 
walking test). CSD had 
 additional effect on  reduction 
of LV volumes compared to 
MV surgery alone
Acker, 2011143 Same as 2006 study. 
Aetiology 61% 
idiopathic cardio-
myopathy, 
17% valvular disease
Same as 2006 study. 
Ring size < 28 in 82% of 
patients
1.6% At 5 years, freedom 
from MR grade 3-4+ 
or redo MV surgery 
81% (5 patients 
underwent redo MV 
surgery)
At 1 year: 87%, 
at 2 years: 85%, 
at 5 years: 70%. 
Annual mortality rate 
6% per year
CSD did not influence 
 survival or MR recurrence, 
but had sustained additive 
effect on LV volumes and 
sphericity index
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Braun, 2011 
(2000-2008) 
Chapter 7
69 patients,  
mean EF 26%, 
mean LVEDD 67 mm, 
mean LVEDV 227 mL. 
28 patients 
MV   surgery only, 
41 patients also CSD 
implantation (when 
LVEDD >65 mm, from 
2002 onwards)
Complete semirigid ring. 
Median ring size 26. 
Tricuspid annuloplasty 71% 
5.8% for 
whole group; 
3.6% for MV 
surgery only, 
7.3% for MV 
surgery + CSD 
(p=0.64)
Median TTE FU 2.3 
years, 95% complete. 
MR ≥ grade 2+ in 
16% of patients for 
whole group; 23% 
for MV surgery only, 
8.3% for MV surgery 
+ CSD (P=0.067) 
For whole group 
at 1 year: 87%, 
at 2 years: 79%, 
at 5 years: 63%. 
For MV surgery only: 
86%, 75% and 55%, 
 respectively; 
for MV surgery + CSD: 
85%, 82% and 74%, 
 respectively (P=0.27) 
Mean FU 3.1 years.
CSD, cardiac support device; EF, ejection fraction; FU, follow-up; HTX, heart transplantation; LV, left ventricle/ventricular; 
LVEDD, left ventricular end-diastolic diameter; LVEDV, left ventricular end-diastolic volume; LVESV, left ventricular end-systolic volume; 
MR, mitral regurgitation; MV, mitral valve; NS, not significant; NYHA, New York Heart Association; TTE, transthoracic echocardiogram
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Abstract
Background: Data on combined coronary artery bypass grafting (CABG) and 
restrictive annuloplasty in patients with ischemic cardiomyopathy are scarce, and 
the effect on reverse left ventricular (LV) remodeling is unknown.
Methods and Results: 51 patients with ischemic LV dysfunction (LV ejection 
 fraction 31±8%) and severe mitral regurgitation (grade 3 to 4+) underwent CABG 
and restrictive annuloplasty with stringent downsizing of the mitral annulus (by 
2 sizes, Physio ring, mean size 28±2). Serial transthoracic echocardiographic studies 
were performed (before surgery and within 3 months and 1.5 years after surgery) to 
assess mitral regurgitation, transmitral gradient, leaflet coaptation, and left atrial 
and LV reverse remodeling. Clinical follow-up (New York Heart Association 
[NYHA] class, survival, events) was assessed at 2-year follow-up. Early operative 
mortality was 5.6%; at 2-year follow-up, all patients were free of endocarditis and 
thromboembolism, and 1 needed re-operation for recurrent mitral regurgitation; 
2-year survival was 84%. NYHA class improved from 3.4±0.8 to 1.3±0.4 (P<0.01), 
with all patients in class I/II. Intraoperative transesophageal echo showed minimal 
(grade 1+) mitral regurgitation in 8 patients and none in 43, without stenosis. Leaflet 
coaptation was 0.8±0.2 cm. These values remained unchanged; all patients had no 
or minimal (grade 1+) mitral regurgitation at 2-year follow-up. LV end-systolic and 
end-diastolic dimensions decreased from 51±10 to 43±12 mm (P<0.001) and from 
64±8 to 58±11 mm (P<0.001). Left atrial dimension decreased from 53±8 to 47±7 mm 
(P<0.001).
Conclusion: Excellent results of combined restrictive annuloplasty and CABG were 
obtained. Residual mitral regurgitation was absent/minimal at 2-year follow-up, 
associated with a significant reduction in left atrial dimension and LV reverse 
remodeling.
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Mitral regurgitation is frequently observed in patients1 with ischemic left ventricular (LV) dysfunction and can be related to dysfunction of the posterior mitral leaflet 
in patients with previous infarction of the inferior, posterior, or lateral wall, or can be 
related to annular dilatation and altered geometry in LV dilatation.2 Ischemic mitral 
regurgitation results in LV volume overload, resulting in further LV remodeling with 
progressive mitral regurgitation.2–4 This condition is associated with a high morbidity 
and mortality when treated conservatively.5,6 Alternatively, surgical correction of 
ischemic mitral regurgitation (in combination with coronary artery bypass grafting 
[CABG]) may be preferred. In particular, when CABG is considered, Aklog et al5 have 
recently demonstrated that revascularization alone does not resolve mitral regurgitation. 
However, cardiac surgery is associated with a relatively high (peri)operative morbidity 
and mortality.
Currently, data on combined CABG and surgical correction of mitral regurgitation in 
patients with ischemic LV dysfunction are scarce. Bolling et al7 have initially reported 
on the feasibility of restrictive mitral annuloplasty in patients with ischemic cardiomyo-
pathy. In addition, the authors have reported on the short-term and mid-term survival 
after restrictive mitral annuloplasty.8,9 The same group has also reported on reverse LV 
remodeling in 26 patients without coronary artery disease after mitral annuloplasty.10 
At present, however, not much information (in large patient populations) is available on 
the feasibility and outcome after CABG and restrictive mitral annuloplasty in patients 
with ischemic LV dysfunction. Accordingly, we have evaluated 51 patients with ischemic 
LV dysfunction and severe mitral regurgitation who underwent CABG and restrictive 
annuloplasty with stringent undersizing of the mitral annulus (by 2 ring sizes). From 
these data, operative morbidity and mortality and 2-year outcome are presented. 
In   addition, serial transthoracic echocardiographic studies were performed (one echo-
cardiogram before surgery, and two echocardiograms after surgery within 3 months after 
surgery and at 1.5-year follow-up), allowing for assessment of left atrial and LV reverse 
remodeling and also to determine the time-course of reverse remodeling.
Methods
Patients and Study Protocol
The study population consisted of 51 patients with ischemic cardiomyopathy and severe 
mitral regurgitation (grade 3 to 4+). The patients presented with heart failure and 58% 
had accompanying angina pectoris. In particular, 38 (75%) patients were in New York 
Heart Association (NYHA) class III and 9 (18%) were in class IV. The baseline 
 characteristics are presented in Table 1. All patients had multivessel disease (on average 
2.6±0.8 stenosed coronary arteries) and were scheduled for CABG with mitral valve 
repair.
Chapter 2110
CABG and Mitral Valve Surgery
The procedures were performed with the use of cardiopulmonary bypass with antegrade 
warm blood cardioplegia for myocardial protection. After median sternotomy, patients 
underwent conventional multivessel CABG, and internal mammary arteries were used 
if possible. Next, the right atrium was opened, and after a transseptal approach, mitral 
valve repair was performed. All patients underwent restrictive annuloplasty with implan-
tation of an undersized semirigid ring (aiming at stringent downsizing of the mitral 
annulus by 2 sizes).
TABLE 1
Patient Characteristics (n=51)
Age, y 64±8
Gender, M/F 43/8
DM 11 (22%)
HT  9 (18%)
Severe COPD 4 (8%)
Renal insufficiency  8 (16%)
Previous CVA 0
Previous MI 42 (82%)
Inferior, posterior, lateral 32 (76%)
Anterior  5 (12%)
Both  5 (12%)
Infarct >3 months 37 (88%)
Infarct <6 weeks  5 (12%)
Previous CABG  5 (10%)
NYHA  3.4±0.8
CCS  2.4±0.3
VD  2.6±0.8
LVEF, % 31±8
CVA, cerebrovascular accident; CABG, coronary artery bypass grafting; CCS, Canadian 
Cardiovascular Score; COPD, chronic obstructive pulmonary disease; DM, diabetes 
mellitus; HT, hypertension; LVEF, left ventricular ejection fraction; MI, myocardial 
 infarction; NYHA, New York Heart Association; VD, vessel disease.
Echocardiography
The clinical echocardiographic evaluation was as follows. A transthoracic (TTE) and 
transesophageal echocardiogram (TEE) were performed within 5 days before surgery. 
The TTE and TEE were performed without general anaesthesia to avoid underestima-
tion of the severity of the mitral regurgitation. For the TTE, patients were imaged in the 
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left lateral decubitus position using a commercially available system (Vingmed Vivid 
Seven; General Electric–Vingmed). Images were obtained using a 3.5 MHz transducer 
at a depth of 16 cm in the parasternal and apical views (standard long-axis, 2-chamber, 
and 4-chamber images). The left atrial diameter and LV dimensions (end-systolic and 
end-diastolic diameter) were determined from parasternal M-mode acquisitions. The 
severity of mitral regurgitation was graded semiquantitatively from color-flow Doppler 
in the conventional parasternal long-axis and apical 4-chamber images. Mitral regurgi-
tation was characterized as: mild, 1+ (jet area/left atrial area <10%); moderate, 2+ (jet 
area/left atrial area 10% to 20%); moderately severe, 3+ (jet area/left atrial area 20% to 
45%); and severe, 4+ (jet area/left atrial area >45%).11 Immediately after the TTE, a TEE 
was performed. The severity and precise mechanism of the mitral regurgitation were 
confirmed from the TEE images.
When the severity of the mitral regurgitation was less than 3+, a loading test (as described 
by Byrne et al12) was performed just before surgery during anesthesia. Briefly, a preload 
test is performed by rapid infusion of volume until the pulmonary artery capillary wedge 
pressure reaches 15 to 18 mmHg, whereas afterload testing includes administration of 
intravenous phenylephrine until the mean arterial pressure reaches 100 mmHg. After 
these provocative tests, the severity of mitral regurgitation is reassessed, and patients 
with 3 to 4+ mitral regurgitation underwent mitral valve repair.
Immediately after surgery, the TEE was repeated to assess residual mitral regurgitation, 
transmitral diastolic gradient (determined from continuous-wave Doppler), mitral valve 
area (by direct planimetry), and length of coaptation of the mitral leaflets. Serial TTEs 
were performed after surgery. The first TTE was performed within 3 months (average 
2.7±0.3) and the second TTE was performed 1.5 years after surgery. From these TTEs, 
the severity of mitral regurgitation, transmitral diastolic gradient, length of coaptation, 
left atrial diameter, and LV dimensions were assessed. All TTEs were analyzed in random 
order by 2 combined readers, blinded to the clinical data and the timing of the 
echocardiogram.
Assessment of Functional Status and Long-Term Follow-Up
Functional status was assessed according to the NYHA criteria (for symptoms of heart 
failure) and the Canadian Cardiovascular Society (CCS) classification (for angina 
 pectoris). Symptoms were evaluated within 1 week before surgery and at 2-year  follow-up. 
The long-term follow-up was performed by an independent physician at the outpatient 
clinic. In all patients, follow-up data (events) were (according to the protocol) assessed 
to maximum 2-year follow-up. Events included cardiac death, myocardial infarction, 
cerebrovascular accident, and endocarditis.
Moreover, the number of days the patient stayed in the intensive care unit was noted. 
The need for intra-aortic balloon pumping to sustain adequate hemodynamic status, 
dialysis, and reoperation for bleeding were also noted.
Chapter 2112
Statistical Analysis
Continuous data were expressed as mean±SD and compared using the Student t test for 
paired and unpaired data when appropriate. Comparison of proportions was performed 
using χ2 analysis. Repeated measurements were compared by 1-way ANOVA analysis. 
Survival over time was analyzed by the method of Kaplan–Meier. P<0.05 was consid-
ered significant.
Results
CABG, Mitral Valve Surgery, and Outcome
In 41 (80%) patients, severe (grade 3 to 4+) mitral regurgitation was confirmed by TTE 
and TEE performed within 5 days before surgery. In 10 (20%) patients, grade 2+ mitral 
regurgitation was observed during the TTE and TEE performed within 5 days before 
surgery. In these patients, provocative testing was performed in the operating room, 
resulting in grade 3 to 4+ mitral regurgitation in all patients. None of the patients had 
primary organic valvular disease. The mechanism underlying the mitral regurgitation 
was systolic restriction with annular dilatation in 43 patients (resulting in a central 
regurgitant jet) and restriction and isolated dysfunction of the posterior leaflet in 
8 patients (resulting in a slightly eccentric jet toward the lateral wall of the left atrium).
Mean cardiopulmonary bypass time was 168±21 minutes and mean ischemic time was 
121±32 minutes. On average, 3.3±0.8 grafts were placed. In 84% of patients, left and/or 
right mammarian arteries were used. For the mitral valve repair, semirigid rings 
(Carpentier–Edwards, Physio ring) were used; the mean ring size was 28±2 (range, 24 to 
30). In 16% of patients with severe tricuspid regurgitation, a concomitant tricuspid 
annuloplasty was performed.
The mean stay in the intensive care unit was 5±3 days, with a mean total hospital stay of 
12±4 days. The early operative mortality (<30 days) was 5.9% with 1 arrhythmic death 
(day 3) and 2 deaths caused by multi-organ failure (day 3 and day 9). Perioperative and 
postoperative complications included 1 myocardial infarction, 4 patients requiring an 
intra-aortic balloon pump, 3 patients requiring re-operation for bleeding, and 4 patients 
requiring temporary dialysis. During the 2-year follow-up, there were 4 heart failure 
deaths and 1 noncardiac death, resulting in 84% survival (Figure 1). One patient needed 
re-operation (at 9 months) for recurrent severe (3+) mitral regurgitation; endocarditis 
and cerebrovascular/thromboembolic events were not observed.
At 2-year follow-up, NYHA class had improved from 3.4±0.8 to 1.3±0.4 (P<0.01), and 
all surviving patients were in NYHA class I or II (Figure 2). The mean CCS score had 
improved from 2.4±0.3 to 1.2±0.5 (P<0.01). During the 2-year follow-up period, 
 2 patients required hospitalization for heart failure; 1 of these patients had recurrent 
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mitral regurgitation (see previous) and needed re-operation. After re-operation, the 
patient was in NYHA class II.
Echocardiography
All echocardiographic results are summarized in Table 2. Transthoracic echocardio-
graphy within 5 days before surgery demonstrated severe (grade 3 to 4+) mitral regurgi-
tation in 80% of patients. In the remaining 20% of patients, provocative testing during 
Figure 1. Kaplan–Meier mortal-
ity curve, demonstrating an 84% 
survival at 2-year follow-up.
Figure 2. Individual changes 
in NYHA class before surgery 
(baseline) and at 2-year fol-
low-up (2-year F-up). At 2-year 
 follow-up, NYHA class had 
improved from 3.4±0.8 to 1.3±0.4 
(P<0.01).
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TEE in the operating room (just before surgery) increased the mitral regurgitation, 
resulting in severe mitral regurgitation in all of these patients. On average, the patients 
had grade 3.4±0.6 mitral regurgitation (with 24 patients having grade 4+).
TABLE 2
Echocardiographic Results
Baseline TTE 
(51 pts)
Introperative  
TEE (51 pts)
3 mo TTE 
(48 pts)
1.5 y TTE 
(45 pts)
P
MR grade  3.4±0.6 0.2±0.4 0.4±0.3  0.8±0.8 <0.001
LA (mm) 53±8 — 51±8 47±7 <0.001
LVEDD (mm) 64±8 — 61±9  58±11 <0.001
LVESD (mm)  51±10 —  48±10  43±12 <0.001
Coaptation (cm) — 0.8±0.2  0.8±0.1  0.8±0.2 NS
Transmitral grade 
(mmHg)
— 2.7±0.6  2.5±0.4  2.4±0.6 NS
MVA (cm2) — 2.6±0.8 — — — 
LA, left atrium; LVEDD, left ventricular end-diastolic dimension; LVESD, left ventricular end-systolic 
dimension; MR, mitral regurgitation; MVA, mitral valve area; TEE, transesophageal  echocardiography; 
TTE, transthoracic echocardiography; Transmitral grade, mean diastolic transmitral gradient.
On the baseline TTE, the mean left atrial dimension was 53±8 mm (range, 38 to 75 mm). 
The LV end-diastolic and end-systolic dimensions were 64±8 mm (range, 45 to 88 mm) 
and 51±10 mm (range, 38 to 75 mm).
TEE immediately after surgery showed minimal residual mitral regurgitation (grade 1+) 
in 8 (16%) patients, whereas the remaining 43 (84%) patients had no residual mitral 
regurgitation. On average, the patients had grade 0.2±0.4 mitral regurgitation. The 
mean length of coaptation was 0.8±0.2 cm (range, 0.5 to 1.1 cm). The mean transmitral 
diastolic gradient was 2.7±0.6 mmHg (range, 1.8 to 4.3 mmHg). No systolic anterior 
movement of the anterior leaflet was observed in any patient. The mitral valve area 
(assessed by direct planimetry) was 2.6±0.8 cm2 (range, 2.1 to 3.4 cm2).
The first follow-up TTE (<3 months after surgery) showed similar results. The mean 
mitral regurgitation grade was 0.4±0.3; the mean transmitral diastolic gradient was 
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2.5±0.4 mmHg; the mean length of coaptation was 0.8±0.1 cm. Comparable results were 
obtained from the second follow-up TTE, obtained at 1.5 years after surgery. The mean 
mitral regurgitation grade was 0.8±0.8 (1 patient had grade 2+ mitral regurgitation and 
10 patients had grade 1+ mitral regurgitation); the transmitral diastolic gradient was 
2.4±0.6 mmHg, and the length of coaptation was 0.8±0.2 cm.
The mean left atrial dimension decreased gradually from 53±8 mm at baseline to 51±8 mm 
at early follow-up and to 47±7 mm at late follow-up (P<0.001; Figure 3).
Figure 3. Scatter plot showing 
the mean left atrial (LA) 
dimension at baseline, and at 
early (within 3 months after 
surgery) and late (1.5 years 
after surgery) follow-up.
The mean LV end-systolic dimension decreased significantly from 51±10 mm at baseline 
to 48±10 mm at early follow-up and to 43±12 mm at late follow-up (P<0.001; Figure 4). 
Of interest, when 10% reduction in dimension was considered indicative of significant 
reverse remodeling, 33% of patients demonstrated reverse remodeling at early follow-up, 
40% at late follow-up, and 27% did not exhibit reverse remodeling. The patients without 
reverse remodeling had a significantly larger LV end-systolic dimension as compared 
with the patients with early or late remodeling (62±8 mm versus 48±8 mm versus 
47±5 mm, P<0.05).
The mean LV end-diastolic dimension decreased significantly from 64±8 mm at baseline 
to 61±9 mm at early follow-up to 58±11 mm at late follow-up (P<0.001; Figure 5); 22% 
of patients demonstrated reverse remodeling at early follow-up, 36% at late follow-up, 
and 42% did not exhibit reverse remodeling. The patients without reverse remodeling 
had a significantly larger LV end-diastolic dimension as compared with the patients with 
early or late remodeling (69±8 mm versus 61±6 mm versus 60±5 mm, P<0.05).
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Discussion
The number of patients presenting with heart failure and a severely dilated LV is 
 increasing exponentially,13 with the majority having coronary artery disease as the 
 underlying cause.14 Data from the Duke Cardiovascular Databank1 have demonstrated 
that mitral regurgitation is observed frequently in these patients, with 30% having severe 
mitral regurgitation. In these patients, conservative management is associated with a 
poor prognosis, with a 1-year survival of 30% to 40%.15 Moreover, Grigioni et al16 have 
demonstrated that the mortality risk is directly related to the severity of mitral regurgi-
tation. In addition, further analysis of the data from the Duke Cardiovascular Databank 
demonstrated that in patients with ischemic mitral regurgitation, CABG with mitral 
Figure 4. Scatter plot show-
ing the mean left ventricu-
lar end-systolic dimension 
(LVESD) at baseline, and at 
early (within 3 months after 
surgery) and late (1.5 years 
after surgery) follow-up.
Figure 5. Scatter plot show-
ing the mean left ventricu-
lar end-diastolic dimension 
(LVEDD) at baseline, and at 
early (within 3 months after 
surgery) and late (1.5 years 
after surgery) follow-up.
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valve surgery is associated with an improved survival as compared with medical 
therapy.6
Still, surgical interventions in patients with ischemic cardiomyopathy are associated 
with a relatively high mortality, and CABG procedures alone do not reduce the severity 
of mitral regurgitation in these patients.5 However, recent data from Bolling et al7 have 
demonstrated the feasibility of mitral valve repair by downsizing the mitral annulus 
using a flexible ring. Using their initial results, the authors have demonstrated a 1- and 
2-year survival of 82% and 71%, respectively, in 48 patients (with ≈50% having ischemic 
cardiomyopathy) undergoing restrictive mitral valve annuloplasty.9 More recently, Szalay 
et al17 reported an early mortality of 6.6% with an 85% survival at 2 years in 91 patients 
with ischemic cardiomyopathy and moderate–severe mitral regurgitation undergoing 
CABG and mitral valve repair. In addition, Gummert et al18 reported a 1-year survival of 
86% (although the majority [80%] of the 66 patients in that study had dilated cardiomyo-
pathy and only 20% had ischemic cardiomyopathy). The results in the current study are 
in line with these results: the early mortality was 5.9% with an 84% survival at 2-year 
follow-up, and all surviving patients had minimal heart failure symptoms and were in 
NYHA class I or II at 2-year follow-up. Finally, the truly restrictive annuloplasty resulted 
in virtually no recurrence of mitral regurgitation at late follow-up, with restoration of 
leaflet coaptation, without inducing mitral valve stenosis. Only 1 (2%) patient needed 
re-operation for recurrent mitral regurgitation. In addition, no endocarditis or thrombo-
embolic events occurred.
In these patients, serial echocardiographic studies were performed, allowing evaluation 
of LV reverse remodeling after surgery. The results demonstrated that significant reverse 
remodeling occurred after surgery, in line with results of Szalay et al.17 Bolling et al2 
hypothesized that stabilization of the mitral annulus and unloading of the LV may be 
responsible for the reverse remodeling. It is well-known that a reduction in LV dimen-
sions is associated with a favorable prognosis.19
A novel aspect of the current study is the serial echocardiographic assessment of 
LV dimensions after surgery. The results showed that reverse remodeling of the LV is a 
 gradual and time-dependent process. A regression in LV end-systolic dimension was 
observed in 73% of patients, with 33% occurring at early follow-up. In contrast, a 
decrease in LV end-diastolic dimension was observed less frequently (56% of patients), 
with 22% occurring at early follow-up. Moreover, in 27% and 42% of patients, no 
 reductions in LV end-systolic and end-diastolic dimensions were observed. These 
patients were characterized by larger LV dimensions at baseline; this finding may suggest 
that extensive LV dilation may be an irreversible process and surgery should preferably 
be performed before extensive dilatation has occurred.
Finally, the left atrium also exhibited reverse remodeling over time; the clinical value of 
this phenomenon is not entirely clear, although some studies have suggested that an 
enlarged left atrium was independently predictive of worse long-term outcome.20
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Limitations
In the current study, only patients with severe (grade 3 to 4+) mitral regurgitation were 
included, and additional studies are needed in patients with ischemic cardiomyopathy 
and mild-to-moderate mitral regurgitation.
In 16% of patients, a concomitant repair of the tricuspid valve was performed; this may 
have influenced results.
Although reverse remodeling was demonstrated in the current study, identification of 
patients who will benefit from surgery remains difficult. The patients without reverse 
remodeling had significantly larger LV end-diastolic and end-systolic dimensions, 
 suggesting that severe dilatation will prevent reverse remodeling. Larger studies are 
needed to further evaluate this issue. Moreover, viability testing was not routinely 
 performed in these patients and LV reverse remodeling may be partially related to 
improvement of function of hibernating myocardium after CABG. Inclusion of  viability 
assessment may further optimize selection of patients who may benefit most from 
 combined revascularization and mitral valve repair.
Conclusion
CABG and truly restrictive mitral annuloplasty in patients with ischemic cardiomyo-
pathy and severe mitral regurgitation corrected mitral regurgitation in virtually all 
patients, with a 2-year survival of 84%. Leaflet coaptation was restored without inducing 
mitral stenosis. Significant reverse LV remodeling appeared over time, with a reduction 
in LV end-systolic dimension occurring earlier and more frequently as compared with 
LV end-diastolic dimension.
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Abstract
Objective: Ischemic mitral regurgitation can be treated with a restrictive mitral 
annuloplasty, with or without coronary revascularization. In this study, the extent of 
reverse remodeling of the left ventricle following this strategy is assessed, as well as 
the factors that influence it.
Methods: Eighty-seven consecutive patients with ischemic mitral regurgitation and 
a mean ejection fraction of 32±10% underwent restrictive mitral annuloplasty 
(downsizing by two ring sizes, median ring size 26), with additional coronary 
 revascularization in 75 patients. All underwent transthoracic echocardiography 
18 months after surgery to assess residual mitral regurgitation, mitral valve gradient 
and left ventricular end-systolic and end-diastolic dimensions. Univariate and 
 multivariate analysis was performed to identify predictors for reverse remodeling, 
defined as a 10% reduction in left ventricular dimension. Receiver-operating 
 characteristic  analysis was used to identify cut-off values for preoperative left 
 ventricular dimensions in predicting reverse remodeling.
Results: Early mortality was 8.0% (seven patients, three non-cardiac), late mortality 
was 7.5% (six patients, four non-cardiac). There were two reoperations (redo 
 annuloplasty), and four readmissions for heart failure. At 29 months follow-up, 
NYHA class improved from 3.0±0.9 to 1.3±0.5 (P<0.01). Mitral regurgitation grade 
decreased from 3.1±0.5 to 0.6±0.6 at 18 months, left ventricular end-systolic 
 dimension decreased from 52±8 to 44±11 mm (P<0.01), and end-diastolic dimension 
from 64±8 to 58±10 mm (P<0.01). Multivariate analysis identified preoperative left 
ventricular end-diastolic dimension as the single best factor in predicting  occurrence 
of reverse remodeling. For end-systolic dimension, 51 mm was the optimal cut-off 
value to predict reverse remodeling (specificity and sensitivity 81%, area under curve 
0.85); for end-diastolic dimension, the cut-off value was 65 mm (specificity and 
 sensitivity 89%, area under curve 0.92).
Conclusions: Stringent restrictive mitral annuloplasty with or without revasculari-
zation provides excellent clinical results with acceptable mortality. At 18 months 
follow-up, there is no significant residual mitral regurgitation. Reverse remodeling 
occurs in the majority of patients, but is limited by preoperative left ventricular 
dimensions. In patients with a left ventricular end-diastolic dimension exceeding 
65 mm, additional surgical procedures are necessary to try and obtain reverse 
 remodeling in this subgroup.
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Chronic ischemic mitral regurgitation (IMR) should be defined as mitral  regurgitation (MR) resulting from coronary artery disease (CAD).1,2 This definition excludes all 
cases in which MR merely coincides with CAD. Regional wall motion abnormalities 
secondary to ischemia, whether persistent—following myocardial infarction—or 
 transient, give rise to functional MR.3 Echocardiographically, functional MR is 
 characterized by leaflet coaptation failure due to systolic restrictive motion of one or 
both valve leaflets (Carpentier type IIIb)4, often combined with annular dilatation.
In the past, revascularization alone was believed to correct IMR by improving LV 
 function.5,6 This may seem attractive, since isolated CABG carries a lower perioperative 
risk than a combined procedure. Nowadays, there are convincing arguments that negate 
a conservative approach.
First, IMR is not a benign condition, but instead carries a two-fold excess mortality of 
62% at 5 years in post-infarction patients irrespective of other risk factors.1 In addition, 
it is a progressive disorder in which MR-related LV volume overload promotes further 
LV remodeling, leading to worsening of MR. Follow-up in moderate chronic IMR 
patients has shown that isolated CABG does not always cure MR.7 Intervention on the 
mitral valve can be limited to a stringent ‘restrictive’ (down-sized) ring annuloplasty, 
which is a relatively simple technique with an acceptable mortality even in high-risk 
end-stage heart failure patients with dilated cardiomyopathy.8
There is still controversy regarding the outcome of chronic IMR patients treated with 
combined CABG and restrictive mitral annuloplasty (RMA). We describe our  experience 
with this approach in 87 consecutive patients with respect to clinical outcome and echo-
cardiographic follow-up. We focus on durability of the annuloplasty technique by 
assessment of MR, and on LV reverse remodeling, especially in relation to the extent of 
preoperative LV dilatation. In an earlier report9 we demonstrated that not all patients 
show reverse remodeling following successful RMA with or without CABG. In this 
study, we assessed the influence (and predictive value of ) several preoperative variables 
on reverse LV remodeling.
Materials and methods
Patient Population
Between January 2000 and March 2004, 87 consecutive patients with chronic ischemic 
mitral regurgitation underwent coronary revascularization and restrictive mitral annulo-
plasty. Mean age was 66.0±10.0 years (range 36.8–84.6 years), and 57 (65.5%) patients 
were male. All patients had coronary artery disease and previous myocardial infarction. 
Patients with signs and symptoms of heart failure and/or evidence of mitral  regurgitation 
on LV angiography underwent preoperative transthoracic echocardiography (TTE) to 
assess severity of MR. All patients with MR grade 2+ or more underwent outpatient 
preoperative transesophageal echocardiography (TEE) to establish the mechanism 
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of MR. Criteria for IMR were presence of systolic restrictive leaflet motion, with or 
without annulus dilatation and absence of other mitral valve pathology. Patients with 
ischemic MR grade 3+ or 4+ were scheduled for RMA with or without CABG. In patients 
who were scheduled for CABG anyway, with MR grade 2+ or fluctuating MR, an intra-
operative loading test was performed by canulation of the ascending aorta and  increasing 
the pulmonary capillary wedge pressure with 15 mmHg compared to baseline value by 
rapid filling through the aortic cannula,2,10 prior to the institution of cardiopulmonary 
bypass. If MR increased to grade 3+ or 4+ patients underwent RMA.
Patients with coexisting aortic valve disease or previous aortic valve surgery and patients 
who had concomitant surgery for LV aneurysm were excluded from this study, as were 
patients with functional MR based on idiopathic dilating cardiomyopathy. Patients 
with organic mitral valve abnormalities were also excluded. There were no patients 
excluded based on critical preoperative status; mean logistic EuroSCORE was 11.0±10.7 
(range 2–63). Fourteen (16.1%) patients had their last myocardial infarction 6 weeks or 
less before surgery, three patients were ventilator-dependent preoperatively, three had 
IABP support and eight had intravenous inotropic drugs. Preoperative clinical and 
angiographic characteristics are presented in Table 1.
Mean preoperative MR grade was 3.1±0.5 (86.2% of patients had grade 3+ or 4+). Mean 
LV ejection fraction was 32±10%, baseline LV end-systolic dimension (LVESD) was 
52±8 mm, LV end-diastolic dimension (LVEDD) was 64±8 mm.
Operative Technique
All operations were performed through midline sternotomy on normothermic 
 cardiopulmonary bypass with intermittent antegrade warm blood cardioplegia. 
An intraoperative loading-test was performed in 16 (18.4%) patients with grade 2+ or 
fluctuating MR, and showed increase to grade 3+ or 4+ in all cases.
CABG was performed in 75 (86.2%) patients; 12 patients did not undergo  revascularization 
because of absence of angina and of ischemia on myocardial scintigraphy or because of 
patent coronary artery bypass grafts in redo operations. Revascularization of the anterior 
myocardium was always achieved with the LITA. For other territories, the RITA was 
used in patients under the age of 65 with good target vessels—either as an in situ graft 
or as a free graft with proximal anastomosis to the LITA. In other cases, the saphenous 
vein was used. In one patient, the gastroepiploic artery was used for the inferior wall.
Exposure of the mitral valve was through a vertical transseptal approach. Mitral 
 annuloplasty ring size (Carpentier Edwards Physioring, Edwards Lifesciences, Irving, 
CA, USA) was determined by standard measurement of the intertrigonal distance and 
anterior leaflet height, and then stringent downsizing by two ring sizes was performed. 
The rings were anchored using multiple (14–16) deep u-shaped stitches of Ethibond 2-0 
(Ethicon, Inc., Somerville, NJ, USA) or Ti-Cron 2-0 (Syneture, Norwalk, CT, USA).
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TABLE 1
Preoperative Clinical and Echocardiographic Data
NYHA functional class 3.0±0.9
≤ II 16 (18.4%)
III 44 (50.6%)
IV 27 (31.0%)
CCS score 2.3±1.3
Logistic EuroSCORE 11.0±10.8 (range 2–63)
Previous myocardial infarction 87 (100%)
Inferior/posterior/lateral  75 (86.2%)
Last MI <6 weeks  14 (16.1%)
Duration of symptoms (years)    5.2±6.7 (range 0.5–23)
IABP 3
Intravenous inotropes 8
Ventilator dependency 3
Previous CABG 6 (6.9%)
Preoperative CAD 87 (100%)
1-vessel  7 (8.0%)
3-vessel  65 (74.7%)
Wall motion abnormality
Regional  71 (81.6%)
Global (dilated cardiomyopathy)  16 (18.4%)
NYHA, New York Heart Association; CCS, Canadian Cardiovascular Society; MI, myocardial 
infarction; IABP, intra-aortic balloon pump; CABG, coronary artery bypass grafting; CAD, 
coronary artery disease.
Ninety-three percent of the rings were size 28 or less (mean size 26). Tricuspid ring 
 annuloplasty was performed in 16 (18.4%) patients when annulus enlargement had been 
observed on echocardiography (≥40 mm), or was present on intraoperative inspection. A 
Carpentier Edwards Classic annuloplasty ring or Edwards MC3 annuloplasty ring (both 
manufactured by Edwards Lifesciences, Irving, CA, USA) was used. In six (6.9%) 
patients with persistent or chronic atrial fibrillation endocardial unipolar radiofrequency 
ablation was done with the Cardioblate device (Medtronic, Inc., Minneapolis, MN, 
USA), as described by Melo et al.11 One patient underwent simultaneous left upper lobe 
lobectomy for non-small cell lung carcinoma. Mean cardiopulmonary bypass time and 
aortic cross-clamping time were 189±52 and 125±37 min, respectively. Surgical aspects are 
summarized in Table 2.
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TABLE 2
Surgical Data
Positive loading test 16 (18.4%)
CABG 75 (86.2%)
No. of distal anastomoses/patient 3.3±1.3
Mitral annuloplasty ring size median 26
24 13 (14.9%)
26 32 (36.8%)
28 36 (41.4%)
30 3 (5.7%)
32 1 (1.1%)
Tricuspid valve annuloplasty 16 (18.4%)
Median ring size 28
CPB time (min) 189±52
Aortic cross-clamp time (min) 125±37
CPB, Cardiopulmonary bypass.
Intra- and Post-operative Echocardiography and Clinical Follow-up
Intraoperative TEE was used in all patients to evaluate residual MR, mitral valve 
 gradient, mitral valve area and leaflet coaptation length (defined as the length of 
 coaptation of the anterior and posterior leaflet at the level A2-P2 in end-systole), 
 residual tricuspid regurgitation (TR) and LV function. We aimed at no MR and a 
 minimum coaptation length of 8 mm.
Before discharge, TTE was used to determine left atrial and LV dimensions, severity of 
MR and TR, and mitral valve gradient. All patients were rescheduled for TTE between 
3 and 6 months following surgery and after 18 months. All echocardiograms were 
 analyzed in random order by two combined readers, blinded to clinical data and to the 
timing of the study. Clinical follow-up was achieved at the outpatient clinic concurrent 
with TTE, and by telephone interviews in August 2004. NYHA functional class was 
assessed, events scored included reoperation; balloon angioplasty; myocardial infarction; 
readmission for heart failure; thrombo-embolic complications and endocarditis. Surface 
electrocardiograms were made to assess cardiac rhythm.
Statistical Analysis
Continuous data are expressed as mean±standard deviation unless otherwise stated, and 
compared using Student’s t-test for paired and unpaired data when appropriate. 
Proportions were compared by χ2 analysis with Yates’ correction. Actuarial survival over 
time and event-free survival were analyzed using the method of Kaplan–Meier. 
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Univariate and multivariate logistic regression analyses were performed to characterize 
predictors of reverse left ventricular remodeling. Variables considered were: gender, age, 
baseline NYHA class, left ventricular ejection fraction, severity of MR, left atrial 
 dimension, left ventricular end-systolic and end-diastolic dimensions. Optimal cut-off 
values of LVESD and LVEDD to predict reverse remodeling were determined by 
receiver- operating characteristic (ROC) curve analysis. The optimal cut-off value was 
defined as that providing maximal accuracy to distinguish between responders and non -
responders. For all tests, a P value <0.05 was considered significant. SPSS statistical 
 software (SPSS version 11.5, SPSS, Inc., Chicago, IL, USA) was used for calculations.
Results
Mitral valve repair could be achieved in all patients, irrespective of the degree of leaflet 
tethering. Intraoperative post-repair TEE showed absence of MR in 78 (90%) patients 
and trace or grade 1+ MR in 9 (10%); mean MR grade was 0.2±0.3. Leaflet coaptation 
length was 8±2 mm; no patient showed mitral stenosis (mean transvalvular gradient 
2.9±1.1 mmHg, mean valvular area 2.8±0.6 cm2).
Immediate Outcome
There were no intraoperative deaths. In the post-operative course, three (3.7%) patients 
required intra-aortic balloon counterpulsation because of low cardiac output. Six (6.9%) 
patients needed temporary dialysis for renal failure. One patient sustained a myocardial 
infarction (for which he underwent emergency redo coronary revascularization). 
There were no neurologic complications. One (1.1%) patient developed mediastinitis. 
Mean ICU stay was 5±3 days.
Early mortality (30-day mortality and in-hospital mortality when length of stay after 
surgery exceeded 30 days) was 8.0% (seven patients). Causes of death were: intractable 
ventricular arrhythmia (n=2), multi-organ failure (MOF) following myocardial 
 infarction (1), intractable vasoplegia (1), septicemia and MOF following duodenal 
 perforation after feeding tube insertion (1), RV rupture following mediastinitis (1) and 
pneumonia following exacerbation of leukemia (1).
Long-term Follow-up
Follow-up for surviving patients was complete. Mean duration of clinical follow-up was 
29±14 months (range 6–54 months). Six patients (7.5%) died during follow-up of 
 congestive heart failure (1), ventricular arrhythmia (1), traumatic intracranial hemor-
rhage (1) and malignant disease (3). Therefore, actuarial survival at 2 years was 85.6% 
(Figure 1).
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Figure 1. Kaplan–Meier plot showing 
actuarial survival. Number of patients at 
risk is added above the time axis.
Two patients needed reoperation for recurrent MR. The first patient, with dilated 
 ischemic cardiomyopathy had no MR directly after surgery with 6 mm leaflet  coaptation 
(initial ring size 28). Over time, MR gradually increased with progressive heart failure. 
After 12 months, she was reoperated and a size 26 annuloplasty ring was inserted, with 
no MR 17 months after her second operation. The other patient, an acromegalic man, 
had a size 32 ring without regurgitation initially. After 6 months, he was readmitted for 
congestive heart failure with massive MR. On reoperation, a partial ring dehiscence was 
observed at the posterior commissure. Refixation of the ring was successful and the 
patient is asymptomatic 17 months later. Two patients underwent PTCA during the 
follow-up period, and four were readmitted for congestive heart failure. NYHA class 
improved from 3.0±0.9 to 1.3±0.5 (P<0.01), with 18 patients in NYHA class II and 
1 patient in class III.
Mitral Regurgitation and LV Remodeling at Long-term Follow-up
At 18 months follow-up, mean MR grade was 0.6±0.6 (MR trace or grade 1+ in 28 
patients and grade 2+ in 5).
Left atrial dimension decreased from 54±6 mm at baseline measurement to 48±6 mm at 
18 months (P<0.01). LVESD decreased from 52±8 to 44±11 mm (P<0.01), and LVEDD 
decreased from 64±8 to 58±10 mm (P<0.01).
Forty-six (60.5%) surviving patients demonstrated significant reverse LV remodeling, 
considering a 10% reduction in LVEDD as significant. In this subset of patients, LVEDD 
decreased from 60±5 to 51±4 mm (P<0.01), whereas LVESD changed from 47±6 to 
37±5 mm (P<0.01). Echocardiographic data are presented in Table 3.
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Baseline characteristics for patients with and without LV reverse remodeling were 
 comparable, except for baseline LVEDD (71±6 versus 60±5 mm, P<0.01) and LVESD 
(58±8 versus 47±6 mm, P<0.01).
ROC curve analysis showed that the optimal cut-off value for LVESD to predict reverse 
remodeling was 51 mm; application of this cut-off value yielded a predictive sensitivity 
and specificity of 81% (area under the curve 0.85, see Figure 2). ROC curve analysis on 
LVEDD identified an optimal cut-off value of 65 mm, which yielded a sensitivity and 
specificity of 89% (area under the curve 0.92, see Figure 3) to predict reverse left 
 ventricular remodeling. Multivariate analysis demonstrated that LVEDD was the single 
best  predictor of reverse remodeling.
TABLE 3
Echocardiography Data before Surgery and at late Follow-up
Baseline Late follow-up 
(18 months)
MR grade 3.1±0.5 0.6±0.6 P<0.01
None - 30
Trace or 1 + - 28
2 + 12 (13.8%)  5
3 + 56 (64.4%) -
4 + 19 (21.8%) -
Coaptation length (mm)  3±1  8±1 P<0.01
Left atrial dimension (mm) 54±6 48±6 P<0.01
LV end-systolic dimension (mm) 52±8  44±11 P<0.01
LV end-diastolic dimension (mm) 64±8  58±10 P<0.01
LV ejection fraction (%) 32±10 -
MR, mitral regurgitation; LV, left ventricular.
Discussion
IMR is a complication of coronary artery disease that is frequently overlooked, in spite 
of its prevalence of 19% in post-infarction patients.12 The high prevalence of IMR 
 combined with a dismal prognosis warrants a search for its presence in patients at risk. 
Since IMR is a form of functional MR, preload and afterload conditions influence the 
severity of MR present on echocardiographic examination. Therefore, patients with 
CAD who present with signs and symptoms of heart failure, especially following 
(infero posterior) myocardial infarction, should undergo a sound workup to exclude 
IMR.
Patients with chronic IMR represent a heterogeneous group when it comes to 
LV   dysfunction; the spectrum of LV performance comprises both well-preserved 
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ventricles with near-normal ejection fractions, and dilated cardiomyopathies with 
 ejection fraction below 10%. However, echocardiographic studies from the Mayo Clinic 
have shown that the presence and degree of IMR is unrelated to the severity of LV 
 dysfunction; local LV remodeling leads to excess valvular tenting independent of global 
LV remodeling.13
IMR should be treated with mitral valve surgery. Earlier reports from a cohort of 
58 patients5,6 who received CABG alone in the presence of grade 3+ MR between 1977 
and 1983, compared with 20 patients who underwent CABG and mitral valve 
 replacement, showed worse outcome in the latter group. This study has given many 
 surgeons an  argument against an intervention on the valve rather than CABG alone in 
IMR. However, the cohorts were not comparable, as there were large differences 
between  ischemia being the cause of MR (74% versus 30% in the control group), the 
mean  ejection fraction was very high (53%) and only 10% of patients were in NYHA 
class III or IV.
Figure 2. ROC curve analysis (panel A)  demonstrated 
that the optimal cut-off value for LV end-systolic 
dimension (LVESD) was 51 mm to predict reverse LV 
remodeling (dashed line crossing at intersection of 
sensitivity and specificity curves). Using this cut-off 
value, a sensitivity and specificity of 81% were 
obtained. Panel B shows that the area under the curve 
(AUC) was 0.85.
Figure 3. ROC curve analysis (panel A)  demonstrated 
that the optimal cut-off value for LV end-diastolic 
dimension (LVEDD) was 65 mm to predict reverse 
LV remodeling (dashed line crossing at intersection of 
sensitivity and specificity curves). Using this cut-off 
value, a sensitivity and specificity of 89% were 
obtained. Panel B shows that the area under the curve 
(AUC) was 0.92.
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A report by Tolis et al.14 suggests that MR grade is reduced following isolated CABG in 
patients with ‘mild-to-moderate’ IMR and ischemic cardiomyopathy (mean EF 22.4%, 
range 10–30%). However, 18 out of 49 patients had grade 1+ MR, and 6 had grade 3+. 
Follow-up is based on 26 out of 49 patients, and gives only a mean value for residual MR 
without a distribution. Aklog et al.7 have shown that CABG alone for moderate IMR 
leaves many patients with significant residual MR and is therefore an inadequate 
approach. Harris15 has reported on 176 patients with CAD and grade 2+ or 3+ IMR, of 
whom 142 underwent CABG alone and 34 CABG with mitral valve repair or 
 replacement. Patients in NYHA class III or IV showed superior late survival when the 
mitral valve was operated, and MR grade was increasing over time in the CABG group 
while it was stable in the CABG+valve group. However, operative mortality was lower in 
the CABG group (9 versus 21%).
The reverse LV remodeling observed in this study is obvious, and largely a consequence 
of the disappearance of mitral regurgitation and LV volume overload. The design of our 
study does not allow to differentiate between the effects of revascularization (of 
 hibernating myocardium) versus those of mitral valvuloplasty on reverse LV remodeling. 
Preoperative medical therapy was continued without modification after surgery for the 
duration of the study. In particular, the use and dosage of ACE-inhibiting agents was 
not changed during the course of follow-up, and therefore its influence on LV reverse 
remodeling in this patient group is negligible. Additional tricuspid annuloplasty— 
performed whenever annulus diameter equaled or exceeded 40 mm—is thought to be 
 beneficial in that it optimizes the filling of the left ventricle which is particularly useful 
in patients with impaired diastolic function.
Our operative and 30-day mortality of 8.0% is acceptable, when related to EuroSCORE 
and to other series. Comparing operative mortality scores for treatment of IMR requires 
again a strict look at patient selection. Strictly speaking, IMR can also be applied to 
patients with papillary muscle rupture, a patient group with an obviously dismal 
 prognosis. A large series from Cleveland16 has shown 13% overall 30-day mortality in all 
IMR cases (including ruptured papillary muscle and including MV replacement); in a 
 ‘better-risk’ group, mortality with MV repair was 6%. Grossi17 has reported from a  similar 
group of patients, showing 10% operative mortality for repair. Our series is restricted to 
patients with functional MR only, although we did not exclude patients because of 
 critical preoperative state as can be seen from the number of patients requiring  ventilatory 
or inotropic support preoperatively. We have reported on the use of restrictive mitral 
annuloplasty in the emergency setting in IMR patients with acute deterioration with 
intact papillary muscle.18
Calafiore19 recently reported a 3.9% 30-day mortality (2.4% for MV repair) in IMR. 
Long-term follow-up shows excellent survival and improvement in functional status.
Several studies report the use of restrictive mitral annuloplasty in functional IMR.8,16 
Calafiore chooses a posterior annuloplasty only,19 whereas he promotes MV replacement 
in cases with extensive leaflet tethering (as measured by the distance from the coaptation 
point up to the mitral annulus). We prefer a true annuloplasty to really reduce the 
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anterior–posterior distance of the annulus and enforce at least 8 mm coaptation length. 
In all cases, even in the presence of extensive tethering, this approach was successful with 
stringent downsizing by two ring sizes. The technique is simple and does not add much 
time to myocardial ischemia. The durability of this technique is illustrated by the 
sequential echocardiograms showing absence of residual MR at 18 months. We never 
performed mitral valve replacement. The fear of systolic anterior motion following 
downsizing is unnecessary, because of the widened aorto-mitral angle in this type of 
pathology. We never encountered elevated transmitral gradients, because the leaflet 
tissue is normal in this type of pathology.
The most important finding in this study is, that preoperative LV dimensions predict the 
likelihood of reverse remodeling, which is the ultimate goal of the surgeon. Reverse 
remodeling decreases the stress on the valvular and subvalvular apparatus and therefore 
consolidates the result. In our series, the chance of reverse remodeling to occur is low 
when preoperative LVEDD exceeds 65 mm and/or LVESD is more than 51 mm. Even in 
the absence of recurrent MR, a left ventricle with dilatation beyond these cut-off values 
does not achieve reverse remodeling, suggesting that the extent of disease of the left 
ventricle is the limiting factor in the process of reverse remodeling. Of interest, 8 of 13 
(61.5%) patients who died in this series had an LVEDD >65 mm, and 7 of 13 patients 
(53.8%) had an LVESD >51 mm.
Restrictive mitral annuloplasty with or without CABG can be applied in patients with 
ischemic mitral regurgitation with an acceptable operative risk. Clinical outcome at 
2 years follow-up remains favorable. Recurrent MR is seldom observed if proper  stringent 
downsizing is performed, and LV reverse remodeling occurs within the limitations set 
by the extent of preoperative LV dilatation.
The finding that baseline LV dimensions seem to play a key role in the likelihood of 
reverse remodeling indicates that CABG with RMA is not sufficient to ensure a  favorable 
long-term outcome in patients with LV dimensions beyond the cut-off value. We now 
apply a CorCap cardiac support device (Acorn Cardiovascular, Inc., St Paul, MN, USA) 
in all patients with IMR and dilated cardiomyopathy with LVEDD >65 mm. Another 
approach to these patients might be found in a more aggressive left ventricular  restoration 
surgery, especially when LVEDD >80 mm.20 Future follow-up will show whether this 
strategy will contribute to LV reverse remodeling in this subset of patients. A close 
 follow-up of patients that approach these LV dimensions on preoperative evaluation is 
necessary to observe further dilatation.
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Abstract
Background: Restrictive mitral annuloplasty with revascularization is considered 
the best approach to ischemic mitral regurgitation with heart failure, but late results 
are controversial. We report late outcome in relation to preoperative left ventricular 
end-diastolic diameter (LVEDD) cutoff values, previously identified to predict 
intermediate-term left ventricular reverse remodeling. 
Methods: One hundred consecutive ischemic mitral regurgitation patients 
 underwent restrictive mitral annuloplasty (stringent downsizing by 2 ring sizes; 
median size, 26) and coronary revascularization. Survivors were clinically and echo-
cardiographically assessed at intermediate (18 months) and late (mean, 46 months) 
follow-up.
Results: Early mortality was 8%, and late mortality was 18%. Actuarial 1-, 3- and 
5-year survival rates were 87±3.4%, 80±4.1%, and 71±5.1%. Mortality predictors 
(Cox regression) were preoperative inotropic support (hazard ratio, 6.2, confidence 
 interval, 2.3 to 16.9) and preoperative LVEDD greater than 65 mm (hazard ratio, 
4.5, confidence interval, 1.9–10.9). Five-year survival rate for patients with LVEDD 
of 65 mm or less was 80±5.2%, versus 49±11% for LVEDD greater than 65 mm 
(P=0.002). At 4.3 years’ follow-up, New York Heart Association functional class had 
improved from 2.9±0.8 to 1.6±0.6 (P<0.01). Mitral regurgitation grade was 0.8±0.7, 
and less than grade 2+ in 85% of patients. Left ventricular reverse remodeling was 
sustained with time for the LVEDD of 65 mm or less group. Late deaths did not 
show intermediate-term systolic left ventricular reverse remodeling, indicating a 
more extensive intrinsic left ventricular abnormality.
Conclusions: At 4.3 years’ follow-up, intermediate-term cutoff values for left 
 ventricular reverse remodeling proved to be predictors for late mortality. For patients 
with preoperative LVEDD of 65 mm or less, restrictive mitral annuloplasty with 
revascularization provides a cure for ischemic MR and heart failure; however, when 
LVEDD exceeds 65 mm, outcome is poor and a ventricular approach should be 
considered.
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The deleterious effects of ischemic mitral regurgitation (MR), often accompanied by heart failure and leading to excess mortality, are well known.1,2 Although there is no 
evidence from randomized trials, observational studies have shown that treatment of 
ischemic MR by mitral valve repair and coronary artery bypass grafting leads to a better 
outcome with regard to recurrence of MR than coronary artery bypass grafting alone,3-6 
but there is still debate with regard to survival benefit,4-8 which is also reflected in the 
latest American College of Cardiology/American Heart Association Guidelines.9
The pathophysiology of ischemic MR is complex, and its poor outcome is related to left 
ventricular (LV) injury as a consequence of remodeling.10 Although it is the ventricle 
that is diseased, the resulting functional MR can be successfully treated by a relatively 
simple intervention on the valve, i.e., undersizing the mitral annulus by a restrictive 
mitral annuloplasty.11,12 In our institution, this means implanting a complete semirigid 
annuloplasty ring two sizes smaller than that which would be normally used if the 
patient had degenerative disease. We have reported a favorable clinical outcome and 
reverse left atrial and LV remodeling at 18 months’ follow-up in a subset of patients, 
namely those with a preoperative LV end-diastolic dimension (LVEDD) of 65 mm or 
less.13,14 However, the long-term benefit of mitral valve repair in ischemic MR is 
debated.7,15
In the present study, long-term clinical and echocardiographic outcome up to 7 years’ 
follow-up (mean follow-up, 4.3 years) in a consecutive series of 100 patients has been 
evaluated. We tried to identify predictors for early and late mortality, and to correlate 
late outcome with intermediate findings.
Patients and methods
Study Population
One-hundred nonselected, consecutive patients with ischemic MR, who all underwent 
restrictive mitral annuloplasty, either combined with (n=90) or after prior (n=10) 
 coronary revascularization, between January 2000 and July 2004, had clinical and echo-
cardiographic assessment before surgery, at intermediate follow-up (18 months) and late 
follow-up (mean, 4.3 years; range, 2.4 to 6.8 years). All patients had coronary artery 
disease and MR grade 3+ or 4+ (either at resting conditions or after intraoperative 
provocative testing) owing to restrictive systolic leaflet motion (Carpentier type IIIb) 
following previous infarction (n=95) or ischemia in the inferior or posterolateral region. 
Intraoperative provocative testing was performed in patients scheduled for coronary 
artery bypass grafting with MR grade 2+ or fluctuating MR (n=16), as previously 
described.16,17 Patients with concomitant aortic valve surgery or requiring surgical 
 ventricular restoration for LV aneurysm were not included. All patients had symptoms 
of heart failure and the majority presented in New York Heart Association (NYHA) 
class III (n=54) or IV (n=26). Thirty-four patients were operated on in a nonelective 
setting.
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TABLE 1 Preoperative Clinical and Echocardiographic Characteristics (n=100).
Clinical Characteristics
Age (years) 67.1±9.8
Gender (male/female)  67/33
NYHA functional class  3.0±0.8
NYHA class III 54
NYHA class IV 26
CCS class  2.3±1.1
Previous myocardial infarction 95
Inferior/posterior/lateral 85 (89%)
Anterior 25 (26%)
Both 15 (16%)
Infarction < 6 weeks before surgery 22 (23%)
Previous cardiac surgery 10
Two-vessel disease 19
Three-vessel disease 76
Preoperative intravenous inotropes 10
Preoperative IABP  4
Preoperative mechanical ventilation  5
Preoperative acute hemodialysis  2
Echocardiographic Characteristics
MR grade  3.2±0.6
Grade 3+ 59
Grade 4+ 28
Leaflet coaptation length (mm)  3±1
Left atrial dimension (mm) 47±8
LV end-diastolic dimension (mm) 61±9
indexed to BSA (mm/m2) 33±6
LV end-systolic dimension (mm)  48±11
indexed to BSA (mm/m2) 26±6
Fractional shortening (%) 23±9
LV ejection fraction (%) 27±8
Tenting area (cm2)  4.9±1.4
Transtricuspid pressure gradient (mmHg)  32±11
BSA, Body Surface Area; CCS, Canadian Cardiovascular Society; IABP, intra-aortic balloon 
pump; LV, left ventricle; MR, mitral regurgitation; NYHA, New York Heart Association.
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Coronary artery bypass grafting was performed in 90 patients; revascularization was not 
performed in 10 patients with previous coronary artery bypass grafting and patent grafts. 
Mean logistic European System for Cardiac Operative Risk Evaluation (EuroSCORE) 
was 13±14. Baseline characteristics of the study population are presented in Table 1. Our 
institution’s ethics committee approved conducting this study and waived the need for 
individual consent. 
Operative Technique
All surgical procedures were performed through midline sternotomy under  normothermic 
cardiopulmonary bypass with intermittent antegrade warm-blood cardioplegia. 
The mitral valve was exposed through a vertical transseptal approach along the right 
border of the foramen ovale, leaving the left atrial roof untouched. Ring size (Carpentier 
Edwards Physioring; Edwards Lifesciences, Irving, CA) was determined after careful 
measurement of the height of the anterior leaflet, and then downsizing by two sizes (i.e., 
size 26 when measuring 30). Rings were inserted using 14 to 16 deep U-shaped simple 
horizontal sutures using Ethibond 2-0 (Ethicon, Inc, Somerville, NJ) or Ti-Cron 2-0 
(Syneture, Norwalk, CT). Tricuspid annuloplasty was performed with a Carpentier 
Edwards Classic or MC3 ring in patients with tricuspid regurgitation exceeding grade 2+, 
or—from the year 2003 onward—in presence of a dilated tricuspid annulus exceeding 
40 mm (or 21 mm/m2 indexed to body surface area) on transthoracic echocardiography. 
Surgical data are summarized in Table 2.
All patients had intra-operative transesophageal echocardiography assessment of LV and 
valve function. Mitral valve repair was considered successful if there was no residual MR 
and a leaflet coaptation length of at least 8 mm at the A2-P2 level. If these criteria were 
not met, further downsizing was performed (n=2). 
TABLE 2
Surgery Parameters (n=100).
Median mitral annuloplasty ring size 26 (range: 24 – 32)
Ring size 24 17
Ring size 26 37
Coronary artery bypass grafting 90
Distal anastomoses  3.3 ± 1.3
Tricuspid valve annuloplasty 20 
Extracorporeal circulation time (min) 187±51
Aortic cross-clamp time (min) 126±39
Intraoperative IABP insertion  9
IABP, intra-aortic balloon pump.
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Echocardiography
Preoperative echocardiographic evaluation consisted of standard transthoracic 
 echocardiography examination performed within 5 days before surgery, including 
 grading of severity of MR (semiquantitatively from color-flow Doppler) and tricuspid 
regurgitation, tricuspid annulus diameter, left atrial diameter, LVEDD, LV end-systolic 
diameter (LVESD) and fractional shortening (Table 1). Postoperatively, transthoracic 
echocar diography was repeated before discharge, at early follow-up (3 to 6 months), 
intermediate follow-up (18 months)—as previously reported14—and at late follow-up 
(mean, 46 months; range, 25 to 72 months; all examinations were performed in our 
institution between February 2006 and June 2006). During postoperative transthoracic 
echocar diography evaluation, all preoperative variables were reassessed with the  addition 
of transmitral diastolic gradient and leaflet coaptation length.
Clinical Assessment and Follow-up
Preoperative clinical status was determined according to the criteria of the NYHA (for 
heart failure) and the Canadian Cardiovascular Society (for angina) up to 5 days before 
surgery. This status was reassessed at intermediate and late follow-up in the outpatient 
clinic, and ultimately reassessed in the first week of December 2006 by telephone 
interview.
Statistical Analysis
Continuous data are expressed as mean ± standard deviation unless otherwise stated, 
and compared using Student’s t test for paired and unpaired data when appropriate. 
Proportions for dichotomous data were compared by χ2 analysis with Yates’ correction. 
Where appropriate, odds ratios are presented with confidence intervals (CI). Actuarial 
survival and other time-related events were analyzed with the Kaplan-Meier method, 
using Cox regression to assess the contribution of different factors. Factors that were 
found to be significant were subsequently tested in a multivariable comparison, with 
outcomes presented as hazard ratios (HR). For all tests, a probability value of less than 
0.05 was considered significant. We used SPSS statistical software (SPSS version 14.0.0; 
SPSS Inc, Chicago, IL) for calculations.
Results
Successful mitral valve repair was achieved in all patients, irrespective of the degree of 
leaflet tethering. Median ring size was 26 (range, 24 to 32). Intraoperative transesopha-
geal echocardiography showed a competent mitral valve in all patients with a mean 
leaflet coaptation length of 9±2 mm. There were no cases of mitral stenosis (mean 
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transvalvular gradient, 3.0±1.2 mmHg; mean mitral valve area, 2.8±0.6 cm2). These 
values were independent of the ring size used.
Immediate Outcome
There was no intraoperative mortality. One patient sustained a myocardial infarction 
requiring emergent repeat surgical revascularization. In 15 patients, perioperative 
intra-aortic balloon counterpulsation was used (4 already preoperatively); 12 patients 
required temporary hemodialysis (2 already before surgery). Mean intensive care unit 
stay was 6.3±6.7 days. Early mortality (all in-hospital mortality and 30-day mortality) 
was 8.0% (n=8), including 4 as a result of cardiac causes, as previously reported.14
Long-term Clinical Outcome
Clinical follow-up was complete, with a mean duration of 4.3±1.4 years (range, 2.4 to 6.8 
years). Seventeen patients died during further follow-up; 10 late deaths were as a result 
of cardiac causes (heart failure, arrhythmias, death from unknown cause). Actuarial 
survival rates at 1, 3 and 5 years were 87±3.4%, 80±4.1%, and 71±5.1% (Figure 1).
Two patients underwent reoperation for recurrent MR; one because of progressive LV 
dilatation requiring further downsizing annuloplasty (12 months after the initial 
 procedure), and one for partial anterior ring dehiscence requiring refixation (after 
3 months). Eleven patients (12.0%) were readmitted for congestive heart failure; 6 died 
during follow-up. Four patients received a biventricular pacemaker or defibrillator, of 
whom one died. Four patients underwent percutaneous coronary interventions, and 
one sustained a myocardial infarction. There were no cases of endocarditis or thrombo-
embolic events. Adverse events are presented per subgroup (based on previously 
described baseline LVEDD and LVESD cutoff values) in Table 3. This shows that 82% 
Figure 1. Kaplan–Meier actuarial 
survival for all patients.
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of readmissions for CHF occurred in patients with higher LVESD, and all biventricular 
pace makers or defibrillators were inserted in the larger dimension groups. Mean NYHA 
class improved from 2.9±0.8 to 1.6±0.6 (P<0.01), with only 5 patients (6.7%) in NYHA 
class III.
Predictors of Mortality
Potential predictors for early and late mortality were tested using logistic and Cox 
 regression, respectively. Seven predictors for early mortality were identified, mostly indi-
cators of a critical preoperative state, but also preoperative LVEDD greater than 65 mm 
(Table 4). Preoperative need for inotropic support was the strongest univariable  predictor 
and the only multivariable predictor positively associated with early mortality (odds 
ratio, 19.0; 95% CI, 4.6 to 81.6).
Positive predictors of late mortality were LVEDD greater than 65 mm, enlarged left 
atrium, and previous anterior myocardial infarction. Postoperative increased length of 
intensive care unit stay, higher NYHA functional status at intermediate follow-up, and 
readmission for congestive heart failure also led to increased late mortality. In a multi-
variable analysis, preoperative LVEDD greater than 65 mm proved to be the only 
 significant predictor (HR, 2.4; CI, 1.3 to 5.4; Table 4).
Total mortality, including hospital deaths, was predicted by preoperative need for 
 inotropic support (HR, 6.2; CI, 2.3 to 16.9) and preoperative LVEDD greater than 
65 mm (HR, 4.5; CI, 1.9 to 10.9; Table 4). When removing the latter factor from the 
model, LVESD greater than 50 mm proved to be the next significant predictor (HR, 3.5; 
CI, 1.4 to 8.7). This confirms the value of the previously identified cutoff values at long-
term follow-up.
The two absolute cutoff parameters for end-systolic and end-diastolic LV dimensions are 
used for practical purposes in the majority of patients; however, in patients with extreme 
values of body surface area, indexed parameters might be more suitable and further 
analysis revealed an indexed LVEDD cutoff value of 34 mm/m2, and an indexed LVESD 
of 26 mm/m2.
Mortality at all times is higher in larger LV dimension cohorts. Actuarial survival rates 
are plotted per preoperative LV dimension cohort in Figures 2 and 3. For LVEDD of 
65 mm or less, actuarial survival rates at 1, 3, and 5 years are 93±3.0%, 87±4.0%, and 
80±5.2%, respectively, whereas for LVEDD greater than 65 mm these rates are 71±8.5%, 
61±9.2%, and 49±11% (HR, 3.4; 95% CI, 1.5 to 7.4; P=0.002).
Long-Term Echocardiographic Outcome
Late echocardiographic examination was performed in all 75 survivors with a follow-up 
interval of 3.8±1.3 years (range, 2.1 to 6.0 years). Mean MR grade was 0.8±0.7; 11 patients 
had grade 2+ MR (LVEDD greater than 65 mm: 3 of 14 patients; LVEDD of 65 mm or 
less, 8 of 61 patients), 1 had grade 3+ MR (in the LVEDD 65 mm or less group). 
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TABLE 3
Clinical Outcomes for Different Strata of Preoperative Left Ventricular Dilatation
Preoperative LVEDD Preoperative LVESD
Outcome ≤65 mm >65 mm p Value ≤50 mm >50 mm p Value
Early mortality 3/72 (4.2%)  5/28 (17.9%) 0.037 2/58 (3.4%)  6/42 (14.3%) NS
Late mortality  8/69 (11.6%)  9/23 (39.1%) 0.016  7/56 (12.5%) 10/36 (27.7%) NS
All mortality 11/72 (15.3%) 14/28 (50.0%) <0.0001  9/58 (15.5%) 16/42 (38.1%) 0.018
Readmission CHF 6/69 (8.7%)  5/23 (21.7%) NS 2/56 (3.6%)  9/36 (25.0%) 0.005
Biventricular ICD 0/69  4/23 (17.4%) <0.0001 0/56  4/36 (11.1%) <0.0001
CHF, congestive heart failure; ICD, implantable cardioverter defibrillator; LVEDD, left ventricular end-diastolic diameter; LVESD, left ventricular  end-systolic 
diameter; NS, not significant.
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TABLE 4
Predictors for Mortality
Univariable analysis Multivariable analysis
Predictor p Value Odds Ratio 95% Confidence 
Interval
p Value Odds Ratio 95% Confidence 
Interval
Early mortalitya
NYHA class IV  0.005 10.8 2.0–57.7
CCS class 4  0.013  6.9 1.5–31.4
Infarction < 6 weeks before surgery  0.008  7.9 1.7–36.5
Nonelective surgery  0.023  6.9 1.3–36.1
Preoperative inotropic support  <0.0005 29.0  5.3–157.4 0.001 19.0 4.8–81.6
Preoperative mechanical ventilation  0.001 26.7  3.6–197.9
LVEDD >65 mm  0.037  4.1 1.1–19.2
Preoperative hemodialysis  0.003  7.9 2.0–31.8
Hazard Ratio Hazard Ratio
Late mortalityb
Anterior wall infarction  0.036 3.1 1.1–8.8
LVEDD (continuous)  0.015 1.1 1.0–1.2
LVEDD (>65 mm)  0.027 2.9 1.1–7.6 0.03 3.4 1.3–5.4
Left atrial dimension  0.003 1.1 1.0–1.2
Longer ICU stay 0.02 1.1 1.0–1.1
Readmission for CHF  0.002 5.1  1.9–14.1
NYHA class at intermediate FU 0.02 4.0  1.2–13.3
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Hazard Ratio Hazard Ratio
Overall mortalityb
Infarction < 6 weeks before surgery  0.023 2.6 1.1–5.8
Anterior wall infarction  0.011 3.0 1.3–6.9
Preoperative inotropic support  0.001 4.3  1.7–10.6 0.002 6.2 2.3–16.9
Preoperative mechanical ventilation 0.02 4.3  1.3–14.3
LVEDD (>65 mm)  0.002 3.4 1.5–7.4 0.001 4.5 1.9–10.9
LVESD (>50 mm)  0.012 2.8 1.3–6.4
Preoperative MR grade 4+  0.033 2.4 1.1–5.1
Perioperative IABP  0.042 1.1 1.0–1.1
Perioperative hemodiaysis  0.002 4.1 1.7–9.9
Longer ICU stay  0.042 1.1 1.0–1.1
Readmission for CHF  0.002 5.1  1.9–14.1
NYHA class at intermediate FU  0.045 4.0 1.0–6.5
a Early mortality was calculated using logistic regression, and outcomes are presented as odds ratios. b Late and overall mortality were calculated using Cox 
regression, and outcomes are presented as hazard ratios.
CCS, Canadian Cardiovascular Society; CHF, congestive heart failure; FU, follow-up; ICU,  intensive care unit; IABP,  intra-aortic balloon pump;  
LVEDD,  left ventricular end-diastolic diameter; LVESD, left ventricular end-systolic diameter; MR, mitral regurgitation; NYHA,  New York Heart Association.
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Mitral valve stenosis was not observed. Overall, there was a significant reduction in the 
dimensions of the left heart: LVEDD (from 60±9 to 54±9 mm), LVESD (from 46±11 to 
39±11 mm) and left atrium size (from 45±7 to 43±6 mm). Echocardiographic results are 
summarized in Table 5.
Figure 2. Actuarial 
survival rates for two 
 different preoperative left 
 ventricular end-diastolic 
 diameter (LVEDD) cohorts, 
 comparing LVEDD greater 
than 65  mm and LVEDD 
65 mm or less (hazard ratio, 
3.4; 95% confidence interval, 
1.5 to 7.4; P=0.002). Patients 
at risk per cohort are shown 
under the x-axis (LVEDD 
greater than 65 mm in bold; 
LVEDD 65 mm or less in 
regular setting).
Figure 3. Actuarial 
survival rates for two 
 different preoperative left 
 ventricular end-systolic 
diameter (LVESD) cohorts, 
 comparing LVESD greater 
than 50  mm and LVESD 
50 mm or less (hazard ratio, 
2.8; 95% confidence interval, 
1.3 to 6.4; p=0.012). Patients 
at risk per cohort are shown 
under the x-axis (LVESD 
greater than 50 mm in bold; 
LVESD 50 mm or less in 
 regular setting).
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TABLE 5
Echocardiographic Findings at Baseline and Follow-up in Survivors (n=75).
Stratification by year 
after repair
Variable Baseline
Late 
Follow-up p Value
2-3 
Yrs
3-4 
Yrs
4-5 
Yrs
>5 
Yrs
MR grade 3.1 ± 0.6 0.8 ± 0.7  < 0.001
None  - 29 11 5 4  9
Grade 1+  - 34  9 7 7 11
Grade 2+  9 11  5 3 2  1
Grade 3+ 47  1  - - 1  -
Grade 4+ 19 -  - - -  -
Leaflet coaptation length (mm)  3±2 8±2  < 0.001
Transmitral gradient (mmHg)  3.9±1.7
Mitral valve area (cm2)  2.6±0.6
Tenting area (cm2)  4.8±1.4 1.4±0.6 < 0.05
Left atrial dimension (mm) 45±7 43±6 < 0.05
LV end-diastolic dimension (mm) 60±9 54±9  < 0.001
LV end-systolic dimension (mm)  46±11  39±11  < 0.001
Fractional shortening (%) 24±9  29±13 < 0.01
LV ejection fraction (%) 30±8  45±15  < 0.001
Transtricuspid pressure gradient 
(mmHg)
 32±12  29±12 < 0.05
LV, left ventricle; MR, mitral regurgitation.
Comparison of Late versus Intermediate Clinical and Echocardiographic 
Outcome
The 10 patients who died between intermediate and late follow-up differed from 
 survivors in two ways: at intermediate follow-up they were in a significantly higher 
NYHA class, and they did not show systolic reverse remodeling.
Interestingly, in the LVEDD 65 mm or less group, all late survivors showed a sustained 
significant reduction of LVEDD at intermediate follow-up, with a further  nonsignificant 
size decrease at late follow-up. In the LVEDD greater than 65 mm group, in which 14 of 
28 patients died, 7 patients (25%) showed reverse remodeling at late follow-up.
Left-ventricular end-systolic dimension did not decrease significantly at intermediate 
follow-up, but did between intermediate and late follow-up for patients with  preoperative 
LVEDD of 65 mm or less; however, it failed to do so in the LVEDD greater than 65 mm 
group.
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Comment
All patients in this series benefited from the same surgical procedure: complete 
 revascularization and restrictive mitral annuloplasty using the same ring type and the 
same degree of downsizing. This consistency can explain the high level of absence of 
significant recurrent MR, even in the presence of severe tenting preoperatively, which 
contrasts with the findings of others.15,18 In addition, echocardiographic follow-up was 
homogeneous since it was performed in the same institution at different intervals.
Operative mortality (8%) is in line with other studies18-20 and is well below the logistic 
EuroSCORE for this group (13±14). Our favorable overall long-term outcome with an 
actuarial 5-year survival rate of 71% is substantially better than that reported by Grossi 
and colleagues21 and Gillinov and associates22, but comparable to that reported by 
others.6,7,19 Ninety-three percent of survivors are free from heart failure and 85% have less 
than grade 2+ MR. Noteworthy are the decreased tenting area and the absence of 
 significant mitral transvalvular gradient at late follow-up in spite of the stringent 
 restrictive annuloplasty. 
In a previous report, we identified preoperative LV dimension cutoff values (65 mm for 
LVEDD and 50 mm for LVESD) predictive for postoperative LV reverse remodeling at 
intermediate follow-up.14 The present work also establishes these cutoff values as strong 
predictors for late mortality. Indeed, patients with a preoperative LVEDD of 65 mm or 
less have an 80% 5-year survival, whereas those with a preoperative LVEDD greater than 
65 mm have only 49% 5-year survival.
Considering the whole group of survivors, independently of their baseline dimensions, 
diastolic reverse remodeling has occurred in 52%, but, more interestingly, systolic reverse 
remodeling has occurred in 74%. In the LVEDD 65 mm or less group, LV reverse 
remodeling was sustained at late follow-up for both diastolic and systolic diameters. 
In  the LVEDD greater than 65 mm group, only 7 patients (25%) showed reverse 
 remodeling. The predictive value of our preoperative cutoff dimensions thus has also 
been confirmed for long-term reverse remodeling.
A large part of the LVEDD regression may be explained by the disappearance of the 
volume overload caused by MR, thereby reducing LV wall stress and allowing the 
 myocardium to improve performance. Left ventricular end-systolic diameter regression 
at intermediate follow-up was almost absent in the LVEDD greater than 65 mm group. 
Owing to the nature of the study in which restrictive mitral annuloplasty was almost 
always combined with revascularization, the contribution of each cannot be studied 
separately. However, the results in patients with previous revascularization, as well as the 
observations by others in patients with revascularization alone in the presence of 
 ischemic MR,3-6 suggest that our current favorable results could not have been achieved 
by revascularization alone. Obviously a randomized, controlled trial would be needed to 
fully elucidate this matter, but this is unlikely to happen.
In conclusion, restrictive mitral annuloplasty with coronary artery bypass grafting 
 provides a cure for ischemic MR and heart failure in patients with preoperative LVEDD 
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65 mm or less. Although only 25% of the patients with preoperative LVEDD greater 
than 65 mm show reverse remodeling, many patients did not show progressive dilatation 
either, suggesting that restrictive mitral annuloplasty stabilizes the disease to some extent 
in these patients. The absence of reverse remodeling, however, reflects a more advanced 
pathology of the left ventricle and it is our believe that to improve ventricular  performance, 
the ventricle itself needs to be addressed, by either a ventricular restoration procedure or 
an external cardiac restraint device (CorCap; Acorn, St. Paul, MN) in patients with 
LVEDD greater than 65 mm and less than 80 mm. This device has shown promising 
early and mid-term results in functional MR,23 although long-term results have yet to 
be established.
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Acute severe mitral insufficiency following myocardial infarction usually results from rupture of a papillary muscle, which should be treated on an emergency basis by 
either mitral valve repair or replacement. In the case of acute postinfarction mitral 
regurgitation with intact papillary muscle, no consensus exists, even with regard to the 
indication for surgery.
Restrictive mitral annuloplasty (RMA) has been applied in chronic ischemic mitral 
insufficiency, with encouraging mid-term results.1,2 In this report, we describe 2 patients 
in whom RMA was applied as a lifesaving procedure in the presence of refractory 
 cardiogenic shock in postinfarction mitral insufficiency with intact papillary muscle.
Clinical Summaries
Patient 1. A 55-year-old woman had an acute inferior wall infarction with cardiogenic 
shock. She received an intra-aortic balloon pump (IABP) and inotropes and was 
 intubated. Coronary angiography revealed occlusion of the right coronary and 
 circumflex arteries. Transesophageal echocardiography (TEE) showed grade 4+ mitral 
insufficiency resulting from systolic restrictive motion of both leaflets (Carpentier 
type IIIb; Figures 1 and 2). The regurgitation jet was slightly eccentric because of the 
more restrictive posterior leaflet. Because of further hemodynamic deterioration, we 
decided to attempt correction of the mitral regurgitation as a lifesaving procedure.
During the operation, a fresh infarction of the posterolateral wall involving the posterior 
papillary muscle was observed. The subvalvular apparatus was intact, and there was no 
structural anomaly of the mitral valve leaflets. RMA was performed with a size 28 
Carpentier Edwards Physio ring (Edwards Lifesciences, Irvine, CA), thereby downsizing 
the prosthetic ring by two sizes. Tentative revascularization of the circumflex and right 
coronary artery territory was performed with a sequential saphenous vein graft. 
The  patient was weaned from extracorporeal circulation with inotropic support 
 (epinephrine at 0.22 mg/kg/min, dobutamine at 15 mg/kg/min, dopamine at 
8  mg/ kg / min, and enoximon at 4 mg/kg/min). Intraoperative TEE showed trivial mitral 
 regurgitation with a mean transvalvular mitral gradient of 3 mmHg (mitral valve surface 
area > 2 cm2) and a leaflet coaptation length of 9 mm. 
Troponin T rose to 22 mg/L on day 1. The IABP was removed after 8 days. The patient 
was discharged after 23 days. Nine months after surgery she is in New York Heart 
Associaton functional class I, with no mitral insufficiency on echocardiographic follow 
up.
Patient 2. A 69-year-old woman was referred because of hemodynamic deterioration 
3 days after an inferior wall infarction. Coronary angiography revealed occlusion of the 
right coronary artery. During balloon angioplasty, the patient went into cardiogenic 
shock, was resuscitated, and received an IABP. Troponin T rose to 19 mg/L. TEE showed 
grade 4+ mitral regurgitation as a result of restrictive leaflet motion in systole 
(Carpentier IIIb).
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Figure 1. Transesophageal echocardiogram showing restrictive systolic motion 
of anterior and posterior leaflets with reduced coaptation. 
LA, Left atrium; LV, left ventricle; ECG, electrocardiogram.
Figure 2. Color Doppler echocardiographic imaging demonstrating grade 4+ 
mitral regurgitation resulting from systolic restriction with reduced 
 coaptation. ECG, Electrocardiogram.
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Initially, hemodynamic stabilization was obtained with inotropes in addition to the 
IABP. Three weeks later, the patient could not be weaned from mechanical ventilation. 
She acquired gram-negative sepsis, and during exchange of the IABP catheter she 
 suffered hemodynamic collapse and was again resuscitated. Apart from nonoliguric 
renal insufficiency, she had neither major organ dysfunction nor neurological 
 complications, but she required continuous administration of epinephrine at 
0.20  mg/ kg/ min, dobutamine at 10 mg/kg/min and enoximon at 2 mg/kg/min. In an 
attempt to overcome this deadlock situation, we decided to try to correct the mitral 
insufficiency 27 days after the initial infarction. We performed RMA with size 26 
(instead of 30) Physio ring. The patient could then be weaned from ECC with the same 
inotropic support. Postoperative TEE showed no mitral insufficiency, with a mean 
transvalvular gradient of 2 mmHg and leaflet coaptation length of 9 mm.
The postoperative course was uneventful. The IABP was removed on day 7. The patient 
was extubated after 20 days and was discharged after 32 days. Two months after surgery, 
she is in New York Heart Association functional class II, with grade 1 mitral  insufficiency 
on echocardiography.
Discussion
Cardiogenic shock in postinfarction mitral insufficiency portends a poor prognosis, 
with approximately 55% in-hospital mortality in the SHOCK trial.3 Coronary 
 revascularization with or without mitral valve surgery in that study showed a somewhat 
reduced but still high mortality of 40%, versus 71% in nonsurgically treated patients. 
Most patients who did not undergo surgery could not be stabilized and died. Thus the 
timing of surgery may be important in determining outcome, and early surgery before 
or immediately at the onset of cardiogenic shock might save lives. Our first patient 
underwent surgery on an emergency basis. In the second case, initial stabilization 
allowed us to postpone surgery.
The question as to whether mitral valve repair is preferable to replacement in acute 
 ischemic mitral insufficiency is still unanswered. Grossi and colleagues4 and Gillinov 
and associates5 reported similar survivals after replacement versus repair in patients with 
complex and acute mitral regurgitation. However, preference of the operating surgeon 
certainly introduced selection bias in these retrospective studies.
It has been established that preservation of the subvalvular apparatus positively  influences 
post-operative left ventricular function. Therefore in cases where mitral valve surgery is 
proposed as a lifesaving procedure, we believe, as illustrated by the cases reported here, 
that a successful mitral valve repair is preferable, especially in the absence of papillary 
muscle rupture. In our hands RMA has proven its value in curing chronic ischemic 
mitral insuffiency by restoring an adequate length of leaflet coaptation.2 Similarly, we 
believe that the stress in the subvalvular apparatus can also be reduced by this technique 
in acute cases, thereby decreasing the risk of postrepair rupture of the infarcted 
myocardium.
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Abstract
Objective: Magnetic resonance imaging was used to evaluate left ventricular reverse 
remodeling at long-term follow-up (3–4 years) after restrictive mitral annuloplasty 
in patients with early stages of nonischemic, dilated cardiomyopathy, and severe 
mitral regurgitation.
Methods: Twenty-two selected patients (eligible to undergo magnetic resonance 
imaging) with mild to moderate heart failure (mean New York Heart Association 
class 2.2±0.4), dilated cardiomyopathy (left ventricular ejection fraction 37±5%, left 
ventricular end-diastolic volume 215±34 mL), and severe mitral regurgitation (grade 
3–4+) underwent restrictive mitral annuloplasty. Magnetic resonance imaging was 
performed 1 week before surgery and repeated after 3 to 4 years.
Results: There was no hospital mortality or major morbidity. Two patients died 
during follow-up (9%), and 2 patients could not undergo repeat magnetic resonance 
imaging because of comorbidity. New York Heart Association class improved from 
2.2±0.4 to 1.2±0.4 (P<0.05). Mitral regurgitation was minimal at late echocardio-
graphic follow-up. There were significant decreases in indexed (to body surface area) 
left atrial end-systolic volume (from 84±20 mL/m2 to 68±12 mL/m2, P<0.01), 
left ventricular end-systolic volume (from 42±14 mL/m2 to  31±12 mL/m2, P<0.01), 
left ventricular end-diastolic volume (from 110±18 mL/m2 to 80±17 mL/m2, P<0.01) 
and left ventricular mass (from 76±21 g/m2 to 66±12 g/m2, P=0.03). Forward left 
ventricular ejection fraction improved from 37±5% to 55±10% (P<0.01). Indexed left 
atrial end-diastolic volume did not show a significant decrease (from 48±16 mL/m2 
to 44±10 mL/m2, P=0.15)
Conclusions: Magnetic resonance imaging confirms sustained significant reverse 
left atrial and ventricular remodeling at late (3–4 years) follow-up in patients with 
nonischemic, dilated cardiomyopathy, and mild to moderate heart failure after 
restrictive mitral annuloplasty.
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Magnetic resonance imaging (MRI) is currently considered the gold standard for the assessment of left ventricular (LV) function and volumes.1 Advantages of MRI 
over echocardiography are the superior image quality and the 3-dimensional quantifica-
tion possibilities with high reproducibility, implying that smaller sample sizes are needed 
to prove statistical significance of changes in LV volumes after therapy.2 MRI may 
 therefore be the most appropriate imaging technique for the evaluation of surgical 
 treatments for heart failure. In a previous study, we presented MRI data on short-term 
follow-up after restrictive annuloplasty in patients with nonischemic, dilated cardiomyo-
pathy and severe mitral regurgitation (MR).3 Significant left atrial (LA) and LV reverse 
remodeling were noted 2 months after surgery. Moreover, LV ejection fraction (LVEF) 
improved significantly. However, whether these beneficial effects are sustained at 
 long-term  follow-up is not clear.4 In the current study, the persistence of reverse 
 remodeling at long-term follow-up after restrictive mitral annuloplasty is evaluated with 
MRI. Twenty-two selected patients with nonischemic, dilated cardiomyopathy, mild to 
moderate heart failure, and severe MR were evaluated by MRI within 1 week before 
restrictive mitral annuloplasty, and repeat imaging with MRI was performed at 3 to 4 
years after surgery.
Methods
Patients
Twenty-two selected patients (18 male, 4 female, mean age 57±15 years) with  mild to 
moderate heart failure and dilated cardiomyopathy (New York Heart Association 
[NYHA] class 2.2±0.4, LV end-diastolic dimension 61±5 mm, forward LVEF 37±5%, 
LV  end-diastolic volume [LVEDV] 215±34 mL) who were scheduled for restrictive 
mitral annuloplasty were included. All patients presented with nonischemic, dilated 
cardio myopathy (coronary artery disease excluded on coronary angiography) and severe 
functional MR on echocardiography. The patients had 3+ to 4+ MR (central jet) 
 secondary to LV and annular dilatation and systolic restrictive motion of mitral leaflets 
(Carpentier type IIIb). All patients were receiving optimized medical therapy and kept 
on an  optimal regimen during the study period.
Patients selected for this study had to be eligible to undergo repeat MRI examination. 
Therefore, in addition to general MRI exclusion criteria (i.e., pacemakers/defibrillators, 
intracranial clips, pregnancy, claustrophobia), disease-related specific criteria were 
applied. These included the presence of (supra)ventricular arrhythmias or an existing 
indication for postoperative (biventricular) pacemaker/defibrillator implantation. 
To maintain uniformity of surgical intervention in this small patient group, additional 
valve surgery, including tricuspid valve repair, was another exclusion criterion. These 
factors inevitably limited the patient selection to those with relatively mild heart failure, 
a group of patients representing the better part of our heart failure program. None of 
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the patients had pulmonary hypertension, and all patients had preserved right 
 ventricular function. MRI was performed within 1 week before surgery and repeated 3 to 
4 years later (43±8 months). At follow-up, a routine transthoracic echocardiographic 
examination was performed.
Surgery
All surgical procedures were performed via midline sternotomy under normothermic 
cardiopulmonary bypass with intermittent antegrade warm blood cardioplegia. 
The mitral valve was exposed through a vertical transseptal approach along the right 
border of the foramen ovale, leaving the roof of the left atrium untouched. Ring size 
(Carpentier-Edwards Physio ring, Edwards Lifesciences, Irving, CA) was determined 
after careful measurement of the intercommisural distance and height of the anterior 
leaflet, and then downsizing by two ring sizes (i.e., size 26 when measuring 30). 
All patients had intraoperative transesophageal echocardiographic assessment of valve 
function. Mitral valve repair was considered successful if there was no residual MR and 
a leaflet coaptation length of at least 8 mm at the A2-P2 level was achieved on intra-
operative echocardiography.
Magnetic Resonance Imaging
MRI was performed using a 1.5 T MRI scanner (ACS-NT15 Gyroscan with the 
Powertrack 6000 gradient system; Philips Medical Systems, Best, The Netherlands). 
The body coil was used for transmission and a 5-element phased-array synergy 
 cardiac-coil was placed on the chest for signal reception. Standard 2- and 4-chamber 
long-axis series and a complete set of short-axis cine acquisitions were performed 
 (conform standard cardiac MRI protocols5 using steady-state free-precession6) with the 
patient performing a breath hold in end-expiration. Imaging parameters of the 2- and 
4-chamber long-axis and for the short-axis series were as follows: TE/TR = 1.52/3.0, 
flip angle = 50 degrees, field of view = 350 mm, scan matrix = 192 ×153, slice thickness = 
8 mm, and gated cardiac triggering with retrospective reconstruction of 30 phases. 
For the short-axis series, 10 to 12 parallel oriented slices were acquired with a 2-mm slice 
gap, 1 slice during each breath hold. LVEDV and LV end-systolic volume (LVESV) 
(from short-axis MRI7) and LAEDV and LAESV (from measuring biplane area-length 
in orthogonal long-axis 2- and 4-chamber views3) were obtained by manual segmenta-
tion. Image analysis was performed blinded with respect to echocardiographic data.
In the presence of significant MR, LVEF does not represent the true forward blood flow 
(through the aortic valve) because a substantial part of the blood volume leaks back into 
the left atrium. To correct for this effect, we have recently used the ‘‘forward LVEF,’’ 
which was derived by calculating the ratio of the forward stroke volume and the EDV.3 
The forward stroke volume was obtained from aortic flow measurements derived from 
velocity-encoded MRI.8 QMass and QFlow software (Medis, Leiden, The Netherlands) 
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were used for image analysis. MRI examination was repeated at 3 to 4 years follow-up, 
and similar parameters were assessed. Significant reverse remodeling was defined as a 
volume reduction exceeding 15%. An increase in forward LVEF of 5% or more and a 
decrease in LV mass 10 g or more were considered significant.3 The medical ethics com-
mittee of our institute approved all examinations. All patients gave informed consent.
Statistical Analysis
Continuous data were expressed as mean ± standard deviation and compared using the 
Student t test for paired data.
Results
Clinical Outcome
All patients underwent successful mitral valve repair. The median annuloplasty ring size 
was 26. Intraoperative transoesophageal echocardiography showed a mean coaptation 
length of 8±1 mm. Residual MR was trivial in 4 patients and absent in the remaining 
patients. None of the patients had mitral stenosis, and systolic anterior movement of the 
anterior leaflet was not observed on echocardiography. There was no in-hospital or 
30-day mortality, and no major complications occurred.
During follow-up, 2 patients died (9%) of refractory heart failure before repeat MRI. In 
2 additional patients, follow-up MRI could not be performed because of comorbidity 
(Alzheimer’s disease and amyotrophic lateral sclerosis). There were no cases of endocar-
ditis or thromboembolic events.
At late follow-up (43±8 months) NYHA class was 1.2±0.4 (P<0.05 vs. baseline), and 
transthoracic echocardiography showed minimal MR (mean grade 0.6±0.5), with a 
mean leaflet coaptation length of 8±3, without mitral stenosis.
Reverse Remodeling on Magnetic Resonance Imaging
Figure 1 shows the LA and LV reverse remodeling assessed by MRI. The MRI results are 
summarized in Table 1. Although LAEDVi (‘i’ indicating indexation to body surface 
area) did not decrease significantly (predefined by a volume reduction ≥15%) (from 
48±16 mL/m2 to 44±10 mL/m2, P=0.15), significant LA reverse remodeling for EDV 
occurred in 56% of the patients. Individual data are presented in Figure 2A. LAESVi 
decreased significantly from 84±20 mL/m2 to 68±12 mL/m2 (P<0.01), with significant 
LA reverse remodeling for ESV occurring in 67% of (Figure 2B). LVEDVi decreased 
 significantly from 110±18 mL/m2 to 80±17 mL/m2 (P<0.01). Significant reverse remode-
ling of LVEDV occurred in the majority of patients (89%); individual data are shown in 
Figure 3A. LVESVi significantly decreased from 42±14 mL/m2 to 31±12 mL/m2 (P<0.01), 
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with 72% of patients showing significant reverse remodeling of LVESV (Figure 3B). 
Overall, 2 patients (11%) did not show any (LA or LV) reverse remodeling.
Forward LVEF increased significantly over time: from 37±5% at baseline to 55±10% 
(P<0.01). Of note, 94% of patients showed a significant increase in forward LVEF 
 (predefined as an increase of ≥5% in forward LVEF); individual results are shown in 
Figure 4A. Indexed LV mass showed a statistically significant decrease (predefined as a 
mass reduction ≥10 g): from 76±21 g/m2 to 66±12 g/m2 (P=0.03). In addition, 83% of the 
patients showed a significant decrease in LV mass (Figure 4B).
Figure 1. Patient example illustrating reverse remodeling of the left atrium and left ventricle 43 months 
after mitral valve repair. Four-chamber views during end diastole (A) and end systole (B) before 
 surgery show severe dilatation of the left atrium (LAEDV 128 mL, LAESV 216 mL) and left ventricle 
(LVEDV 311 mL, LVESV 90 mL) caused by volume overload secondary to severe MR. The 4-chamber 
views during end-diastole (C) and end-systole (D), 43 months after surgery, show a reduction in 
LA volumes (LAEDV 88 mL, LAESV 145 mL) and LV volumes (LVEDV 210 mL, LVESV 89 mL). 
A restrictive semirigid ring is implanted in the mitral annulus, resulting in signal loss because of 
 paramagnetic material inside the ring.
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Table 1.
MRI Results: Pre-surgery and at 43±8 Months Follow-up.
Presurgery 43±8 months’ 
follow-up
P value
LAESV (mL) 165±43 132±20 <0.01
LAESVi (mL/m
2)  84±20  68±12 <0.01
LAEDV (mL)  95±32  85±19  0.14
LAEDVi (mL/m
2)  48±16  44±10  0.15
LVESV (mL)  82±25  60±22 <0.01
LVESVi (mL/m
2)  42±14  31±12 <0.01
LVEDV (mL) 215±34 157±32 <0.01
LVEDVi (mL/m
2) 110±18  80±17 <0.01
Forward LVEF (%) 37±5  55±10 <0.01
LV mass/BSA (g/m2)  76±21  66±12  0.03
LAESV, Left atrial end-systolic volume; LAEDV, left atrial end-diastolic volume; LVESV, left ventricular 
end-systolic volume; LVEDV, left ventricular end-diastolic volume; LVEF, left ventricular ejection 
 fraction; LV, left ventricular; BSA, body surface area; i, indexation to body surface area.
 
Figure 2. Individual data of patients demonstrating the changes over time in LAEDVi(A) and 
LAESVi(B). Examination 1 concerns MRI before surgery; examination 2 concerns MRI at 43±8 
months follow-up. Mean values (circular data points and solid line); individual data (triangles and 
dotted lines).
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Discussion
This study demonstrates the ability of MRI to report in a detailed fashion on various 
aspects of the LV reverse remodeling process (forward LVEF, LV and LA volumes). 
All  previous studies on improvement in LVEF and LV reverse remodeling after 
 restrictive mitral repair in patients with dilated cardiomyopathy used echocardiography, 
which is limited by substantial intra– and interobserver variations and geometric 
assumptions needed for quantification of LVEF and LV volumes. The same 
 measurements done with MRI have been reported to be highly accurate and 
 reproducible.3,7 MRI has a superior image quality compared with echocardiography and 
is not  hampered by technical limitations, such as suboptimal acoustic windows. 
Figure 3. Individual data of patients demonstrating the changes over time in LVEDVi (A) and 
LVESVi (B). Examination 1 is MRI before surgery; examination 2 is MRI at 43±8 months follow-up. 
Mean values (circular data points and solid line); individual data (triangles and dotted lines).
Figure 4. Individual data of patients demonstrating the changes over time in forward LVEF (A) and 
LV mass indexed by body surface area (B). Examination 1 is MRI before surgery; examination 2 is 
MRI at 43±8 months follow-up. Mean values (circular data points and solid line); individual data 
(triangles and dotted lines).
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Moreover, MRI has the advantage of acquiring every arbitrary double obliquely oriented 
imaging plane in 3 dimensions. Accordingly, MRI is considered the gold standard for 
assessment of LA and LV volumes, and its noninvasive nature and high reproducibility 
make this technique ideal for  follow-up studies after therapy.9 The high reproducibility 
allows for smaller study sample sizes to prove statistical significance. For example, to 
demonstrate a 10 mL  difference in LVEDV with a P value less than .05 and a power of 
90%, evaluation of only 12 patients is needed when MRI is used, compared with 
121 patients when echocardiography is used.2 Indeed, in the current study,  significant LA 
and LV reverse remodeling were statistically significantly proven with only 18 patients. 
Moreover, MRI permits easy correction for the influence of MR on LVEF by the use of 
the forward stroke volume (reflecting true forward blood flow through the aortic valve), 
as applied in the current study. This approach also permits a better appreciation of the 
true effect of mitral valve surgery on forward blood flow, reflected in the current study 
by a significant increase in forward LVEF.
However, the use of MRI for follow-up purposes is still limited by technical factors, and, 
as explained before, the patient group presented here represents the better part of our 
heart failure program. Currently, all patients with heart failure undergo MRI before 
surgery, but only those not requiring implantation of an epicardial LV lead or a 
 pacemaker/defibrillator and those without (supra)ventricular arrhythmias are eligible to 
undergo follow-up MRI. These contraindications currently hamper widespread use of 
MRI in patients with heart failure. It is expected that these technical limitations of MRI 
will be overcome in the near future, which will greatly increase the possibilities of 
 follow-up imaging in patients with heart failure.
In the current study, the beneficial effects of restrictive mitral annuloplasty in a selected 
group of patients with mild to moderate heart failure was shown. Currently, not much 
information on the effects of restrictive mitral annuloplasty in this patient category is 
available. Acker et al10 recently reported initial results from the Acorn trial. In this study, 
a subgroup of patients with mild heart failure (NYHA class II and relatively preserved 
LVEF and functional MR) underwent isolated mitral valve surgery, similar to the 
patients in the current study. The outcome of this subset of patients was not reported 
separately, making direct comparison with the current findings impossible.
Another conclusion that can be drawn from the present study is that treatment of 
 functional MR in nonischemic dilated cardiomyopathy by restrictive annuloplasty 
alone eliminates MR and leads to LA and LV reverse remodeling in the majority of this 
selected patient population. It has been questioned whether LV reverse remodeling is 
maintained over longer follow-up periods. Our current results confirm that LV reverse 
remodeling is indeed present at long-term follow-up. These favorable results may be 
related to the fact that only patients with milder heart failure were included (mean 
NYHA class 2.2±0.4 and mean forward LVEF 37±5%), reflecting the less ill patients in 
our heart failure program. In addition, only patients with preserved right ventricular 
function and without pulmonary hypertension or significant tricuspid regurgitation 
were selected. For reference, in our institution patients with more advanced stages of 
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heart failure undergo tricuspid annuloplasty when significant tricuspid regurgitation or 
severe annular dilatation (annular diameter ≥40 mm) is present. When LV end-diastolic 
diameter exceeds 65 mm, an external cardiac constraint device (CorCap cardiac support 
device; Acorn Cardiovascular, St Paul, Minn) is also applied. These patients have a 
6%  operative mortality, and long-term results are currently being evaluated. When 
LV  end-diastolic dimension exceeds 80 mm, surgical LV restoration is considered as 
described by Isomura et al.11
The current results strengthen the hypothesis that grades 3 to 4+ functional MR can be 
successfully treated by restrictive mitral annuloplasty in patients with LV dilatation but 
relatively mild heart failure (NYHA class II to III). On a patient basis, 89% and 72% of 
patients exhibited a significant reduction in LV volumes. These observations are  clinically 
relevant because LV function and volumes have been demonstrated to be important 
predictors of long-term outcome in patients with LV dysfunction.12,13
Also, LA  dimensions have been shown to provide prognostic information.14,15 In the 
present study, LA volume in end-systole showed a significant decrease, although 
LA volume in end-diastole did not exhibit a decrease in the entire study population.
On the basis of the reverse remodeling observed in the current study, one could  speculate 
that the point of no return (irreversible LV dilatation) was not yet reached in this patient 
category, suggesting that mitral valve surgery may be considered at an earlier stage in 
patients with nonischemic dilated cardiomyopathy. Further prospective studies are 
needed to confirm the benefit of early surgical intervention in patients with mild heart 
failure.
Conclusions
MRI provides a powerful tool for the evaluation of the LV and LA reverse remodeling 
process in patients with mild heart failure with functional MR and nonischemic dilated 
cardiomyopathy who underwent isolated restrictive annuloplasty. At late (3–4 years) 
 follow-up, sustained significant LV and LA reverse remodeling was demonstrated using 
MRI. It should be emphasized that the current findings have been obtained in a highly 
selected patient population and that further MRI experience in patients with more 
advanced stages of heart failure is needed.
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Abstract
Objective: Nonischemic dilated cardiomyopathy with functional mitral 
 regurgitation carries a poor prognosis. Mitral valve surgery with implantation of a 
cardiac support device can treat mitral regurgitation and promote left ventricular 
reverse remodeling. This observational study evaluates clinical and echocardio-
graphic outcomes of an individualized medico–surgical approach, focusing on 
mitral regurgitation recurrence and left ventricular reverse remodeling.
Methods: Sixty-nine consecutive heart failure patients (New York Heart Association 
class III/IV) with functional mitral regurgitation (grade 3+/4+) and left ventricular 
remodeling (end-diastolic volume 227±73 mL, ejection fraction 26±8%) underwent 
restrictive mitral annuloplasty (median ring size 26), with (n=41) or without (n=28) 
a cardiac support device and optimal postoperative medical treatment. Patients were 
clinically and echocardiographically evaluated up to 3.1 years’ median follow-up. 
Results: Early mortality was 5.8%. Actuarial survival at 1, 2 and 5 years was 86±4%, 
79±5%, and 63±7%. New York Heart Association class improved from 3.1±0.4 to 
2.0±0.5 (P<0.01). Cardiac support device implantation in addition to mitral valve 
surgery, applied in patients with more advanced left ventricular remodeling, resulted 
in similar clinical outcome, greater left ventricular end-diastolic volume decrease 
(33% vs 18%, P=0.007), and in a trend towards less recurrent mitral regurgitation of 
grade 2+ or more (actuarial freedom at 3 years 89±8% vs 63±11%, P=0.067).
Conclusions: An individualized medico–surgical approach to nonischemic 
 cardiomyopathy combining restrictive mitral annuloplasty, cardiac support device 
implantation, and optimal medical management leads to favorable survival and 
improved functional status, low incidence of significant recurrent mitral  regurgitation, 
and sustained left ventricular reverse remodeling.
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Congestive heart failure resulting from nonischemic dilated cardiomyopathy with secondary functional mitral regurgitation (MR) carries a poor prognosis.1-4 Medical 
treatment results in a 1-year survival of 52% to 87%, and a 5-year survival of 22% to 
54%,1,2,4,5 with highest survivals presented in more recent years, probably reflecting 
improvements in medical therapy. Nonsurgical interventions involve cardiac resynchro-
nization therapy (CRT)6 and cardiac rehabilitation.7 Implantation of an internal 
 cardio verter defibrillator (ICD), often combined with CRT, improves survival by 
 preventing death from life-threatening arrhythmias.8 Surgery is considered a third-line 
treatment for selected patients, and includes cardiac transplantation and assist device 
implantation, or nontransplantion surgery. In the latter category, the use of an  undersized 
mitral annuloplasty ring to cure mitral regurgitation and to restore the shape of the 
spherical left ventricle (LV) to its normal ellipsoid form has been advocated by Bach and 
Bolling9,10 and has been adopted by others.11 The true benefit of this approach over 
 nonsurgical treatment with regard to survival has been debated.12 More recently,  external 
cardiac restraint or cardiac support devices (CSDs), for example the CorCap device 
(Acorn CV, St Paul, Minn), have become available as additional surgical alternatives to 
treat non ischemic dilated cardiomyopathy. In a randomized trial, survival of patients 
with MR and nonischemic dilated cardiomyopathy who underwent mitral valve surgery 
with concomitant CSD implantation was similar to that of patients with mitral valve 
surgery alone after 2 years (85%). Implantation of a CSD, however, resulted in a more 
extensive decrease of LV volumes.13
In this study, the clinical and echocardiographic outcome is assessed of all consecutive 
heart failure patients who had nonischemic dilated cardiomyopathy and underwent 
restrictive mitral annuloplasty, with (n=41) or without (n=28) CSD implantation, in our 
nontransplantation surgical heart failure treatment program. Clinical outcome includes 
death, functional status and adverse events (reoperation, readmission for heart failure). 
Echocardiographic examination focuses on recurrence of MR and LV reverse 
remodeling.
Patients and methods
Patient Population and Indications for Surgery
Sixty-nine consecutive patients with nonischemic dilated cardiomyopathy and 
 functional MR who underwent surgery for heart failure since the start of our  medico–
surgical treatment program in August 2000 until January 2008 were included in this 
analysis, except patients with concomitant aortic valve disease. Patients were accepted 
for surgery regardless of ejection fraction or mitral valve geometry (i.e., tenting height, 
leaflet angulation). Patients were in New York Heart Association (NYHA) heart failure 
class III (86%) or IV; mean NYHA class was 3.1±0.4 with optimal medical management. 
Mean MR grade was 3.1±0.6. Mean logistic EuroSCORE was 11.9±9.2 (range, 2.3–48). 
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Seventy-four percent of patients had at least 1 contraindication for cardiac 
 transplantation. Patient characteristics are presented in Table 1.
MR was treated using a restrictive semirigid complete ring annuloplasty. A tricuspid 
ring annuloplasty was performed in patients with significant tricuspid regurgitation 
(≥ grade 2+), or (starting in 2003) when the tricuspid annulus diameter exceeded 40 mm, 
or exceeded 21 mm/m2 indexed to body surface area on transthoracic echocardiography. 
The use of external cardiac restraint by means of a CSD started in late 2002 in patients 
with an LV end-diastolic diameter exceeding 65 mm or exceeding 30 mm/m2 indexed to 
body surface area.
Our institution’s medical ethics committee approved this analysis of clinical data and 
waived the need for individual consent.
Preoperative Clinical and Echocardiographic Assessment
Preoperative clinical status was determined according to the NYHA criteria directly 
before surgery. Echocardiographic evaluation consisted of standard transthoracic 
 examination within 5 days before surgery, including semiquantitative grading of severity 
of MR and tricuspid regurgitation,14 measurement of tricuspid annulus diameter, 
LV end-diastolic and end-systolic diameter, and left atrial size. LV volumes and 
LV  ejection fraction were calculated according to Simpson’s biplane method of disks.15 
Baseline echocardiographic data are summarized in Table 1.
Operative Technique
All surgical procedures were performed via midline sternotomy with normothermic 
 cardiopulmonary bypass and intermittent antegrade warm blood cardioplegia. 
In patients receiving a CSD, a CorCap CSD was implanted first on the beating heart 
with suture fixation of the device to the dorsal base of the heart along the 
 atrioventricular groove. At the end of the surgical procedure, the CSD was tailored to 
meet the preoperative LV dimensions measured on transesophageal echocardiography, 
as described earlier.16 The mitral valve was exposed through a vertical transseptal 
approach along the right border of the foramen ovale. Ring size (Carpentier–Edwards 
Physioring; Edwards Lifesciences, Irving, CA) was determined after careful measure-
ment of the height of the anterior leaflet, and then downsizing by 2 ring sizes (i.e., size 
26 when measuring 30).17 Tricuspid annuloplasty was performed with a Carpentier–
Edwards Classic (until 2003) or MC3 ring. Surgical data are summarized in Table 2.
Mitral valve repair was considered successful only if there was no residual MR and 
a  leaflet coaptation length of at least 8 mm at the A2–P2 level on intraoperative 
echocardiogram.
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TABLE 1
Preoperative Clinical, Laboratory and Echocardiographic Data for all Patients, and Arranged 
by CSD Status
Variable All patients Without CSD With CSD P value
No. of patients  69 28 41
Age (y)  60±12 56±14 62±10   0.07
Female gender (n)  37 (54%) 19 (68%) 18 (44%)   0.08
NYHA class III  59 (86%) 26 (93%) 33 (80%)   0.18
NYHA class IV  10 (14%) 2 (7%)  8 (20%)   0.18
Logistic EuroSCORE  11.9±9.2 0.8±7.2 12.7±10.2 >0.2
Diabetes  16 (23%)  7 (25%)  9 (22%) >0.2
Chronic obstructive pulmonary disease  12 (17%)  5 (18%)  7 (17%) >0.2
Atrial fibrillation 18 (26%)  6 (21%) 12 (29%) >0.2
ICD before surgery 12 (17%)  3 (11%)  9 (22%) >0.2
CRT before surgery  8 (12%) 2 (7%)  6 (15%) >0.2
ACE-inhibitor or AT2 receptor antagonist 
therapy
62 (90%) 24 (86%) 38 (93%) >0.2
Beta-blocker therapy 54 (78%) 22 (79%) 32 (79%) >0.2
Diuretic therapy 64 (93%) 25 (91%) 39 (95%) >0.2
Spironolactone therapy 35 (51%) 17 (62%) 18 (44%) >0.2
Systolic blood pressure (mmHg)  115±17 122±19  113±15   0.09
Pulmonary hypertension 27 (40%) 10 (36%) 17 (41%) >0.2
Creatinin (μmol/L)  110±42 120±50  103±35   0.17
Plasma sodium (μmol/L) 140±4 140±5 140±4 >0.2
Mitral regurgitation grade
Grade 2+   8   3   5
Grade 3+  45  19  26
Grade 4+  16   6  10
LV end-diastolic diameter (mm) 67±9  65±11 69±7   0.07
LV end-systolic diameter (mm)  60±10  57±12 63±7   0.03
LV end-diastolic volume (mL) 227±73 201±80 245±63   0.02
indexed to BSA (mL/m2) 118±38 108±39 133±32    0.009
LV end-systolic volume (mL) 171±65 150±71 186±57   0.03
LV ejection fraction (%) 26±8 28±9 25±8   0.13
Left atrial diameter (mm) 46±8  45±10 47±6 >0.2
Mean transtricuspid pressure gradient 
(mmHg)
 31±10 30±9  31±11 >0.2
CSD, Cardiac support device; NYHA, New York Heart Association; ICD, internal cardioverter 
 defibrillator; CRT, cardiac resynchronization therapy; ACE, angiotensin-converting enzyme; 
AT2, angiotensin II type 2; LV, left ventricular; BSA, body surface area. 
P values given for comparison between patients with and without CSD.
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TABLE 2
Surgical and Early Postoperative Data for all Patients, and Arranged by CSD Status.
Variable All patients Without CSD With CSD P value
Cardiopulmonary bypass time (min) 132±33 126±25 136±36 >0.2
Aortic crossclamp time (min)  73±22  74±18 72±24 >0.2
Median mitral annuloplasty ring size (range)  26 (24–30)  26 (24–30)  26 (24–30) >0.2
Ring size 24 (n) 28 (41%) 11 (40%) 17 (42%) >0.2
Ring size 26 (n) 21 (30%)  8 (29%) 13 (32%) >0.2
Tricuspid valve annuloplasty (n) 50 (73%) 16 (57%) 34 (83%)   0.04
Median postoperative ventilator assist 
(d;range)
 0.5 (0.5–40)   1 (0.5–40)  0.5 (0.5–10) >0.2
Median postoperative ICU stay (d;range)  2 (1–49)  3 (1–49)  2 (1–24) >0.2
Median postoperative hospital stay (d;range) 12 (6–80)  12 (5–80)  12 (5–30) >0.2
ICU: intensive care unit. P values given for comparison between patients with and without CSD
Postoperative Clinical and Echocardiographic Follow-up
Transthoracic echocardiography was repeated before discharge on the seventh 
 postoperative day and included assessment of the same parameters as in the preoperative 
examination, with the addition of mean transmitral diastolic gradient and mitral valve 
area calculated based on pressure half-time. After hospital discharge, all but 3 patients 
were followed up in our outpatient heart failure clinic and received standardized 
 optimal medical management, with regular echocardiographic follow-up.
Diastolic and systolic reverse remodeling at follow-up were defined as at least 15% 
 reduction of LV end-diastolic or end-systolic volume, respectively, compared with 
 baseline volume.
Statistical Analysis
Continuous data are expressed as mean ± standard deviation unless otherwise stated, 
and they were compared using the Student t test for paired and unpaired data when 
appropriate. Proportions for dichotomous data were compared by χ2 analysis with Yates’ 
correction. Survival and freedom from time-related events were estimated using the 
Kaplan-Meier method and analyzed using Cox proportional hazard regression. 
Repeated measurements were analyzed using 2-way analysis of variance. SPSS statistical 
software (SPSS version 16.0.2; SPSS, Inc, Chicago, IL) was used for calculations.
Results
All patients underwent successful mitral valve repair. Seventy-one percent of patients 
received a mitral ring size 24 or 26. A CSD was implanted in 59% of patients, tricuspid 
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ring annuloplasty was performed in 73% of patients. Intraoperative echocardiography 
showed a competent mitral valve in all patients, without evidence of mitral stenosis.
Immediate Outcome
There was no intraoperative mortality. Nine patients (13%) were supported by peri-
operative intra-aortic balloon counterpulsation, and 6 (9%) required temporary 
 hemodialysis, with an equal distribution among CSD and no-CSD patients. Overall 
early mortality (in-hospital and 30-day mortality) was 5.8% for the entire group 
 (no-CSD 3.6%, n=1; CSD 7.3%, n=3; P=0.641). Three patients died of circulatory  failure 
and 1 of septicemia secondary to pulmonary infection.
Twenty-two patients (34%) were scheduled preoperatively to receive CRT/ICD therapy, 
which was realized within 1 week after surgery during the same admission period.
Survival
Clinical follow-up was complete for the remaining 65 patients. Median follow-up was 
3.1 years (interquartile range [IQR]: 1.4–4.1 years). For the no-CSD group it was 4.3 
years (IQR, 1.9–5.8 years) and for the CSD group it was 2.4 years (IQR, 1.3–4.0 years).
There were 18 late deaths during follow-up (no-CSD, 12; CSD, 6), with 50% of deaths 
resulting from cardiac causes. Overall survival (Kaplan–Meier estimate) at 1 year, 2 years 
and 5 years is 86±4%, 79±5%, and 63±7%, respectively (Figure 1, A). For the no-CSD 
group, these percentages were 86±7%, 75±8% and 55±10%, respectively, versus 85±6%, 
82±6% and 74±8% for the CSD group, without significant difference (Figure 1, B).
Adverse Events
Thirteen patients (20%) were readmitted for heart failure. The incidence of hospital 
readmissions for heart failure was 1 per 5.84 patient years (38 readmissions in 222.3 
patient years). Eight of these 13 patients (62%) died during follow-up (mean interval 
between first readmission and death, 8 months; range 1–17 months), and 1 is on the 
cardiac transplantation waiting list.
Eleven patients received CRT/ICD therapy during follow-up. Of 42 patients with ICD 
registration analysis, 24 (57%) had at least 1 episode of ventricular tachycardia, of whom 
14 had sustained ventricular tachycardia requiring antitachycardia pacing or shock (n=3). 
Two patients had successful shock therapy for ventricular fibrillation.
There were 3 cases of partial mitral ring dehiscence. One patient (CSD group)  underwent 
successful refixation 2 months after the initial operation. Two other patients (without 
CSD) did not have reoperation; 1 had malignant disease, and the other declined redo 
surgery. Two patients had an ischemic cerebrovascular accident (1 fatal and the other 
with complete recovery), and another patient had a peripheral arterial embolism.
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Long-term Clinical Outcome 
For long-term survivors, mean NYHA class improved from 3.2±0.4 to 2.0±0.5 (P<0.01) 
with 5 patients (11%) in NYHA class III, with similar results in the CSD and no-CSD 
groups. Forty-three surviving patients (91%) experienced improvement of symptoms 
(Figure 2).
Figure 1. A, Survival 
 estimated by Kaplan–Meier 
method for all patients. 
B, Survival estimated by 
Kaplan–Meier method for 
cohorts with and without a 
cardiac support device (CSD). 
Patients at risk per cohort are 
shown under the horizontal 
axis (CSD presented in bold-
face; no-CSD in regular type). 
HR, Hazard ratio; CI, confi-
dence intervals.
A
B
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Echocardiographic Outcome
Echocardiographic follow-up for hospital survivors was available for all but 3 patients 
(95% complete). Mean late echocardiographic follow-up time was 2.3±1.4 years (IQR 
1.0–3.5) and was similar for the CSD and no-CSD group (2.2±1.4 years and 2.6±1.4 years, 
respectively). Echocardiographic data, summarized in Table 3, also include results in 
patients who died during follow-up. Therefore, these data truly represent therapeutic 
effects, rather than being the consequence of attrition through death.
Mitral Regurgitation and Stenosis
MR decreased significantly at early postoperative and late follow-up. At late follow-up, 
16% of patients had MR grade 2+ or more. In the no-CSD group this percentage was 
28% versus 8.3% in the CSD group. Actuarial freedom from recurrent MR of grade 2+ 
or more at 3 years is 89±8% in the CSD group versus 63±11% in the no-CSD group 
(P=0.067). Cox regression analysis did not reveal any predictors for recurrence of MR 
(forcing CSD implantation, CRT/ICD therapy and LV end-diastolic volume at baseline 
into the model). Sixty percent of patients who had recurrent MR died during follow-up. 
Mean transmitral gradient was elevated (>5 mmHg) in 3 patients (5%).
LV Reverse Remodeling and Function
LV volumes decreased over time (Figure 3). Initial reduction of volumes (from pre-
operatively to early postoperatively) was similar in both groups, At late follow-up, a 
higher decrease was observed in the CSD group: mean LV end-diastolic volume 
 reduction was -82 mL versus -39 mL, or 33% vs 18% (P=0.007). LV end-systolic volume 
reduction was -66 mL versus -34 mL, or 34% versus 20% (P=0.042). Whereas baseline 
volumes in the CSD group were significantly higher, the values at late follow-up did not 
differ between the 2 groups. Two-way analysis of variance showed that the difference in 
Figure 2. Clinical status according to 
New York Heart Association (NYHA) 
 criteria at baseline and at late follow-up.
Chapter 7180
magnitude of reverse remodeling comparing the CSD and no-CSD groups is 
 statistically significant; linear regression indicated that both implantation of CSD 
(P=0.041) and end-diastolic volume at baseline (P<0.001) were determinants of final 
end-diastolic volume, with the effect of CSD implantation being independent of initial 
end-diastolic volume (interaction variable P=0.658). Diastolic reverse remodeling at late 
follow-up was present in 76% of patients (CSD, 88%; no-CSD, 61%), and systolic 
reverse remodeling occurred in 73% (CSD, 81%; no-CSD, 61%). LV ejection fraction 
increased from 29±8% to 30±7% in the no-CSD group (P=0.426) and from 25±8% to 
29±13% in the CSD group (P=0.123).
TABLE 3
Echocardiographic Parameters for all Patients with Available Complete Preoperative, Early 
Postoperative and Long-term Follow-up Data
Variable Preoperatively Early 
 postoperatively
Long-term 
 follow-up
MR grade
None  —  53 30
Grade 1+  —  15 22
Grade 2+   8  —  7
Grade 3+  45  —  2
Grade 4+  16  —  1
LV end-diastolic diameter (mm) 68±9  63±9*   60±11*
LV end-systolic diameter (mm)  61±10   56±10*   54±12*
LV end-diastolic volume (mL) 227±73  205±72*   161±63*†
LV end-systolic volume (mL) 171±65  153±66*   116±55*†
LV ejection fraction (%) 26±8  25±8   29±11
Left atrial diameter (mm) 46±8  44±8*  44±8*
Mean transmitral diastolic gradient (mmHg)  1.8±0.9   4.0±1.3*   3.6±1.8*
Mitral valve area (cm2)  3.8±1.2   3.3±0.8   3.0±1.0*
Mean transtricuspid pressure gradient (mmHg)   3±10  24±8*   28±10*
MR, Mitral regurgitation; LV, Left ventricular.
* P<0.001 versus preoperative echo. † P<0.001 versus early postoperative echo.
Comparison Between Survivors and Nonsurvivors
There were no differences between survivors and nonsurvivors with regard to  preoperative 
demographics, medical treatment, laboratory values, or baseline echocardiographic 
characteristics. Although survivors had relatively more often CRT/ICD therapy (77% vs. 
44%) and CSD implantation (68% vs. 33%), differences were not significant using Cox 
regression; for CRT/ICD therapy: hazard ratio, 0.50; 95% CI, 0.16–1.55, P=0.228; for 
CSD: hazard ratio, 0.27; 95% CI 0.26–1.45; P=0.267.
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Comment
This study describes the long-term clinical and echocardiographic outcome of a non-
transplantion medico–surgical treatment program in a consecutive series of patients 
with nonischemic dilated cardiomyopathy and functional MR, with moderately severe 
or severe congestive heart failure despite optimal medical treatment. The main findings 
of this study are as follows: (1) mitral valve repair with a restrictive mitral annuloplasty 
with or without external LV constraint using a CSD leads to improvement of functional 
status and a favorable long-term survival; (2) restrictive mitral annuloplasty, with or 
without external LV constraint, leads to a low incidence of significant recurrent MR and 
to reverse LV remodeling in a vast majority of patients, which is sustained at long-term 
follow-up; (3) additional CSD implantation in patients with more advanced LV remod-
eling leads to more LV volume reduction, resulting in similar LV end-diastolic volumes 
at late follow-up comparing patients with and without CSD; and (4) CSD implantation 
shows a trend towards a lower incidence of recurrent MR.
Figure 3 Top panel: Evolution of left 
ventricular end-diastolic volumes 
(LVEDV) preoperatively, at early 
postoperative follow-up, and at long-
term follow-up in patients with a car-
diac support device (CSD+, solid 
line) and without a cardiac support 
device (CSD–, interrupted line). 
P  value given for 2-way analysis of 
variance for repeated measurements, 
comparing between subjects effects 
with CSD as a factor. Significant 
value indicates a difference in 
 development of volumes over time 
between both groups. Comparisons 
within groups for volumes at different 
times were performed with Bonferroni 
post-hoc comparisons and indicated 
as  follows: *P<.01 versus preoperative, 
†P<.01 versus early postoperative 
echocardiogram.
Lower panel: Similarly, evolution of 
left ventricular end-systolic volumes 
(LVESV) throughout the follow-up.
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The treatment strategies presented result from an ongoing conceptualization, 
 implementation, and evaluation of individualized surgical and nonsurgical  interventions 
in heart failure patients. The surgical mainstay of this approach is the treatment of 
 functional MR as described by Bach and Bolling,9,10 with a consistent and reproducible 
technique: implantation of a (semi-)rigid complete mitral annuloplasty ring using 
 stringent downsizing by 2 ring sizes. In patients with ischemic cardiomyopathy and 
preoperative LV end-diastolic dimension of 65 mm or less, this strategy provides good 
clinical outcome, absence of significant recurrent MR and sustained LV reverse 
 remodeling, but in patients with more extensive LV remodeling results remain poor.17,18 
This finding initiated the use of external cardiac constraint with a CorCap CSD in 
patients with heart failure who had an LV end-diastolic dimension greater than 65 mm 
or greater than 30 mm/m2 indexed to body surface area, starting November 2002. 
Another strategy change involved the extended indication for a tricuspid ring 
 annuloplasty in patients with annular dilatation (diameter on transthoracic 
 echocardiography >40 mm) from September 2003 onward, initiated by the results of 
Dreyfus and associates.19 Patients with an LV ejection fraction less than 30% to 35% 
receive ICD therapy to lower the risk of sudden cardiac death since the results of the 
DEFINITE trial8 became available, while CRT is used as an adjuvant therapy to address 
mechanical and electrical dyssynchrony after the results of the CARE-HF trial.6
It is impossible to distinguish the separate effects of pharmacologic therapy, CRT/ICD 
therapy, cardiac rehabilitation, and all different surgical interventions on survival, MR, 
and LV reverse remodeling. However, a critical appraisal of what is known in the 
 literature regarding the effects of these different treatment modalities is necessary in 
order to put the conclusions of the current study into perspective.
Studies on Surgical Treatment of Nonischemic Cardiomyopathy
Outcome data for surgical treatment of nonischemic cardiomyopathy are scarce, and 
most studies combine ischemic and nonischemic etiologies. Bolling10 presented 
140 patients with end-stage heart failure, of whom two thirds had a nonischemic  etiology. 
Patients had low ejection fraction (16%) and increased LV end-diastolic volume (281 mL). 
All patients received an undersized mitral ring annuloplasty. The series from Gummert 
and colleagues11 includes 53 patients with nonischemic cardiomyopathy who received an 
undersized mitral ring annuloplasty (median ring size 28). Mean ejection fraction was 
25%, and LV end-diastolic dimension was 69 mm. In the Acorn trial,13 300 patients (90% 
nonischemic cardiomyopathy) were randomized to either mitral valve surgery with or 
without CSD, or medical therapy with or without CSD. Patients were in NYHA class 
II to IV with a 24% LV ejection fraction (up to 45%) and an LV end-diastolic volume of 
270±100 mL. For comparison, our study involves 69 patients with only nonischemic 
cardiomyopathy, NYHA class III/IV, ejection fraction 26±8% and LV end-diastolic 
volume 227±73 mL.
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Effects on Survival and Functional Status
Early mortality in the present study (5.8%) is comparable with that in the series of 
Bolling10 (6%) and Gummert and associates11 (6.1%), but higher than reported in the 
Acorn trial (1.6%),13 which however also includes patients with less severe heart failure 
(23% of patients in NYHA class II and 41% of patients with MR grade 2+). Our long-
term actuarial survival in the no-CSD group equals that of Bolling10 (52% at 5 years vs. 
55% in the current study); Gummert and associates11 report a crude mortality of 25% and 
7 cardiac transplantations at 2.3 years’ follow-up. Crude mortality in the Acorn trial was 
26% at 3 years, without differences between CSD and no-CSD groups20 as also noted in 
our study. Actuarial 5-year survival for the CSD group in the current study (74±8%) 
cannot be compared with other studies.
The beneficial effect of mitral valve surgery for functional MR on survival has been 
debated by Wu and associates12 in a study reflecting data from 1995 to 2002, when this 
type of surgery was emerging. Wu’s group uses propensity analysis to compare event-free 
survival—freedom from death, LV assist device implantation or cardiac  transplantation— 
between patients who underwent undersized mitral annuloplasty and patients who were 
candidates for mitral valve repair based on echocardiography but did not undergo 
 surgery. In the non-ischemic group (276 patients), only 37 patients underwent mitral 
valve surgery. Event-free survival is similar for surgically and medically treated patients. 
However, the group not undergoing mitral valve surgery was favored by younger age, 
greater likelihood of spironolactone treatment, and more ICD therapy; LV ejection 
fraction was lower. In addition, no information on clinical status of these patients is 
provided, no echocardiographic examinations were performed, and a high likelihood of 
lead-time bias favoring the nonsurgical group is present. As such, statements on the true 
benefit of mitral valve surgery over medical therapy remain speculative.
Mortality in heart failure is directly related to LV remodeling. In the BEST trial (Beta-
blocker Evaluation of Survival), LV end-diastolic volume indexed to body surface area 
exceeding 120 ml/m2 was an independent predictor of death.21 Interestingly, in our 
group 51% of patients had an indexed LV end-diastolic volume exceeding 120 mL/m2 
(CSD 60%; no-CSD 35%), but mortality was similar for these 2 groups, indirectly 
 suggesting a relative survival benefit for patients with a more dilated left ventricle in the 
current treatment program.
Survival in our series is certainly positively influenced by standardized optimal 
 pharmacologic therapy and by CRT/ICD therapy, which are mainstays of nonsurgical 
heart failure treatment. CRT improves survival in patients with NYHA class III/IV 
heart failure who have LV dyssynchrony,6 but the high incidence of sudden death in 
CRT patients in the CArdiac REsynchronization–Heart Failure (CARE-HF) trial leaves 
room for additional ICD therapy.22 In our series, CRT/ICD therapy was always 
combined.
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Effects on Mitral Regurgitation and LV Reverse Remodeling
All available echocardiographic data, including those of nonsurvivors, were analyzed, 
and therefore echocardiographic results reflect the true effects of the combined medico–
surgical treatment program.
The sustained abolishment of functional MR by stringent downsizing by 2 ring sizes 
using a complete semirigid ring has been shown before.10,18 High MR recurrence rates in 
(ischemic) patients as reported in other series might be related to inconsistencies in 
patient selection and surgical techniques.23
In the current study, patients receiving a CSD had a trend towards a lower incidence of 
recurrent MR of grade 2 or more. This effect was also found in the Acorn trial. Most 
likely, the potentially beneficial effects of CSD implantation on LV volumes result from 
reduced tethering of the mitral valve subvalvular apparatus with reduction of MR, 
which in turn further decreases LV volumes. 
CRT has shown a decrease in MR severity in nonischemic cardiomyopathy both acutely 
and after 1 year; effective regurgitant orifice area decreased by 40 to 50%24,25 and average 
MR jet area by 45%.26 This is explained by shorter closing time of the mitral valve due to 
improved left ventricular contraction. However, the effect is highly variable between 
patients, and approximately 35% of patients do not show any response.
In the current study, long-term LV reverse remodeling was observed in 75% of patients. 
The magnitude of LV volume decrease was significantly greater in the CSD group: 
although these patients had significantly higher LV volumes at baseline, these 
 differences had disappeared at late follow-up.
Bolling10 showed a 27% decrease of LV end-diastolic volume at 2 years by mitral valve 
repair alone. In our series, LV end-diastolic volume decreased by 18% after mitral repair 
only, and by 35% after CSD implantation. 
In the Acorn trial at 2.3 years, LV end-diastolic volume after mitral valve surgery 
decreased by only 17% compared with 24% in the mitral valve surgery plus CSD group. 
These effects appeared 3 to 6 months after surgery and were maintained thereafter.
It is reasonable to expect that the initial drop of LV volumes results from the abrupt 
decrease in LV volume overload following restoration of mitral valve competence, and 
that it is independent of initial LV volume. Further decrease (true reverse remodeling), 
however, is probably the consequence of changes at a cellular level that are intuitively 
more likely to occur in less dilated ventricles. Therefore, we believe that the progressive 
LV volume decrease in the CSD group, leading to similar LV end-diastolic volumes at 
late follow-up, reflects a true beneficial effect of the CSD.
The effect of CRT on LV reverse remodeling was evaluated in the CARE-HF trial.27 
It appeared between 3 and 9 months after initiation, and was sustained at 29 months; at 
that time, LV end-diastolic volume had decreased by 19%, and end-systolic volume by 
26%. Forty-nine percent of patients showed at least 15% volume reduction at 18 months’ 
follow-up, as compared to 19% in the medically treated group. 
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In conclusion, an individualized combined medical and surgical approach to patients 
with congestive heart failure of nonischemic etiology and MR that includes 
 standardized pharmacologic treatment, CRT/ICD therapy, consistent restrictive mitral 
annuloplasty surgery in all patients, and CSD implantation in patients with advanced 
LV remodeling leads to favorable survival, clinical improvement, low incidence of 
 significant recurrent MR, and sustained LV reverse remodeling at longer follow-up. 
Additional CSD implantation in patients with more advanced LV remodeling leads to 
greater LV volume reduction, and to a tendency towards less recurrent MR. Longer 
 follow-up is necessary to establish whether this can further improve survival.
Study Limitations
This study has an observational nature without a control group. Patients were subjected 
to individualized treatments, which have changed over time with growing knowledge, 
and which were based on preoperative characteristics. By definition, selection bias was 
introduced. Among 12 patients who underwent surgery before the CSD became 
 available, 9 actually would have qualified to receive a CSD on the basis of LV end -
diastolic dimension. When these patients are left out of the analyses, the conclusions of 
this study remain unchanged with regard to survival, LV reverse remodeling and 
 recurrence of mitral regurgitation.
In addition, the lack of a control group makes it hard to draw conclusions regarding 
observed differences in this study. We would emphasize, however, that patients in the 
CSD group, on the basis of their higher baseline LV volumes, would be expected to have 
a poorer survival and a lower chance of reverse remodeling with an associated higher 
chance of recurrent MR. In this study, clinical and echocardiographic outcomes are at 
least similar, indirectly suggesting a beneficial effect of applying the CSD in these sicker 
patients.
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Abstract
Restrictive mitral annuloplasty is a surgical treatment option for patients with heart 
failure (HF) and functional mitral regurgitation (MR). However, recurrent MR has 
been reported at mid-term follow-up. The aim of the present study was to identify 
the echocardiographic predictors of recurrent MR in patients with HF undergoing 
mitral annuloplasty. During a mean follow-up of 2.6±1.6 years, 109 patients with 
HF (49% ischemic and 51% idiopathic dilated cardiomyopathy) who had undergone 
mitral valve repair were followed (of 122 total patients). The severity of MR was 
quantified, and the following parameters were measured before intervention and at 
the mid-term follow-up examination: left ventricular (LV) and left atrial volumes 
and dimensions, LV sphericity index, mitral annular area, and mitral valve geometry 
parameters. At mid-term follow-up, 21 patients presented with significant MR 
(grade 2 to 4), and 88 patients had only MR grade 0 to 1. Both groups of patients 
had had a similar preoperative MR grade, mitral annular area, and LV volume and 
dimension. In contrast, patients with recurrent MR had had increased preoperative 
posterior and anterior leaflet angles, tenting height, tenting area, and LV sphericity 
index compared to the patients without recurrent MR. Of the different parameters 
of mitral and LV geometry, the distal mitral anterior leaflet angle (hazard ratio 1.48, 
95% confidence interval 1.32 to 1.66, P<0.001) and posterior leaflet angle (hazard 
ratio 1.13, 95% confidence interval 1.07 to 1.19, P<0.001) were independent 
 determinants of MR at mid-term follow-up. In conclusion, in patients with HF of 
ischemic or idiopathic etiology and functional MR, distal mitral leaflet tethering 
and posterior mitral leaflet tethering were associated with recurrent MR after 
 restrictive mitral annuloplasty.
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The mechanism of functional mitral regurgitation (MR) is complex, with mitral annular dilation and tethering of mitral leaflets contributing to the MR 
 pathophysiology.1 Some of these pathophysiologic issues, either related to left  ventricular 
(LV) geometry or mitral valve geometry itself, could contribute to recurrent MR after 
mitral annuloplasty. Previous studies focusing on the mechanisms of recurrent MR have 
been conducted in separate series of patients with ischemic and idiopathic dilated 
 cardiomyopathy.2,3 The present study identified the preoperative echocardiographic 
 predictors of mid-term recurrent MR after successful mitral valve annuloplasty in a 
cohort of patients with heart failure with idiopathic dilated or ischemic 
cardiomyopathy.
Methods
Patients 
A total of 122 patients with heart failure and moderate to severe MR were included. 
The  patients were scheduled for restrictive mitral annuloplasty, accompanied by 
 coronary artery bypass grafting if indicated. In patients with heart failure with 
 idiopathic cardiomyopathy, restrictive mitral annuloplasty was performed with 
 concomitant placement of a CorCap (Acorn Cardiovascular, St. Paul, Minnesota) 
 cardiac support device if significant LV dilatation (LV end-diastolic diameter >65 mm) 
was measured on the preoperative echocardiographic examination. All patients 
 underwent surgery using a midline sternotomy with normothermic cardiopulmonary 
bypass and intermittent antegrade warm blood cardioplegia. The mitral valve was 
exposed through a transseptal approach. The ring size (Carpentier-Edwards Physioring, 
Edwards Lifesciences, Irving, California) was determined after careful measurement of 
the height of the anterior leaflet. Then, downsizing by 2 sizes was performed (i.e., when 
a ring size 30 was measured, the size of the annuloplasty ring was 26). The rings were 
inserted using 14 to 16 deep U-shaped simple horizontal sutures using Ethibond 2-0 
(Ethicon, Inc, Somerville, New Jersey) or Ti-Cron 2-0 (Syneture, Norwalk, 
Connecticut). Tricuspid annuloplasty was performed with a Carpentier Edwards Classic 
or MC3 ring (Edwards Lifeseciences) in patients with tricuspid regurgitation exceeding 
grade 2 or in the presence of a dilated tricuspid annulus >40 mm (or 21 mm/m2 indexed 
to body surface area) on the echocardiogram. In all patients, the results of mitral 
 annuloplasty were assessed by intraoperative trans oesophageal echocardiography. No 
residual MR and a mitral leaflet coaptation length of ≥8 mm at the A2-P2 level were the 
criteria for successful mitral valve repair. If these criteria were not fulfilled, additional 
downsizing was performed.
In patients undergoing surgical revascularization, coronary artery bypass grafting was 
performed before mitral valve annuloplasty. If a cardiac support device was used it was 
applied on the beating heart, and fixed by sutures to the dorsal base of the heart, along 
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the atrioventricular groove. After completion of the mitral valve repair, the extracorpor-
eal circulation was weaned out and the final fitting of the CorCap was ensured on a full 
and beating heart with appropriate filling. The aim was to obtain a snug fit, without 
reduction of LV diameter of >10% (as measured by transesophagal echocardiography), 
compared to preoperative dimensions, as described earlier.4
Before surgical intervention, transthoracic echocardiography (System Five or Vivid 7, 
GE Norway, Horten, Norway) was performed and repeated at hospital discharge and 
mid-term follow-up (2.6±1.6 years). Transthoracic echocardiography at discharge was 
used to confirm the absence of MR, and the preoperative and mid-term follow-up 
 echocardiographic examinations were used to perform measurements of LV and left 
atrial (LA) volumes and dimensions, geometric analysis of the left ventricle and mitral 
valve, and quantification of MR.
The severity of MR was quantitatively determined by proximal isovelocity surface area 
and by vena contracta method according to the current guidelines.5 The effective regur-
gitant orifice and regurgitant volume were calculated according to the formula.5 The vena 
contracta was defined as the narrowest part of the regurgitant jet recorded in the 
 parasternal long-axis view. The LV and LA volumes and LV geometry were measured 
according to the recommendations of the American Society of Echocardiography and 
European Association of Echocardiography for chamber quantification.6 In the 
 parasternal long-axis view, LV end-diastolic diameter, LV end-systolic diameter, and 
LA  diameter were measured. LV end-diastolic volume, LV end-systolic volume, and 
LV ejection fraction were estimated using Simpson’s disk method from the apical 4- and 
2-chamber apical views. The LA volume was assessed using the area-length method.6 
The systolic and diastolic LV sphericity indexes were calculated as the ratio between the 
LV short-axis diameter and the LV long-axis diameter at end-systole and end-diastole, 
respectively.7
To evaluate the apical displacement of mitral leaflets, the leaflet tethering lengths were 
measured in the apical 4- and 2-chamber views in mid-systole (Figure 1).7 The end -
diastolic and end-systolic frames were determined from the mitral leaflet closure and 
opening, respectively, and the middle frame was used for measurements in mid systole. 
In the apical 4-chamber view, the distance between the posterior papillary muscle and 
median portion of the mitral annulus was measured (posterior papillary muscle  tethering 
length in the apical 4-chamber view; Figure 1). In the apical 2-chamber view, the  distance 
between the anterior and posterior papillary muscles and the contralateral part of the 
mitral annulus were measured (anterior papillary muscle tethering length and posterior 
papillary muscle tethering length in the 2-chamber view, respectively; Figure 1).7 
In the long-axis view, the coaptation-to-septum distance was measured in mid-systole, 
as the distance between the septum at the hinge point of the aortic valve cups and 
 coaptation point of the mitral valve leaflets (Figure 1).8 Evaluation of the geometry of 
the mitral valve was performed in mid-systole, as previously described.3,9 In the 
 parasternal long-axis view, tenting area, tenting height and coaptation length were 
 measured. The tenting area was measured as the area enclosed between the annular line 
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and the mitral leaflets, and the tenting height was defined as the distance between the 
coaptation point and the annular line (Figure 1). The coaptation length was measured as 
the length of apposition of the anterior and posterior mitral leaflets. 
The tethering of mitral leaflets was estimated by calculation of the basal mitral anterior 
leaflet angle (ALAbase), the distal mitral anterior leaflet angle (ALAtip), and the posterior 
mitral leaflet angle (PLA). The ALAbase was defined as the angle between the annular 
plane and the basal portion of the anterior leaflet, and the PLA was defined as the angle 
between the annular plane and the posterior leaflet (Figure 2). The ALAtip was defined 
as the angle between the annular plane and the anterior leaflet tip distance (which 
Figure 1. Measurements of PM tethering lengths, mitral tenting area, and mitral tenting height. 
(A) White line represents posterior PM tethering length measured in apical 4-chamber view. 
(B) Measurements of papillary muscle tethering lengths, as measured in 2-chamber view. White lines 
represent anterior and posterior PM tethering lengths measured from head of anterior and posterior 
PM to contralateral part of mitral annulus, respectively. (C) White line represents measurement of 
coaptation-to-septum distance, defined as distance between septum at hinge point of aortic valve cups 
and coaptation point of mitral valve leaflets. (D) Measurements of mitral tenting area and tenting 
height in long-axis view. Tenting area depicted by continuous white line, and tenting height  corresponds 
to dotted line drawn between coaptation point and mitral annulus in long-axis view..
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 corresponded to the distance between the median part of the mitral annulus and the 
coaptation point; Figure 2). The angles were calculated according to previously reported 
formulas.3,9 The mitral annular area was obtained from its dimensions in the 4- and 
2-chamber views, using an ellipsoid assumption.10
Operative risk was calculated according to EuroSCORE.11 Continuous data are  presented 
as the mean ± SD and dichotomous as the number of patients (percentage), as 
 appropriate. Patients were divided into 2 groups according to the presence of MR at 
mid-term follow-up: patients without recurrent MR if no or mild MR was observed—
effective regurgitant orifice area <0.20 cm2, regurgitant volume <30 mL/beat, and vena 
contracta <0.3 cm—and patients with recurrent MR if moderate or severe MR was 
observed—effective regurgitant orifice area ≥0.20 cm2, regurgitant volume ≥30 mL/beat, 
and vena contracta ≥0.3 cm. The preoperative and mid-term follow-up  echocardiographic 
measurements of the patients without recurrent MR were compared to those of the 
patients with recurrent MR. The differences in clinical and echocardiographic baseline 
(preoperative) characteristics between the patients with and without recurrent MR were 
evaluated using Student’s t-test or the chi-square test, as appropriate. Changes (from 
baseline to follow-up) in echocardiographic data were analyzed by repeated  measurements 
analysis of variance, and the interaction between the evaluation point (preoperatively vs. 
during follow-up) and group (patients with recurrent MR vs. patients without recurrent 
MR) was tested.
Univariate and multivariate Cox proportional hazard regression analysis were applied to 
further study the relation between baseline characteristics and recurrent MR. 
On   multivariate analysis, the stepwise backward method was used to indentify predic-
tors of MR, with significant univariate predictors entered as covariates. The variables 
were checked for colinearity, and, if the correlation coefficient between 2 variables was 
Figure 2. Method of quantifica-
tion of ALAbase, ALAtip, and PLA. 
Measurements depicted on echo-
cardiographic image of mitral 
valve in apical 4-chamber view in 
mid-systole.
Formulas used for calculations of 
angles were as  follows:
•	 ALAbase = sinus-1(bending 
distance/anterior leaflet 
bending distance);
•	 ALAtip = sinus-1 (coaptation 
distance/anterior tip leaflet 
distance);
•	 PLA = sinus-1 (coaptation 
distance/posterior leaflet 
length).
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>0.7, only one variable was retained in the model. A P value <0.05 was regarded as 
 statistically significant. Statistical analysis was performed using the Statistical Package 
for Social Sciences for Windows, version 16.0 (SPSS, Chicago, Illinois).
Results
The demographic, clinical and surgical characteristics of the patients are listed in Table 1. 
The mean age was 62±11 years, and 61% of patients were men. Most patients (85%) had 
New York Heart Association functional class III or IV. Patients were receiving optimal 
medical treatment for Heart failure. No clinically relevant difference was found in the 
demographic or clinical characteristics between the patients with recurrent MR and 
those without recurrent MR at mid-term follow-up
In 37% of patients, the CorCap cardiac support device was implanted concomitantly 
with restrictive mitral annuloplasty (Table 1). The average mitral ring size used for 
 annuloplasty was 26; in 53% of patients, tricuspid annuloplasty was also performed. 
Twelve patients had chronic atrial fibrillation and underwent a perioperative ablation 
procedure. No clinically relevant differences were found in the surgical characteristics 
between the patients with and without recurrent MR.
Preoperative echocardiographic quantitative analysis of MR revealed moderate to severe 
MR with a mean effective regurgitant orifice area of 0.33 cm2, regurgitant volume of 
47 mL, and vena contracta of 5.5 mm (Table 2)
Of 122 patients, 10 died during the peroperative period, 112 were discharged from the 
hospital (with MR grade 0 to 1) and 3 patients died before the mid-term echocardio-
graphic follow-up examination. In the final analysis, 109 patients with heart failure were 
included (56 patients with dilated cardiomyopathy and 53 with ischemic cardiomyopa-
thy). All 109 patients underwent echocardiographic and clinical follow-up. At mid-term 
follow-up, 88 patients (81%) continued to have MR grade 0 or 1, and MR grade 2 or 
greater was observed in 21 patients (19%). Of the patients with recurrent MR, grade 2, 3, 
and 4 MR was present in 14 (13%), 6 (5%) and 1 (1%), respectively.
The LV end-diastolic and end-systolic volume decreased from 217±72 mL to 167±61 mL 
and from 162±65 mL to 119±55 mL, respectively (P<0.001). LV end-diastolic  diameter 
decreased from 66±8 mm to 60±10 mm (P<0.001), and LV end-systolic  diameter 
decreased from 59±9 mm to 52±12 mm (P<0.001). A slight increase in LV   ejection 
 fraction was observed (from 27±9% to 31±12%, P<0.001).
The preoperative MR severity was similar in patients with and without recurrent MR 
(Table 2). In addition, no difference was noted in the preoperative LV and LA diameters 
or volumes (Table 3). Concerning mitral valve geometry, patients with recurrent MR 
had greater preoperative ALAbase, ALAtip, and PLA than patients without recurrent MR 
(P<0.05; Table 4). In addition, patients with recurrent MR were found to have a 
 significantly increased tenting area and tenting height before surgery, and the coaptation 
length was lower than that in patients without recurrent MR (P<0.05; Table 4). 
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TABLE 1 
Preoperative Clinical and Surgical Characteristics
Variable All (n=109) MR at follow-up
No (n=88) Yes (n=21)
Age (years)  62±11  62±11  62±12
Men 66 (61%) 54 (61%) 12 (57%)
Body surface area (m2)  1.9±0.2  1.9±0.2  1.8±0.3
Systolic blood pressure (mmHg) 118±24 118±25 115±19
Diastolic blood pressure (mmHg)  72±11  72±12  70±10
NYHA functional class
I 2 (2%) 1 (1%) 1 (5%)
II 14 (13%) 11 (12%)  3 (14%)
III 77 (70%) 63 (72%) 14 (67%)
IV 16 (15%) 13 (15%)  3 (14%)
Serum creatinine (μmol/L) 110±41 108±36 116±60
Glomerular filtration rate (mL/min) 61±22  62±22  58±23
Ischemic cardiomyopathy 53 (49%) 47 (53%)  9 (43%)
Hypertension 20 (18%) 17 (20%)  3 (14%)
Diabetes mellitus 28 (26%) 26 (30%)  2 (10%)
Chronic obstructive pulmonary disease 24 (22%) 20 (23%)  4 (19%)
Stroke 6 (6%) 6 (7%) 0%
Peripheral vascular disease 8 (7%) 5 (6%)  3 (14%)
Logistic EuroSCORE  13±11 14±12 10±7
Medications
β Blockers 81 (74%) 66 (75%) 15 (71%)
Calcium antagonists 6 (6%) 6 (7%) 0%
ACE inhibitor or angiotensin receptor blocker 89 (82%) 73 (83%) 16 (76%)
Diuretics 92 (84%) 74 (84%) 18 (86%)
Spironolactone 41 (38%) 33 (38%)  8 (38%)
Surgical characteristics
Mitral valve ring size 26±2 26±2 26±2
CorCap cardiac support device 40 (37%) 36 (41%)  4 (19%)
Tricuspid valve annuloplasty 58 (53%) 50 (57%)  8 (38%)
Cardiopulmonary bypass time (min) 155±45 151±42 166±54
Aortic cross clamp time (min) 93±39  93±38 95±41
NYHA, New York Heart Association; ACE, Angiotensin-converting enzyme
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TABLE 2
Preoperative Mitral Regurgitation Severity
Variable All (n=109) MR at follow-up
No (n=88) Yes (n=21)
Mitral regurgitation grade
2 17 (15%) 14 (16%) 3 (14%)
3 67 (62%) 57 (65%) 10 (48%)
4 25 (23%) 17 (19%) 8 (38%)
Mean mitral regurgitation grade 3.1±0.6 3.0 ± 0.6 3.2±0.7
Effective regurgitant orifice (cm2) 0.33±0.09 0.32±0.09 0.35±0.09
Regurgitant volume (mL) 47±13 46±13 50±12
Vena contracta (mm) 5.5±1.5 5.4±1.2 6.0±2.0
Furthermore, the systolic and diastolic LV sphericity indexes were greater in patients 
with recurrent MR than in those without recurrent MR (P<0.05; Table 4). The posterior 
and anterior papillary muscle tethering length and the coaptation-to-septum distance 
were similar in patients with and without recurrent MR. Finally, the mitral annulus area 
was similar in both groups of patients.
The LA volume and LV diameters and volumes decreased during follow-up in patients 
without recurrent MR (Table 3). In contrast, the LA and LV dimensions remained 
unchanged in patients with recurrent MR (P<0.05; Table 3). The LV  ejection  fraction 
decreased in patients with recurrent MR and increased in patients without recurrent 
MR (P<0.01; Table 3). The ALAbase and ALAtip had decreased at mid-term  follow-up in 
patients without recurrent MR but remained unchanged in patients with recurrent MR 
(Table 4). The PLA had increased in both groups, but this increase was more 
 pronounced in patients with recurrent MR at follow-up. The tenting area decreased in a 
similar manner in both groups, but the tenting height decreased only in patients 
 without recurrent MR. The coaptation length at mid-term follow-up had increased 
more in the patients without recurrent MR than in those with recurrent MR. The mitral 
annulus area had decreased more in patients without recurrent MR than in those with 
recurrent MR during follow-up.
The diastolic sphericity index decreased in both groups after restrictive mitral annu-
loplasty to a similar extent, but the systolic sphericity index decreased only in patients 
without recurrent MR. The posterior papillary muscle tethering length decreased in a 
similar manner in both groups. The anterior papillary muscle tethering length and 
 coaptation-to-septum distance decreased to a larger extent in patients without recurrent 
MR than in the patients with recurrent MR.
Univariate Cox regression analysis revealed that ALAbase, ALAtip, PLA, tenting height, 
tenting area, coaptation length, and sphericity index in diastole and systole were 
 predictors of recurrent MR (Table 5). On multivariate analysis, ALAtip, PLA, tenting 
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height, systolic sphericity index, and etiology of cardiomyopathy (ischemic or non-
ischemic) were tested. On multivariate analysis, only the ALAtip and PLA remained asso-
ciated with recurrent MR at mid-term follow-up (Table 6). The ALAtip and PLA 
remained associated with recurrent MR when cardiac support device use was included 
in the final model.
Discussion
The results of the present study have identified baseline echocardiographic predictors of 
mid-term recurrent MR after restrictive mitral annuloplasty for functional MR. In a 
cohort of patients with heart failure of ischemic or nonischemic origin, distal mitral 
anterior leaflet tethering, as estimated by the ALAtip, and posterior leaflet tethering, as 
estimated by PLA, were independent predictors of recurrent MR after mitral 
annuloplasty.
The spherical shape of the left ventricle plays an important role in the pathophysiology 
of functional MR, because it provokes the displacement of the papillary muscles, which 
exert traction on the mitral leaflets and increase their tethering.12 In previous studies, 
posterior mitral leaflet tethering was evaluated by PLA,2,9 and anterior mitral leaflet 
tethering was estimated by measurement of 2 different angles: ALAtip and ALAbase.2,3,9 
This dual evaluation of the anterior mitral leaflet tethering is because the chordae 
 insertion at the anterior leaflet can be divided into the marginal chordae, which are 
inserted at the leaflet tip, and the basal chordae, which are inserted at the leaflet base.13 
The measurement of the ALAtip permits one to not overlook the tethering of the distal 
mitral anterior leaflet, which can play a role in recurrent MR.3 We found increased 
 preoperative PLA, ALAbase, and ALAtip in patients who developed MR at mid-term 
 follow-up. On multivariate analysis, ALAtip and PLA predicted recurrent MR at mid-
term follow-up. To explain this finding, one should realize that mitral annuloplasty 
immobilizes the posterior mitral leaflet, but the anterior mitral leaflet must be 
 sufficiently mobile to ensure adequate closure of the mitral valve.14 Therefore, excessive 
distal anterior mitral leaflet tethering preoperatively will be prone to suboptimal leaflet 
closure postoperatively. Thus, unless the LV reverse remodeling attenuates the 
 augmented anterior leaflet tethering, the risk of recurrent MR will increase with 
 increasing distal anterior mitral leaflet tethering, as was confirmed by our study.
The role of heart failure etiology has been evaluated in previous studies, analyzing 
patients with ischemic and nonischemic cardiomyopathy who developed recurrent MR 
after annuloplasty separately.2,3,9,15,16 Only one study analyzed the presence of recurrent 
MR in a group of patients, of whom 1/3 had nonischemic and 2/3 had ischemic cardiomyo-
pathy.17 According to the underlying etiology, different parameters of mitral valve 
 geometry have been proposed to predict MR recurrence after restrictive 
 annuloplasty.2,3,9,15,16 In contrast, our study analyzed the predictors of recurrent MR after 
mitral annuloplasty in a mixed population of patients with ischemic and nonischemic 
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dilated cardiomyopathy. In our cohort of patients, distal mitral leaflet tethering and 
posterior mitral leaflet tethering were associated with recurrent MR after restrictive 
mitral annuloplasty, independently of the origin of the underlying cardiomyopathy. 
These findings are of clinical relevance because these parameters can be applied to 
patients with ischemic and nonischemic cardiomyopathy.
The present study also demonstrated the effects of restrictive mitral annuloplasty on the 
LV volume and function and the changes in mitral valve geometry. Patients who 
 presented with recurrent MR at mid-term follow-up had no decrease in LV volume or 
diameter, but those without recurrent MR had a substantial decrease in LV volume and 
diameter. This observation was similar to what has been shown in other trials that 
demonstrated LV reverse remodeling in patients who successfully underwent mitral 
annuloplasty.18–20 Accordingly, the LV ejection fraction increased slightly in patients 
without recurrent MR and decreased in patients with recurrent MR. In addition, the 
evolution of leaflet tethering before and after the intervention was similar to what has 
previously been described. The increase of PLA was noted in both groups, and ALAbase 
and ALAtip decreased only in patients without recurrent MR and remained unchanged 
in patients with recurrent MR.2,3 Patients without recurrent MR had a decrease in the 
tenting distance and tenting height, and those with recurrent MR presented with only 
a slight decrease in the tenting area and no decrease in tenting height. Finally, the 
LV sphericity index, posterior and anterior papillary muscle length, and coaptation -to-
septum distance decreased in both groups. However, the magnitude of these changes 
was more pronounced in patients without recurrent MR and was related to LV reverse 
remodeling.
Some limitations of our study should be acknowledged. The present study was 
 retrospective and included some patients who had undergone concomitant  implantation 
of a cardiac support device. However, the cardiac support device was associated only 
with a trend toward a decrease in recurrent MR at mid-term follow-up. Also, after 
 inclusion of the cardiac support device in the multivariate model, ALAtip and PLA were 
still independent predictors of recurrent MR at mid-term follow-up.
In conclusion, in patients with heart failure of ischemic or idiopathic etiology and 
 functional MR, distal mitral leaflet tethering and posterior mitral leaflet tethering were 
associated with recurrent MR after restrictive mitral annuloplasty.
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TABLE 3
Evolution of Standard Echocardiographic Variables Measured Preoperatively and at Mid-term Follow-up
Variable MR at follow-up P Value (Time vs. Group 
comparison)
No (n=88) Yes (n=21)
Preoperative Follow-up Preoperative Follow-up
Left atrial diameter (mm) 45±7 44±7* 44±6 45±7 NS
Left atrial volume (mL)  93±43  78±38*  83±27  87±43  0.02
Left ventricular ejection fraction (%) 27±9  32±12* 28±9 26±8 <0.01
Left ventricular end-diastolic diameter (mm) 66±8  58±10*  67±10 66±9  <0.001
Left ventricular end-systolic diameter (mm) 59±8  51±12*  60±11  57±11 <0.01
Left ventricular end-diastolic volume (mL) 216±65 159±58* 218±92 201±66  <0.001
Left ventricular end-systolic volume (mL) 161±62 111±51* 164±82 151±59  <0.001
Analysis of variance time versus group comparison, P<0.05, signified that evolution of measured variable was different for patients with versus without 
recurrent MR in time (preoperatively vs. mid-term follow-up).
* Corresponded to P<0.05 versus preoperative measurement in patients without recurrent MR; no difference noted in preoperative variables between 
patients with and without recurrent MR (P values not shown)
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TABLE 4
Evolution of Echocardiographic Geometric Measurements of Left Ventricle and Mitral Valve in Patients Without and With 
Recurrent Mitral Regurgitation at Mid-term Follow-up
Variable MR at Follow-up P Value (Time vs. Group 
comparison)
No (n=88) Yes (n=21)
Preoperative Follow-up Preoperative Follow-up
Mitral valve geometry
Basal mitral anterior leaflet angle (°) 31±6 24±6*  38±5* 38±5  <0.001
Distal mitral anterior leaflet angle (°) 12±3 11±3*  19±3* 19±4 <0.05
Posterior mitral leaflet angle (°)  40±10  60±11*  54±9*  66±9†  0.01
Tenting area (cm2)  2.1±0.3  1.4±0.4*   2.9±0.7*   2.1±0.5†  NS
Tenting height (mm) 10.2±1.2  9.1±1.4*  12.6±2.4* 12.0±1.9  NS
Coaptation length (mm)  5.5±1.2  8.7±1.2*   4.9±1.1*   6.7±1.5†   0.001
Mitral annulus (cm2) 10.1±2.8  5.3±1.5* 10.8±2.9   7.0±2.5†  <0.001
Left ventricular geometry
Sphericity index diastole 68±9 60±8*  75±8*  71±7†  NS
Sphericity index systole 65±9 57±9*  72±9* 69±8  NS
Posterior papillary muscle length 4-ch (mm) 41±5 36±5*  43±5  40±4†  NS
Posterior papillary muscle length 2-ch (mm) 40±6 33±5*  42±5  37±6†  NS
Anterior papillary muscle length 2-ch (mm) 40±5 34±5*  42±5  38±5† <0.05
Coaptation-to-septum distance (mm) 40±5 35±5*  42±6  40±5†  <0.001
4-ch, 4-chamber view; 2-ch, 2-chamber view
* P < 0.05 versus preoperative measurement in patients without MR at follow-up
† P < 0.05 versus preoperative measurement in patients with MR at follow-up.
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TABLE 5
Univariate Cox Proportional Hazard Analysis of Predictors of Mitral Regurgitation 
 Recurrence at Mid-term Follow-up
Variable Hazard Ratio 95% Confidence 
Interval
P Value
Left atrial diameter (mm) 0.98 0.92–1.04 NS
Left atrial volume (mL) 1.00 0.99–1.01 NS
Left ventricular ejection fraction (%) 1.00 1.00–1.05 NS
Left ventricular end-diastolic diameter (mm) 1.03 0.97–1.09 NS
Left ventricular end-systolic diameter (mm) 1.03 0.97–1.09 NS
Left ventricular end-diastolic volume (mL) 1.00 0.99–1.01 NS
Left ventricular end-systolic (mL) 1.00 1.00–1.01 NS
Basal mitral anterior leaflet angle (°) 1.15 1.08–1.23  <0.001
Distal mitral anterior leaflet angle (°) 1.48 1.32–1.66  <0.001
Posterior leaflet angle (°) 1.12 1.07–1.17  <0.001
Tenting area (cm2) 5.06 2.82–9.07  <0.001
Tenting height (mm) 1.57 1.32–1.86  <0.001
Coaptation length (mm) 6.84 0.47–0.99 <0.05
Mitral annulus (cm2) 1.07 0.92–1.23 NS
Sphericity index diastole 1.09 1.03–1.14  0.002
Sphericity index systole 1.08 1.03–1.13  0.003
Posterior papillary muscle length, 4-chamber view (mm) 1.07 0.99–1.16 NS
Posterior papillary muscle length, 2-chamber view (mm) 1.08 1.00–1.16 NS
Anterior papillary muscle length, 2-chamber view (mm) 1.05 0.97–1.14 NS
Coaptation-to-septum distance (mm) 1.04 0.97–1.12 NS
TABLE 6
Multivariate Cox proportional hazard ratio analysis of predictors of mitral regurgitation 
(MR) recurrence at mid-term follow-up after mitral annuloplasty
Variable Hazard Ratio 95% Confidence 
Interval
P Value
Distal mitral anterior leaflet angle (°) 1.48 1.32–1.66  <0.001
Posterior mitral leaflet angle (°) 1.13 1.07–1.19  <0.001
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Tricuspid annuloplasty prevents 
right ventricular dilatation and progression 
of tricuspid regurgitation in patients with 
tricuspid annular dilatation undergoing 
mitral valve repair 
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Abstract
Objectives: We hypothesize that concomitant tricuspid annuloplasty in patients 
with tricuspid annular dilatation who undergo mitral valve repair could prevent 
progression of tricuspid regurgitation and right ventricular remodeling.
Methods: In 2002, 80 patients underwent mitral valve repair. Concomitant  tricuspid 
annuloplasty was performed in 13 patients with grade 3 or 4 tricuspid regugitation. 
In 2004, 102 patients underwent mitral valve repair. Concomitant tricuspid 
 annuloplasty was performed in 21 patients with grade 3 or 4 tricuspid regugitation 
and in 43 patients with an echocardiographically determined tricuspid annular 
diameter of 40 mm or greater. Patients underwent transthoracic echocardiographic 
analysis preoperatively and at the 2-year follow-up.
Results: In the 2002 cohort right ventricular dimensions did not decrease (right 
ventricular long-axis, 69±7 vs. 70±8 mm; right ventricular short-axis, 29±7 vs. 
30±7 mm); tricuspid regurgitation grade and gradient remained unchanged. In the 
2004 cohort right ventricular reverse remodeling was observed (right ventricular 
long-axis, 71±6 vs. 69±9 mm, right ventricular short-axis, 29±5 vs. 27±5 mm; 
P<0.0001; tricuspid regurgitation diminished (1.6±1.0 vs. 0.9±0.6, P<0.0001) and 
transtricuspid gradient decreased (28±13 vs. 23±15 mmHg, P=0.021). Subanalysis of 
the 2002 cohort showed that in 23 patients without grade 3 or 4 tricuspid  regurgitation 
but with baseline tricuspid annular dilatation, the degree of tricuspid regurgitation 
was worse at the 2-year follow-up. Moreover, this caused right ventricular dilatation. 
Subanalysis of the 2004 cohort demonstrated reverse right ventricular remodeling 
and decreased tricuspid regurgitation in 43 patients with preoperative tricuspid 
annular dilatation who underwent tricuspid annuloplasty.
Conclusions: Concomitant tricuspid annuloplasty during mitral valve repair should 
be considered in patients with tricuspid annular dilatation despite the absence of 
important tricuspid regurgitation at baseline because this improves echocardio-
graphic outcome. 
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In patients scheduled for mitral valve surgery, tricuspid regurgitation (TR) is not uncommon. A decrease in TR has been noted after mitral valve surgery because of 
reduced right ventricular pressure or volume overload. Still, progression of TR without 
left-sided valvular dysfunction or de novo TR can be observed during follow-up.1 In 
particular, TR after successful left-sided valve surgery has been reported in up to 74% of 
patients at long-term follow-up and is associated with poor outcome.1-3 Concomitant 
tricuspid valve repair with an annuloplasty ring in patients with moderate or severe TR 
undergoing left-sided valve surgery has been shown to improve (event-free) survival.4 
Various authors have suggested that at the time of mitral valve surgery, tricuspid 
 annuloplasty should be considered when tricuspid annular dilatation is present.2,5-8 
Recently published European Society of Cardiology guidelines recommend tricuspid 
valve repair in case of left-sided valve surgery when there is severe TR but also when 
there is annular dilatation (≥40 mm) of the tricuspid valve.9 The American College of 
Cardiology and American Heart Association guidelines state that tricuspid annuloplasty 
might be considered in patients undergoing mitral valve surgery when there is tricuspid 
annular dilatation.10 The absence of TR and right ventricular reverse remodeling after 
restrictive tricuspid annuloplasty would support this approach. However, echocardio-
graphic studies addressing these specific questions are scarce. Accordingly, we evaluated 
echocardiographic outcome at 2-year follow-up in patients with organic or functional 
mitral regurgitation who underwent mitral valve repair in 2002 and 2004, respectively.
Materials and methods
Study Population
The patient population consisted of 182 patients who underwent mitral valve repair in 
2002 or 2004 and completed a 2-year follow-up echocardiographic analysis.
The 2002 cohort included 80 consecutive patients with severe mitral valve regurgitation 
who underwent mitral valve repair and completed the 2-year echocardiographic 
 follow-up. The mechanism of mitral regurgitation was organic in 71% of cases and 
 functional in 29% of cases. Coronary artery bypass graft surgery was performed 
 simultaneously in 24% of patients.
The 2004 cohort included 102 consecutive patients with severe mitral regurgitation who 
underwent mitral valve repair and completed the 2-year echocardiographic follow-up. 
The mechanism of mitral regurgitation was organic in 50% of cases, and functional in 
50% of cases. Coronary artery bypass graft surgery was performed simultaneously in 24% 
of patients. Our institution’s ethics committee approved conducting this retrospective 
study and waived the need for individual consent.
Chapter 9208
Clinical Assessment
Every patient underwent clinical assessment by a physician who was blinded to the 
echocardiographic data. New York Heart Association class and Canadian Cardiac 
Society score were used at baseline and at the 2-year follow-up.
Echocardiography 
The clinical echocardiographic evaluation was as follows. A transthoracic echocardio-
gram was performed within 5 days before the operation and at the 2-year follow-up. 
Patients were imaged in the left lateral decubitus position using a commercially available 
system (Vingmed System Five or Vivid Seven; GE, Horten, Norway). Images were 
obtained with a 3.5-MHz transducer at a depth of 16 cm in the parasternal and apical 
views (standard long-axis, 2-chamber and 4-chamber images). The left atrial diameter 
and left ventricular dimensions (end-systolic and end-diastolic diameters) were 
 determined from parasternal M-mode acquisitions. Color flow was applied in the apical 
views to evaluate mitral regurgitation and TR. The severity of mitral regurgitation was 
characterized as mild (1; jet area/left atrial area < 10%), moderate (2; jet area/left atrial 
area 10%–20%), moderately severe (3; jet area/left atrial area 20%–45%), and severe 
 ( 4 ; jet area/left atrial area >45%).11 The severity of TR was characterized as trivial (1; jet 
area/right atrial area < 10%), mild (2; jet area/right atrial area 10–20%), moderate (3; jet 
area/right atrial area 20–33%), and severe (4; jet area/right atrial area ≥33%).12 The trans-
tricuspid regurgitation gradient was quantified (modified Bernoulli equation) by using 
continuous-wave Doppler scanning. From the apical 4-chamber view, the ultrasound 
beam was orientated to obtain the maximum dimensions of the right ventricular 
 chamber. Measurements were made of the right ventricular long and short axis, as well 
as the tricuspid valve annulus.13 The tricuspid annulus was measured in the transthoracic 
apical 4-chamber view in late diastole at the time of maximal tricuspid opening 
(Figure 1).
Surgical Procedure
The procedures were performed with the use of normothermic cardiopulmonary bypass 
with intermittent antegrade warm blood cardioplegia for myocardial protection. After 
median sternotomy, patients with an indication for revascularization underwent 
 coronary artery bypass grafting; for patients younger than 70 years, a strategy of total 
arterial revascularization was used. Next, the right atrium was opened and after a vertical 
transseptal approach, mitral valve repair was performed after thorough intraoperative 
valve analysis. In the case of organic disease, mitral valve reconstruction was conducted 
by using standard Carpentier techniques.14 Mitral annuloplasty ring size (Carpentier–
Edwards Physioring; Edwards Lifesciences, Irvine, Calif ) was determined by means of 
standard measurement of the height of the anterior leaflet. In the case of functional 
Structured approach to functional tricuspid regurgitation 209
mitral regurgitation, stringent downsizing by 2 ring sizes was performed. In the 2002 
cohort tricuspid annuloplasty was performed only when the preoperative echocardio-
gram demonstrated grade 3 or 4 TR. In the 2004 cohort tricuspid annuloplasty was 
 performed when the preoperative echocardiogram demonstrated grade 3 or 4 TR or in 
any case when tricuspid annulus enlargement (≥40 mm) had been observed, as proposed 
recently.15 A Carpentier–Edwards Classic annuloplasty ring (18%) or Edwards MC3 
annuloplasty ring (82%; both manufactured by Edwards Lifesciences) was used. 
The ring size was determined by means of standard measurement of the surface of the 
anterior leaflet. After weaning from cardiopulmonary bypass, the result of the valve 
reconstructions was checked with transesophageal echocardiographic analysis.
Statistical Analysis
Continuous data were expressed as means ± standard deviations and compared by using 
the Student t test for paired and unpaired data when appropriate. Comparison of 
 categorical data was performed with χ2 analysis. Comparisons within each cohort of 
patients were performed by using the Student t test or nonparametric tests for paired 
and unpaired data, as appropriate. In addition, each cohort was divided into 
3   subgroups: patients with TR grade 3 or 4, patients without TR grade 3 or 4 but with 
tricuspid annular dilatation of 40 mm or greater, and patients without TR grade 3 or 4 
or tricuspid annular dilatation of 40 mm or greater. Comparisons among the 3 different 
subgroups were performed with 1-way analysis of variance or the Kruskal–Wallis test, as 
appropriate. All statistical analyses were performed with SPSS software (version 15.0; 
SPSS, Inc, Chicago, Ill).
Figure 1. The tricuspid 
annular diameter is 
 measured from the pre-
operative, trans thoracic, 
apical 4-chamber view in 
late diastole, as recom-
mended by Foale and 
 associates.13 In this exam-
ple the tricuspid annulus 
(45 mm) is dilated
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Results
Baseline Characteristics
Baseline clinical characteristics of the 2002 and 2004 cohorts are presented in Table 1. 
There is a male predominance in both cohorts, and 34% of the patients have a history of 
myocardial infarction. Patients from the 2004 cohort were older than patients from the 
2002 cohort. All patients were receiving optimized medical treatment. Risk factors, 
medical history, and functional class were similar. Preoperative echocardiographic 
 characteristics are presented in Table 2. Left ventricular dimensions and function, as 
well as severity of mitral regurgitation, were comparable between the 2 cohorts. TR was 
similar between both cohorts, as were right ventricular dimensions.
TABLE 1
Baseline clinical characteristics
2002 cohort
(n=80)
2004 cohort
(n= 102)
P Value
Men/women 44 (55%)/36 (45%) 62 (61%)/40 (39%) 0.50
Mean age ± SD, y 60±15 66±12  0.010
Arterial hypertension 10 (13%) 20 (20%)  0.091
Diabetes 6 (8%) 10 (10%) 0.67
Severe COPD 6 (8%) 8 (8%) 0.99
Previous stroke 3 (4%) 3 (3%) 0.84
Previous infarction 19 (24%) 31 (30%) 0.19
NYHA Class 2.6±0.8 2.6±0.8 0.49
CCS Class 1.3±0.6 1.3±0.8 0.61
SD, Standard deviation; COPD, chronic obstructive pulmonary disease; CABG, coronary artery bypass 
grafting; NYHA, New York Heart Association; CCS, Canadian Cardiac Society
Surgical Details
All patients underwent successful mitral valve repair (i.e., no residual mitral regurgita-
tion and a coaptation length ≥8 mm). The mitral mean ring size used was 30±4 in the 
2002 cohort compared with 28±3 in the 2004 cohort. Tricuspid annuloplasty was 
 performed in 13 (16%) patients of the 2002 cohort and in 64 (63%) patients of the 2004 
cohort. The tricuspid mean ring size used was 32±3 in the 2002 cohort compared with 
29±2 in the 2004 cohort. Coronary artery bypass grafting was performed in 19 patients 
of the 2002 cohort and 35 patients of the 2004 cohort. Cardiopulmonary bypass time 
and aortic cross clamp time were comparable between the groups: 173±52 versus 162±52 
minutes and 119±44 versus 101±46 minutes, respectively.
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TABLE 2
Baseline echocardiographic characteristics
2002 cohort
(n=80)
2004 cohort
(n= 102)
P Value
Left atrial diameter (mm) 50±10 47±7  0.092
LV end-diastolic diameter (mm) 61±9 59±8 0.25
LV end-systolic diameter (mm) 42±11 42±11 0.93
Fractional shortening (%) 31±12 29±13 0.84
Mitral regurgitation grade 3.4±0.7 3.2±0.7 0.20
RV long axis (mm) 69±7 72±8 0.15
RV short axis (mm) 29±7 29±5 0.98
Tricuspid valve annulus (mm) 38±7 39±5 0.34
Tricuspid regurgitation grade 1.6±1.0 1.6±1.0 0.85
Transtricuspid gradient (mmHg) 25±10 28±13 0.11
LV, Left ventricular; RV, right ventricular
TABLE 3
Two-year follow-up: Entire 2002 cohort
Baseline Follow-up P Value
New York Heart Association class  2.6±0.8  1.4±0.6  <0.0001
Canadian Cardiac Society class  1.3±0.6  1.0±0.2 <0.001
LA diameter (mm)  50±10 43±8  <0.0001
LV end-diastolic diameter (mm) 61±9  52±10  <0.0001
LV end-systolic diameter (mm)  42±11  35±11  <0.0001
Mitral regurgitation grade  3.4±0.7  0.7±0.8 <0.0001
RV long axis (mm) 69±7 70±8  0.301
RV short axis (mm) 29±7 30±7  0.080
Tricuspid regurgitation grade  1.6±1.0  1.3±1.0  0.211
Transtricuspid gradient (mmHg)  25±10 23±9  0.091
LA, Left atrial; LV, left ventricular; RV, right ventricular
Two Year Follow-up
Clinical and echocardiographic 2-year follow-ups of the entire 2002 and 2004 cohorts 
are presented in Tables 3 and 4. A significant difference in New York Heart Association 
functional class was observed at follow-up. In both groups the expected reduction of 
mitral regurgitation was noted after surgical intervention. This observation was 
 accompanied by a matched reduction in left atrial and left ventricular dimensions, 
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indicating reverse remodeling after surgical intervention. In the 2002 cohort, right 
 ventricular dimensions, TR grade, and gradient remained unchanged after surgical 
intervention. In the 2004 cohort, the right ventricular dimensions decreased after 
 surgical intervention accompanied by a reduction in TR and transtricuspid gradient.
In summary, echocardiographic outcome at the 2-year follow-up did not improve in the 
2002 cohort patients who did not undergo tricuspid annuloplasty in case of tricuspid 
annular dilatation. In contrast, 2004 cohort patients who underwent combined mitral 
valve repair and tricuspid annuloplasty in case of severe TR or tricuspid annular 
 dilatation demonstrated reverse right ventricular remodeling and reduction of TR.
TABLE 4
Two-year follow-up: Entire 2004 cohort
Baseline Follow-up P Value
New York Heart Association class  2.6±0.8  1.8±0.8  <0.0001
Canadian Cardiac Society class  1.3±0.8  1.1±0.2 <0.001
LA diameter (mm) 48±7 44±7  <0.0001
LV end-diastolic diameter (mm) 59±8 53±9  <0.0001
LV end-systolic diameter (mm)  42±11  38±12  <0.0001
Mitral regurgitation grade  3.3±0.5  0.8±0.8  <0.0001
RV long axis (mm) 71±6 69±9  0.001
RV short axis (mm) 29±5 27±5  <0.0001
Tricuspid regurgitation grade  1.6±1.0  0.9±0.6  <0.0001
Transtricuspid gradient (mmHg)  28±13  23±15  0.021
LA, Left atrial; LV, left ventricular; RV, right ventricular
Subgroup Analysis of the 2002 Cohort
At the 2-year follow-up, the expected reduction of mitral regurgitation and left atrial and 
ventricular reverse remodeling was also observed in the different subgroups of the 2002 
cohort (Table 5). In 2002, only patients with a grade 3 or 4 TR underwent tricuspid 
valve annuloplasty. In these 13 patients TR was absent or mild at the 2-year follow-up, 
and there was also a significant decrease of the transtricuspid gradient (Figure 2). 
Moreover, these patients showed reverse right ventricular remodeling, as expressed by a 
significant decrease of the right ventricular long- and short-axis diameters (Figure 3). 
In the 44 patients without significant TR and without tricuspid annular dilatation at 
baseline, the degree of TR and right ventricular dimensions remained unchanged 
(Figures 2 and 3). However, in patients with a dilated tricuspid annulus (≥40 mm), the 
degree of TR at the 2-year follow-up was worse, and the transtricuspid gradient had 
increased significantly in these 23 patients (Figure 2). Moreover, this was associated with 
right ventricular dilatation (Figure 3). Note that these patients did not undergo  tricuspid 
annuloplasty.
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Figure 2. 
Echo cardio graphic 
evaluation of 
tricuspid regurgita-
tion and gradient at 
baseline and at the 
2-year follow-up in 
the 2002 cohort 
according to 
subgroups. 
NS, Not significant; 
TVP, tricuspid valve 
annuloplasty.
Figure 3. 
Echocardiographic 
evaluation of right 
ventricular (RV) 
dimensions at 
baseline and at the 
2-year follow-up in 
the 2002 cohort 
according to 
subgroups. 
NS, Not significant; 
TVP, tricuspid valve 
annuloplasty.
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TABLE 5
Echocardiographic Left-sided Follow-up of 2002 Cohort by Subgroup
Tricuspid regurgitation ≥ 3
(TVP),
 n=13
Tricuspid regurgitation < 3 and 
tricuspid annulus ≥ 40 mm,
n=23
Tricuspid regurgitation < 3 and 
tricuspid annulus < 40 mm,
n=44
Left atrial diameter (mm)
Baseline 50±13 52±9 48±9*
Follow-up 41±10 (P=0.001) 46±9 (P=0.004) 42±8* (P<0.0001)
Left ventricular end-diastolic diameter (mm)
Baseline 59±11 63±10 59±8*
Follow-up 51±10 (P=0.016) 56±10 (P<0.0001) 51±9* (P<0.01)
Left ventricular end-systolic diameter (mm)
Baseline 45±10 42±13 40±11*
Follow-up 36±10 (P=0.005) 38±13(P=0.037) 33±11* (P<0.0001)
Mitral regurgitation grade
Baseline 3.3±0.6 3.4±0.5 3.5±0.7*
Follow-up 0.9±0.8 (P<0.0001) 0.9±0.8 (P<0.0001) 0.5±0.9* (P<0.0001)
P values refer to baseline versus follow-up comparison. TVP, Tricuspid valve annuloplasty. 
*Not significant for comparison among the 3 groups (analysis of variance)
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TABLE 6
Echocardiographic Left-sided Follow-up of 2004 Cohort by Subgroup
Tricuspid regurgitation ≥ 3
(TVP),
 n=21
Tricuspid regurgitation < 3 and 
tricuspid annulus ≥ 40 mm,
n=43
Tricuspid regurgitation < 3 and 
tricuspid annulus < 40 mm,
n=38
Left atrial diameter (mm)
Baseline 47±7 47±8 49±5*
Follow-up 44±6 (P=0.025) 44±8 (P=0.08) 44±7* (P<0.001)
Left ventricular end-diastolic diameter (mm)
Baseline 60±8 60±8 57±9*
Follow-up 54±10 (P=0.007) 54±9 (P<0.001) 53±9* (P=0.04)
Left ventricular end-systolic diameter (mm)
Baseline 44±12 42±12 40±10*
Follow-up 39±13 (P=0.010) 39±12(P=0.019) 36±12* (P=0.014)
Mitral regurgitation grade
Baseline 3.3±0.8 3.3±0.6 3.2±0.5*
Follow-up 0.6±0.6 (P<0.0001) 0.7±0.8 (P<0.0001) 1.0±0.9* (P<0.0001)
P values refer to baseline versus follow-up comparison. TVP, Tricuspid valve annuloplasty. 
*Not significant for comparison among the 3 groups (analysis of variance).
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Subgroup Analysis of the 2004 Cohort 
At the 2-year follow-up, significant reduction of mitral regurgitation and left atrial and 
ventricular reverse remodeling was observed in all subgroups of the 2004 cohort 
Figure 4. 
Echocardiographic 
evaluation of 
tricuspid regurgita-
tion and gradient at 
baseline and at the 
2-year follow-up in 
the 2004 cohort 
according to 
subgroups. 
NS, Not significant; 
TVP, tricuspid valve 
annuloplasty.
Figure 5. 
Echocardiographic 
evaluation of right 
ventricular (RV) 
dimensions at 
baseline and the 
2-year follow-up in 
the 2004 cohort 
according to 
subgroups. 
NS, Not significant; 
TVP, tricuspid valve 
annuloplasty
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(Table  6). In the 2004 cohort, patients underwent annuloplasty of the mitral and 
 tricuspid valves if grade 3 or 4 TR was present at baseline or if the tricuspid annulus was 
dilated (≥40 mm), irrespective of the degree of TR preoperatively. Both in the 
21  patients with severe baseline TR and in the 43 patients with tricuspid annular 
 dilatation who underwent tricuspid annuloplasty, TR and transtricuspid gradient 
decreased significantly at the 2-year follow-up (Figure 4). Moreover, these patients 
showed a significant decrease of right ventricular dimensions, indicating reverse right 
ventricular remodeling (Figure 5). Patients without important TR and without tricuspid 
annular dilatation at baseline did not undergo tricuspid annuloplasty. The degree of TR 
regurgitation and right ventricular dimensions remained unchanged in these 38 patients 
(Figures 4 and 5).
Discussion
The main novel findings of the current study are as follows. In patients with tricuspid 
annular dilatation undergoing mitral valve reconstruction without concomitant 
 tricuspid surgery, right ventricular dimensions increased, and TR was aggravated at the 
2-year follow-up. In contrast, right ventricular reverse remodeling and absence of 
 significant TR were observed at the 2-year follow-up in patients with tricuspid annular 
dilatation who underwent simultaneous tricuspid annuloplasty during mitral valve 
surgery. 
Incidence and Prognostic Implications of Tricuspid Valve Regurgitation 
Following Mitral Valve Surgery
Tricuspid valve regurgitation occurs mainly from annular and right ventricular 
 dilatation, which is often secondary to left-sided valvular causes, right ventricular 
volume and pressure overload, and dilatation of cardiac chambers.8 It was thought for a 
long time that this functional TR would decrease or disappear over time after surgical 
correction of mitral regurgitation.16 There is, however, increasing evidence that TR does 
not always regress after successful surgical treatment of mitral regurgitation. Often, 
 progression of TR is observed after mitral valve surgery or appears de novo during post-
operative  follow-up.17-19 Kwak and colleagues1 investigated the incidence of significant 
TR in 335 patients after left-sided valve surgery (mean follow-up, 11 years; 52% mitral 
valve surgery, 22% aortic valve surgery, and 26% combined aortic/mitral valve surgery). 
The estimated incidence of TR was 27% and was related to poor outcome.1 Matsunaga 
and Duran6 more specifically studied 70 patients with ischemic cardiomyopathy and 
secondary mitral regurgitation who underwent coronary artery bypass graft surgery and 
mitral valve repair with a flexible Duran ring. The incidence of significant TR was 25% 
within the 1-year follow-up and increased to 53% between the 1- and 3-year follow-ups; 
at late follow-up (>3 years), the incidence was 74%.6
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Combining Mitral Valve Surgery and Tricuspid Valve Repair
These observations have encouraged surgeons to perform tricuspid valve repair at the 
time of mitral valve repair. In the 1970s, Carpentier and coworkers20 performed 
 tricuspid valve surgery when medical therapy failed. In the 1980s, Duran and associates21 
suggested that functional TR could only be ignored in cases of predictable and 
 significant reduction in pulmonary resistance and that organic disease always required 
repair. Nowadays, most surgeons agree that moderate-to-severe TR should be repaired, 
and it has been shown that tricuspid annuloplasty is associated with better symptomatic 
results and improved survival.22
Carpentier and coworkers23 were the first to recognize the importance of tricuspid 
 annular dilatation as an indication for tricuspid valve repair. Their method of assessing 
annular dilatation was surgical exploration of the valve and the ability of the annulus to 
admit 3 finger breadths of the surgeon’s hand, in which case it would be repaired.22 
Dreyfus and colleagues5 suggested that in addition to tricuspid dilatation, 3 important 
factors determine whether TR will occur: preload, afterload and right ventricular 
 function. Isolated mitral valve surgery decreases the afterload without correcting 
 tricuspid annulus dilatation, and it does not affect preload or right ventricular function.5 
Tricuspid annular dilatation is an ongoing disease process that will with time lead to 
severe TR.
Surgical Methods to Treat or Prevent TR
There are 2 principal surgical methods to treat or prevent TR: the ring annuloplasty, as 
introduced by Carpentier and associates,23 and the suture annuloplasty method, mostly 
performed as described by De Vega and coworkers.24 Although either method can be 
applied for secondary TR, recent long-term studies suggest that ring annuloplasty 
repairs are more robust.22,25,26 Tang and associates2 compared the long-term results of tri-
cuspid valve repair with or without an annuloplasty ring. The authors included 702 
patients (74% functional TR), of whom 493 underwent a De Vega procedure and 209 
had annuloplasty. Concomitant procedures consisted of mitral valve surgery in 80%, 
aortic valve surgery in 33%, and coronary bypass surgery in 14%. Tricuspid valve repair 
without a ring was associated with TR recurrence over time. The patients who received a 
ring had significantly improved long-term survival and event-free survival.
Results of Tricuspid Valve Surgery in Patients with a Dilated Tricuspid Annulus
The relevance of performing tricuspid annuloplasty in patients with a dilated tricuspid 
valve annulus has been demonstrated in several series. Tager and associates27 evaluated 
144 patients undergoing mitral valve surgery. Tricuspid annuloplasty was performed in 
49 patients, and the criteria used to indicate this procedure were the presence of moder-
ate or severe TR or a tricuspid annular diameter, as assessed with echocardiographic 
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analysis if 30 mm or greater. Interestingly, those patients who did not show significant 
TR but had a tricuspid annular diameter of 30 mm or greater and in whom tricuspid 
annuloplasty was not performed showed an increased prevalence of significant TR at 
follow-up (13%). Sugimoto and colleagues28 demonstrated higher right ventricular 
volume and pressure, which are indicative of right-sided heart failure, in patients 
 undergoing left-sided valvular surgery with a tricuspid annulus of 40 mm or greater 
compared with patients without tricuspid annular dilatation. In patients with a dilated 
tricuspid annulus undergoing combined mitral and tricuspid surgery, TR decreased.28 
In 2005, Dreyfus and colleagues5 reported on 311 patients who underwent mitral valve 
repair. The authors defined a dilated annulus as a diameter of greater than 70 mm 
 measured intraoperatively from the anteroseptal commissure to the anteroposterior 
commissure with a sterile ruler. Tricuspid annuloplasty was performed only if the 
 tricuspid annular diameter was greater than twice the normal size (>70 mm), regardless 
of the grade of TR. In patients who did not undergo annuloplasty, TR increased by 
more than 2 grades in 48% of patients compared with only 2% of patients who under-
went tricuspid annuloplasty.
The present study focused on patients with severe organic or functional mitral 
 regurgitation scheduled for mitral valve repair. The surgical approach for the mitral 
regurgitation was consistent for all patients. In 2002, only patients with TR grade 3 or 4 
underwent tricuspid annuloplasty. In these patients TR improved, and right ventricular 
dimensions decreased. Based on the work of Sugimoto and colleagues,28 tricuspid 
 annular dilatation was defined as an annulus exceeding 40 mm on echocardiographic 
analysis. The patients from the 2002 cohort without preoperative TR grade 3 or 4 but 
with a dilated annulus had a higher degree of TR at the 2-year follow-up. These findings 
are well in line with recent data in comparable patients.29 De Bonis and associates29 
assessed the evolution of functional TR in 95 patients who underwent surgical repair of 
functional mitral regurgitation with or without concomitant tricuspid annuloplasty. 
Tricuspid annuloplasty was only performed in 13 patients with preoperative TR grade 3 
or 4. At the 6-month echocardiographic follow-up, functional TR was moderate in 31%, 
moderate to severe in 10%, and severe in 2%. The mechanism underlying tricuspid 
 dilatation was annular dilatation. Moreover, in the present study right ventricular 
dimensions increased in the patients with tricuspid annular dilatation who did not 
undergo tricuspid repair. These data support the observation of Sugimoto and 
 colleagues28 that tricuspid annular dilatation is associated with evidence of right-sided 
heart failure. In our clinic, from 2004 on, tricuspid annuloplasty was not only applied in 
patients undergoing mitral valve repair with TR grade 3 or 4 but also in patients with 
 tricuspid annular dilatation, irrespective of the degree of regurgitation. Reverse right 
ventricular remodeling and a reduction of TR severity were observed, supporting a more 
aggressive approach in these patients.
Chapter 9220
CONCLUSION
Patients with tricuspid annular dilatation (≥40 mm) undergoing mitral valve repair 
without concomitant tricuspid valve annuloplasty have poor echocardiographic 
 outcomes. They exhibit right ventricular dilatation and significantly increased TR at the 
2-year follow-up. A more aggressive surgical approach favoring tricuspid annuloplasty in 
case of tricuspid annular dilatation improves echocardiographic outcome significantly. 
These patients demonstrate absence of hemodynamically relevant TR and right 
 ventricular reverse remodeling at the 2-year follow-up. Combined mitral repair and 
 tricuspid annuloplasty should be considered in patients with tricuspid annular  dilatation 
despite absence of important TR at baseline.
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Mitral valve surgery in low ejection fraction, 
severe ischemic mitral regurgitation: 
should we repair them all? 
Jerry BRAUN, Robert JM KLAUTZ 
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Abstract
Purpose of review: The optimal surgical treatment of chronic ischemic mitral 
regurgitation still is the subject of much debate in the surgical and cardiological 
communities. Although combined restrictive mitral annuloplasty and 
 revascularization has demonstrated good results with regard to improvement of clin-
ical status, low rates of recurrent mitral regurgitation, and sustained left ventricular 
reverse remodeling, a survival benefit still has not been demonstrated. In addition, 
not all patients improve. Remaining issues in this field relate to identification of 
patients who will benefit from treatment, and to further improve and individualize 
treatment modalities. 
Recent findings: More data support the use of restrictive mitral annuloplasty and 
revascularization. New surgical techniques to improve mitral competence (posterior 
leaflet  augmentation) and to promote left ventricular reverse remodeling in severely 
dilated hearts (addressing the subvalvular apparatus) are promising. Disease-specific 
 annuloplasty rings have not (yet) proven additional value. New imaging modalities 
are available to assess the many components that constitute the complex 
 pathophysiology of remodeling.
Summary: The remaining challenge for cardiologists and surgeons is how to 
 integrate data from different imaging techniques that assess mitral valve geometry 
and left ventricular size, geometry, function and potential functional recovery in 
order to individualize and optimize the surgical approach to patients with chronic 
ischemic mitral regurgitation.
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Chronic ischemic mitral regurgitation  is a disease condition that carries a poor  prognosis.1,2 The pathophysiology of ischemic mitral regurgitation involves left 
 ventricular remodeling secondary to coronary artery disease that has caused either 
 localized ischemia or infarction, or global left ventricular dysfunction. Either way, 
remodeling leads to papillary muscle displacement, causing mitral leaflet tethering, and 
to decreased contractility and dyssynchrony, causing reduced mitral valve closing. 
Because the degree of remodeling may vary, ischemic mitral regurgitation can occur 
within a broad range of left ventricular injury. Even small ischemic or infarcted areas, 
especially in the posterolateral region, may cause significant ischemic mitral  regurgitation, 
while the ventricle still has a good overall performance. Typically, such patients express 
a dynamic, paroxysmal pattern of mitral regurgitation, and they are expected to have a 
good outcome after surgical treatment. At the other end of the spectrum are patients 
with a severely dilated left ventricle with often very low ejection fraction; outcome in 
these patients is less predictable and often disappointing.
Because clinical and echocardiographic outcomes in ischemic mitral regurgitation are 
still ambiguous and as such the subject of debate, there is an urgent need to better 
 identify patients who will benefit from surgery. This is a complex matter involving two 
different—but interrelated—subjects: restoring mitral valve competence and promoting 
left ventricular reverse remodeling. The latter relates not only to successful mitral repair 
with reduction of both left ventricular volume overload and wall stress, but also to left 
ventricular functional improvement following revascularization and possibly adjunctive 
procedures.
This review will focus on recent developments in surgical techniques that try to improve 
mitral valve competence and initiate and sustain left ventricular reverse remodeling, and 
on new ways to identify patients who will benefit from a surgical approach to ischemic 
mitral regurgitation.
History and Current State of Surgery for Chronic Ischemic Mitral Regurgitation
The revolutionary concept of undersized mitral annuloplasty to treat (ischemic) 
 functional mitral regurgitation in heart failure patients was introduced by Bolling and 
co-workers.3,4 Their low mortality and good early echocardiographic results 
 demonstrated that restoring mitral competence is not detrimental to an already 
extremely compromised left ventricular function. Ongoing research has learnt that 
proper application of this technique implies strict adherence to three criteria: the use of 
a complete (semi–)rigid ring; stringent downsizing (for an Edwards Physio ring, this 
means two ring sizes down, i.e. when size 30 is measured, a ring 26 should be inserted); 
and achieving leaflet coaptation 8 mm or more on intraoperative transesophageal 
 echocardiography. When combined with complete coronary revascularization, 
 acceptable early mortality, absence of significant recurrent mitral regurgitation in 85% of 
patients and sustained left ventricular reverse remodeling have been demonstrated by 
several authors.5-8 However, in patients with more advanced remodeling expressed by 
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larger left ventricular dimensions, long-term mortality remains high and left ventricular 
reverse remodeling is less predictable, even when recurrent mitral regurgitation is 
absent.9 For patients showing midterm recurrence of mitral regurgitation and/or 
 ongoing left ventricular remodeling, it is generally accepted that the extent of 
 ventricular deterioration, at the time of surgery or during the further course of the 
 disease, determines prognosis.10,11
Reports of high mitral regurgitation recurrence rates are always associated with the use 
of incomplete or flexible rings, or inappropriate downsizing.12,13 Repair failure typically 
occurs early, indicating inappropriate surgical correction of mitral regurgitation which 
should not be interpreted as proof to support the concept that an intervention on the 
valve alone cannot solve a ventricular disease.
No study has demonstrated that combined mitral valve surgery and coronary artery 
bypass grafting (CABG) offers survival benefit.
Several recent studies corroborate the findings described above. Pocar et al.14  additionally 
demonstrate that stiffer rings lead to earlier reverse remodeling and better recovery of 
ejection fraction and left ventricular wall motion compared to flexible rings. Grossi et 
al.15 reports 2 years of follow-up in 73 patients who constituted the control arm in the 
RESTOR-MV (Randomized Evaluation of a Surgical Treatment for Off-Pump Repair 
of the Mitral Valve) trial (comparing in a randomized setting CABG and mitral repair 
versus CABG and external ventricular reshaping), and confirm functional improvement 
and low mitral regurgitation recurrence. Another recent study16 retrospectively  compares 
percutaneous coronary intervention, CABG and CABG plus mitral repair in ischemic 
mitral regurgitation. Although overall survival was not different, the latter technique 
demonstrated the best event-free survival and highest freedom from recurrent mitral 
regurgitation.
Results from a single-center randomized trial were presented by Fattouch et al.17 Forty-
eight patients with moderate ischemic mitral regurgitation underwent restrictive mitral 
annuloplasty with revascularization and 52 underwent CABG only. Early mortality was 
similar. The mitral surgery group showed better clinical improvement (by New York 
Heart Association class), more left ventricular reverse remodeling, reduction of left atrial 
size and lower pulmonary artery pressures at 2.5 years. With short follow-up and 
 relatively small groups, no conclusions can be drawn with regard to survival.
New Annuloplasty Rings
An undersizing annuloplasty ring effectively reduces mitral septal-to-lateral dimension, 
but also decreases valve orifice area. The fear of creating a relative mitral stenosis18 
prompted the introduction of so-called disease-specific annuloplasty rings. These are 
designed to provide further reduction in septal-to-lateral dimension while maintaining 
or even increasing the commisure-to-commisure dimension, providing a relatively larger 
orifice area. Evaluating and comparing these rings is highly complex, and actually makes 
a proper ring choice even harder for the surgeon. A paper by Bothe et al.19 provides 
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measured dimensions of four disease-specific rings and compares them with those of a 
standard semi-rigid ring. Disease-specific rings provide a varying amount of additional 
septal-to-lateral dimension reduction compared with the standard ring of the same size, 
but, when compared with a standard ring that is two sizes smaller, the septal-to-lateral 
dimension is actually larger in three out of four rings. Preferably, the effects of these 
devices on mitral valve and left ventricular geometry should be tested ex vivo, for 
instance in a finite element model.20
The single intermediate term follow-up study performed with a disease-specific ring 
does not reveal better freedom from recurrent mitral regurgitation or more extensive left 
ventricular remodeling, but also does not show significant mitral stenosis on exercise.21 
In our opinion, these rings introduce more ambiguity into the discussion on downsizing, 
whereas their potential benefit is still unproven.
Additional Valvular Procedures
Valvular adjunctive procedures address loss of coaptation due to excessive tethering. 
In  2007, Borger et al.22 presented preliminary clinical results of cutting secondary 
chords as an adjunctive procedure to reduce tethering in ischemic mitral regurgitation. 
Theoretically, this approach may further compromise the already diminished left 
 ventricular function because it disrupts the continuity between the mitral valve and the 
left ventricle. No long-term follow-up studies have been published, and, despite the fact 
that this technique in a chronic ischemic mitral regurgitation animal model led to 
 limited progression of LV remodeling compared to control animals,23 we feel that this 
technique may only be used as a bailout procedure in cases in which valve replacement 
should be avoided at all cost.
Another valvular approach is posterior leaflet augmentation. The largest clinical series 
was presented by De Varennes,24 including 44 ischemic MR patients who underwent 
partial posterior leaflet augmentation using bovine pericardium, and true-sized 
 annuloplasty rings. At 2 years, freedom from moderate mitral regurgitation was 90%. 
This technique may also be used as an adjunct to restrictive annuloplasty in cases of 
severe tethering, especially with a small posterior leaflet.
Ventricular Approaches
The fact that ischemic mitral regurgitation is initiated by a ventricular disease has 
 traditionally placed focus on treating the ventricular problem as well. In ischemic mitral 
regurgitation, part of the ventricular disease is addressed by concomitant revasculariza-
tion. When left ventricular dilatation is limited (below 65 mm at end-diastole), CABG 
with restrictive mitral annuloplasty ‘cures’ ischemic mitral regurgitation. However, poor 
survival and low rates of left ventricular reverse remodeling in patients with left 
 ventricular end-diastolic diameters exceeding 65 mm9,25 urge the need for an adjunctive 
procedure in this patient group. Such procedures can be applied from outside and from 
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inside the left ventricle. From the outside, external ventricular restraint may interrupt 
the vicious circle of ongoing remodeling by reducing wall stress.26 Combined with 
restrictive mitral annuloplasty, this approach has shown good results in nonischemic 
functional mitral regurgitation,27 but the technical challenges that occur when 
 combining this approach with bypass grafting make its application in ischemic mitral 
regurgitation not straightforward. Another device, examined in a multicenter 
 randomized study,28 is used as an adjunct to revascularization alone in ischemic mitral 
regurgitation. Applied on the beating heart, the device narrows the mitral annulus and 
brings the papillary muscles together. Promising results at 2 years were demonstrated.
Several techniques have been applied from inside the left ventricle. Hvass and Joudinaud29 
reported on 37 ischemic mitral regurgitation patients with low ejection fraction using 
the papillary muscle sling technique (approximating the papillary muscles with a 
polytetrafluoroethylene tube) combined with mitral annuloplasty and CABG. Results 
after 4.5 years are impressive, with low mortality, low mitral regurgitation recurrence 
and significant left ventricular reverse remodeling (end-diastolic diameter changing 
from 70 to 55 mm and ejection fraction from 29 to 45%). Langer et al.30 introduced the 
RING + STRING technique, which adds repositioning of the posterior papillary muscle 
using a polytetrafluoroethylene suture that is exteriorized through the aortomitral 
 continuity and then tied in the loaded beating heart under echocardiographic guidance. 
In 30 patients with extensive tethering (tenting height ≥ 10 mm), this approach led to 
low mitral regurgitation recurrence (4% mitral regurgitation > grade 2) and left ventricu-
lar reverse remodeling (end-diastolic dimension from 62 to 55 mm) after 2 years.
Functional Mitral Stenosis Following (Restrictive) Mitral Annuloplasty 
Magne et al.18 demonstrated some degree of functional mitral stenosis (mean transmitral 
gradient ≥5 mmHg, mitral valve area ≤ 1.5 cm2) in more than 50% of patients following 
restrictive mitral annuloplasty.18  Gradients increased with exercise echocardiography. 
A  possible mechanism was recently identified by Kubota.31 In 31 ischemic mitral 
 regurgitation patients treated with a nonrestrictive annuloplasty, 13 patients had a mitral 
valve area 1.5 cm2 or less. This was caused by restricted leaflet opening secondary to 
 tethering, and occurred at the level of the leaflet tips and not at the level of the surgical 
intervention, i.e., the annulus. This may explain why stenosis can occur in the presence 
of a ring with an effective orifice area of at least 2.7 cm2. The clinical relevance of 
 elevated gradients has not been demonstrated, however.32
Indications for Mitral Valve Replacement
Calafiore has advocated that with severe tethering (tenting height >10 mm), the mitral 
valve should be replaced. In his experience this is only necessary in less than 7% of 
patients.33 No other studies have presented unambiguous criteria that guide the choice 
for replacement instead of repair. A recent meta-analysis of studies featuring 
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head-to-head comparisons between mitral repair and replacement in chronic ischemic 
MR showed better short-term and long-term survival in repair patients.34 In contrast to 
what is generally believed, patients who underwent repair had significantly more 
 comorbidities. While direct evidence from randomized trials is lacking, it seems 
 reasonable to believe that especially in compromised left ventricles a proper repair will 
be better than replacement, as has been demonstrated convincingly in organic mitral 
valve disease.
Patient Selection and Prediction of Success or Failure
The problem of recurrent MR after mitral repair in some patients, associated with 
 ongoing LV remodeling—post aut propter—still awaits a solution. The same holds true 
for progressive remodeling that occurs when the valve is still competent, which is also 
possible. Identifying who will benefit from surgery remains a challenge for cardiologists 
and surgeons. Current imaging techniques can study the mitral valve (geometry), but 
also left ventricular size (volumes and diameters), function (global and localized), 
expected functional recovery (viability, scar) and geometry (sphericity). All these 
 parameters are interrelated in a complex way.
Components of mitral valve geometry that have been identified to predict failure are all 
related to the degree of tethering. The most specific and sensitive markers are posterior 
leaflet angle >45° and distal anterior leaflet angle >25°, followed by tenting height 
>10 mm and tenting area >2.5 cm2.35-37 In these cases, adjunctive measures as described 
might be advisable and in less experienced hands valve replacement could be better.
Penicka demonstrated that 93% of patients with moderate ischemic MR improved after 
revascularization only when sufficient viable myocardium was present (≥5 segments out 
of 16, assessed by SPECT) and there was no dyssynchrony between papillary muscles.38 
However, no correlation was made with LV geometry, while it is known that the degree 
of LV remodeling (especially end-systolic volume) negatively influences both clinical 
and echocardiographic outcomes.39 Viability alone also did not predict survival benefit 
from CABG in the STICH trial.40 Once remodeling has led to severe LV dilatation 
(volumes or dimensions above twice the upper limit of normal, i.e., LV end-diastolic 
dimension >70 mm), even if viability is documented, revascularization has not  produced 
clinical benefit.41 Viability assessment should therefore always be integrated with other 
imaging modalities.
New echocardiographic techniques can assess local myocardial function, which is of 
greater value than global functional assessment by ejection fraction alone. Tatsumi used 
tissue Doppler strain rate imaging to show a quantitative relationship between inferior 
regional myocardial dysfunction and mitral valve tenting and MR,42 and demonstrated 
how both were attenuated with improvement of myocardial contraction using 
dobutamine. EF is often incorrectly considered to reflect the severity of LV injury, and 
has limited value, both preoperatively and postoperatively. In ischemic MR, EF may 
drop for different reasons: secondary to reduced LV contractility, but also due to 
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progressive LV dilatation with end-diastolic volume increase and maintained stroke 
volume.43 
Cardiac MRI allows more reliable volume measurements and assessment of LV  geometry 
than echocardiography. Ideally such information should be integrated with wall motion, 
scar and viability data. Flynn showed how minimal scarring already produces wall 
motion abnormalities,44 but that the overall scar burden correlates poorly with severity 
of wall motion abnormalities. Severity of scarring in the posterior papillary muscle 
region correlated with recurrent MR after 6 months, although observations were made 
in patients with mostly flexible annuloplasties. Takeda in a small study demonstrated 
how the extent of local (basal) fibrosis predicted less improvement of EF and restrictive 
diastolic filling following restrictive mitral annuloplasty.45 There still is no single solution 
to answer the question how to best identify patients who will benefit from which 
 procedure. To make it even more complex, it is important to realize that what we 
 perceive as LV remodeling is an epiphenomenon, an expression of changes that occur at 
a cellular or even molecular level, which remains invisible to our observation. However, 
integration of available tools will likely improve decision making.
Randomized Controlled Trials
Currently there are five interventional randomized controlled studies registered in this 
field (http\\:clinicaltrials.gov). Three studies focus on patients with moderate ischemic 
regurgitation and compare CABG alone versus CABG with mitral annuloplasty. 
One study compares mitral valve repair versus replacement in severe ischemic MR, and 
there is one study with multiple treatment arms (CABG only, CABG with repair and 
CABG with replacement).
Setting up surgical trials is difficult, and strict criteria should be set with regard to 
patient inclusion, surgical therapy and follow-up. Failing to do so will lead to outcomes 
that are not unequivocally accepted.46
For ischemic MR it is important to include true ischemic MR patients and to have clear 
(quantitative) criteria for assessment of MR severity. Repair should be performed with 
complete (semi-)rigid annuloplasty rings with appropriate downsizing and proper intra-
operative assessment of success. Undoubtedly, studies should have sufficient follow-up 
time and be sufficiently powered to test their hypotheses. As stated, survival benefit 
from surgical interventions for ischemic MR has not yet been demonstrated. Therefore 
it is disappointing that only one study uses mortality as a non-composite secondary 
 endpoint. Nevertheless, since other important outcomes will be studied (e.g., 
 components of LV reverse remodeling, objective functional improvement, and quality 
of life), outcomes of these trials will add to our knowledge.
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Conclusion
Recent outcome data support the combination of restrictive mitral annuloplasty using a 
(semi–)rigid complete ring and revascularization in patients with significant chronic 
ischemic MR with regard to MR reduction and LV reverse remodeling. Late failure is 
related to progressive LV remodeling, and several promising novel techniques to 
improve results at a valvular and at a ventricular level are under investigation. Optimal 
application of these techniques requires invidualization of treatment, starting with 
proper identification of patients who need them. For that purpose, new imaging 
 modalities are available, and optimal integration of these will be the next challenge in 
this intriguing field.
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Summary
In this thesis the surgical options for treatment of functional mitral regurgitation (MR) are described. In functional MR, the mitral valve has a normal anatomy, which 
 distinguishes this type of insufficiency from organic MR. Regurgitation in functional 
MR is related to an abnormal geometry of the left ventricle, which can be the result of 
an infarction or ischaemia, or may be caused by another—intrinsic—disease of the 
myocardium. Based on aetiology, we can distinguish ischaemic and non-ischaemic 
 functional MR. Patients with functional MR often present with signs and symptoms of 
heart failure. Current guidelines do not offer clear treatment algorithms for these 
patients, and an intervention on the mitral valve is often discouraged, mainly because of 
contradictory results from studies on surgical interventions on the valve.
In this thesis, the role of surgery in the multidisciplinary treatment of patients with 
functional MR, typically associated with heart failure, is evaluated with regard to  clinical 
and echocardiographic outcomes. The ultimate goal is to establish an individualised 
medico-surgical approach to this pathology. As such, this thesis results from close 
 collaboration between the departments of Cardiothoracic Surgery and Cardiology of 
the Leiden University Medical Center.
Chapter 1 reviews and comments the currently available literature on the subject of 
functional MR, starting with a definition. A historical overview of the pathophysiologic 
thoughts and considerations regarding this condition is presented. Normal anatomy 
and function of the mitral valve are discussed, followed by the pathophysiologic changes 
that occur in functional MR – in clinical and experimental settings. The consequent 
surgical interventional options are discussed and analysed. The clinical relevance of 
functional MR is illustrated by publications on incidence and prevalence, on its natural 
course, and on predictors for mortality. Different imaging techniques to identify and 
quantify functional MR are discussed. Outcomes of surgery for both ischaemic and 
non-ischaemic functional MR are presented and reviewed.
The surgical basis for functional MR is a restrictive mitral annuloplasty (RMA). This 
concerns implantation of a so-called undersized ring—a complete, non-flexible (i.e., 
rigid or semi-rigid) ring that is 2 sizes smaller than would be chosen if organic pathology 
were present. Considerations that determine ring choice are discussed based on available 
research on this topic. Next, the problem of recurrent MR following surgery is discussed. 
The chapter ends with an overview of the available additional surgical techniques—
at the level of the mitral valve, but also directed at the left ventricle and the tricuspid 
valve. Finally, the role of current non-surgical interventions (cardiac resynchronization) 
in this pathology is mentioned.
In chapter 2, the initial experience with RMA combined with coronary revasculariza-
tion (CABG) is described in 51 patients with ischaemic functional MR and left  ventricular 
dysfunction (mean ejection fraction, 31%). In these patients, a 2-year survival of 84% is 
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described (including 6% early mortality), as well as a significant improvement of 
 functional status and improvement of left ventricular dimensions. The latter  phenomenon 
is referred to as reverse remodelling.
Chapter 3 further explores this reverse remodelling, which is the ultimate goal of the 
(surgical) treatment of functional MR. The occurrence of reverse remodelling is the 
most important demonstrable manifestation of breaking the vicious cycle that consists 
of MR, ongoing left ventricular remodelling and consequent progression of MR. In a 
study with 87 patients with ischaemic functional MR it is demonstrated that treatment 
with RMA and CABG (median ring size, 26, mean number of distal anastomoses 
3.3 ± 1.3) in most cases leads to reverse remodelling in patients with limited left  ventricular 
dilatation preoperatively. Using ROC (receiver-operating characteristic) curve analysis, 
a cut-off value of 65 mm left ventricular end-diastolic dimension (LVEDD) on pre-
operative transthoracic echocardiography is found to be the most important predictor 
for the occurrence of reverse remodelling after surgery, with a sensitivity and specificity 
of 89%.
In chapter 4, mid-term follow-up results are described for 100 patients with ischaemic 
functional MR treated with RMA and CABG. After a mean follow-up of 4.3 years, 
 survival of patients with a preoperative left ventricular end-diastolic dimension  exceeding 
65 mm is demonstrated to be significantly lower than that of patients with a less dilated 
left ventricle. Five-year survival for the whole patient group was 71 ± 5.1%; for patients 
with LVEDD of 65 mm or less, survival was 80 ± 5.2%, compared to 49 ± 11% for patients 
with a higher preoperative LVEDD. In addition, it is demonstrated that patients with a 
preoperative LVEDD >65 mm also after longer follow-up have a very limited chance of 
left ventricular reverse remodelling. The percentage of recurrent MR exceeding grade 2 
is 15% after 4 years’ follow-up.
Chapter 5 features 2 patients with refractory cardiogenic shock resulting from acute 
ischaemic MR, without papillary muscle rupture. Both patients underwent uneventful 
implantation of a restrictive mitral annuloplasty ring and CABG with good short-term 
results. Acute ischaemic MR without papillary muscle rupture is a rare phenomenon 
that can be treated with RMA and CABG in acute settings.
In chapter 6, the application of MRI (magnetic resonance imaging) to assess left 
 ventricular reverse remodelling is described in patients with mild to moderate heart 
failure with functional MR and non-ischaemic cardiomyopathy (NYHA class 2.2 ± 0.4; 
LVEDD 61 ± 5 mm, forward LV ejection fraction 37 ± 5%, LV end-diastolic volume 
215 ± 34 mL). MRI is a technique that can provide insight into changes in LV dimension, 
shape and volumes in a more accurate fashion compared to echocardiography. 
The  technique as yet however has a limitation in that it cannot be used in patients with 
an internal defibrillator (ICD). This implies that MRI to assess postoperative reverse 
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remodelling can only be used in patients without an ICD, thereby excluding patients 
with more advanced stages of heart failure. Using MRI, in 22 patients sustained reverse 
remodelling and increase of forward ejection fraction of the left ventricle are described 
up to 3.5 years after surgery (isolated RMA). When the technique can be expanded to 
patients with an ICD, MRI will become an important modality in the follow-up of 
heart failure patients.
In chapter 7, the experience with RMA in non-ischaemic functional MR is described. 
The most important difference with patients with ischaemic MR lies in the fact that in 
those patients the ventricular component of the disease can be addressed by coronary 
revascularization. In non-ischaemic cardiomyopathy the underlying left ventricular 
problem has no clear substrate that can be addressed. Possible treatments are cardiac 
transplantation or a left ventricular assist device, with their inherent limitations.
In this patient group, changes in the (surgical) treatment strategy are implemented 
based on ongoing research. This is reflected in the application of additional  interventions, 
which may include techniques directed at the level of the ventricle (e.g., external cardiac 
restraint by implantation of a CorCap cardiac support device in patient with an LVEDD 
>65 mm), but also a more ‘aggressive’ approach to tricuspid valve repair. In addition, 
these patients also undergo cardiac resynchronization therapy often combined with 
ICD placement. In this chapter, the experience with 69 patients with a 3.1 year  follow-up 
is described. After 3 years, survival is more favourable compared to the natural history, 
combined with a low rate of recurrent MR and sustained LV reverse remodelling. 
This has led to a structured and individualised approach to patients in the Mission! Heart 
Failure programme.
Chapter 8 reflects the results from studying echocardiographic parameters that can 
 predict recurrence of functional MR following RMA. This is a fairly detailed analysis 
aimed at geometric ultrasound parameters of the mitral valve that express the degree of 
left ventricular remodelling. The most important predictors are the angle made between 
the tip of the anterior mitral leaflet and the line perpendicular to the annulus (distal 
anterior mitral leaflet angle), and the angle made between the tip of the posterior mitral 
leaflet and the line perpendicular to the annulus (posterior mitral leaflet angle). 
Ultimately, these angles are determined by the degree of geometric changes in the sub-
valvular apparatus as a result of left ventricular remodelling.
Functional tricuspid regurgitation is the subject of chapter 9. This condition results 
from left-sided valve dysfunction (often mitral regurgitation) and is often not well 
 recognized in the surgical and cardiology communities. For a long time it was thought 
that a limited tricuspid valve insufficiency would cure from successful treatment of the 
mitral valve. Long-term studies have shown, however, that this thought is not true. 
Other studies have demonstrated that the degree of tricuspid valve regurgitation is an 
unreliable parameter for treatment decision making, because regurgitation is highly 
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dependent on preload and afterload. Instead, the degree of tricuspid annular dilatation 
(which is independent of the previously mentioned parameters and is easily and reliably 
measured by transthoracic echocardiography) should be leading. Since the latter 
approach has been adopted at the LUMC since 2003, in this chapter two patient groups 
are compared: one group of patients who underwent tricuspid valve repair in the earlier 
era—during which the decision to perform valve surgery was only based on severity of 
tricuspid regurgitation—and another group of patients treated according to the new 
algorithm (which included surgery with annular dilatation >40 mm, even in the absence 
of tricuspid regurgitation). It was demonstrated that patients who were treated in the 
more recent era had significantly better echocardiographic outcome regarding severity 
of tricuspid regurgitation, right ventricular dimensions, and right ventricular function, 
after 2 years’ follow-up.
Chapter 10 is an overview and analysis of the most relevant literature on the subject of 
ischaemic MR published between 2008 and 2011. During this time frame, treatment of 
functional MR with RMA has gradually gained more support. In addition, new 
 techniques have been developed to reduce MR recurrence rate, especially in patients 
with advanced stages of remodelling. New imaging techniques aimed at functional MR 
are discussed, with a focus on integration of mitral valve geometry and LV  characteristics—
geometry, dimensions, function and potential functional recovery. For the future, it will 
be important to further develop these techniques in order to further individualise and 
optimise the medico-surgical treatment of patients with functional MR.
Final considerations
Functional MR has tremendous impact on functional status and survival of heart failure 
patients. Following myocardial infarction, functional MR frequently develops, with 
 percentages varying between 20 and 60 percent. In ischaemic MR, left ventricular 
 function may still be relatively preserved with MR resulting from local LV wall motion 
abnormalities. In non-ischaemic cardiomyopathy, global LV dilatation is invariably 
present. Regardless of aetiology, functional MR carries an increased risk of death, which 
is approximately two-fold and is related to the severity of MR
Functional MR is a dynamic phenomenon, which has specific  implications for MR 
assessment: this should preferably be performed prior to surgery and the induction of 
 anaesthesia, and should incorporate several techniques in order to assess severity. 
Exercise echocardiography should be performed in patients with heart failure symptoms 
and non-significant MR at rest.
Ischaemic MR treated by revascularization only does not improve in two-thirds of 
patients and leads to ongoing LV remodelling. There are no criteria to identify patients 
with ischaemic MR who may benefit from revascularization only. Series reporting on 
the results of mitral valve repair in functional MR are difficult to compare because of 
different patient populations and different surgical techniques.
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For ischaemic MR, good and durable results with regard to recovery of functional status, 
absence of recurrent MR, and reverse LV remodelling have been described in this thesis 
following complete revascularization and restrictive mitral valve annuloplasty (RMA). 
In our institution, RMA needs to fulfill three criteria: (1) stringent downsizing of the 
ring by 2 ring sizes, using a semi-rigid or rigid ring, and (2) verifying absence of residual 
MR with (3) sufficient coaptation length: 8 mm at the A2-P2 level. This technique seems 
insufficient in patients with too advanced LV remodelling, which can be assumed in 
severe LV dilatation (more than 65 mm end-diastolic dimension and/or severe mitral 
valve tethering). For functional MR in non-ischaemic cardiomyopathy, a similar 
approach to the mitral valve applies, although the ventricular component of the disease 
cannot be addressed in a straightforward manner. In this thesis, external cardiac restraint 
has been shown to lead to more extensive LV reverse remodelling in these patients.
MR recurrence should be distinguished from residual MR; regurgitation within 
6 months after surgery should be considered to result from insufficient repair and not be 
regarded as secondary to progress of the underlying ventricular disease. True MR recur-
rence may occur in patients without LV reverse remodelling but also in patients with 
reverse remodelling. Specific indicators to predict MR recurrence are not available, but 
the extent of preoperative LV remodelling—partially reflected by mitral valve leaflet 
geometry on echocardographic examination—might identify patients in whom 
 adjunctive measures are necessary to prevent recurrence. Patients with an  estimated 
increased risk of MR recurrence might benefit from adjunctive measures; these can be 
directed at the mitral valve leaflets, at the subvalvular apparatus, or at the left ventricle.
Patients with heart failure and functional MR should benefit from a practical medico –
surgical approach in a heart failure team, in which knowledge of and experience with 
both interventional and  non-interventional treatment strategies are incorporated. 
A   tailored surgical approach to functional MR also involves assessment of the left 
 ventricle, the tricuspid valve and cardiac resynchronisation therapy.
One of the major challenges in the field of functional MR remains patient selection: 
who will benefit from an individualized surgical strategy, and who will not. Imaging 
techniques are rapidly improving and a further integration of techniques will provide 
better answers to the question which patients have already too extensive remodelling 
and thus will not benefit from current techniques.
With the advent of percutaneous techniques to address MR, it seems that an increasing 
number of patients with functional MR is being treated. Although this technology  has 
the  advantage of avoiding major surgery, results have not yet been evaluated in large 
cohort studies. At this moment, it is our opinion that this new technology might be 
useful for extremely high-risk patients, but for all other patients a proven surgical 
 concept exists and as such should be the therapy of choice. Moreover, it is our strong 
believe that the same principles as described in this thesis apply to patients treated with 
percutanous devices, and that the indication for treatment—which should be discussed 
in a heart failure team—should not be expanded before further evidence has been 
obtained.
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Functional MR has tremendous impacts on functional status and survival of heart 
 failure patients. Surgical techniques have developed over more than 15 years, and our 
 current knowledge indicates that—when properly applied and evaluated—these 
 techniques have an important place in the treatment of heart failure patients with 
 functional MR.
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Samenvatting
In dit proefschrift worden de chirurgische mogelijkheden bij de behandeling van  functionele mitraalklepinsufficiëntie (MI) beschreven. Bij functionele MI is de 
mitraalklep anatomisch normaal, waarmee deze vorm van mitraalklepinsufficiëntie zich 
 onderscheidt van organische MI. De lekkage hangt bij een functionele MI samen met 
een gestoorde geometrie van de linkerkamer, welke het gevolg kan zijn van een infarct 
dan wel  ischemie, of van een andere—intrinsieke—aandoening van het myocard. 
Op  basis van etiologie spreken we dan van een ischemische of niet-ischemische MI. 
Patiënten met functionele MI presenteren zich vaak met het klinische syndroom van 
hartfalen. De huidige  richtlijnen bieden geen duidelijke behandelingsalgoritmen voor 
deze patiënten, en een ingreep aan de mitraalklep wordt vaak niet geadviseerd— 
voornamelijk op grond van tegenstrijdige resultaten na chirurgie.
In dit proefschrift wordt de rol van chirurgie in de multidisciplinaire behandeling van 
 patiënten met functionele MI, overwegend in combinatie met hartfalen, onderzocht 
met  betrekking tot klinische en echocardio grafische  uitkomsten. Uiteindelijk is het doel 
om tot een geïndividualiseerde  medico-chirurgische benadering van deze pathologie te 
komen. Dit werk is dan ook het resultaat van  intensieve samenwerking tussen de 
 afdelingen Thoraxchirurgie en Hartziekten van het Leids Universitair Medisch Centrum.
Hoofdstuk 1 is een weergave en analyse van de beschikbare literatuur op het gebied van 
functionele MI, en begint met een definitie. Daarnaast wordt een  historisch overzicht 
gegeven van de pathofysiologische gedachten rond deze entiteit. De normale anatomie 
en functie van de mitraalklep worden besproken, gevolgd door de pathofysiologische 
veranderingen die optreden bij functionele MI—zowel op het niveau van de klep als van 
de linkerventrikel—in klinische en experimentele setting. In het verlengde daarvan 
worden de chirurgische interventiemogelijkheden besproken en geanalyseerd. 
De  klinische relevantie van functionele MI wordt geduid aan de hand van publicaties 
over incidentie en prevalentie, over het natuurlijk beloop, en over factoren die 
 voorspellend zijn voor mortaliteit. De verschillende beeldvormende technieken om 
functionele MI aan te tonen en te kwantificeren worden besproken. Daarna worden de 
uitkomsten van chirurgie voor zowel ischemische als niet-ischemische functionele MI 
gepresenteerd en van commentaar voorzien.
De basis van de chirurgische behandeling van functionele MI is de restrictieve 
mitraalklepannulo plastiek (RMA). Hierbij wordt een zogenaamde “undersized” ring 
geïmplanteerd—een gesloten,  niet-flexibele (d.w.z. rigide of semi-rigide) ring die 
2  klepmaten kleiner wordt gekozen dan de ring die zou worden geïmplanteerd indien er 
sprake zou zijn van organische pathologie. De overwegingen die de keuze voor een 
 dergelijke ring bepalen worden besproken aan de hand van beschikbare onderzoeken op 
dit terrein. Daarna wordt het probleem van recidief MI na chirurgie behandeld. 
Het hoofdstuk eindigt met een overzicht van de beschikbare aanvullende chirurgische 
therapieën naast RMA—op het niveau van de mitraalklep, maar ook gericht op de 
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linkerventrikel en de tricuspidaalklep. De rol van huidige niet-chirurgische interventies 
(cardiale resynchronisatie) bij deze pathologie wordt tot slot benoemd.
In hoofdstuk 2 wordt de eerste ervaring met het gebruik van RMA in combinatie met 
coronair revascularisatie (CABG) beschreven bij 51 patiënten met een ischemische 
 functionele MI en dysfunctie van de linkerkamer (gemiddelde ejectiefractie 31%). 
Bij deze patiënten wordt na 2 jaar follow-up een overleving van 84% beschreven  (inclusief 
6% vroege mortaliteit), alsmede een significante verbetering van hun functionele status 
en een verbetering van de dimensies van de linkerkamer. Dit laatste fenomeen wordt 
aangeduid met de Engelse term “reverse remodelling” (omgekeerde vervorming of 
remodellering).
In hoofdstuk 3 wordt verder ingegaan op deze reverse remodelling, welke het 
 uiteindelijke doel is van de (chirurgische) behandeling van functionele MI. Het  optreden 
van reverse remodelling is de belangrijkste meetbare uiting van het tot stilstand brengen 
van de vicieuze cirkel die bestaat uit MI, verdere remodelling en als gevolg daarvan 
 progressie van de MI. In een onderzoek met 87 patiënten met ischemische functionele 
MI wordt aangetoond dat behandeling door middel van RMA en CABG (mediane 
ringmaat 26,  gemiddeld 3,3 ± 1,3 distale anastomoses) in de meeste gevallen leidt tot het 
optreden van reverse remodelling bij patiënten met een beperkte dilatatie van de linker-
kamer voorafgaand aan de operatie. Middels ROC (receiver-operating characteristic) 
curve analyse wordt een afkapwaarde van 65 mm eind-diastolische dimensie van de 
 linkerkamer (LVEDD) op preoperatief transthoracaal echocardiografisch onderzoek 
gevonden als de belangrijkste voorspeller voor het optreden van reverse remodelling na 
een operatie, met een  sensitiviteit en specificiteit van 89%.
In hoofdstuk 4 worden de uitkomsten op middellange termijn beschreven van 
100  patiënten met ischemische functionele MI die behandeld zijn met RMA en CABG. 
Bij een gemiddelde follow-up van 4,3 jaar wordt aangetoond dat de overleving van 
 patiënten met een preoperatieve eind-diastolische dimensie van de linkerkamer groter 
dan 65 mm significant lager is dan die van patiënten met een minder gedilateerde linker-
kamer. De 5-jaarsoverleving voor de gehele patiëntengroep is 71 ± 5,1%; voor de  patiënten 
met een LVEDD van 65 mm of minder is deze overleving 80 ± 5,2%, tegenover 49 ± 11% 
voor patiënten met een hogere LVEDD. Daarnaast wordt aangetoond dat  patiënten met 
een preoperatieve LVEDD >65 mm ook op langere termijn een zeer beperkte kans 
hebben op reverse remodelling van de linkerkamer. Het percentage recidief MI meer 
dan graad 2 is 15% na 4 jaar follow-up.
Hoofdstuk 5 wordt gevormd door de presentatie van een tweetal patiënten met een 
onbehandelbare cardiogene shock als gevolg van acute ischemische MI, zonder ruptuur 
van een papillairspier. Beide patiënten ondergingen een restrictieve mitraalklepannulo-
plastiek met CABG, welke goed werd doorstaan en leidde tot een goed resultaat op 
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korte termijn. Acute ischemische MI zonder ruptuur van een papillairspier is een 
 zeldzaam fenomeen dat in acute situaties behandeld kan worden door RMA met CABG.
In hoofdstuk 6 wordt de toepassing van MRI (magnetic resonance imaging) beschreven 
om reverse remodelling van de linkerkamer te onderzoeken bij patiënten met licht tot 
matig hartfalen bij functionele MI en niet-ischemische cardiomyopathie (NYHA klasse 
2,2 ± 0,4; LVEDD 61 ± 5 mm, voorwaartse LV ejectiefractie 37 ± 5%, LV eind-diastolisch 
volume 215 ± 34 ml). MRI is een techniek die op een meer accurate wijze inzicht kan 
verschaffen in veranderingen in dimensies, vorm en volumina van de linkerkamer in 
vergelijking tot echocardiografie. De techniek heeft echter vooralsnog als beperking dat 
deze niet kan worden toegepast bij patiënten met een inwendige defibrillator (ICD). 
Dat betekent dat voor het vaststellen van postoperatieve reverse remodelling, MRI alleen 
kan worden toegepast bij patiënten zonder ICD, hetgeen neerkomt op patiënten met 
een mildere vorm van  hartfalen. Met MRI werd bij 22 patiënten een aanhoudende 
reverse remodelling en een  toename van de voorwaartse ejectiefractie van de linkerkamer 
beschreven tot 3,5 jaar na de operatie (geïsoleerde RMA). Zodra MRI kan worden 
 toegepast bij  patiënten met een ICD zal deze techniek een belangrijke modaliteit worden 
bij de follow-up van patiënten met hartfalen.
In hoofdstuk 7 wordt de ervaring beschreven met RMA bij patiënten met 
 niet-ischemische functionele MI. Het belangrijkste verschil met patiënten die een 
 ischemische MI hebben is de mogelijkheid om iets te doen aan de ventriculaire 
 component van de functionele MI bij de laatste groep, in de vorm van coronair 
 revascularisatie. Bij niet-ischemische cardiomyopathie ontbreekt een duidelijk aangrij-
pingspunt voor behandeling van het onderliggende probleem van de linkerventrikel. 
Mogelijke behandelingen zijn harttransplantatie of implantatie van een steunhart, met 
de daarbij horende beperkingen.Binnen deze patiëntengroep vindt door voortschrij-
dend inzicht een voortdurende  aanpassing van de (chirurgische) behandelstrategie plaats. 
Deze vindt zijn weerslag in de toepassing van aanvullende interventies, waarbij gedacht 
moet worden aan technieken op het niveau van de ventrikel (zoals het toepassen van 
externe compressie door een  zogenaamd CorCap device bij patiënten met een LVEDD 
van meer dan 65 mm), maar ook een laagdrempeliger reparatie van de  tricuspidaalklep. 
Daarnaast wordt bij deze patiënten op indicatie ook cardiale  resynchronisatie toegepast, 
meestal in combinatie met een ICD. In het hoofdstuk wordt de ervaring met 69  patiënten 
over een periode van 3,1 jaar beschreven. Hieruit blijkt dat er na 3 jaar  follow-up sprake 
is van een gunstiger overlevingspatroon ten opzichte van het natuurlijk beloop, een lage 
incidentie van  recidief MI, en het optreden van  aanhoudende reverse remodelling. 
Dit  alles heeft in het LUMC geleid tot een  gestructureerde en  geïndividualiseerde 
behandeling van patiënten in het Mission! Hartfalen programma.
Hoofdstuk 8 is een weergave van het onderzoek naar echocardiografische parameters 
die kunnen voorspellen in hoeverre een functionele MI kan terugkeren na een RMA. 
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Dit is een vrij gedetailleerde analyse die zich richt op geometrische echoparameters van 
de mitraalklep, die een uiting zijn van de mate van remodelling van de linkerkamer. 
De belangrijkste voorspellers zijn de hoek die gevormd wordt door het uiteinde van het 
voorste mitraalklepblad ten opzichte van een lijn evenwijdig aan de annulus (distal 
mitral anterior leaflet angle), en de hoek die gevormd wordt door het uiteinde van het 
achterste mitraalklepblad met de lijn evenwijdig aan de annulus (posterior mitral leaflet 
angle). Uiteindelijk worden deze hoeken bepaald door de mate van geometrische 
 verandering in het subvalvulaire apparaat, als gevolg van remodelling van de 
linkerkamer.
Hoofdstuk 9 is gericht op functionele tricuspidaalklepinsufficiëntie. Deze aandoening 
is het gevolg van een linkszijdige klepprobleem (mitraalklepinsufficiëntie) en wordt in 
de cardiologische en chirurgische gemeenschap vaak onvoldoende onderkend. Lange 
tijd werd gedacht dat een beperkte lekkage van de tricuspidaalklep zou genezen door een 
succesvolle behandeling van de mitraalklep. Lange-termijn onderzoeken hebben echter 
aangetoond dat deze gedachte onjuist is. Andere studies hebben uitgewezen dat de mate 
van  lekkage van de tricuspidaalklep geen betrouwbare parameter in de besluitvorming 
rond behandeling, omdat de lekkage sterk afhankelijk is van factoren als preload en 
afterload. In plaats daarvan zou de mate van dilatatie van de tricuspidaalklepannulus 
(welke onafhankelijk is van de genoemde hemodynamische parameters en daarnaast 
goed te meten is met echocardiografie) leidend moeten zijn. Daar in het LUMC de 
laatste benadering sinds 2003 wordt gevolgd, worden in dit hoofdstuk patiëntengroepen 
vergeleken die een tricuspidaalklepplastiek hebben ondergaan in de “oude” periode—
waarbij het besluit tot reparatie van de klep louter gebaseerd was op de ernst van de 
insufficiëntie—en die welke behandeld werden volgens de nieuwste inzichten (ernst van 
de lekkage of louter annulusdilatatie). Aangetoond wordt dat patiënten die volgens de 
nieuwe principes zijn behandeld een beduidend betere echocardio grafische uitkomst 
hebben op het gebied van tricuspidaalklepinsufficiëntie, rechter kamerdimensies en 
rechterkamerfunctie, na een follow-up van 2 jaar.
Hoofdstuk 10 bestaat uit een overzicht en beschouwing van de belangrijkste literatuur 
die is verschenen op het gebied van ischemische functionele MI in de periode 2008–2011. 
In deze periode is er geleidelijk aan meer steun gekomen voor de behandeling van 
 functionele ischemische MI door middel van RMA. Daarnaast zijn er enkele  aanvullende 
technieken ontwikkeld om de kans op recidief MI verder te verminderen, met name bij 
 patiënten met gevorderde remodelling. Nieuwe beeldvormende technieken gericht op 
 functionele MI worden beschreven, waarbij het focus ligt op een integratie van het 
 bepalen van de geometrie van de mitraalklep en van de eigenschappen van de 
 linkerkamer—geometrie, afmeting, functie en potentieel tot herstel van functie. Voor de 
toekomst is het van belang deze  technieken verder te ontwikkelen met als doel de 
 medico-chirurgische behandeling van  patiënten met functionele MI verder te 
 individualiseren en te optimaliseren.
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Slotoverwegingen
Functionele mitraalklepinsufficiëntie heeft een aanzienlijke invloed op het functioneren 
van patiënten met hartfalen en hun overleving. Na een myocardinfarct komt functionele 
MI vaak voor, met een percentage tussen de 20 en 60 procent. Bij ischemische MI kan 
de functie van de linkerventrikel nog redelijk goed bewaard zijn, en kan de MI het 
gevolg zijn van regionale wandbewegingsstoornissen van de linkerkamer. Bij niet -
ischemische cardiomyopathie is er altijd sprake van een algehele dilatatie van de linker-
kamer. Ongeacht de etiologie is functionele MI geassocieerd met een toegenomen 
 overlijdensrisico—bij benadering een verhoging met een factor 2—die bovendien 
 gerelateerd is aan de ernst van de MI
Functionele MI is een dynamisch verschijnsel. Dit heeft specifieke gevolgen voor het 
beoordelen van de MI, welke bij voorkeur plaats zou moeten vinden voorafgaand aan 
een operatie en narcose, en verscheidene technieken zou moeten omvatten om de ernst 
van de MI te bepalen. Bij patiënten met hartfalen en een niet-hemodynamisch 
 belangrijke MI in rust dient een inspanningsechocardiogram verricht te worden.
Ischemische MI die alleen door revascularisatie behandeld wordt verbetert niet bij twee 
derde van de patiënten en leidt tot verdergaande remodelling van de linkerkamer. Er zijn 
geen betrouwbare criteria om patiënten aan te duiden die baat zouden hebben bij alleen 
revascularisatie. Onderzoeken naar de uitkomsten van reparaties van de mitraalkep bij 
functionele MI zijn niet eenvoudig te vergelijken vanwege de uiteenlopende patiënten-
samenstelling en de verschillende chirurgische technieken.
Bij ischemische MI worden in dit proefschrift goede en duurzame resultaten beschreven 
met betrekking tot verbetering van de functionele status, uitblijven van recidief MI, en 
het optreden van reverse remodelling na volledige revascularisatie en een restrictieve 
mitraalklepannuloplastiek (RMA). Een geslaagde RMA dient aan drie voorwaarden te 
voldoen: (1) stringente downsizing van de ring met 2 klepmaten, met een semi-rigide of 
rigide ring, (2) vaststellen van de afwezigheid van resterende MI met daarbij (3)  voldoende 
lengte van coaptatie tussen de beide klepslippen: 8 mm op het niveau A2-P2. Deze 
 benadering lijkt echter  onvoldoende bij patiënten met een te ver gevorderde mate van 
linkerkamer remodelling, welke verondersteld mag worden bij ernstige kamerdilatatie 
(meer dan 65 mm eind -diastolische dimensie en/of ernstige ‘tethering’ van de mitraal-
klep). Bij functionele MI in het kader van niet-ischemische cardiomyopathie geldt 
 eenzelfde benadering van de mitraalklep, echter de ventriculaire component van de 
ziekte kan niet op een directe manier worden aangepakt. In dit proefschrift wordt 
 aangetoond dat externe cardiale compressie leidt tot een meer uitgebreide reverse 
 remodelling van de linkerkamer bij deze patiënten.
Terugkeer van MI dient te worden onderscheiden van resterende MI; insufficiëntie 
binnen 6 maanden na chirurgie dient beschouwd te worden als een uiting van een 
onvolkomen reparatie, en niet als een uiting van progressie van de onderliggende 
 aandoening van het myocard. Terugkeer van MI kan optreden bij patiënten bij wie geen 
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reverse remodelling optreedt, maar ook bij patiënten met reverse remodelling. Er zijn 
geen specifieke indicatoren waarmee terugkeer van MI te voorspellen is, maar de mate 
van preoperatieve remodelling van de linkerkamer—die ten dele tot uiting komt in de 
geometrie van de mitraalklep bij echocardiografisch onderzoek—kan patiënten 
 aanduiden bij wie aanvullende maatregelen noodzakelijk zijn om een recidief te 
voorkomen. Dergelijke maatregelen kunnen gericht zijn op de mitraalklepslippen, op 
het subvalvulaire apparaat, of op de linkerventrikel.
Patiënten met hartfalen en functionele MI dienen de voordelen te kunnen ondervinden 
van een praktische medico –chirurgische benadering in een hartfalenteam, waarin kennis 
over en ervaring met zowel  interventies als non-interventionele behandelstrategieën 
voorhanden zijn. Een op maat gemaakte chirurgische benadering van functionele MI 
behelst ook een beoordeling van de linkerventrikel en de tricuspidaalklep.
Eén van de grootste uitdagingen op het gebied van de functionele MI blijft de selectie 
van patiënten: wie zal wel baat hebben van een geïndividualiseerde chirurgische aanpak, 
en wie niet? Beeldvormde technieken worden in hoog tempo verbeterd, en een verdere 
integratie van de verschillenden technieken zal betere antwoorden verschaffen op de 
vraag welke patiënten al een te ver gevorderde mate van remodelling hebben ondergaan 
en dus geen baat zullen hebben bij de huidige behandeltechnieken.
Met de introductie van percutane technieken voor de behandeling van MI lijkt het erop 
dat steeds meer patiënten met een functionele MI worden behandeld. Ofschoon deze 
 techniek het voordeel heeft een grote chirurgische ingreep te vermijden, moeten we ons 
realiseren dat de resultaten ervan nog niet in grote cohortstudies zijn onderzocht. Op dit 
moment is onze mening dat deze techniek nuttig kan zijn voor patiënten met een zeer 
sterk verhoogd operatierisico. Voor alle andere patiënten is er echter een degelijke 
 chirurgische therapie voorhanden die als zodanig de behandeling van keuze zou moeten 
zijn. Daarnaast dienen voor patiënten voor wie een percutane behandeling wordt 
 overwogen dezelfde principes gevolgd te worden als voor patienten die een chirugische 
interventie ondergaan, zoals in dit proefschrift beschreven. Dit betekent ook dat de 
indicatie voor behandeling niet moet worden uitgebreid alvorens meer informatie over 
de resultaten bekend zijn. Ook hierin speelt het hartfalenteam een belangrijke rol.
Functionele MI heeft een aanzienlijke invloed op het functioneren van patiënten met 
hartfalen en op hun overleving. Chirurgische technieken zijn gedurende een periode van 
meer dan 15 jaar beschikbaar gekomen en verder ontwikkeld, en onze huidige kennis 
geeft aan dat deze technieken—mits juist toegepast en geëvalueerd—een belangrijke 
plaats hebben binnen de behandeling van patiënten met hartfalen en functionele MI.
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